<SEC-DOCUMENT>0001104659-25-119336.txt : 20251208
<SEC-HEADER>0001104659-25-119336.hdr.sgml : 20251208
<ACCEPTANCE-DATETIME>20251208164903
ACCESSION NUMBER:		0001104659-25-119336
CONFORMED SUBMISSION TYPE:	N-CSR
PUBLIC DOCUMENT COUNT:		24
CONFORMED PERIOD OF REPORT:	20250930
FILED AS OF DATE:		20251208
DATE AS OF CHANGE:		20251208
EFFECTIVENESS DATE:		20251208

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			abrdn Healthcare Opportunities Fund
		CENTRAL INDEX KEY:			0001604522
		ORGANIZATION NAME:           	
		EIN:				465317248
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		N-CSR
		SEC ACT:		1940 Act
		SEC FILE NUMBER:	811-22955
		FILM NUMBER:		251556700

	BUSINESS ADDRESS:	
		STREET 1:		1900 MARKET STREET
		STREET 2:		SUITE 200
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
		BUSINESS PHONE:		617-772-8500

	MAIL ADDRESS:	
		STREET 1:		1900 MARKET STREET
		STREET 2:		SUITE 200
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tekla Healthcare Opportunities Fund
		DATE OF NAME CHANGE:	20140407

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tekla Healthcare Growth & Income Fund
		DATE OF NAME CHANGE:	20140402
</SEC-HEADER>
<DOCUMENT>
<TYPE>N-CSR
<SEQUENCE>1
<FILENAME>tm2527059d10_ncsr.htm
<DESCRIPTION>N-CSR
<TEXT>
<!-- Assembled by CompSci Transform  (tm) - http://www.compsciresources.com - version 1.2 -->
<!-- Created: Fri Dec 05 15:56:40 UTC 2025 -->
<html>
<head>
     <title></title>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2527059d10_ncsrcvrpage.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2527059-10/tm2527059-10_ncsrseq1" -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>


<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#xa0;</div></div><!-- Field: /Rule-Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#xa0;N-CSR</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT
INVESTMENT COMPANIES</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 51%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment Company Act file number:</font></td>
    <td style="width: 4%">&#xa0;</td>
    <td style="width: 45%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">811-22955</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exact name of registrant as specified in charter:</font></td>
    <td>&#xa0;</td>
    <td style="font-size: 14pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 14pt">abrdn Healthcare Opportunities
    Fund</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address of principal executive offices:</font></td>
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1900 Market Street, Suite&#xa0;200</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philadelphia, PA 19103</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name and address of agent for service:</font></td>
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sharon Ferrari</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">abrdn Inc.</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1900 Market Street Suite&#xa0;200</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philadelphia, PA 19103</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#x2019;s telephone number, including area code:</font></td>
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1-800-522-5465</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date of fiscal year end:</font></td>
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September&#xa0;30</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date of reporting period:</font></td>
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September&#xa0;30, 2025</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;&#xa0;</p>


<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#xa0;</div></div><!-- Field: /Rule-Page -->


<p style="margin: 0"></p>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->


<p style="margin: 0"></p>


</div><div style="font: 10pt Times New Roman, Times, Serif"><div style="Page-Break-Before: Always"></div><!-- BannerFile="tm2527059d10_item1.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2527059-10/tm2527059-10_ncsrseq1" -->

<p style="margin: 0">&#xa0;&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1. Reports to Stockholders.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a)&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->


<p style="margin: 0"></p>


</div><div style="Page-Break-Before: Always"></div><!-- BannerFile="tm2527059d10_thqreport.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2527059-10/tm2527059-10_ncsrseq1" --><div style="width:100%">
<div style="overflow:hidden; width:100%">
<div style="margin-top:0pt; position:relative; text-align:left; width:100%">
<img src="tm2527059d10thqreporti001.gif" alt=" ">
<div style="left:43pt; position:absolute; top:44pt"><img src="tm2527059d10thqreporti002.gif" alt=" ">
</div><div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; left:43pt; line-height:10pt; position:absolute; text-decoration:none; text-transform:none; top:44pt">&#x2009;</div></div>


</div>
<div style="margin-top:29pt; width:93.96%">
<div style="color:#000000; font-family:Arial; font-size:20pt; font-style:Normal; font-weight:bold; line-height:23pt; text-align:left; text-decoration:none; text-transform:none">abrdn Healthcare Opportunities Fund (THQ)</div>
<div style="color:#000000; font-family:Arial; font-size:14pt; font-style:Normal; font-weight:bold; line-height:17pt; margin-top:14pt; text-align:left; text-decoration:none; text-transform:none">Annual Report</div>
<div style="color:#000000; font-family:Arial; font-size:14pt; font-style:Normal; font-weight:Normal; line-height:17pt; margin-top:2pt; text-align:left; text-decoration:none; text-transform:none">September 30, 2025</div>
</div>
<div style="margin-top:67pt; width:93.96%">
<div style="color:#000000; font-family:Arial; font-size:21.5pt; font-style:Normal; font-weight:bold; line-height:24.5pt; margin-top:2pt; text-align:right; text-decoration:none; text-transform:none">aberdeeninvestments.com</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Distribution Policy &#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)<br>
</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:22.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">The Board of Trustees (the "Board") of the
abrdn Healthcare Opportunities Fund (the "Fund") has authorized a stable distribution policy ("SDP") of paying monthly distributions at an annual rate set once a year. The Fund's current monthly distribution is set at
a rate of $0.18 per share. The SDP is subject to regular review by the Board. The SDP seeks to provide investors with a distribution out of current income, supplemented by realized capital gains and, to the extent
necessary, paid-in capital.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:9pt; text-align:justify; text-decoration:none; text-transform:none">With each distribution, the
Fund will issue a notice to shareholders and an accompanying press release which will provide detailed</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">information regarding the amount and
estimated composition of the distribution and other information required by the Fund's SDP exemptive order. The Fund's Board may amend or terminate the SDP at any time without prior notice to shareholders; however, at
this time, there are no reasonably foreseeable circumstances that might cause the termination of the SDP. You should not draw any conclusions about the Fund's investment performance from the amount of distributions or
from the terms of the Fund's SDP.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:34.5pt; width:92.99%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Distribution Disclosure
Classification &#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)<br>
</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
</div>
<div style="padding-top:22.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund&#x2019;s policy is to provide
investors with a stable distribution rate. Each monthly distribution will be paid out of current income, supplemented by realized capital gains and, to the extent necessary, paid-in capital.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:9pt; text-align:justify; text-decoration:none; text-transform:none">The Fund is subject to U.S.
corporate, tax and securities laws. Under U.S. tax rules, the amount applicable to the Fund and character of distributable income for each fiscal period depends on the actual exchange rates during the entire year
between the U.S. Dollar and the currencies in which the Fund assets are denominated and on the aggregate gains and losses realized by the Fund during the entire year.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:9pt; text-align:justify; text-decoration:none; text-transform:none">Therefore, the exact amount
of distributable income for each fiscal year can only be determined as of the end of the Fund&#x2019;s fiscal year,</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">September 30. Under Section 19 of the
Investment Company Act of 1940, as amended (the &#x201c;1940 Act&#x201d;), the Fund is required to indicate the sources of certain distributions to shareholders. The estimated distribution composition may vary from
month-to-month because it may be materially impacted by future income, expenses and realized gains and losses on securities and fluctuations in the value of the currencies in which Fund assets are denominated.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:9pt; text-align:left; text-decoration:none; text-transform:none">The distributions for the fiscal
year ended September 30, 2025 consisted of 4% net investment income and 96% return of capital.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:9pt; text-align:justify; text-decoration:none; text-transform:none">In January 2026, a Form
1099-DIV will be sent to shareholders, which will state the final amount and composition of distributions and provide information with respect to their appropriate tax treatment for the 2025 calendar year.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:239.5pt; width:100%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; text-align:left; text-decoration:none; text-transform:none">abrdn Healthcare Opportunities Fund</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Letter to Shareholders &#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;</font></div>
</div>
<div style="margin-top:8pt; width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:20.5pt">
<div style="float:left; overflow:hidden; position:relative; width:47.96%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">Dear Shareholder,</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">We present the Annual Report,
which covers the activities of abrdn Healthcare Opportunities Fund&#xa0;(the &#x201c;Fund&#x201d;), for the fiscal year ended September 30, 2025. The Fund&#x2019;s investment objective is to seek current income and
long-term capital appreciation.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Total Investment Return<sup style="font-size:85%; font-style:Normal; text-transform:none">1</sup></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">For the fiscal year ended
September 30, 2025, the total return to shareholders of the Fund based on the net asset value (&#x201c;NAV&#x201d;) and market price of the Fund, respectively, compared to the Fund&#x2019;s benchmark, &#xa0;is as
follows:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; border-top:0.5pt solid #000000; empty-cells:show; margin-top:6pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:4pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:81.48%; background-color: #F0F0F0;">NAV<sup style="font-size:85%; font-style:Normal; text-transform:none">2</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">3</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5.88pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:22.00%; background-color: #F0F0F0;">-12.19%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:81.48%; background-color: #F0F0F0;">Market Price<sup style="font-size:85%; font-style:Normal; text-transform:none">2</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:4pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:22.00%; background-color: #F0F0F0;">-12.29%
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2.5pt; padding-left:16pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:top; width:81.48%; background-color: #F0F0F0;">80% S&amp;P Composite 1500 Healthcare Index, 15% S&amp;P 500 HealthCare
Corporate Bond Index, 5% S&amp;P Composite 1500 Health Care REITS Index<sup style="font-size:85%; font-style:Normal; text-transform:none">4</sup>
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2.5pt; padding-left:7.63pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:22.00%; background-color: #F0F0F0;">-4.87%
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">For more information about
Fund performance, please visit the Fund on the web at www.aberdeenthq.com. Here, you can view quarterly commentary on the Fund's performance, monthly fact sheets, distribution and performance information, and other
Fund literature.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">NAV, Market Price and
Premium(+)/Discount(-)</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The below table represents a
comparison between the current fiscal year end and the prior fiscal year end of the&#xa0;Fund's market price to&#xa0;NAV and associated Premium(+) and Discount(-).</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:6pt; width:97.67%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="padding-bottom:1.75pt; padding-right:4pt; padding-top:3pt; text-align:left; vertical-align:bottom; width:42.80%; background-color: #D9D9D9;">&#xa0;
</td><td style="padding-bottom:1.75pt; padding-right:6pt; padding-top:3pt; text-align:center; vertical-align:bottom; width:14.52%; background-color: #D9D9D9;">&#xa0;
</td><td style="padding-bottom:1.75pt; padding-right:6pt; padding-top:3pt; text-align:right; vertical-align:bottom; width:16.02%; background-color: #D9D9D9;">&#xa0;
</td><td style="padding-bottom:1.75pt; padding-right:12pt; padding-top:3pt; text-align:right; vertical-align:bottom; width:24.28%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:2.5pt; padding-right:4pt; padding-top:1.75pt; text-align:left; vertical-align:bottom; width:42.80%; background-color: #D9D9D9;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2.5pt; padding-left:4pt; padding-right:6pt; padding-top:1.75pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.52%; background-color: #D9D9D9;">NAV
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.02%; background-color: #D9D9D9;">Closing<br>
Market<br>
Price
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:24.28%; background-color: #D9D9D9;">Premium(+)/<br>
Discount(-)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:4pt; padding-top:3.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:42.80%; background-color: #F0F0F0;">9/30/2025
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:4pt; padding-right:6pt; padding-top:3.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:14.52%; background-color: #F0F0F0;">$<font style="padding-left:2.05pt"></font>17.89
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:3.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:16.02%; background-color: #F0F0F0;">$<font style="padding-left:2.92pt"></font>17.29
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:12pt; padding-top:3.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:24.28%; background-color: #F0F0F0;">-3.35%
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2.5pt; padding-left:6pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:42.80%; background-color: #F0F0F0;">9/30/2024
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2.5pt; padding-left:4pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:14.52%; background-color: #F0F0F0;">$22.82
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:16.02%; background-color: #F0F0F0;">$22.08
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2.5pt; padding-left:6.12pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:24.28%; background-color: #F0F0F0;">-3.24%
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">During the fiscal year ended
September 30, 2025, the Fund&#x2019;s NAV was within a range of $16.78 to $22.83 and the Fund&#x2019;s market price traded within a range of $15.26 to $22.58. During the fiscal year ended September 30, 2025, the
Fund&#x2019;s shares traded within a range of a premium(+)/discount(-) of -9.07% to 3.85%.</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:47.96%">
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">Change in Non-Fundamental Investment Policy</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Fund's Board of Trustees
approved, effective on or about January 28, 2026 (the "Effective Date"), to permit the Fund to employ leverage, both traditional and effective, up to the maximum extent permitted by the 1940 Act, and to eliminate the
following non-fundamental investment policy:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">"The Fund will not incur
effective leverage (as such term is defined in this report) in an amount that exceeds 20% of its Managed Assets as measured at the time when leverage is incurred, except that effective leverage incurred through the
use of covered calls will not be counted toward the Trust's limit on the use of effective leverage."</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Aberdeen Name Change</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">On March 4, 2025, abrdn plc,
the parent company of the Fund's adviser, announced that it would change its name, and from that date, will use 'Aberdeen' as the principal trading identity for its Investments business. On March 12, 2025, abrdn plc
completed the steps to legally change its name to Aberdeen Group plc. Aberdeen has retained 'abrdn' as an operational abbreviation across its subsidiary legal entities (including the Fund's adviser, fund names and
descriptors).</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Stable Distribution Policy</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Fund has a stable
distribution policy (the "Policy") that provides for monthly distributions at a rate set by the Board of Trustees (the "Board"). In December 2024, the Board determined the 2025 annual rate of distributions to be a
stable rate of $0.18 per month commencing with the distribution payable in January 2025. Under the current Policy, the Fund intends to make monthly distributions at a rate of $0.18 per share to shareholders of record.
This Policy will be subject to regular review by the Board. The distributions will be made from current income, supplemented by realized capital gains and, to the extent necessary, paid-in capital, which is a
nontaxable return of capital.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">On October 9, 2025 and
November 11, 2025, the Fund announced that it will pay on October 31, 2025 and November 28, 2025 a distribution of $0.18 per share to all shareholders of record as of October 24, 2025 and November 21, 2025,
respectively.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:12.5pt; width:94%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:11pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:2.22%"><sup style="font-size:85%; font-style:Normal; text-transform:none">1</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:justify; text-decoration:none; text-transform:none; vertical-align:top; width:97.78%">Past performance is no guarantee of future results. Investment returns and principal value will fluctuate and shares, when sold, may be worth more or less than original cost. Current performance may be
lower or higher than the performance quoted. NAV return data include investment management fees, custodial charges and administrative fees (such as Trustee and legal fees) and assumes the reinvestment of all
distributions.
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:46pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:2.22%"><sup style="font-size:85%; font-style:Normal; text-transform:none">2</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:97.78%">Assuming the reinvestment of dividends and distributions.
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:57pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:2.22%"><sup style="font-size:85%; font-style:Normal; text-transform:none">3</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:97.78%">The Fund&#x2019;s total return is based on the reported NAV for each financial reporting period end and may differ from what is reported on the Financial Highlights due to financial statement rounding or adjustments.
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:80pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:2.22%"><sup style="font-size:85%; font-style:Normal; text-transform:none">4</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:justify; text-decoration:none; text-transform:none; vertical-align:top; width:97.78%">The S&amp;P Composite 1500<sup style="font-size:85%; font-style:Normal; text-transform:none">&#xae;</sup> Health Care Index is an unmanaged index that comprises those companies included in the S&amp;P Composite 1500 that are classified as members of
the GICS<sup style="font-size:85%; font-style:Normal; text-transform:none">&#xae;</sup> Health Care sector. S&amp;P 500<sup style="font-size:85%; font-style:Normal; text-transform:none">&#xae;</sup> Health Care Corporate Bond Index, a subindex of the S&amp;P 500 Bond Index, seeks to measure the performance of the U.S. corporate debt issued
by constituents in the health care sector of the S&amp;P 500. The S&amp;P 500 Bond Index is designed to be a corporate-bond counterpart to the S&amp;P 500. The S&amp;P Composite 1500 Health Care REITs&#xa0; Index
comprises those companies included in the S&amp;P Composite 1500 that are classified as members of the GICS Health Care REITS industry. Indexes are unmanaged and have been provided for comparison purposes only. No
fees or expenses are reflected. You cannot invest directly in an index.
</td></tr></table>
</div>
</div>
</div>
<div style="padding-top:9.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:24.07%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">1
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Letter to Shareholders &#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(concluded)</font></div>
</div>
<div style="margin-top:8pt; width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:20.5pt">
<div style="float:left; overflow:hidden; position:relative; width:47.96%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Distributions to common shareholders for the
fiscal year ended September 30, 2025 totaled $2.16 per share. Based on the market price of $17.29 on September 30, 2025, the distribution rate was 12.5%. Based on the NAV of $17.89 on September 30, 2025 the
distribution rate was 12.1%.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Fund is covered under
exemptive relief received by the Fund&#x2019;s investment manager from the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) that allows the Fund to distribute capital gains as frequently as monthly in any
one taxable year.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Unclaimed Share Accounts</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">Please be advised that
abandoned or unclaimed property laws for certain states require financial organizations to transfer (escheat) unclaimed property (including Fund shares) to the state. Each state has its own definition of unclaimed
property, and Fund shares could be considered &#x201c;unclaimed property&#x201d; due to account inactivity (e.g., no owner-generated activity for a certain period), returned mail (e.g., when mail sent to
a&#xa0;shareholder&#xa0; is returned to the Fund's transfer agent as undeliverable), or a combination of both. If your Fund shares are categorized as unclaimed, your financial advisor or the Fund's transfer agent will
follow the applicable state&#x2019;s statutory requirements to contact you, but if unsuccessful, laws may require that the shares be escheated to the appropriate state. If this happens, you will have to contact the
state to recover your property, which may involve time and expense. For more information on unclaimed property and how to maintain an active account, please contact your financial adviser or the Fund's transfer
agent.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Open Market Repurchase Program</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Board has approved an
open market repurchase and discount management policy (the &#x201c;Program&#x201d;). The Program allows the Fund to purchase, in the open market for a one-year period ending September 30, 2026, up to 12% of its
outstanding common shares, with the amount and timing of any repurchase determined at the discretion of the Fund's investment adviser. Such purchases may be made opportunistically at certain discounts to NAV per share
in the reasonable judgment of management based on historical discount levels and current market conditions. If shares are repurchased, the Fund reports repurchase activity on its website on a monthly basis. For the
fiscal year ended September 30, 2025, the Fund did not repurchase any shares through the Program.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">On a quarterly basis, the Board
will receive information on any transactions made pursuant to this policy during the prior quarter.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Portfolio Holdings Disclosure</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Fund's complete schedule
of portfolio holdings for the second and fourth quarters of each fiscal year are included in the Fund's semi-annual and annual reports to shareholders. The Fund files its</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:47.96%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">complete schedule of portfolio holdings with
the SEC for the first and third quarters of each fiscal year as an exhibit to its reports on Form N-PORT. These reports are available on the SEC&#x2019;s website at&#xa0;www.sec.gov. The Fund makes the information
available to shareholders upon request and without charge by calling Investor Relations toll-free at 1-800-522-5465.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Proxy Voting</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">A description of the policies
and procedures that the Fund uses to determine how to vote proxies relating to portfolio securities and information regarding how the Fund voted proxies relating to portfolio securities during the most recent 12-month
period ended June 30 is available by August 31 of the relevant year: (1) upon request without charge by calling Investor Relations toll-free at 1-800-522-5465; and (2) on the SEC&#x2019;s website
at&#xa0;www.sec.gov.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Investor Relations Information</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">As part of Aberdeen's
commitment to shareholders, we invite you to visit the Fund on the web at www.aberdeenthq.com. Here, you can view monthly fact sheets, quarterly commentary, distribution and performance information, as well as other
Fund literature. Enroll in Aberdeen's email services to receive content related to your fund. In addition, you will receive monthly factsheets based on your preferences. Sign up today at www.aberdeenthq.com.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Contact Us:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:5pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:5.81%">&#x2022;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:94.19%">Visit: www.aberdeenthq.com
</td></tr></table>
</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:2pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:5.81%">&#x2022;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:94.19%">Email: Investor.Relations@aberdeenplc.com; or
</td></tr></table>
</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:1pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:5.81%">&#x2022;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:94.19%">Call: 1-800-522-5465 (toll free in the U.S.).
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Yours sincerely,</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">/s/ Alan Goodson<br>
<font style="font-weight:bold">Alan Goodson<br>
</font>President&#xa0;</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:8.5pt; width:100%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:17pt; text-align:center; text-decoration:none; text-transform:none">All amounts are U.S.
Dollars unless otherwise stated.</div>
</div>
</div>
<div style="padding-top:21.79pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">2
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Report of the Investment Adviser &#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;</font></div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:20.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">Performance Review</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">For the fiscal year ended
September 30, 2025, THQ returned -12.19%<sup style="font-size:85%; font-style:Normal; text-transform:none">1</sup> on a net asset value<sup style="font-size:85%; font-style:Normal; text-transform:none">2</sup> (NAV) basis versus &#x2013;4.87% for the Fund&#x2019;s blended performance target<sup style="font-size:85%; font-style:Normal; text-transform:none">3</sup>. On a market&#x2013;price basis for the same period, shares returned -12.29%.&#xa0; As a domestically focused strategy, results reflected a year in
which U.S. healthcare lagged the broader market and, importantly, one marked by wide dispersion across healthcare subsectors, which limited portfolio gains despite solid contributions from select holdings.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Market Review</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:left; text-decoration:none; text-transform:none">U.S. stocks, as measured by the
broad S&amp;P 500 Index, posted strong gains over the 12 months to September 30, 2025.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Global markets fluctuated
over the review period amid monetary policy shifts, trade developments, and geopolitical tensions. The U.S. Federal Reserve cut rates twice in late 2024 and again in mid-2025, supporting sentiment alongside hopes for
a soft landing and easing inflation. President Trump&#x2019;s election initially boosted equities, but optimism faded as tariff concerns and tighter immigration policies weighed on markets, leading to a sharp sell-off
in April before rebounding after most tariffs were paused. Further support came from a U.S.-China tariff truce extension and new trade agreements with the EU and Japan, though optimism was tempered by steep new
tariffs on pharmaceuticals and higher duties on several countries. Geopolitical risks, including Middle East violence, briefly pressured markets, but a U.S.-brokered ceasefire helped stabilize conditions. However, the
partial shutdown of the U.S. government starting in September added to economic and political uncertainty. Inflation eased earlier in the year, but remaining above target, central banks maintained a data-dependent
stance. Global economic growth held up better than expected, with early-2025 fears of a U.S. recession proving to be short-lived.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The performance of the U.S.
healthcare sector notably lagged that of the S&amp;P 500 Index over the period due to the sector&#x2019;s defensive nature. In addition, the nomination of Robert F. Kennedy Jr. to run the Department of Health and Human
Services affected the healthcare sector&#x2019;s returns shortly after the announcement. Subsequently, healthcare stocks faced headwinds from regulatory uncertainty, including proposed Medicaid work requirements and
uncertainty in biotechnology regulation and funding. Although the Trump administration announced high tariffs on branded and patented</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">pharmaceutical imports, the tariff rate
implemented was lower than initially feared. Moreover, companies building manufacturing facilities in the U.S. were exempted, which helped to limit the policy&#x2019;s perceived impact on the healthcare sector.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Portfolio Review</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">THQ remained broadly
diversified across the full healthcare ecosystem, balancing large&#x2013;cap defensives, mid&#x2013;cap growth, and select early&#x2013;stage innovators. We made only limited shifts within SMID&#x2013;cap exposures,
favoring targeted, name&#x2013;by&#x2013;name adjustments over wholesale factor tilts. The portfolio emphasized durable cash&#x2013;flow franchises in therapeutics and diversified healthcare, complemented by measured
allocations to diagnostics/tools and medical technology, with select, sizing&#x2013;aware exposure to managed care (MCO) given elevated utilization and regulatory scrutiny. The year&#x2019;s unusually high dispersion
across subsectors reinforced our bias toward balance and discipline.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Notable positives included
AbbVie, driven by strong growth in Skyrizi (used to treat certain inflammatory conditions) and Rinvoq (used to treat certain autoimmune and inflammatory diseases), and Abbott Laboratories, which advanced on robust
fourth&#x2013;quarter results and improved forward guidance as litigation concerns began to ease. Cytokinetics also contributed on optimism in its cardiomyopathy franchise and increased regulatory clarity. These
holdings exemplify the balance&#x2013;sheet strength, commercial execution, and pipeline visibility we seek in core positions.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">As in any portfolio, some
investments did not perform as anticipated and ultimately detracted from overall results, most notably within MCO, gene therapy, and medical technology (examples include UnitedHealth Group, Sarepta Therapeutics, and
Inspire Medical Systems). The period was marked by unusually wide performance dispersion across healthcare subsectors, amplifying stock&#x2013;specific moves. We have kept measured exposure where we see enduring
competitive advantages and attractive long&#x2013;term opportunity&#x2014;in payers, scale and data assets that support cash generation as visibility around rates and utilization improves; in innovative therapeutics,
significant unmet needs and advancing pipelines with clear milestones; and for med&#x2013;tech, durable adoption curves even as budgets reset. Several positions have derated, improving forward risk&#x2013;reward while
we await greater clarity on utilization, reimbursement, or regulatory pathways. Positions are sized to</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:9.5pt; width:94%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:11pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.20%">1
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:justify; text-decoration:none; text-transform:none; vertical-align:top; width:97.80%">Past performance is no guarantee of future results. Investment returns and principal value will fluctuate and shares, when sold, may be worth more or less than original cost. Current performance may be
lower or higher than the performance quoted. Net asset value return data include investment management fees, custodial charges and administrative fees (such as Director and legal fees) and assumes the reinvestment of
all distributions.
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:57pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.20%">2
</td><td style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:97.80%">Net asset value (&#x201c;NAV&#x201d;) &#x2013; A key measure of the value of a company, fund or trust &#x2013; the total value of assets less liabilities, divided by the number of shares.
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:80pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.20%">3
</td><td style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:97.80%">The blended performance target of the fund consists of 80% S&amp;P Composite 1500 Healthcare Index, 15% S&amp;P 500 HealthCare Corporate Bond Index, 5% S&amp;P Composite 1500 Health Care REITS Index.
</td></tr></table>
</div>
</div>
</div>
<div style="padding-top:9.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:23.55%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">3
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Report of the Investment Adviser &#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)</font></div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:19.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">near&#x2013;term uncertainty, reassessed
around defined catalysts, and balanced within a broadly diversified portfolio (with selective use of options to manage event risk). In short, while conditions are challenging, we believe in the longer&#x2013;term
success and opportunity embedded in these holdings and expect fundamentals&#x2014;rather than headlines&#x2014;to drive value over a full cycle. We will reduce or exit a position and exposure if thesis&#x2013;critical
facts change.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Call&#x2013;option<sup style="font-size:85%; font-style:Normal; text-transform:none">4</sup> writing<sup style="font-size:85%; font-style:Normal; text-transform:none">5</sup> was modest and additive. Selling covered calls on select holdings generated incremental income&#x2014;especially around clinical&#x2013;event
volatility&#x2014;and helped cushion returns when outcomes disappointed. We note the trade&#x2013;offs: capped upside during sharp rallies and potential assignment of called&#x2013;away positions. Leverage, where used,
was prudent and aligned with the opportunity set and market conditions.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The fixed&#x2013;income sleeve
is concentrated in investment&#x2013;grade healthcare issuers, with a tilt to higher&#x2013;quality, shorter&#x2013;duration instruments given our view that credit spreads remain low and tight relative to Treasuries at
the macro level. This allocation is designed to generate income and offset a portion of equity risk, while preserving flexibility to redeploy capital as relative opportunities evolve.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Venture activity was measured
and not a material driver of annual performance. During the year, the Fund participated in the Series A financing of Crystalys Therapeutics (dotinurad for gout/hyperuricemia) and invested in Third Arc Bio, a
preclinical platform developing multi&#x2013;specific antibody therapeutics for oncology and immunology by optimizing T&#x2013;cell activation and trafficking. We also made a new investment in Abcuro. These positions
are sized for risk and intended to introduce longer&#x2013;dated optionality to the portfolio.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Portfolio Activity</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">In late 2024, we established
several new positions, including Humana, Exact Sciences Corporation and Tempus AI. These positions were established for a variety of reasons, including near-term clinical data events and commercial opportunities.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Moving into 2025, we made
several changes to the portfolio. Generally speaking, the portfolio management team identified relative value differentials favoring smaller-cap equities over large-cap pharmaceutical and biotechnology companies.
Additionally, concerns over pending tariffs led us to adopt a more cautious stance toward the large-cap pharmaceutical and biotechnology sector. Examples of new initiations included Neurocrine Biosciences, Arrowhead
Pharmaceuticals, NeoGenomics, ARS Pharmaceuticals, and Sera Prognostics.</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Meanwhile, we initiated Myriad Genetics, a
mid-cap diagnostics company, after a period of share-price underperformance. The decision reflected a turnaround in the genetic testing sector, supported by the launch of new cancer and women&#x2019;s health tests, as
well as ongoing improvements in the company&#x2019;s fundamentals and cost restructuring. We added Repligen, a life science tools provider specializing in bioprocessing equipment for drug manufacturers, after a
pullback in its share price. The decision reflected the company&#x2019;s exposure to recovering biotechnology research and development activity. We initiated Krystal Biotech, a newly commercial-stage gene therapy
company. The firm previously received approval for its lead dermatology gene therapy and has since demonstrated ongoing commercial momentum as that product launch accelerated.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Later in the period, the Fund
initiated or added to CVS Health, uniQure, Arcus Biosciences, Lucid Diagnostics, Abivax, and InspireMD, emphasizing clinical innovation and diversified platforms.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">In terms of the Fund&#x2019;s
venture activities, we made a new investment in a pre-public, venture-backed company, Abcuro. We reassessed our venture capital and convertible bond positions, maintaining a disciplined approach focused on upcoming
catalysts.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Conversely, we sold several
positions, including Edwards Lifesciences based on an assessment of revenue growth trends.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Some sales were motivated by
a lack of confidence in the companies' prospects, while some were as a result of share-price appreciation relative to broader healthcare equities. Examples included Avantor, argenx, and Tempus AI.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Meanwhile, we sold Biogen
after the stock appreciated following approval of its Alzheimer&#x2019;s drug. We also disposed of our holding in Illumina amid ongoing regulatory and competitive pressures. We sold IDEXX Laboratories after a period of
strong share-price performance.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">The portfolio remained balanced
across large-cap defensives, mid-cap growth stocks, and select early-stage innovators.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The monthly distribution<sup style="font-size:85%; font-style:Normal; text-transform:none">6</sup> reflects the Fund&#x2019;s current policy to provide shareholders with a relatively stable cash flow per share. During the 12-month period ended
September 30, 2025, the distributions comprised ordinary income, capital gains, and a return of capital.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Outlook and Strategy</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">Uncertainty continues to
cloud the macroeconomic, geopolitical, and market outlook. A combination of shifting fiscal and monetary policies along with structural changes in global trade dynamics has created an increasingly volatile market
environment. Much of the focus remains on the Trump administration&#x2019;s tariff strategy and its</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:12.5pt; width:94%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:11pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.20%">4
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:97.80%">Call option &#x2013; A contract that gives the buyer the right, but not the obligation, to buy an asset at a specified price within a set period.
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:23pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.20%">5
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:97.80%">Call-option writing &#x2013; Selling a call option, which obligates the seller to sell the asset at the strike price if the option is exercised.
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:34pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.20%">6
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:97.80%">Distribution &#x2013; The payment of any income, capital gains or return of capital by a fund.
</td></tr></table>
</div>
</div>
</div>
<div style="padding-top:20.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">4
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Report of the Investment Adviser &#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(concluded)</font></div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:19.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">potential implications for economic growth
and inflation. However, the broader macroeconomic backdrop is further complicated by labor-market data revisions, proposed tax cuts, widening budget deficits, evolving interest-rate policy, healthcare reform, and a
range of other policy initiatives that may have both intended and unintended consequences. Given the rapidly evolving landscape, market participants are struggling to build meaningful conviction around the trajectory
of both domestic and international economies.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">As policy and macro
cross&#x2013;currents persist, we believe healthcare&#x2019;s relative valuation versus the broader U.S. equity market remains attractive, reflecting multi&#x2013;year de&#x2013;rating and episodic policy headlines.
Against that backdrop, our focus is on fundamentals&#x2014;durable demand, advancing clinical pipelines, and productivity&#x2013;enhancing platforms in diagnostics and tools&#x2014;which we expect to be the primary
driver of share appreciation over a full cycle. We anticipate continued M&amp;A as large&#x2013;cap companies address loss&#x2013;of&#x2013;exclusivity (LOE) challenges and pipeline gaps, a backdrop that can support
valuations across innovation&#x2013;rich small and mid</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">caps as well as enabling&#x2013;technology
franchises. At the same time, we recognize the healthcare sector remains challenging in pockets, especially MCO, where utilization, rate&#x2013;setting, and regulatory scrutiny have contributed to volatility. Our base
case is that volatility should moderate as visibility improves&#x2014;for example, as utilization patterns normalize, rate frameworks are finalized, and regulatory processes move from proposal to implementation. We
expect performance dispersion to remain elevated, which, while a near&#x2013;term headwind, also enlarges the opportunity set for active security selection. For THQ, we plan to maintain broad diversification across
subsectors with only limited SMID&#x2013;cap reallocations around milestone&#x2013;driven opportunities, continue to use option&#x2013;writing selectively, and rely on our investment&#x2013;grade, short&#x2013;duration
fixed&#x2013;income sleeve as a stabilizer. In our view, the combination of reasonable relative valuations, healthy secular fundamentals, and a supportive business&#x2013;development backdrop leaves the strategy
well&#x2013;positioned as uncertainty recedes and fundamentals reassert themselves as the dominant driver of returns.&#xa0;</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:419.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:23.55%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">5
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Total Investment Return &#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;</font></div>
</div>
<div style="margin-top:6pt; width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:33.5pt; width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">The following table summarizes
the average annual Fund performance compared to the Fund&#x2019;s primary benchmark&#xa0;for the 1-year, 3-year, 5-year and 10-year periods ended September 30, 2025.</div>
<div style="text-align:left">
<table style="border-bottom:0.5pt solid #000000; border-collapse:collapse; empty-cells:show; margin-top:10pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:9.5pt; padding-bottom:3.5pt; padding-right:12pt; padding-top:5pt; text-align:left; vertical-align:bottom; width:59.54%; background-color: #D9D9D9;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:12pt; padding-right:12pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.40%; background-color: #D9D9D9;">1 Year
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:12pt; padding-right:12pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.77%; background-color: #D9D9D9;">3 Years
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:12pt; padding-right:12pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.72%; background-color: #D9D9D9;">5 Years
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:12pt; padding-right:6pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.58%; background-color: #D9D9D9;">10 Years
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:6pt; padding-right:12pt; padding-top:2.12pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:59.54%; background-color: #F0F0F0;">Net Asset Value (NAV)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:12pt; padding-right:12pt; padding-top:2.12pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.40%; background-color: #F0F0F0;">-12.19%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:12.40pt; padding-right:12pt; padding-top:2.12pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.77%; background-color: #F0F0F0;">5.39%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:12.26pt; padding-right:12pt; padding-top:2.12pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.72%; background-color: #F0F0F0;">5.73%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:13.80pt; padding-right:6pt; padding-top:2.12pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.58%; background-color: #F0F0F0;">7.91%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:6pt; padding-right:12pt; padding-top:1pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:59.54%; background-color: #F0F0F0;">Market Price
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:12pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.40%; background-color: #F0F0F0;">-12.29%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:12pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.77%; background-color: #F0F0F0;">8.04%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:13.67pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.72%; background-color: #F0F0F0;">7.44%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:12.19pt; padding-right:6pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.58%; background-color: #F0F0F0;">9.07%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:6pt; padding-right:12pt; padding-top:1pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:59.54%; background-color: #F0F0F0;">80% S&amp;P Composite 1500 Healthcare Index, 15% S&amp;P 500 HealthCare Corporate Bond Index, 5% S&amp;P Composite 1500 Health Care REITS
Index
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:15.48pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.40%; background-color: #F0F0F0;">-4.87%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:13.80pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.77%; background-color: #F0F0F0;">7.30%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:12pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.72%; background-color: #F0F0F0;">6.52%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:12pt; padding-right:6pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.58%; background-color: #F0F0F0;">8.84%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:4.5pt; padding-left:6pt; padding-right:12pt; padding-top:1pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:59.54%; background-color: #F0F0F0;">S&amp;P Composite 1500 Healthcare Index
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:4.5pt; padding-left:17.28pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.40%; background-color: #F0F0F0;">-7.83%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:4.5pt; padding-left:12.13pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.77%; background-color: #F0F0F0;">6.33%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:4.5pt; padding-left:13.67pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.72%; background-color: #F0F0F0;">7.08%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:4.5pt; padding-left:12.19pt; padding-right:6pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.58%; background-color: #F0F0F0;">9.59%
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:13pt; text-align:left; text-decoration:none; text-transform:none">Performance of a $10,000
Investment<font style="font-weight:Normal"> (as of September 30, 2025)</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:7pt; text-align:left; text-decoration:none; text-transform:none">This graph shows the change in
value of a hypothetical investment of $10,000 in the Fund for the periods indicated. For comparison, the same investment is shown in the indicated&#xa0;index.</div>
<div style="margin-left:26.48%; margin-top:5pt; text-align:Center; width:47.22%">
<img src="tm2527059d10thqreporti003.jpg" alt=" ">
</div>


<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:12pt; text-align:justify; text-decoration:none; text-transform:none">The performance above
reflects fee waivers and/or expense reimbursements made by the Fund&#x2019;s current investment manager. Absent such waivers&#xa0;and/or reimbursements, the Fund&#x2019;s returns would be lower. Additionally, Aberdeen
entered into an agreement with the Fund to limit investor relations&#xa0;services fees. This agreement aligns with the term of the management agreement and may not be terminated prior to the end of the current term of
the&#xa0;advisory agreement. See Note 3 in the Notes to Financial Statements.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Returns represent past
performance. Total investment return at NAV is based on changes in the NAV of Fund shares and assumes reinvestment of dividends and distributions, if any, at market prices pursuant to the dividend reinvestment program
sponsored by the Fund&#x2019;s transfer agent. All return data at NAV includes fees charged to the Fund, which are listed in the Fund&#x2019;s Statement of Operations under &#x201c;Expenses.&#x201d; Total investment
return at market value is based on changes in the market price at which the Fund&#x2019;s shares traded on the NYSE during the period and assumes reinvestment of dividends and distributions, if any, at market prices
pursuant to the dividend reinvestment program sponsored by the Fund&#x2019;s transfer agent. The Fund&#x2019;s total investment return is based on the reported NAV as of the financial reporting period end date of
September 30, 2025. Because the Fund&#x2019;s shares trade in the stock market based on investor demand, the Fund may trade at a price higher or lower than its NAV. Therefore, returns are calculated based on both
market price and NAV. <font style="font-weight:bold">Past performance is no guarantee of future results</font>. The performance information provided does not reflect the deduction of taxes that a shareholder would pay on distributions received
from the Fund or the sale of Fund shares. The current performance of the Fund may be lower or higher than the figures shown. The Fund&#x2019;s yield, return, market price and NAV will fluctuate. Performance information
current to the most recent month-end is available at www.aberdeenthq.com&#xa0;or by calling 800-522-5465.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">The gross operating expense
ratio based on the fiscal year ended September 30, 2025 was 3.02%.The net operating expense ratio, net of fee waivers and excluding interest expense based on the fiscal year ended September 30, 2025, was
1.42%.&#xa0;</div>
</div>
<div style="margin-top:45pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">6
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Portfolio Composition &#xa0;<font style="font-size:11pt; line-height:14pt">(as a percentage of net assets) (unaudited)&#xa0;</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of&#xa0;September 30, 2025</div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:14.5pt; width:100%">
<div style="text-align:left">
<table style="border-bottom:0.5pt solid #000000; border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.81%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:4pt; padding-top:5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:90.89%; background-color: #D9D9D9;">Asset Allocation
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:9pt; padding-top:5pt; text-align:right; vertical-align:bottom; width:7.25%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:90.89%; background-color: #F0F0F0;">Common Stocks
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:5.64pt; padding-right:9pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:7.25%; background-color: #F0F0F0;">104.8%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:90.89%; background-color: #F0F0F0;">Non-Convertible Notes
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:11.25pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:7.25%; background-color: #F0F0F0;">21.0%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:90.89%; background-color: #F0F0F0;">Convertible Preferred Stocks
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:14.97pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:7.25%; background-color: #F0F0F0;">3.8%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:90.89%; background-color: #F0F0F0;">Short-Term Investments
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:14.73pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:7.25%; background-color: #F0F0F0;">0.8%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:90.89%; background-color: #F0F0F0;">Call Options Written
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:11.08pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:7.25%; background-color: #F0F0F0;">(0.1%)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:90.89%; background-color: #F0F0F0;">Liabilities in Excess of Other Assets
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:7.25%; background-color: #F0F0F0;">(30.3%)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:3.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:bottom; width:90.89%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:5.56pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:7.25%; background-color: #F0F0F0;">100.0%
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
<div style="text-align:left">
<table style="border-bottom:0.5pt solid #000000; border-collapse:collapse; empty-cells:show; margin-top:6pt; width:99.81%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:4pt; padding-top:5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:90.86%; background-color: #D9D9D9;">Industries
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:9pt; padding-top:5pt; text-align:right; vertical-align:bottom; width:7.29%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:90.86%; background-color: #F0F0F0;">Health Care Equipment &amp; Supplies
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:10.55pt; padding-right:9pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:7.29%; background-color: #F0F0F0;">32.0%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:90.86%; background-color: #F0F0F0;">Biotechnology
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:10.31pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:7.29%; background-color: #F0F0F0;">28.6%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:90.86%; background-color: #F0F0F0;">Pharmaceuticals
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:10.14pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:7.29%; background-color: #F0F0F0;">28.0%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:90.86%; background-color: #F0F0F0;">Health Care Providers &amp; Services
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:10.58pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:7.29%; background-color: #F0F0F0;">23.9%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:90.86%; background-color: #F0F0F0;">Life Sciences Tools &amp; Services
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:15.10pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:7.29%; background-color: #F0F0F0;">8.6%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:90.86%; background-color: #F0F0F0;">Health Care REITs
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:15.18pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:7.29%; background-color: #F0F0F0;">8.3%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:90.86%; background-color: #F0F0F0;">Health Care Technology
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:15.35pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:7.29%; background-color: #F0F0F0;">0.2%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:90.86%; background-color: #F0F0F0;">Short-Term Investments
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:14.93pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:7.29%; background-color: #F0F0F0;">0.8%
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:90.86%; background-color: #F0F0F0;">Liabilities in Excess of Other Assets
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:7.29%; background-color: #F0F0F0;">(30.4%)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:3.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:bottom; width:90.86%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:5.76pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:7.29%; background-color: #F0F0F0;">100.0%
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
<div style="text-align:left">
<table style="border-bottom:0.5pt solid #000000; border-collapse:collapse; empty-cells:show; margin-top:6pt; width:99.81%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:4pt; padding-top:5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.93%; background-color: #D9D9D9;">Top Ten Holdings
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:9pt; padding-top:5pt; text-align:right; vertical-align:bottom; width:5.21%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.93%; background-color: #F0F0F0;">Eli Lilly &amp; Co.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4.18pt; padding-right:9pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.21%; background-color: #F0F0F0;">8.5%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.93%; background-color: #F0F0F0;">AbbVie, Inc.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:5.58pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.21%; background-color: #F0F0F0;">7.8%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.93%; background-color: #F0F0F0;">Abbott Laboratories
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:7.88pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.21%; background-color: #F0F0F0;">7.1%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.93%; background-color: #F0F0F0;">Merck &amp; Co., Inc.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4.55pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.21%; background-color: #F0F0F0;">4.7%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.93%; background-color: #F0F0F0;">Medtronic PLC
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4.19pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.21%; background-color: #F0F0F0;">4.5%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.93%; background-color: #F0F0F0;">Intuitive Surgical, Inc.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4.12pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.21%; background-color: #F0F0F0;">3.6%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.93%; background-color: #F0F0F0;">Danaher Corp.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4.39pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.21%; background-color: #F0F0F0;">3.5%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.93%; background-color: #F0F0F0;">UnitedHealth Group, Inc.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.21%; background-color: #F0F0F0;">3.4%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.93%; background-color: #F0F0F0;">Thermo Fisher Scientific, Inc.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4.41pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.21%; background-color: #F0F0F0;">3.2%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.93%; background-color: #F0F0F0;">Becton Dickinson &amp; Co.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:4.39pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.21%; background-color: #F0F0F0;">2.9%
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">&#xa0;</div>
</div>
<div style="margin-top:292pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:24.07%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">7
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Portfolio of Investments&#xa0;<font style="font-size:11pt; line-height:14pt">&#xa0;</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of September 30, 2025</div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:13.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.48%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:4pt; text-align:left; vertical-align:top; width:57.41%; background-color: #CCCCCC;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:4pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #CCCCCC;" colspan="2">Shares or<br>
Principal<br>
Amount
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:6pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #CCCCCC;">Value
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">Convertible Preferred Stocks<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(c)</sup>&#x2014;3.8%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:96.92%; background-color: #F0F0F0;" colspan="4">Biotechnology&#x2014;2.6%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Abcuro, Inc. Series B
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:7.55pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;601,124
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">$<font style="padding-left:0.07pt"></font>&#x2002;&#x2007;&#x2007;3,299,990
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Abcuro, Inc. Series C1
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.78pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;133,045
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.49pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;803,419
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Atalanta Therapeutics, Inc. Series B
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4.95pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2007;1,944,444
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.70pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2007;&#x2007;3,499,999
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Glycomine, Inc. Series C, 8.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.11pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2007;6,872,036
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.05pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2007;&#x2007;4,123,222
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Seismic Therapeutics, Inc. Series B
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.79pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;730,764
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.73pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2007;&#x2007;3,299,984
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Third Arc Bio, Inc. Series A, 8.00%
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.65pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2007;2,091,056
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.57pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2007;&#x2007;4,400,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:57.41%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:14.97pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">19,426,614
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">Health Care Equipment &amp; Supplies&#x2014;0.0%
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">IO Light Holdings, Inc. Series A2
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.60pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;189,858
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.74pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;19
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:96.92%; background-color: #F0F0F0;" colspan="4">Pharmaceuticals&#x2014;1.2%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Crystalys Therapeutics, Inc. Series A
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6.54pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2007;2,508,159
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.95pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2007;&#x2007;2,512,799
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Endeavor Biomedicines, Inc. Series B, 8.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:7.53pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;742,138
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.34pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2007;&#x2007;3,499,997
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Endeavor Biomedicines, Inc. Series C, 8.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:7.22pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;137,039
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.66pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;894,125
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Engrail Therapeutics, Inc., 8.00%
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6.21pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2007;1,652,502
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.67pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2007;&#x2007;1,750,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:57.41%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:18.93pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">8,656,921
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:75.03%; background-color: #F0F0F0;" colspan="3">Total Convertible Preferred Stocks
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:13.45pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">28,083,554
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Non-Convertible Notes&#x2014;21.0%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:left; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:6pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:96.92%; background-color: #F0F0F0;" colspan="4">Biotechnology&#x2014;3.5%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">AbbVie, Inc., 3.20%, 05/14/26
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">$<font style="padding-left:0.93pt"></font>&#x2002;3,245,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.86pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">3,230,061
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">AbbVie, Inc., 4.25%, 11/14/28
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:8.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">5,303,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.72pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">5,345,068
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">AbbVie, Inc., 4.45%, 05/14/46
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:7.70pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">3,080,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:22.77pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">2,726,132
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Amgen, Inc., 3.20%, 11/02/27
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:8.23pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">2,200,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.30pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">2,164,390
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Amgen, Inc., 2.00%, 01/15/32
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:9.07pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">2,795,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.70pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">2,426,133
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Gilead Sciences, Inc., 2.95%, 03/01/27
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4.18pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">10,000,000
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.91pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">9,859,209
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:57.41%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:14.40pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">25,750,993
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">Health Care Equipment &amp; Supplies&#x2014;3.1%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Abbott Laboratories, 4.75%, 11/30/36
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4.44pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">10,498,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.84pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">10,594,164
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Becton Dickinson &amp; Co., 3.70%, 06/06/27
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:9.23pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">2,413,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.49pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">2,396,719
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">DH Europe Finance II SARL, 3.25%, 11/15/39
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:9.65pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">1,760,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.54pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">1,442,002
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Stryker Corp., 3.65%, 03/07/28
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:8.04pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">3,500,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.86pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">3,467,941
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-indent:-8pt; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Zimmer Biomet Holdings, Inc., 4.25%, 08/15/35
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:7.61pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">6,000,000
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.39pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">5,586,734
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:57.41%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:14.59pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">23,487,560
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">Health Care Providers &amp; Services&#x2014;7.9%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Cigna Group, 4.38%, 10/15/28
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:9.00pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">1,504,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:24.92pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">1,511,911
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Cigna Group, 2.38%, 03/15/31
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:7.86pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">5,800,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:22.79pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">5,218,411
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Cigna Group, 6.13%, 11/15/41
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:8.24pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">8,250,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.57pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">8,742,384
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">CVS Health Corp., 4.30%, 03/25/28
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.70pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">789,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:26.54pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">789,520
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">CVS Health Corp., 1.88%, 02/28/31
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:7.54pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">4,400,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:22.60pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">3,824,113
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">CVS Health Corp., 4.78%, 03/25/38
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:9.62pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">2,100,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:22.06pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">1,968,198
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">CVS Health Corp., 5.05%, 03/25/48
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:8.37pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">3,700,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.30pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">3,292,029
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Elevance Health, Inc., 4.10%, 03/01/28
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:9.23pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">2,975,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.61pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">2,973,389
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Elevance Health, Inc., 2.55%, 03/15/31
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:7.86pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">5,800,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.06pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">5,265,830
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Elevance Health, Inc., 4.65%, 08/15/44
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:8.97pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">2,325,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.32pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">2,062,148
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">UnitedHealth Group, Inc., 3.85%, 06/15/28
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:8.78pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">1,460,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.55pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">1,454,450
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">UnitedHealth Group, Inc., 3.88%, 12/15/28
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:8.55pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">4,970,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.91pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">4,942,807
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">UnitedHealth Group, Inc., 4.20%, 05/15/32
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4.41pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">10,940,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.74pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">10,783,748
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">UnitedHealth Group, Inc., 4.50%, 04/15/33
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:7.86pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">5,800,000
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.37pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">5,738,743
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:57.41%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:15.70pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">58,567,681
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">Life Sciences Tools &amp; Services&#x2014;0.9%
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-indent:-8pt; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Thermo Fisher Scientific, Inc., 5.40%, 08/10/43
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:7.97pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">6,500,000
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.64pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">6,571,558
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:96.92%; background-color: #F0F0F0;" colspan="4">Pharmaceuticals&#x2014;5.6%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">AstraZeneca PLC, 6.45%, 09/15/37<sup style="font-size:85%; font-style:Normal; text-transform:none">(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:8.54pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">4,750,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:22.16pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">5,414,777
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:2.5pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Bristol-Myers Squibb Co., 3.20%, 06/15/26
</td><td style="line-height:0pt; padding-bottom:2.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:2.5pt; padding-left:9.36pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">7,500,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:2.5pt; padding-left:20.94pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">7,462,834
</td></tr></table>
</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.48%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-right:4pt; padding-top:4pt; text-align:left; vertical-align:top; width:57.41%; background-color: #CCCCCC;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:4pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #CCCCCC;" colspan="2">Shares or<br>
Principal<br>
Amount
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:0pt; padding-right:6pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #CCCCCC;">Value
</td></tr>
<tr style="page-break-inside:avoid"><td style="padding-right:4pt; padding-top:1.5pt; text-align:left; vertical-align:top; width:57.41%; background-color: #F0F0F0;">
</td><td style="padding-top:1.5pt; text-align:left; vertical-align:bottom; width:0%; background-color: #F0F0F0;">
</td><td style="padding-right:4pt; padding-top:1.5pt; text-align:center; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">
</td><td style="padding-right:6pt; padding-top:1.5pt; text-align:center; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">
</td></tr>
<tr style="page-break-inside:avoid"><td style="padding-right:6pt; text-align:left; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Bristol-Myers Squibb Co., 3.40%, 07/26/29
</td><td style="line-height:0pt; padding-bottom:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0pt; padding-right:4pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">$<font style="padding-left:-2.19pt"></font>&#x2002;&#x2007;2,100,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4pt; padding-right:6pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">$<font style="padding-left:1.20pt"></font>&#x2002;&#x2007;&#x2007;2,047,620
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">IQVIA, Inc., 5.00%, 05/15/27<sup style="font-size:85%; font-style:Normal; text-transform:none">(e)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.14pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2007;1,290,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.42pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2007;&#x2007;1,286,409
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Johnson &amp; Johnson, 2.90%, 01/15/28
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4.20pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2007;2,200,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.21pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2007;&#x2007;2,161,897
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Johnson &amp; Johnson, 3.70%, 03/01/46
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6.17pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">10,130,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.88pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2007;&#x2007;8,333,563
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Merck &amp; Co., Inc., 3.40%, 03/07/29
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:3.47pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2007;4,000,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.51pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2007;&#x2007;3,918,833
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Pfizer, Inc., 3.45%, 03/15/29
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.24pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2007;8,100,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.25pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2007;&#x2007;7,969,070
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Pfizer, Inc., 4.00%, 12/15/36
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4.02pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2007;3,200,000
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.85pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2007;&#x2007;2,987,030
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:57.41%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:14.26pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">41,582,033
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:75.03%; background-color: #F0F0F0;" colspan="3">Total Non-Convertible Notes
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:10.80pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">155,959,825
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Common Stocks&#x2014;104.8%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:left; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:6pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:96.92%; background-color: #F0F0F0;" colspan="4">Biotechnology&#x2014;22.5%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">AbbVie, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.88pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;249,937
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.13pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2007;57,870,413
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Abivax SA, ADR<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6.64pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;95,261
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.80pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2007;&#x2007;8,087,659
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Arcus Biosciences, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:7.22pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;131,629
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.68pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2007;&#x2007;1,790,154
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">ARS Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.41pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2007;1,330,994
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.08pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2007;13,376,490
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">BioMarin Pharmaceutical, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(f)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6.07pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;242,472
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.62pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2007;13,132,283
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Cytokinetics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(f)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.27pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">300,343
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.60pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">16,506,851
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Exact Sciences Corp.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(f)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.89pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">177,529
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:22.83pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">9,712,612
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Galera Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.45pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">314,430
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:34.77pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">5,565
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">I-Mab, ADR<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.18pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">43,738
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:26.77pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">165,330
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Myriad Genetics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.72pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">639,053
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.91pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">4,620,353
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Regeneron Pharmaceuticals, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:25.66pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">7,797
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.20pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">4,384,019
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Sarepta Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(f)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.72pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">778,658
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.01pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">15,004,740
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Sera Prognostics, Inc., Class A<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.49pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">1,133,977
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.19pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">3,469,970
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">uniQure NV<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:16.27pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">103,074
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.60pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">6,016,429
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Veracyte, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.43pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">162,102
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.19pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">5,564,962
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Vericel Corp.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.72pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">224,324
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.75pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">7,059,476
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:57.41%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:11.54pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">166,767,306
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">Health Care Equipment &amp; Supplies&#x2014;28.9%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Abbott Laboratories
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:16.67pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">392,156
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.39pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">52,525,375
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Becton Dickinson &amp; Co.<sup style="font-size:85%; font-style:Normal; text-transform:none">(f)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:18.70pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">115,741
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.05pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">21,663,243
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Boston Scientific Corp.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.86pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">193,269
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:16.12pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">18,868,853
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Dexcom, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.32pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">108,639
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:23.23pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">7,310,318
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Inspire Medical Systems, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.49pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">165,830
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:16.45pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">12,304,586
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">InspireMD, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.22pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">810,124
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.22pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">1,952,399
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Insulet Corp.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.83pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">22,678
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:22.43pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">7,001,379
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Intuitive Surgical, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.34pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">60,410
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.70pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">27,017,164
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">LivaNova PLC<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.82pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">165,092
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:22.13pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">8,647,519
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Lucid Diagnostics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:8.21pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">2,500,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.06pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">2,525,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Medtronic PLC
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.48pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">349,732
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.90pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">33,308,476
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">ResMed, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.47pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">16,139
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:22.49pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">4,417,728
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Stryker Corp.<sup style="font-size:85%; font-style:Normal; text-transform:none">(f)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.90pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">35,162
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.30pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">12,998,337
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Tandem Diabetes Care, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.78pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">306,067
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.66pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">3,715,653
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:57.41%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:9.91pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">214,256,030
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">Health Care Providers &amp; Services&#x2014;16.0%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Acadia Healthcare Co., Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.73pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">273,647
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.78pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">6,775,500
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Community Health Systems, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.09pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">927,537
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.94pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">2,977,394
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">CVS Health Corp.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.91pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">275,073
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:18.15pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">20,737,754
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Elevance Health, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.00pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">51,603
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:18.14pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">16,673,961
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">HCA Healthcare, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:24.43pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">9,180
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:22.25pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">3,912,516
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Humana, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.14pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">65,358
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.96pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">17,004,191
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">McKesson Corp.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:23.83pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">6,735
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.56pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">5,203,057
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Molina Healthcare, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.01pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">45,598
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.67pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">8,725,633
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">NeoGenomics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.59pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">792,263
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:22.84pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">6,116,270
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Tenet Healthcare Corp.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.17pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">25,976
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:23.22pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">5,274,167
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">UnitedHealth Group, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(f)</sup>
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.88pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">71,799
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:18.40pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">24,792,195
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:0.25pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:57.41%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:0.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:0.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:0.25pt; padding-left:12.16pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">118,192,638
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:18pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">8
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Portfolio of Investments&#xa0;<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(continued)</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of September 30, 2025</div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:22.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.48%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:4pt; text-align:left; vertical-align:top; width:57.41%; background-color: #CCCCCC;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:4pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #CCCCCC;" colspan="2">Shares or<br>
Principal<br>
Amount
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:6pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #CCCCCC;">Value
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Common Stocks (continued)
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.5pt; text-align:left; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.5pt; text-align:center; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:6pt; padding-top:1.5pt; text-align:center; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">Health Care REITs&#x2014;8.3%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Diversified Healthcare Trust, REIT
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.49pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;293,879
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">$<font style="padding-left:0.71pt"></font>&#x2002;&#x2007;&#x2007;1,296,006
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Global Medical REIT, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.36pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;6,333
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.05pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;213,485
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Healthcare Realty Trust, Inc., REIT
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:8.05pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;25,119
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.26pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;452,895
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Healthpeak Properties, Inc., REIT
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:7.69pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;567,701
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.45pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2007;10,871,474
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">LTC Properties, Inc., REIT
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.69pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;166,842
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.65pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2007;&#x2007;6,149,796
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Medical Properties Trust, Inc., REIT
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.89pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;266,557
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.59pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2007;&#x2007;1,351,444
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">National Health Investors, Inc., REIT
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.65pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;5,596
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.44pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;444,882
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Omega Healthcare Investors, Inc., REIT
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6.34pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;297,889
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.41pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2007;12,576,874
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Sabra Health Care REIT, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.05pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;626,862
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.33pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2007;11,684,708
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Ventas, Inc., REIT
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6.76pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;106,216
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.72pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2007;&#x2007;7,434,058
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Welltower, Inc., REIT
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6.94pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;51,783
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.57pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2007;&#x2007;9,224,624
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:57.41%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:14.84pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">61,700,246
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">Health Care Technology&#x2014;0.2%
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Veradigm, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6.46pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;338,217
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.83pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2007;&#x2007;1,623,442
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">Life Sciences Tools &amp; Services&#x2014;7.7%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Danaher Corp.<sup style="font-size:85%; font-style:Normal; text-transform:none">(f)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:7.51pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;130,135
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.77pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">&#x2007;25,800,565
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Repligen Corp.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:18.84pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">54,330
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:22.72pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">7,262,291
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Thermo Fisher Scientific, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(f)</sup>
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:18.27pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">48,406
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.92pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">23,477,878
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:57.41%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:13.72pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">56,540,734
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:96.92%; background-color: #F0F0F0;" colspan="4">Pharmaceuticals&#x2014;21.2%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Bristol-Myers Squibb Co.<sup style="font-size:85%; font-style:Normal; text-transform:none">(f)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.59pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">394,693
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.40pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">17,800,654
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Eli Lilly &amp; Co.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.51pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">82,475
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:16.07pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">62,928,425
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Fusion Pharmaceuticals, Inc. CVR<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:25.89pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">7,160
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:34.92pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">9,881
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Johnson &amp; Johnson
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:29.03pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">338
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:30.94pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">62,672
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Merck &amp; Co., Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:16.24pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">412,754
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.25pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">34,642,443
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Oculis Holding AG<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.98pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">426,422
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.17pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">7,560,462
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Perrigo Co. PLC
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.39pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">28,292
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:25.41pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">630,063
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Pfizer, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.64pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">482,171
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:18.93pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">12,285,717
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">Zoetis, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(f)</sup>
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.71pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #F0F0F0;">144,562
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.12pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">21,152,312
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:57.41%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:12.05pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">157,072,629
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.5pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:75.03%; background-color: #F0F0F0;" colspan="3">Total Common Stocks
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.5pt; padding-left:12.15pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">776,153,025
</td></tr></table>
</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.48%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:4pt; text-align:left; vertical-align:top; width:57.41%; background-color: #CCCCCC;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:4pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #CCCCCC;" colspan="2">Shares or<br>
Principal<br>
Amount
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:6pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #CCCCCC;">Value
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">Short-Term Investment&#x2014;0.8%
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-indent:-8pt; text-transform:none; vertical-align:top; width:57.41%; background-color: #F0F0F0;">State Street Institutional U.S. Government Money Market Fund, Premier Class, 4.09%<sup style="font-size:85%; font-style:Normal; text-transform:none">(g)</sup>
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:0%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:7.59pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #F0F0F0;">&#x2007;5,487,182
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">$<font style="padding-left:2.88pt"></font>&#x2002;&#x2007;&#x2007;5,487,182
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:75.03%; background-color: #F0F0F0;" colspan="3">Total Short-Term Investment
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:20.61pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">5,487,182
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:75.03%; background-color: #F0F0F0;" colspan="3">Total Investments (Cost $872,482,125)<sup style="font-size:85%; font-style:Normal; text-transform:none">(h)</sup>&#x2014;130.4%
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:9.00pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">965,683,586
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:75.03%; background-color: #F0F0F0;" colspan="3">Long Term Debt Securities&#x2014;(30.4%)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:8.36pt; padding-right:6pt; padding-top:1.5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">(225,000,000)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:75.03%; background-color: #F0F0F0;" colspan="3">Other Assets in Excess of Liabilities&#x2014;0.0%
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:31.37pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.89%; background-color: #F0F0F0;">18,827
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:0.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:75.03%; background-color: #F0F0F0;" colspan="3">Net Assets&#x2014;100.0%
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:0.25pt; padding-left:4pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.89%; background-color: #F0F0F0;">$<font style="padding-left:2.52pt"></font>740,702,413
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:10pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.01%">(a)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:10pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.56%">Level 3 security. See Note 2(a) of the accompanying Notes to&#xa0;Financial Statements.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.01%">(b)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.56%">Non-income producing security.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.01%">(c)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.56%">Restricted security.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.01%">(d)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.56%">Foreign security.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.01%">(e)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.56%">Denotes a security issued under Regulation S or Rule 144A.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.01%">(f)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.56%">A portion of security is pledged as collateral for call options written.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.01%">(g)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.56%">Registered investment company advised by State Street Investment Management. The rate shown is the 7 day yield as of&#xa0;September 30, 2025.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:6pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.01%">(h)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:6pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.56%">See accompanying Notes to Financial Statements for tax unrealized appreciation/(depreciation) of securities.
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; text-align:left; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:6pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:5.94%">ADR
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:6pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:94.63%">American Depositary Receipt
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:5.94%">CVR
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:94.63%">Contingent Value Right
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:5.94%">PLC
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:94.63%">Public Limited Company
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:6pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:5.94%">REIT
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:6pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:94.63%">Real Estate Investment Trust
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; width:100%">
</div>
</div>
<div style="padding-top:274pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:23.55%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">9
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Portfolio of Investments&#xa0;<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(concluded)</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of September 30, 2025</div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:13.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.91%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:5pt; text-align:left; vertical-align:bottom; width:32.98%; background-color: #CCCCCC;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:26.17%; background-color: #CCCCCC;">Number of Contracts<br>
(100 shares each)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:26.04%; background-color: #CCCCCC;">Notional Amount ($)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:12pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:19.14%; background-color: #CCCCCC;">Value ($)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%; background-color: #E6E6E6;" colspan="4">Option Contracts Written&#x2014;(0.1)%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%; background-color: #E6E6E6;" colspan="4">Call Options Written&#x2014;(0.1)%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:32.98%; background-color: #E6E6E6;">Becton Dickinson &amp; Co. Oct25 190 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:26.17%; background-color: #E6E6E6;">126
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:26.04%; background-color: #E6E6E6;">(2,394,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.14%; background-color: #E6E6E6;">(28,728)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:32.98%; background-color: #E6E6E6;">BioMarin Pharmaceutical, Inc. Oct25 57.5 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:26.17%; background-color: #E6E6E6;">417
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:26.04%; background-color: #E6E6E6;">(2,397,750)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.14%; background-color: #E6E6E6;">(25,020)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:32.98%; background-color: #E6E6E6;">Bristol-Myers Squibb Co. Oct25 45.5 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:26.17%; background-color: #E6E6E6;">211
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:26.04%; background-color: #E6E6E6;">(960,050)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.14%; background-color: #E6E6E6;">(6,330)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:32.98%; background-color: #E6E6E6;">Cytokinetics, Inc. Oct25 55 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:26.17%; background-color: #E6E6E6;">523
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:26.04%; background-color: #E6E6E6;">(2,876,500)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.14%; background-color: #E6E6E6;">(138,595)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:32.98%; background-color: #E6E6E6;">Danaher Corp. Oct25 195 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:26.17%; background-color: #E6E6E6;">74
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:26.04%; background-color: #E6E6E6;">(1,443,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.14%; background-color: #E6E6E6;">(32,560)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:32.98%; background-color: #E6E6E6;">Exact Sciences Corp. Oct25 56 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:26.17%; background-color: #E6E6E6;">342
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:26.04%; background-color: #E6E6E6;">(1,915,200)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.14%; background-color: #E6E6E6;">(18,810)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:32.98%; background-color: #E6E6E6;">Sarepta Therapeutics, Inc. Oct25 20 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:26.17%; background-color: #E6E6E6;">719
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:26.04%; background-color: #E6E6E6;">(1,438,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.14%; background-color: #E6E6E6;">(25,165)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:32.98%; background-color: #E6E6E6;">Stryker Corp. Oct25 390 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:26.17%; background-color: #E6E6E6;">61
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:26.04%; background-color: #E6E6E6;">(2,379,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.14%; background-color: #E6E6E6;">(6,100)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:32.98%; background-color: #E6E6E6;">Thermo Fisher Scientific, Inc. Oct25 490 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:26.17%; background-color: #E6E6E6;">49
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:26.04%; background-color: #E6E6E6;">(2,401,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.14%; background-color: #E6E6E6;">(21,413)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:32.98%; background-color: #E6E6E6;">UnitedHealth Group, Inc. Oct25 340 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:26.17%; background-color: #E6E6E6;">71
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:26.04%; background-color: #E6E6E6;">(2,414,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.14%; background-color: #E6E6E6;">(57,510)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:32.98%; background-color: #E6E6E6;">Zoetis, Inc. Oct25 150 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:26.17%; background-color: #E6E6E6;">96
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:26.04%; background-color: #E6E6E6;">(1,440,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.14%; background-color: #E6E6E6;">(16,128)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:3.5pt; padding-left:14pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-indent:-8pt; text-transform:none; vertical-align:bottom; width:85.19%; background-color: #E6E6E6;" colspan="3">Total Call Options Written<br>
(Premiums received $(350,461))
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.14%; background-color: #E6E6E6;">(376,359)
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;</div>
<div style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; margin-top:9pt; text-align:left; text-decoration:none; text-transform:none">See accompanying Notes to Financial
Statements.</div>
</div>
<div style="margin-top:448pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">10
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Statement of Assets and Liabilities<font style="font-size:11pt; line-height:14pt">&#xa0;</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of September 30, 2025</div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:14.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:85.44%">Assets
</td><td style="border-bottom:1pt solid #000000; line-height:9.5pt; padding-bottom:3pt; padding-right:12pt; padding-top:5pt; text-align:right; vertical-align:bottom; width:13.74%">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.44%">Investments, at value (cost $866,994,943)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.74%; background-color: #F0F0F0;">$&#x2003;960,196,404
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.44%">Short-term investment, at value (cost $5,487,182)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:24.89pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.74%; background-color: #F0F0F0;">&#x2003;5,487,182
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.44%">Receivable for investments sold
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:29.51pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.74%; background-color: #F0F0F0;">2,075,940
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.44%">Interest and dividends receivable
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:33.01pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.74%; background-color: #F0F0F0;">2,247,194
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.44%">Prepaid expenses in connection with bank loan  (Note 8)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:47.55pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.74%; background-color: #F0F0F0;">1,362
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.44%">Prepaid expenses
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:35.88pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.74%; background-color: #F0F0F0;">203,834
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.44%">Total assets
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:20.17pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.74%; background-color: #F0F0F0;">970,211,916
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:85.44%">Liabilities
</td><td style="line-height:9.5pt; padding-bottom:1.5pt; padding-right:12pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:13.74%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.44%">Revolving Credit Facility payable (Note 8)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:18.41pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.74%; background-color: #F0F0F0;">225,000,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.44%">Interest payable on Revolving Credit Facility
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:31.23pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.74%; background-color: #F0F0F0;">2,385,196
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.44%">Investment advisory fees payable (Note 3)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:36.48pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.74%; background-color: #F0F0F0;">788,288
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.44%">Payable for investments purchased
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:40.18pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.74%; background-color: #F0F0F0;">657,107
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.44%">Written options, at value (premiums received $350,461)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:37.40pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.74%; background-color: #F0F0F0;">376,359
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.44%">Investor relations fees payable (Note 3)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:40.46pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.74%; background-color: #F0F0F0;">40,834
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.44%">Trustee fees payable
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:42.95pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.74%; background-color: #F0F0F0;">35,188
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.44%">Administration fees payable
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:42.73pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.74%; background-color: #F0F0F0;">18,497
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.44%">Other accrued expenses
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:35.63pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.74%; background-color: #F0F0F0;">208,034
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.44%">Total liabilities
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:16.81pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.74%; background-color: #F0F0F0;">229,509,503
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.44%">Commitments and Contingencies (Notes 7 &amp; 10)
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:12pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:13.74%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:9.5pt; padding-bottom:3pt; padding-right:12pt; padding-top:2.38pt; text-align:left; vertical-align:bottom; white-space:nowrap; width:99.18%" colspan="2">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.44%">Net Assets
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.74%; background-color: #F0F0F0;">$<font style="padding-left:5.76pt"></font>740,702,413
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.44%">Composition of Net Assets
</td><td style="line-height:9.5pt; padding-bottom:1.5pt; padding-right:12pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:13.74%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.44%">Common stock (par value $0.010 per share) (Note 5)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:7.5pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.74%; background-color: #F0F0F0;">$<font style="padding-left:17.24pt"></font>&#x2003;414,079
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.44%">Paid-in capital in excess of par
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:14.51pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.74%; background-color: #F0F0F0;">&#x2003;674,479,612
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.44%">Distributable earnings
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.21pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.74%; background-color: #F0F0F0;">&#x2003;65,808,722
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.44%">Net Assets
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.74%; background-color: #F0F0F0;">$<font style="padding-left:5.76pt"></font>740,702,413
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.44%">Net asset value per share based on 41,407,879 shares issued and outstanding
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.74%; background-color: #F0F0F0;">$<font style="padding-left:36.32pt"></font>17.89
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:19pt; text-align:left; text-decoration:none; text-transform:none">See accompanying Notes to
Financial Statements.</div>
</div>
<div style="margin-top:249pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:23.55%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">11
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Statement of Operations<font style="font-size:11pt; line-height:14pt">&#xa0;</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">For the Year Ended September 30, 2025</div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:14.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.72%">Net Investment Income
</td><td style="border-bottom:1pt solid #000000; line-height:9.5pt; padding-bottom:3pt; padding-right:12pt; padding-top:5pt; text-align:right; vertical-align:bottom; width:13.46%">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.72%">Investment Income:
</td><td style="line-height:9.5pt; padding-bottom:1.5pt; padding-right:12pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:13.46%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:85.72%">Dividends
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:7.5pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.46%; background-color: #F0F0F0;">$<font style="padding-left:3.15pt"></font>&#x2003;14,243,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.72%">Interest and amortization of discount and premium and other income
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.84pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.46%; background-color: #F0F0F0;">&#x2003;7,190,531
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.72%">Total investment income
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:25.39pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.46%; background-color: #F0F0F0;">21,433,531
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:85.72%">Expenses:
</td><td style="line-height:9.5pt; padding-bottom:1.5pt; padding-right:12pt; padding-top:2.38pt; text-align:right; vertical-align:bottom; width:13.46%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.72%">Investment advisory fee (Note 3)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:20.25pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.46%; background-color: #F0F0F0;">&#x2003;10,310,161
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.72%">Legal fees and expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:29.76pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.46%; background-color: #F0F0F0;">&#x2003;160,105
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.72%">Investor relations fees and expenses (Note 3)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:29.36pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.46%; background-color: #F0F0F0;">&#x2003;158,821
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.72%">Trustees' fees and expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:29.93pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.46%; background-color: #F0F0F0;">&#x2003;144,129
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.72%">Reports to shareholders and proxy solicitation
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:29.19pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.46%; background-color: #F0F0F0;">&#x2003;135,795
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.72%">Independent auditors&#x2019; fees and tax expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:30.66pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.46%; background-color: #F0F0F0;">&#x2003;119,291
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.72%">Insurance expense
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:33.92pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.46%; background-color: #F0F0F0;">&#x2003;55,100
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.72%">Custodian&#x2019;s fees and expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:33.81pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.46%; background-color: #F0F0F0;">&#x2003;51,542
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.72%">Administration fee
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:33.80pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.46%; background-color: #F0F0F0;">&#x2003;49,571
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.72%">Transfer agent&#x2019;s fees and expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:38.30pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.46%; background-color: #F0F0F0;">&#x2003;7,043
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.72%">Bank loan fees and expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:37.48pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.46%; background-color: #F0F0F0;">&#x2003;6,932
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:85.72%">Miscellaneous
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:27.52pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.46%; background-color: #F0F0F0;">&#x2003;209,523
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.72%">Total operating expenses, excluding interest expense
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:25.14pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.46%; background-color: #F0F0F0;">11,408,013
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.72%">Interest expense  (Note 8)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:19.40pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.46%; background-color: #F0F0F0;">&#x2003;12,911,578
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.72%">Total expenses
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:25.65pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.46%; background-color: #F0F0F0;">24,319,591
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:9.5pt; padding-bottom:3pt; padding-right:12pt; padding-top:2.5pt; text-align:left; vertical-align:bottom; white-space:nowrap; width:99.18%" colspan="2">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.72%">Net Investment Loss
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:23.91pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.46%; background-color: #F0F0F0;">(2,886,060)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.72%">Net Realized/Unrealized Gain/(Loss):
</td><td style="line-height:9.5pt; padding-bottom:1.5pt; padding-right:12pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:13.46%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.72%">Net realized gain/(loss) from:
</td><td style="line-height:9.5pt; padding-bottom:1.5pt; padding-right:12pt; padding-top:1.5pt; text-align:right; vertical-align:bottom; width:13.46%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.72%">Investments
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:24.50pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.46%; background-color: #F0F0F0;">(8,944,788)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.72%">Written options
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:31.53pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.46%; background-color: #F0F0F0;">2,787,871
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; vertical-align:bottom; width:85.72%">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:28.29pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.46%; background-color: #F0F0F0;">(6,156,917)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.72%">Net change in unrealized appreciation/depreciation on:
</td><td style="line-height:9.5pt; padding-bottom:1.5pt; padding-right:12pt; padding-top:2.38pt; text-align:right; vertical-align:bottom; width:13.46%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.72%">Investments
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:15.37pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.46%; background-color: #F0F0F0;">(105,584,666)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.72%">Written options
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:33.20pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.46%; background-color: #F0F0F0;">(216,320)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; vertical-align:bottom; width:85.72%">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:14.81pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.46%; background-color: #F0F0F0;">(105,800,986)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.72%">Net realized and unrealized gain from investments and written options
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:19.56pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.46%; background-color: #F0F0F0;">(111,957,903)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.72%">Change in Net Assets Resulting from Operations
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.46%; background-color: #F0F0F0;">$(114,843,963)
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:19pt; text-align:left; text-decoration:none; text-transform:none">See accompanying Notes to
Financial Statements.</div>
</div>
<div style="margin-top:152pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">12
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Statements of Changes in Net Assets<font style="font-size:11pt; line-height:14pt">&#xa0;</font></div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:14.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:9.5pt; padding-bottom:3pt; padding-right:7.5pt; padding-top:5pt; text-align:left; vertical-align:bottom; width:64.00%">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:7.5pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.56%">For the<br>
Year Ended<br>
September 30, 2025
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:12pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%">For the<br>
Year Ended<br>
September 30, 2024
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:64.00%">Increase/(Decrease) in Net Assets:
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:7.5pt; padding-top:2.75pt; text-align:right; vertical-align:bottom; width:17.56%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:12pt; padding-top:2.75pt; text-align:right; vertical-align:bottom; width:17.62%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:64.00%">Operations:
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:7.5pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:17.56%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:12pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:17.62%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:64.00%">Net investment loss
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:7.5pt; padding-right:7.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.56%; background-color: #F0F0F0;">$<font style="padding-left:9.31pt"></font>(2,886,060)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:7.5pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #D9D9D9;">$<font style="padding-left:12.35pt"></font>(3,891,912)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:64.00%">Net realized gain/(loss) from investments and written options
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:26.16pt; padding-right:7.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.56%; background-color: #F0F0F0;">(6,156,917)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:21.41pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">42,465,748
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:10pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:64.00%">Net change in unrealized appreciation/depreciation investments, milestone interests
and written options
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:12.68pt; padding-right:7.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.56%; background-color: #F0F0F0;">(105,800,986)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.14pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">150,988,597
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:64.00%">Net increase/(decrease) in net assets resulting from operations
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:14.14pt; padding-right:7.5pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.56%; background-color: #F0F0F0;">(114,843,963)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:16.63pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">189,562,433
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:64.00%">Distributions to Shareholders From:
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:7.5pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:17.56%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:12pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:17.62%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:64.00%">Distributable earnings
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:23.53pt; padding-right:7.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.56%; background-color: #F0F0F0;">(3,979,432)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:20.07pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">(45,221,413)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:64.00%">Return of capital
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.74pt; padding-right:7.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.56%; background-color: #F0F0F0;">(85,399,220)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:19.25pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">(32,941,565)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:64.00%">Net decrease in net assets from distributions
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:18.45pt; padding-right:7.5pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.56%; background-color: #F0F0F0;">(89,378,652)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:20.97pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">(78,162,978)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:10pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:64.00%">Reinvestment of dividends resulting in the issuance of 51,821 and 0 shares of common
stock, respectively
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:27.21pt; padding-right:7.5pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.56%; background-color: #F0F0F0;">1,002,726
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:60.42pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">&#x2013;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:64.00%">Change in net assets
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:13.45pt; padding-right:7.5pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.56%; background-color: #F0F0F0;">(203,219,889)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:19.08pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">111,399,455
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:64.00%">Net Assets:
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:7.5pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:17.56%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:12pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:17.62%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:9.5pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:64.00%">Beginning of year
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:15.75pt; padding-right:7.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.56%; background-color: #F0F0F0;">943,922,302
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:16.57pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">832,522,847
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:9.5pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:64.00%">End of year
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:7.5pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.56%; background-color: #F0F0F0;">$<font style="padding-left:2.08pt"></font>740,702,413
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">$943,922,302
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Amounts listed as
 &#x201c;&#x2013;&#x201d; are $0 or round to $0.&#xa0;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:19pt; text-align:left; text-decoration:none; text-transform:none">See accompanying Notes to
Financial Statements.</div>
</div>
<div style="margin-top:318pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:23.55%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">13
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Statement of Cash Flows&#xa0;<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">For the Year Ended &#xa0;September 30, 2025</div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:14.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.04%">Cash flows from operating activities:
</td><td style="border-bottom:1pt solid #000000; line-height:9.5pt; padding-bottom:3pt; padding-right:12pt; padding-top:5pt; text-align:right; vertical-align:bottom; width:14.15%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.04%">Net increase/(decrease) in net assets resulting from operations
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.15%; background-color: #F0F0F0;">$&#x2003;(114,843,963)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:10pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:85.04%">Adjustments to reconcile net decrease in net assets resulting<br>
from&#xa0;operations&#xa0;to&#xa0;net&#xa0;cash&#xa0;provided&#xa0;by&#xa0;operating&#xa0;activities:
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:12pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:14.15%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.04%">Investments purchased
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:13.42pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.15%; background-color: #F0F0F0;">&#x2003;(437,148,064)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.04%">Investments sold and principal repayments
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:15.39pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.15%; background-color: #F0F0F0;">&#x2003;469,260,128
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.04%">Proceeds from option contracts written
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:25.67pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.15%; background-color: #F0F0F0;">&#x2003;2,772,926
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.04%">Net change in short-term investments
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:22.01pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.15%; background-color: #F0F0F0;">&#x2003;55,910,182
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.04%">Net amortization/accretion of premium/(discount)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:35.55pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.15%; background-color: #F0F0F0;">&#x2003;(45,137)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.04%">Capital gains and return of capital distributions from investments
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:25.24pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.15%; background-color: #F0F0F0;">&#x2003;1,072,438
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.04%">Decrease in interest, dividends and other receivables
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:37.71pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.15%; background-color: #F0F0F0;">&#x2003;27,203
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.04%">Increase in prepaid expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:35.29pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.15%; background-color: #F0F0F0;">&#x2003;(77,558)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.04%">Decrease in interest payable on Revolving Credit Facility
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:27.34pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.15%; background-color: #F0F0F0;">&#x2003;(333,088)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.04%">Decrease in accrued investment advisory fee payable
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:28.45pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.15%; background-color: #F0F0F0;">&#x2003;(188,858)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.04%">Increase in other accrued expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:38.87pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.15%; background-color: #F0F0F0;">&#x2003;11,814
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.04%">Net change in unrealized depreciation of investments and options
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:13.97pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.15%; background-color: #F0F0F0;">&#x2003;105,800,986
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.04%">Net realized loss on investments transactions and options
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:27.46pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.15%; background-color: #F0F0F0;">&#x2003;6,156,917
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:9.5pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.04%">Net cash provided by operating activities
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:24.41pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.15%; background-color: #F0F0F0;">88,375,926
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.04%">Cash flows from financing activities:
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:12pt; padding-top:2.75pt; text-align:right; vertical-align:bottom; width:14.15%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.04%">Distributions paid to shareholders
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.14pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.15%; background-color: #F0F0F0;">(88,375,926)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:9.5pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.04%">Net cash used in financing activities
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:21.11pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.15%; background-color: #F0F0F0;">(88,375,926)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:9.5pt; padding-right:7.5pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.04%">Unrestricted and restricted cash, beginning of year
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:66.32pt; padding-right:12pt; padding-top:2.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.15%; background-color: #F0F0F0;">&#x2013;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.04%">Unrestricted and restricted cash, end of year
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.15%; background-color: #F0F0F0;">$<font style="padding-left:53.64pt"></font>&#x2013;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.04%">Supplemental disclosure of cash flow information:
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:12pt; padding-top:2.75pt; text-align:right; vertical-align:bottom; width:14.15%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.04%">Cash paid for interest and fees on borrowing
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:-0.10pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.15%; background-color: #F0F0F0;">&#x2003;$<font style="padding-left:15.05pt"></font>13,244,666
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Amounts listed as
 &#x201c;&#x2013;&#x201d; are $0 or round to $0.&#xa0;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:19pt; text-align:left; text-decoration:none; text-transform:none">See accompanying Notes to
Financial Statements.</div>
</div>
<div style="margin-top:253pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">14
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Financial Highlights<font style="font-size:11pt; line-height:14pt">&#xa0;</font></div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:14.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.07%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="line-height:9.5pt; padding-bottom:3pt; padding-right:6.5pt; padding-top:5pt; text-align:left; vertical-align:bottom; width:51.94%; background-color: #D9D9D9;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6.5pt; padding-right:12pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:46.84%; background-color: #D9D9D9;" colspan="5">For the Fiscal Years Ended September 30,
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:6.5pt; padding-top:1.75pt; text-align:left; vertical-align:bottom; width:51.94%; background-color: #D9D9D9;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #D9D9D9;">2025<br>


</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #D9D9D9;">2024<br>
<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup>
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #D9D9D9;">2023<br>


</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #D9D9D9;">2022<br>
<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6.5pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #D9D9D9;">2021<br>
<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:51.94%; background-color: #F0F0F0;">PER SHARE OPERATING PERFORMANCE:
</td><td style="line-height:9.5pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:9.37%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:9.37%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:9.37%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:9.37%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:12pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:9.37%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:51.94%; background-color: #F0F0F0;">Net asset value per common share, beginning of year
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.04pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$22.82
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:18.68pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$20.13
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:16.55pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$20.20
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:16.56pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$23.64
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:16.59pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$20.28
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:51.94%; background-color: #F0F0F0;">Net investment income/(loss)<sup style="font-size:85%; font-style:Normal; text-transform:none">(c)</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:23.67pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(0.07)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:23.10pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(0.09)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:23.05pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(0.06)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:27.20pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">0.01
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:28.35pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">0.16
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:16pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:51.94%; background-color: #F0F0F0;">Net realized and unrealized gains/(losses) on investments, written
options and foreign currency transactions
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.15pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(2.70)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:26.86pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">4.67
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:27.49pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">1.34
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:25.66pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(2.10)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:26.76pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">4.55
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:51.94%; background-color: #F0F0F0;">Total from investment operations applicable to common shareholders
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.92pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(2.77)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:26.36pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">4.58
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:27.69pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">1.28
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:23.56pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(2.09)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:28.04pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">4.71
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:51.94%; background-color: #F0F0F0;">Distributions to common shareholders from:
</td><td style="line-height:9.5pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.37%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.37%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.37%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.37%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:12pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.37%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:51.94%; background-color: #F0F0F0;">Net investment income
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:25.21pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(0.10)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:23.36pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(0.54)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:25.25pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(0.18)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:22.92pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(0.04)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:24.45pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(0.91)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:51.94%; background-color: #F0F0F0;">Net realized gains
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:39.35pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:23.74pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(0.55)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:27.36pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(1.17)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:26.07pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(1.31)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:22.97pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(0.44)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:51.94%; background-color: #F0F0F0;">Return of capital
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:23.5pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(2.06)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:22.91pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(0.80)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:39.35pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:39.35pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:39.35pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">&#x2013;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:51.94%; background-color: #F0F0F0;">Total distributions
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:25.84pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(2.16)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.49pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(1.89)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.91pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(1.35)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.91pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(1.35)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.91pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(1.35)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:51.94%; background-color: #F0F0F0;">Net asset value per common share, end of year
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:19.09pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$17.89
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.04pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$22.82
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:18.68pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$20.13
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:16.55pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$20.20
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:16.56pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$23.64
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:51.94%; background-color: #F0F0F0;">Market price, end of year
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:19.51pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$17.29
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:16.59pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$22.08
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.42pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$16.98
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:19.82pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$18.12
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.15pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$22.65
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:51.94%; background-color: #F0F0F0;">Total Investment Return Based on<sup style="font-size:85%; font-style:Normal; text-transform:none">(d)</sup>:
</td><td style="line-height:9.5pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.37%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.37%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.37%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.37%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:12pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.37%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:51.94%; background-color: #F0F0F0;">Market price
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:12.26pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(12.29%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:13.70pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">42.99%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:18.60pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">0.56%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:11.26pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(14.84%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:13.74pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">33.28%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:51.94%; background-color: #F0F0F0;">Net asset value
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:14.14pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(12.19%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:13.89pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">24.66%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:18.43pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">6.94%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:15.28pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(9.08%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:15.93pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">24.14%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.62pt; padding-left:16pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:51.94%; background-color: #F0F0F0;">Ratio to Average Net Assets Applicable to Common Shareholders/Supplementary Data:
</td><td style="line-height:9.5pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; vertical-align:bottom; width:9.37%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; vertical-align:bottom; width:9.37%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; vertical-align:bottom; width:9.37%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; vertical-align:bottom; width:9.37%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:12pt; padding-top:1.62pt; text-align:right; vertical-align:bottom; width:9.37%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:16pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:51.94%; background-color: #F0F0F0;">Net assets applicable to common shareholders, end of year (000 omitted)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:8.00pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$740,702
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6.81pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$943,922
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:7.23pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$832,523
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:7.28pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$835,567
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:8.65pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$977,364
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:51.94%; background-color: #F0F0F0;">Average net assets applicable to common shareholders (000 omitted)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6.88pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$806,016
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6.63pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$890,367
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6.52pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$885,296
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:9.59pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$947,190
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6.79pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$942,855
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:51.94%; background-color: #F0F0F0;">Gross operating expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:18.69pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">3.02%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:20.57pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">3.10%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:19.11pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">2.95%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:20.17pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">1.87%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:19.68pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">1.66%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:16pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:51.94%; background-color: #F0F0F0;">Net operating expenses, net of fee waivers and<br>
excluding interest expense
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:19.84pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">1.42%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:19.84pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">1.42%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:20.18pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">1.47%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:19.56pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">1.46%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:19.43pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">1.44%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:51.94%; background-color: #F0F0F0;">Net Investment income (loss)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:15.44pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(0.36%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:15.11pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(0.44%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:15.51pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">(0.28%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:18.43pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">0.05%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:18.39pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">0.69%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:51.94%; background-color: #F0F0F0;">Portfolio turnover
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:25.58pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">43%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:25.58pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">43%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:25.38pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">44%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:25.56pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">49%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:25.76pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">58%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:51.94%; background-color: #F0F0F0;">Senior securities (loan facility) outstanding (000 omitted)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$225,000
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$225,000
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$225,000
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$225,000
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6.5pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$225,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:51.94%; background-color: #F0F0F0;">Asset coverage ratio on senior securities at year end<sup style="font-size:85%; font-style:Normal; text-transform:none">(e)</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:20.77pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">429%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:20.93pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">520%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:20.91pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">470%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:22.23pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">471%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:20.77pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">534%
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:51.94%; background-color: #F0F0F0;">Asset coverage per $1000 on senior securities at year end<sup style="font-size:85%; font-style:Normal; text-transform:none">(f)</sup>
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:16.82pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$4,292
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:18.84pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$5,195
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:16.51pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$4,700
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.88pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$4,714
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:16.41pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.37%; background-color: #F0F0F0;">$5,344
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
<div style="text-align:center">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-right:auto; margin-top:11pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.23%">(a)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.32%">Effective October 27, 2023, abrdn Inc. became the investment adviser of the Fund. Prior to October 27, 2023, the Fund was managed by Tekla Capital Management, LLC. Members of the portfolio management
team from&#xa0;Tekla joined abrdn Inc., and continue to manage the Fund.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.23%">(b)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.32%">Beginning with the year ended September 30, 2023, the Fund&#x2019;s financial statements were audited by KPMG LLP. Previous years were audited by a different independent registered public accounting
firm.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.23%">(c)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.32%">Based on average shares outstanding.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.23%">(d)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.32%">Total investment return based on market value is calculated assuming that shares of the Fund&#x2019;s common stock were purchased at the closing market price as of the beginning of the period, dividends,
capital gains and other distributions were reinvested as provided for in the Fund&#x2019;s dividend reinvestment plan and then sold at the closing market price per share on the last day of the period. The computation
does not reflect any sales commission investors may incur in purchasing or selling shares of the Fund. The total investment return based on the net asset value is similarly computed except that the Fund&#x2019;s net
asset value is substituted for the closing market value.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.23%">(e)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.32%">Asset coverage ratio is calculated by dividing net assets as of each fiscal period end plus the amount of any borrowings for investment purposes outstanding as of each fiscal period end by the amount of
any borrowings as of each fiscal period end.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:3pt; padding-left:0pt; padding-right:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.23%">(f)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:3pt; padding-left:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.32%">Asset coverage per $1,000 is calculated by dividing net assets plus the amount of any borrowings for investment purposes by the amount of any senior securities, which&#xa0;includes
the revolving credit facility and then multiplying by $1,000.
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Amounts listed as
 &#x201c;&#x2013;&#x201d; are $0 or round to $0.&#xa0;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:9pt; text-align:left; text-decoration:none; text-transform:none">See accompanying Notes to
Financial Statements.</div>
</div>
<div style="margin-top:27pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:24.07%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">15
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:17.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">1.&#xa0;&#xa0;Organization</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">abrdn Healthcare
Opportunities Fund (the "Fund") is a Massachusetts business trust formed on April 2, 2014 and registered under the Investment Company Act of 1940, as amended (the "1940 Act"), as a non-diversified closed-end
management investment company. The Fund commenced operations on July 31, 2014. The Fund&#x2019;s investment objective is to seek current income and long-term capital appreciation. The Fund invests primarily in equity
and debt in securities of public and private U.S. and non-U.S. companies in the healthcare industry believed by the Fund&#x2019;s Adviser, abrdn Inc. (the "Adviser" or "Aberdeen")&#xa0;to have significant potential for
above-average growth. The Fund may invest in private companies and other restricted securities, including private investments in public equity and venture capital investments, if these securities would currently
comprise 10% or less of Managed Assets.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">2.&#xa0;&#xa0;Summary of Significant
Accounting Policies</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund is an investment
company and accordingly follows the investment company accounting and reporting guidance of the Financial Accounting Standards Board ("FASB") Accounting Standards Codification Topic 946 Financial Services-Investment
Companies. The following is a summary of significant accounting policies followed by the Fund in the preparation of its financial statements. The policies conform to generally accepted accounting principles in the
United States of America ("U.S.&#xa0;GAAP"). The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of
contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expenses for the period. Actual results could differ from those estimates. The accounting records of
the Fund are maintained in U.S. Dollars and the U.S. Dollar is used as both the functional and reporting currency.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">a.&#xa0;&#xa0;Security Valuation:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund values its
securities at fair value, consistent with regulatory requirements. "Fair value" is defined in the Fund's Valuation and Liquidity Procedures as the price that could be received to sell an asset or paid to transfer a
liability in an orderly transaction between willing market participants without a compulsion to transact at the measurement date, also referred to as market value. Pursuant to Rule 2a-5 under the 1940 Act, the Board
designated Aberdeen as the valuation designee ("Valuation Designee") for the Fund to perform the fair value determinations relating to Fund investments for which market quotations are not readily available or
deemed&#xa0;unreliable and the Fund's investments in securities of early and/or later stage financing of a privately held companies ("Venture Capital Securities").</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">In accordance with the
authoritative guidance on fair value measurements and disclosures under U.S. GAAP, the Fund discloses the fair value of its investments using a three-level hierarchy that</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">classifies the inputs to valuation
techniques used to measure the fair value. The hierarchy assigns Level 1, the highest level, measurements to valuations based upon unadjusted quoted prices in active markets for identical assets, Level 2 measurements
to valuations based upon other significant observable inputs, including adjusted quoted prices in active markets for similar assets, and Level 3, the lowest level, measurements to valuations based upon unobservable
inputs that are significant to the valuation. Inputs refer broadly to the assumptions that market participants would use in pricing the asset or liability, including assumptions about risk, for example, the risk
inherent in a particular valuation technique used to measure fair value including a pricing model and/or the risk inherent in the inputs to the valuation technique. Inputs may be observable or unobservable. Observable
inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability, which are based on market data obtained from sources independent of the reporting entity. Unobservable
inputs are inputs that reflect the reporting entity&#x2019;s own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in
the circumstances. A financial instrument&#x2019;s level within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Open-end mutual funds are
valued at the respective NAV as reported by such company. The prospectuses for the registered open-end management investment companies in which the Fund invests explain the circumstances under which those companies
will use fair value pricing and the effects of using fair value pricing. Closed-end funds and exchange-traded funds ("ETFs") are valued at the market price of the security at the Valuation Time (defined below). A
security using any of these pricing methodologies is generally determined to be a Level 1 investment.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Long-term debt and other
fixed-income securities are valued at the last quoted or evaluated bid price on the valuation date provided by an independent pricing service provider. If there are no current day bids, the security is valued at the
previously applied bid. Pricing services generally price debt securities assuming orderly transactions of an institutional &#x201c;round lot&#x201d; size and the strategies employed by the Valuation Designee generally
trade in round lot sizes. In certain circumstances, some trades may occur in smaller &#x201c;odd lot&#x201d; sizes which may be effected at lower, or higher, prices than institutional round lot trades. Short-term debt
securities (such as commercial paper and U.S. treasury bills) having a remaining maturity of 60 days or less are valued at the last quoted or evaluated bid price on the valuation date provided by an independent
pricing service, or on the basis of amortized cost, if it represents the best approximation of fair value. Debt and other fixed-income securities are generally determined to be Level 2 investments.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:23.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">16
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Equity securities that are traded on an
exchange are valued at the last quoted sale price or the official close price on the principal exchange on which the security is traded at the &#x201c;Valuation Time&#x201d; subject to application, when appropriate, of
the valuation factors described in the paragraph below. Under normal circumstances, the Valuation Time is as of the close of regular trading on the New York Stock Exchange ("NYSE") (usually 4:00 p.m. Eastern Time). In
the absence of a sale price, the security is valued at the mean of the bid/ask price quoted at the close on the principal exchange on which the security is traded. Securities traded on NASDAQ are valued at the NASDAQ
official closing price.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Convertible preferred shares,
warrants or convertible note interests in Venture Capital Securities, milestone interests, and other restricted securities are typically valued in good faith, based upon the recommendations made by&#xa0;the Valuation
Designee pursuant to fair valuation policies and procedures approved by the Board.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Derivative instruments are
valued at fair value. Exchange-traded futures are generally Level 1 investments and centrally cleared swaps and forwards are generally Level 2 investments. Forward foreign currency contracts are generally valued based
on the bid price of the forward rates and the current spot rate. Forward exchange rate quotations are available for scheduled settlement dates, such as 1-, 3-, 6-, 9- and 12-month periods. An interpolated valuation is
derived based on the actual settlement dates of the forward contracts held. Futures contracts are valued at the settlement price or at the last bid price if no settlement price is available. Swap agreements are
generally valued by an approved pricing agent based on the terms of the swap agreement (including future cash flows). When market quotations or exchange rates are not readily available, or if the Adviser concludes
that such market quotations do not accurately reflect fair value, the fair value of the Fund&#x2019;s assets are determined in good faith in accordance with the Valuation Procedures.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Foreign equity securities
that are traded on foreign exchanges that close prior to the Valuation Time are valued by applying valuation factors to the last sale price or the mean price as noted above. Valuation factors are provided by an
independent pricing service provider. These valuation factors are used when pricing the Fund's portfolio holdings to estimate market movements between the time foreign markets close and the time the Fund values such
foreign securities. These valuation factors are based on inputs such as depositary receipts, indices, futures, sector indices/ETFs, exchange rates, and local exchange opening and closing prices of each security. When
prices with the application of valuation factors are utilized, the value assigned to the foreign securities may not be the same as quoted or published prices of the securities on their primary markets. A security that
applies a valuation factor is generally determined to be a Level 2 investment because the exchange-traded price has been adjusted. Valuation factors are not utilized if the independent pricing</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">service provider is unable to provide a
valuation factor or if the valuation factor falls below a predetermined threshold; in such case, the security is determined to be a Level 1 investment.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Short-term investments are
comprised of cash and cash equivalents invested in short-term investment funds which are redeemable daily. The Fund sweeps available cash into the State Street Institutional&#xa0;U.S. Government Money Market Fund,
which has elected to qualify as a &#x201c;government money market fund&#x201d; pursuant to Rule 2a-7 under the 1940 Act, and has an objective, which is not guaranteed, to maintain a&#xa0;$1.00 per share NAV. Generally,
these investment types are&#xa0;categorized as Level 1 investments.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">In the event that a
security&#x2019;s, other than a Venture Capital Security, market quotations are not readily available or are deemed unreliable (for reasons other than because the foreign exchange on which it trades closes before the
Valuation Time), the security is valued at fair value as determined by the Valuation Designee, taking into account the relevant factors and surrounding circumstances using valuation policies and procedures approved by
the Board. A security that has been fair valued by the Valuation Designee&#xa0;may be classified as Level 2 or Level 3 depending on the nature of the inputs.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Venture Capital Securities
are valued based on a consideration of relevant factors, including both observable and&#xa0;unobservable inputs. Observable and unobservable inputs considered may include (i) the existence of any contractual
restrictions on the disposition of securities; (ii) information obtained from the company, which may include an analysis of the company's financial statements, products, intended markets or technologies; (iii) the
price of the same or similar security negotiated at arm's length in an issuer's completed subsequent round of financing; (iv) the price and extent of public trading in similar securities of the issuer or of comparable
companies; or (v) a probability and time value adjusted analysis of contractual terms. Where available and appropriate, multiple valuation methodologies are applied to confirm fair value.&#xa0;Significant unobservable
inputs are often used in the fair value determination. A significant change in any of these inputs may result in a significant change in the fair value measurement. Additionally, changes in the market environment and
other events that may occur over the life of the investments may cause the gains or losses ultimately realized on these investments to be different from the valuations used at the date of these
financial&#xa0;statements.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">The three-level hierarchy of
inputs is summarized below:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Level 1 - quoted prices
(unadjusted) in active markets for identical investments;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Level 2 - other significant observable
inputs (including valuation factors, quoted prices for similar securities, interest rates, prepayment speeds, and credit risk, etc.); or</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:21.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:24.07%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">17
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">Level 3 - significant unobservable inputs
(including the Fund&#x2019;s own assumptions in determining the fair value of investments).</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Level 3 investments are
valued using significant unobservable inputs. The derived value of a Level 3 investment may not represent the value</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">which is received upon disposition and this
could impact the results of operations.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:8.5pt; width:100%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The following is a
summary of the inputs used as of September 30, 2025 in valuing the Fund's investments and other financial instruments at fair value. The inputs or methodology used for valuing securities are not necessarily an
indication of the risk associated with investing in those securities. Please refer to the Portfolio of Investments for a detailed breakout of the security types:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.89%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:35.11%">Investments, at Value
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.01%">Level 1 &#x2013; Quoted<br>
Prices
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:20.87%">Level 2 &#x2013; Other Significant<br>
Observable Inputs
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.03%">Level 3 &#x2013; Significant<br>
Unobservable Inputs
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.99%">Total
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:69.98%; background-color: #F0F0F0;" colspan="3">Assets
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:2.75pt; text-align:right; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:2.75pt; text-align:right; vertical-align:bottom; width:12.99%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:49.12%; background-color: #F0F0F0;" colspan="2">Investments in Securities
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:20.87%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:12.99%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:35.11%; background-color: #F0F0F0;">Common Stocks
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.01%; background-color: #F0F0F0;">$<font style="padding-left:5.89pt"></font>776,143,144
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:20.87%; background-color: #F0F0F0;">$<font style="padding-left:45.96pt"></font>&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">$<font style="padding-left:25.82pt"></font>9,881
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.99%; background-color: #F0F0F0;">$<font style="padding-left:6.82pt"></font>776,153,025
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:35.11%; background-color: #F0F0F0;">Non-Convertible Notes
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:57.21pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.01%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:13.95pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:20.87%; background-color: #F0F0F0;">155,959,825
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:53.88pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.03%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:16.09pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.99%; background-color: #F0F0F0;">155,959,825
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:35.11%; background-color: #F0F0F0;">Convertible Preferred Stocks
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:57.21pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.01%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:56.92pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:20.87%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:13.81pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.03%; background-color: #F0F0F0;">28,083,554
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:18.99pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.99%; background-color: #F0F0F0;">28,083,554
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:35.11%; background-color: #F0F0F0;">Short-Term Investment
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:25.63pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.01%; background-color: #F0F0F0;">5,487,182
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:56.92pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:20.87%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:53.88pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.03%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:27.48pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.99%; background-color: #F0F0F0;">5,487,182
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:35.11%; background-color: #F0F0F0;">Total Investments
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.01%; background-color: #F0F0F0;">$781,630,326
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:20.87%; background-color: #F0F0F0;">$155,959,825
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.03%; background-color: #F0F0F0;">$28,093,435
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.99%; background-color: #F0F0F0;">$965,683,586
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:35.11%; background-color: #F0F0F0;">Total Investment Assets
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.01%; background-color: #F0F0F0;">$781,630,326
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:20.87%; background-color: #F0F0F0;">$155,959,825
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.03%; background-color: #F0F0F0;">$28,093,435
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.99%; background-color: #F0F0F0;">$965,683,586
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:69.98%; background-color: #F0F0F0;" colspan="3">Liabilities
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:2.38pt; text-align:right; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:2.38pt; text-align:right; vertical-align:bottom; width:12.99%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:49.12%; background-color: #F0F0F0;" colspan="2">Other Financial Instruments
</td><td style="line-height:9.5pt; padding-right:6pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:20.87%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-right:6pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-right:6pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:12.99%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:35.11%; background-color: #F0F0F0;">Written Options
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.01%; background-color: #F0F0F0;">$<font style="padding-left:16.60pt"></font>(376,359)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:20.87%; background-color: #F0F0F0;">$<font style="padding-left:45.96pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">$<font style="padding-left:42.91pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.99%; background-color: #F0F0F0;">$<font style="padding-left:18.45pt"></font>(376,359)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:35.11%; background-color: #F0F0F0;">Total Investment Liabilities
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.01%; background-color: #F0F0F0;">$<font style="padding-left:14.09pt"></font>(376,359)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:20.87%; background-color: #F0F0F0;">$<font style="padding-left:45.75pt"></font>&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">$<font style="padding-left:42.70pt"></font>&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.99%; background-color: #F0F0F0;">$<font style="padding-left:15.94pt"></font>(376,359)
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.26%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:3pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:100.00%" colspan="7">Rollforward of Level 3 Fair Value Measurements<br>
For the Year Ended September 30, 2025
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:32.22%">Investments<br>
in Securities
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%">Balance<br>
as of<br>
September 30,<br>
2024
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.23%">Net Realized<br>
Gain (Loss)<br>
and Change<br>
in Unrealized<br>
Appreciation/<br>
Depreciation
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.75%">Net<br>
Purchases<br>
and<br>
conversions
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.91%">Net<br>
Sales<br>
and<br>
conversions
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%">Balance<br>
as of<br>
September 30,<br>
2025
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%">Net Change in<br>
Unrealized<br>
Appreciation/<br>
Depreciation<br>
from<br>
Investments<br>
Held at<br>
September 30,<br>
2025
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:32.22%; background-color: #F0F0F0;">Common Stocks
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:3.5pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:3.5pt; text-align:right; vertical-align:bottom; width:11.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:3.5pt; text-align:right; vertical-align:bottom; width:10.75%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:3.5pt; text-align:right; vertical-align:bottom; width:9.91%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:3.5pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:3.5pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:32.22%; background-color: #F0F0F0;">Pharmaceuticals
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:26.46pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">$9,881
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:42.49pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.23%; background-color: #F0F0F0;">$&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:44.36pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.75%; background-color: #F0F0F0;">$&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.91%; background-color: #F0F0F0;">$&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:30.38pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">$9,881
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:42.49pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">$&#x2013;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:32.22%; background-color: #F0F0F0;">Convertible Preferred Stocks
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:10.75%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:9.91%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:32.22%; background-color: #F0F0F0;">Biotechnology
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:11.18pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">10,559,974
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:23.74pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">(15,759)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:14.08pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.75%; background-color: #F0F0F0;">8,882,399
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:8.97pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:14.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">19,426,614
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:23.74pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">(15,759)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:32.22%; background-color: #F0F0F0;">Health Care Equipment &amp; Supplies
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:43.89pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">19
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:47.45pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:49.33pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.75%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:8.97pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:47.80pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">19
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:47.45pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">&#x2013;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:32.22%; background-color: #F0F0F0;">Pharmaceuticals
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:15.60pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">7,486,278
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:10.17pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">(1,343,838)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:15.33pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.75%; background-color: #F0F0F0;">2,514,480
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:8.97pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:17.41pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">8,656,920
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:10.17pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">(1,343,838)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:32.22%; background-color: #F0F0F0;">Total
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">$18,056,152
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.23%; background-color: #F0F0F0;">$(1,359,597)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.75%; background-color: #F0F0F0;">$11,396,879
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:4.59pt; padding-right:4pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.91%; background-color: #F0F0F0;">$-
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">$28,093,434
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">$(1,359,597)
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
</div>
</div>
<div style="padding-top:136pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">18
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:10.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.63%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:5pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.53%">Description
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.29%">Fair Value at<br>
September 30, 2025
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:18.44%">Valuation Technique (s)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.54%">Unobservable Inputs
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.03%">Range
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.03%">Weighted<br>
Average
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:4pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%">Relationship<br>
Between<br>
Fair Value<br>
and Input;<br>
if Input value<br>
increases then<br>
Fair Value:
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:4pt; padding-right:5pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.53%; background-color: #F0F0F0;">Common Stocks
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:16.29%; background-color: #F0F0F0;">$9,881
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.44%; background-color: #F0F0F0;">Income approach
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:16.54%; background-color: #F0F0F0;">Probability of events<br>
Timing of events
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:9.03%; background-color: #F0F0F0;">46.00%<br>
3.92 years
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:9.03%; background-color: #F0F0F0;">46.00%<br>
3.92 years
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:4pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:11.96%; background-color: #F0F0F0;">Increases<br>
Decreases
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:14pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:top; width:18.53%; background-color: #F0F0F0;">Convertible Preferred Stocks
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:16.29%; background-color: #F0F0F0;">$28,083,553
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.44%; background-color: #F0F0F0;">Market approach
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:16.54%; background-color: #F0F0F0;">Transaction Price<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:9.03%; background-color: #F0F0F0;">N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:9.03%; background-color: #F0F0F0;">N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">Increases
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:4pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:18.53%; background-color: #F0F0F0;">Total
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:16.29%; background-color: #F0F0F0;">$28,093,434
</td><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; vertical-align:top; width:18.44%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; vertical-align:top; width:16.54%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:9.03%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:9.03%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
<div style="text-align:center">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-right:auto; margin-top:11pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.47%">(a)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.09%">The valuation technique used as a basis to approximate fair value of these investments is based on a transaction price or&#xa0;subsequent financing rounds.
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">b.&#xa0;&#xa0;Restricted
Securities:</div>
</div>
<div style="margin-top:8.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Restricted securities are privately-placed
securities whose resale is restricted under U.S. securities laws. The Fund may invest in restricted securities, including unregistered securities eligible for resale without registration pursuant to Rule 144A and
privately-placed securities of U.S. and non-U.S. issuers offered outside the U.S. without registration pursuant to Regulation S under the Securities Act of 1933, as amended (the "1933 Act"). Rule 144A securities may
be freely traded among certain qualified institutional investors, such as the Fund, but resale of such securities in the U.S. is permitted only in limited circumstances.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">c.&#xa0;&#xa0;Foreign Currency
Translation:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Foreign securities,
currencies, and other assets and liabilities denominated in foreign currencies are translated into U.S. Dollars at the exchange rate of said currencies against the U.S. Dollar, as of the Valuation Time, as provided by
an independent pricing service approved by the Board.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Foreign currency amounts are
translated into U.S. Dollars on the following basis:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">(i) fair value of investment
securities, other assets and liabilities &#x2013; at the current daily rates of exchange at the Valuation Time; and</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">(ii) purchases and sales of
investment securities, income and expenses &#x2013; at the relevant rates of exchange prevailing on the respective dates of such transactions.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Fund does not isolate
that portion of gains and losses on investments in equity securities due to changes in the foreign exchange rates from the portion due to changes in market prices of equity securities. Accordingly, realized and
unrealized foreign currency gains and losses with respect to such securities are included in the reported net realized and unrealized gains and losses on investment transactions balances.</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Net unrealized currency gains or losses from
valuing foreign currency denominated assets and liabilities at period end exchange rates are reflected as a component of net unrealized appreciation/depreciation in value of investments, and translation of other
assets and liabilities denominated in foreign currencies.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Net realized foreign exchange
gains or losses represent foreign exchange gains and losses from transactions in foreign currencies and forward foreign currency contracts, exchange gains or losses realized between the trade date and settlement date
on security transactions, and the difference between the amounts of interest and dividends recorded on the Fund&#x2019;s books and the U.S. Dollar equivalent of the amounts actually received.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Foreign security and currency
transactions may involve certain considerations and risks not typically associated with those of domestic origin, including unanticipated movements in the value of the foreign currency relative to the U.S. Dollar.
Generally, when the U.S. Dollar rises in value against foreign currency, the Fund's investments denominated in that foreign currency will lose value because the foreign currency is worth fewer U.S. Dollars; the
opposite effect occurs if the U.S. Dollar falls in relative value.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">d.&#xa0;&#xa0;Rights Issues and
Warrants:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Rights issues give the
right, normally to existing shareholders, to buy a proportional number of additional securities at a given price (generally at a discount) within a fixed period (generally a short-term period) and are offered at the
company&#x2019;s discretion. Warrants are securities that give the holder the right to buy common stock at a specified price for a specified period of time. Rights issues and warrants are speculative and have no value
if they are not exercised before the expiration date. Rights issues and warrants are valued at the last sale price on the exchange on which they are traded.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:35.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:24.07%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">19
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">Options</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">An option contract is a
contract in which the writer (seller) of the option grants the buyer of the option, upon payment of a premium, the right to purchase from (call option) or sell to (put option) the writer a designated instrument at a
specified price within a specified period of time. Certain options, including options on indices, will require cash settlement by the Fund if the option is exercised.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Fund&#x2019;s obligation
under an exchange traded written option or investment in an exchange traded purchased option is valued at the last sale price, or in the absence of a sale, the mean between the closing bid and asked prices. Gain or
loss is recognized when the option contract expires, is exercised or is closed.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">If the Fund writes a covered
call option, the Fund foregoes, in exchange for the premium, the opportunity to profit during the option period from an increase in the market value of the underlying security above the exercise price. If the Fund
writes a put option it accepts the risk of a decline in the market value of the underlying security below the exercise price. Over-the-counter options have the risk of the potential</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">inability of counterparties to meet the
terms of their contracts. The Fund&#x2019;s maximum exposure to purchased options is limited to the premium initially paid. In addition, certain risks may arise upon entering into option contracts including the risk
that an illiquid secondary market will limit the Fund&#x2019;s ability to close out an option contract prior to the expiration date and that a change in the value of the option contract may not correlate exactly with
changes in the value of the securities or currencies hedged.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">All options on securities and
securities indices written by the Fund are required to be covered. When the Fund writes a call option, this means that during the life of the option the Fund may own or have the contractual right to acquire the
securities subject to the option or may maintain with the Fund&#x2019;s custodian in a segregated account appropriate liquid securities in an amount at least equal to the market value of the securities underlying the
option. When the Fund writes a put option, this means that the Fund will maintain with the Fund&#x2019;s custodian in a segregated account appropriate liquid securities in an amount at least equal to the exercise price
of the option.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:8.5pt; width:100%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">Summary of Derivative
Instruments:</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:left; text-decoration:none; text-transform:none">The&#xa0;Fund may
use derivatives for various purposes as noted above. The following is a summary of the fair value of derivative instruments, not accounted for as hedging instruments, as of September 30, 2025:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.89%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="line-height:9pt; padding-bottom:3pt; padding-right:6pt; padding-top:3pt; text-align:left; vertical-align:bottom; width:36.10%">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:63.91%" colspan="7">Risk Exposure Category
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:6pt; padding-top:2.62pt; text-align:left; vertical-align:bottom; width:36.10%">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%">Interest<br>
Rate<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%">Foreign<br>
Currency<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%">Credit<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.38%">Equity<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.75%">Commodity<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.55%">Other
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.38%">Total
</td></tr>
<tr style="page-break-inside:avoid"><td style="padding-right:6pt; padding-top:2.75pt; text-align:left; vertical-align:top; width:100.00%; background-color: #F0F0F0;" colspan="8">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:100.00%; background-color: #F0F0F0;" colspan="8">Liabilities:
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:100.00%; background-color: #F0F0F0;" colspan="8">Unrealized depreciation on:
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:36.10%; background-color: #F0F0F0;">Written Options, fair value
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.38%; background-color: #F0F0F0;">$<font style="padding-left:2.18pt"></font>376,359
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.75%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:6.55%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.38%; background-color: #F0F0F0;">$<font style="padding-left:2.18pt"></font>376,359
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:36.10%; background-color: #F0F0F0;">Total
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.38%; background-color: #F0F0F0;">$376,359
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.75%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.55%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.38%; background-color: #F0F0F0;">$376,359
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:16pt; text-align:left; text-decoration:none; text-transform:none">Amounts listed as
 &#x201c;&#x2013;&#x201d; are $0 or round to $0.</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">The effect of
derivative instruments on the Statement of Operations for the fiscal year ended September 30, 2025:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.89%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="line-height:9pt; padding-bottom:3pt; padding-right:6pt; padding-top:3pt; text-align:left; vertical-align:bottom; width:40.84%">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:59.17%" colspan="6">Risk Exposure Category
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:6pt; padding-top:2.62pt; text-align:left; vertical-align:bottom; width:40.84%">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%">Interest<br>
Rate<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%">Foreign<br>
Currency<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%">Credit<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.29%">Equity<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.75%">Commodity<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.29%">Total
</td></tr>
<tr style="page-break-inside:avoid"><td style="padding-right:6pt; padding-top:2.75pt; text-align:left; vertical-align:top; width:100.00%; background-color: #F0F0F0;" colspan="7">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:16pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:top; width:100.00%; background-color: #F0F0F0;" colspan="7">Realized Gain/(Loss) on Derivatives Recognized<br>
as a Result of Operations:
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:40.84%; background-color: #F0F0F0;">Written Options
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.29%; background-color: #F0F0F0;">$<font style="padding-left:2.70pt"></font>2,787,871
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.75%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.29%; background-color: #F0F0F0;">$<font style="padding-left:2.70pt"></font>2,787,871
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:40.84%; background-color: #F0F0F0;">Total
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.29%; background-color: #F0F0F0;">$2,787,871
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.75%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.29%; background-color: #F0F0F0;">$2,787,871
</td></tr></table>
</div>
</div>
</div>
<div style="padding-top:77.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">20
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:19.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.89%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="line-height:9pt; padding-bottom:3pt; padding-right:6pt; padding-top:3pt; text-align:left; vertical-align:bottom; width:40.84%">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:59.17%" colspan="6">Risk Exposure Category
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:6pt; padding-top:2.62pt; text-align:left; vertical-align:bottom; width:40.84%">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%">Interest<br>
Rate<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%">Foreign<br>
Currency<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%">Credit<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.29%">Equity<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.75%">Commodity<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.29%">Total
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:16pt; padding-right:6pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:top; width:100.00%; background-color: #F0F0F0;" colspan="7">Net Change in Unrealized Appreciation/Depreciation on<br>
Derivatives Recognized as a Result of Operations:
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:40.84%; background-color: #F0F0F0;">Written Options
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.29%; background-color: #F0F0F0;">$<font style="padding-left:4.37pt"></font>(216,320)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.75%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.29%; background-color: #F0F0F0;">$<font style="padding-left:4.37pt"></font>(216,320)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:40.84%; background-color: #F0F0F0;">Total
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.29%; background-color: #F0F0F0;">$<font style="padding-left:1.90pt"></font>(216,320)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.75%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.29%; background-color: #F0F0F0;">$<font style="padding-left:1.90pt"></font>(216,320)
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:16pt; text-align:left; text-decoration:none; text-transform:none">Amounts listed as
 &#x201c;&#x2013;&#x201d; are $0 or round to $0.</div>
</div>
<div style="margin-top:8.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Information about derivatives reflected as
of the date of this report is generally indicative of the type of activity for the fiscal year ended September 30, 2025. The table below summarizes the weighted average values of derivatives holdings for the Fund
during the fiscal year ended September 30, 2025.</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100.00%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:68.10%">Derivative
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:29.60%">Average Monthly<br>
Notional Value
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:68.10%; background-color: #F0F0F0;">Written Options Contracts
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:29.60%; background-color: #F0F0F0;">$339,546
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">e.&#xa0;&#xa0;Security Transactions,
Investment Income and Expenses:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Security transactions are
recorded on the trade date. Realized and unrealized gains/(losses) from security and currency transactions are calculated on the identified cost basis. Dividend income and corporate actions are recorded generally on
the ex-date, except for certain dividends and corporate actions which may be recorded after the ex-date, as soon as the Fund acquires information regarding such dividends or corporate actions. Interest income and
expenses are recorded on an accrual basis.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The calendar year-end amounts
of ordinary income, capital gains and return of capital included in distributions received from the Fund's investments in real estate investment trusts (&#x201c;REITs&#x201d;) are reported to the Fund after the end of
the fiscal year; accordingly, the Fund estimates these amounts for accounting purposes until the characterization of REIT distributions is reported to the Fund after the end of the fiscal year. Estimates are based on
the most recent REIT distribution information available.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">f.&#xa0;&#xa0;Distributions:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund has a stable
distribution policy to pay distributions from net investment income supplemented by net realized capital gains and return of capital distributions, if necessary, on a monthly basis. The stable distribution policy is
subject to regular review by the Board. The Fund will also declare and pay distributions at least annually from net realized gains on investment transactions. Dividends and distributions to shareholders are recorded
on the ex-dividend date. Dividends and distributions to shareholders are determined in accordance with federal income tax regulations, which may differ from U.S.&#xa0;GAAP.</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">g.&#xa0;&#xa0;Federal Income Taxes:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund intends to
continue to qualify as a &#x201c;regulated investment company&#x201d; ("RIC") by complying with the provisions available to certain investment companies, as defined in Subchapter M of the Internal Revenue Code of 1986,
as amended (the "Code"), and to make distributions of net investment income and net realized capital gains sufficient to relieve the Fund from all federal income taxes. Therefore, no federal income tax provision is
required.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Fund recognizes the tax
benefits of uncertain tax positions only where the position is &#x201c;more likely than not&#x201d; to be sustained assuming examination by tax authorities. Management of the Fund has concluded that there are no
significant uncertain tax positions that would require recognition in the financial statements. Since tax authorities can examine previously filed tax returns, the Fund's U.S. federal and state tax returns for each of
the most recent four fiscal years up to the most recent fiscal year ended September 30, 2025 are subject to such review.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">h.&#xa0;&#xa0;Milestone Interests</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund holds financial
instruments which reflect the current value of future milestone payments the Fund may receive as a result of contractual obligations from other parties. The value of such payments are adjusted to reflect the estimated
risk based on the relative uncertainty of both the timing and the achievement of individual milestones. A risk to the Fund is that the milestones will not be achieved and no payment will be received by the Fund. The
milestone interests were received as part of the proceeds from the sale of one private company. Any payments received are treated as a reduction of the cost basis of the milestone interests with payments received in
excess of the cost basis treated as a realized gain.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:32.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:24.07%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">21
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">The following is a summary of the impact of
the milestone interests on the financial statements as of and for the fiscal year ended September 30, 2025:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100.00%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:16pt; padding-right:6pt; padding-top:3pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:top; width:88.29%; background-color: #F0F0F0;">Statement of Assets and Liabilities, Milestone interests, at value
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.41%; background-color: #F0F0F0;">$&#x2014;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:16pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:top; width:88.29%; background-color: #F0F0F0;">Statement of Assets and Liabilities, Total distributable earnings
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.41%; background-color: #F0F0F0;">$&#x2014;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:16pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:top; width:88.29%; background-color: #F0F0F0;">Statement of Operations, Change in unrealized appreciation/depreciation
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.41%; background-color: #F0F0F0;">$<font style="padding-left:2.36pt"></font>0
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:16pt; text-align:left; text-decoration:none; text-transform:none">Amounts listed as
 &#x201c;&#x2013;&#x201d; are $0 or round to $0.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">3.&#xa0;&#xa0;Agreements and Transactions
with Affiliates</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">a.&#xa0;&#xa0;Investment Advisory and
Other Affiliated Fees</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Aberdeen serves as the
Fund&#x2019;s Adviser pursuant to an investment advisory agreement (the &#x201c;Advisory Agreement&#x201d;) with the Fund. Aberdeen also provides administration services under the same agreement. The Adviser is a
wholly-owned indirect subsidiary of Aberdeen Group plc. In rendering management services, the Adviser may use the resources of investment adviser subsidiaries of Aberdeen Group plc. These affiliates have entered into
procedures pursuant to which investment professionals from affiliates may render portfolio management and research services as associated persons of the Adviser.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">As compensation for its
services to the Fund, the Adviser receives an annual investment advisory fee at an annual rate of 1.00% of the average daily value of the Fund&#x2019;s Managed Assets. Managed Assets means the total assets of the Fund
minus the Fund&#x2019;s liabilities other than the loan payable. For the fiscal year ended September 30, 2025, the Fund paid the Adviser $10,310,161.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Effective upon the close of
business on October 27, 2023, the Adviser entered into a written contract with the Fund to limit the total ordinary operating expenses of the Fund (excluding leverage costs, interest, taxes, brokerage commissions,
acquired fund fees and expenses and any non-routine expenses) from exceeding 1.44% of the average daily net assets of the Fund on an annualized basis for two years (the &#x201c;Expense Limitation Agreement"). The
Expense Limitation Agreement terminated on October 27, 2025. For the fiscal year ended September 30, 2025, the Adviser did not waive any of the Fund's expenses pursuant to the Expense Limitation Agreement.</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">b.&#xa0;&#xa0;Investor Relations:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Effective March 1, 2024,
under the terms of the Investor Relations Services Agreement, Aberdeen is compensated to provide and may pay third parties to provide investor relations services to the Fund and certain other funds advised by Aberdeen
or its affiliates as part of an Investor Relations Program. Under the Investor Relations Services Agreement, the Fund owes a portion of the fees related to the Investor Relations Program (the "Fund's Portion").&#xa0;
However, investor relations services fees are limited by Aberdeen so that the Fund will only pay up to an annual rate of 0.05% of the Fund's average weekly net assets. Any difference between the capped rate of 0.05%
of the Fund's average weekly net assets and the Fund's Portion is paid for by Aberdeen.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Pursuant to the terms of the
Investor Relations Services Agreement, Aberdeen (or third parties engaged by Aberdeen), among other things, provides objective and timely information to shareholders based on publicly-available information; provides
information efficiently through the use of technology while offering shareholders immediate access to knowledgeable investor relations representatives; develops and maintains effective communications with investment
professionals from a wide variety of firms; creates and maintains investor relations communication materials such as fund manager interviews, films and webcasts, publishes white papers, magazine articles and other
relevant materials discussing the Fund's investment results, portfolio positioning and outlook; develops and maintains effective communications with large institutional shareholders; responds to specific shareholder
questions; and reports activities and results to the Board and management detailing insight into general shareholder sentiment.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">During the fiscal year ended
September 30, 2025, the Fund incurred investor relations fees of approximately $158,821. For the fiscal year ended September 30, 2025, Aberdeen did not contribute to the investor relations fees for the Fund because
the Fund&#x2019;s contribution was below 0.05% of the Fund&#x2019;s average weekly net assets on an annual basis.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">4.&#xa0;&#xa0;Investment Transactions</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Purchases and sales of
investment securities (excluding short-term securities) for the fiscal year&#xa0;ended September 30, 2025, were $437,805,171 and $471,391,066, respectively.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:9.5pt; width:100%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">5.&#xa0;&#xa0;Capital</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:left; text-decoration:none; text-transform:none">The Fund is
authorized to issue an unlimited number of common shares of beneficial interest at par value $0.01 per common share. As of September 30, 2025, there were 41,407,879 shares of common stock issued and outstanding.</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">6.&#xa0;&#xa0;Open Market
Repurchase Program</div>
</div>
</div>
<div style="padding-top:7pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">The Board has approved an open market
repurchase and discount management policy (the &#x201c;Program&#x201d;). The Program allows the Fund to</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">purchase, in the open market, up to 12% of
its outstanding common shares in the fiscal year, with the amount and timing of any repurchase</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:21.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">22
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">determined at the discretion of the Fund's
investment adviser. Such purchases may be made opportunistically at certain discounts to NAV per share in the reasonable judgment of management based on historical discount levels and current market conditions. If
shares are repurchased, the Fund reports repurchase activity on its website on a</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">monthly basis. For the fiscal year ended
September 30, 2025, the Fund did not repurchase any shares through the Program.&#xa0;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">On a quarterly basis, the Board
will receive information on any transactions made pursuant to this policy during the prior quarter.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:9.5pt; width:100%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">7.&#xa0;&#xa0;Private
Companies and Other Restricted Securities</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:left; text-decoration:none; text-transform:none">The Fund may invest
in private companies and other restricted securities if these securities would currently comprise 10% or less of Managed Assets. The value of these securities represented 2.91% of the Fund&#x2019;s Managed Assets at
September 30, 2025.</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">At September 30,
2025, the Fund had $6,925,193 in commitments relating to additional investments in private companies.</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">The following table
details the acquisition date, cost, carrying value per unit, and value of the Fund&#x2019;s private companies and other restricted securities at September 30, 2025. The Fund on its own does not have the right to demand
that such securities be registered.</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:4.5pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:50.42%">Security
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.54%">Acquisition<br>
Date
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.75%">Cost
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.08%">Carrying Value<br>
per Unit
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4.5pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.37%">Value
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:50.42%; background-color: #F0F0F0;">Abcuro, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.54%; background-color: #F0F0F0;">8/10/23, 12/19/23
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:9.05pt; padding-right:4.5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.75%; background-color: #F0F0F0;">$3,305,963
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.08%; background-color: #F0F0F0;">$5.49
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:12.39pt; padding-right:6pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.37%; background-color: #F0F0F0;">$3,299,990
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:50.42%; background-color: #F0F0F0;">Abcuro, Inc., Series C1 &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.54%; background-color: #F0F0F0;">2/7/25
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:20.72pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.75%; background-color: #F0F0F0;">804,220
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:8.97pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">6.04
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:24.95pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.37%; background-color: #F0F0F0;">803,419
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:50.42%; background-color: #F0F0F0;">Atalanta Therapeutics, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.54%; background-color: #F0F0F0;">10/11/25
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.30pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.75%; background-color: #F0F0F0;">3,501,659
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:10.14pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">1.80
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.18pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.37%; background-color: #F0F0F0;">3,499,999
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:50.42%; background-color: #F0F0F0;">Crystalys Therapeutics, Inc., Series A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.54%; background-color: #F0F0F0;">6/23/25
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:16.50pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.75%; background-color: #F0F0F0;">2,513,379
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:10.11pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">1.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:19.84pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.37%; background-color: #F0F0F0;">2,512,799
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:50.42%; background-color: #F0F0F0;">Endeavor Biomedicines, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.54%; background-color: #F0F0F0;">1/21/22
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.39pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.75%; background-color: #F0F0F0;">3,507,496
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:10.17pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">4.72
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.93pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.37%; background-color: #F0F0F0;">3,499,997
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:50.42%; background-color: #F0F0F0;">Endeavor Biomedicines, Inc., Series C &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.54%; background-color: #F0F0F0;">4/19/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:21.66pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.75%; background-color: #F0F0F0;">894,707
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:9.82pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">6.52
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:26.35pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.37%; background-color: #F0F0F0;">894,125
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:50.42%; background-color: #F0F0F0;">Engrail Therapeutics, Inc. &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.54%; background-color: #F0F0F0;">3/14/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:19.98pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.75%; background-color: #F0F0F0;">1,751,101
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:10.28pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">1.06
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:18.33pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.37%; background-color: #F0F0F0;">1,750,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:50.42%; background-color: #F0F0F0;">Glycomine, Inc., Series C &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.54%; background-color: #F0F0F0;">7/22/24, 3/26/25
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.31pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.75%; background-color: #F0F0F0;">4,128,090
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:8.93pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.60
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:19.97pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.37%; background-color: #F0F0F0;">4,123,222
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:50.42%; background-color: #F0F0F0;">IO Light Holdings, Inc., Series A2 &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.54%; background-color: #F0F0F0;">4/30/20, 5/17/21,<br>
9/15/21
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:22.02pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.75%; background-color: #F0F0F0;">628,537
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:8.76pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:47.64pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.37%; background-color: #F0F0F0;">19
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:50.42%; background-color: #F0F0F0;">Seismic Therapeutics, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.54%; background-color: #F0F0F0;">8/30/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:16.94pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.75%; background-color: #F0F0F0;">3,307,188
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:9.69pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">4.52
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.22pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.37%; background-color: #F0F0F0;">3,299,984
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:50.42%; background-color: #F0F0F0;">Third Arc Bio, Inc., Series A &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.54%; background-color: #F0F0F0;">7/15/24, 4/24/25
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.81pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.75%; background-color: #F0F0F0;">4,407,836
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:11.55pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">2.10
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.84pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.37%; background-color: #F0F0F0;">4,400,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:50.42%; background-color: #F0F0F0;">Total
</td><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; vertical-align:bottom; width:14.54%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.75%; background-color: #F0F0F0;">$28,750,176
</td><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; vertical-align:bottom; width:12.08%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:4.5pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.37%; background-color: #F0F0F0;">$28,083,554
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">8.&#xa0;&#xa0;Revolving Credit
Facility</div>
</div>
</div>
<div style="padding-top:7pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund maintains a Revolving Credit
Facility with the Bank of Nova Scotia, which was amended on January 24, 2025 to extend the scheduled commitment termination date to January 23, 2026 with a committed facility amount of $225,000,000 ("Revolving Credit
Facility&#x201d;).</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">As of September 30, 2025, the
Fund had drawn down $225,000,000 from the Revolving Credit Facility, which was the maximum borrowing outstanding during the period. The Fund is charged interest at the rate of 0.95% plus a SOFR Adjustment plus the
relevant SOFR rate. The Fund is also charged a commitment fee on the daily unused balance of the Revolving Credit Facility at the rate of 0.10% (per annum). Per the Revolving Credit Facility agreement, the Fund paid
an upfront fee of 0.05% on the total Revolving Credit Facility balance, which is being amortized through January 23, 2026. The Fund pledges its investment securities as the collateral for the Revolving Credit Facility
per the terms of the agreement. The weighted average interest rate and the average outstanding loan payable for the period from October 1, 2024 to September 30, 2025 were 5.66% and $225,000,000, respectively. The
stated carrying amount of the Revolving Credit Facility</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">approximates its fair value based upon the
short term nature of the borrowings and the interest rates being based upon the market terms.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Fund&#x2019;s leveraged
capital structure creates special risks not associated with unleveraged funds having similar investment objectives and policies. The funds borrowed pursuant to the Revolving Credit Facility may constitute a
substantial lien and burden by reason of their prior claim against the income of the Fund and against the net assets of the Fund in liquidation. The Fund is not permitted to declare dividends or other distributions in
the event of default under the Revolving Credit Facility. In the event of a default under the Revolving Credit Facility, the lenders have the right to cause a liquidation of the collateral (i.e., sell portfolio
securities and other assets of the Fund) and, if any such default is not cured, the lenders may be able to control the liquidation as well. A liquidation of the Fund&#x2019;s collateral assets in an event of default,
or a voluntary paydown of the Revolving Credit Facility in order to avoid an event of default, would typically involve administrative expenses and sometimes penalties. Additionally, such liquidations often involve
selling off of portions of the Fund&#x2019;s assets at inopportune times which can result in losses when markets are unfavorable. The Revolving Credit Facility has a term of three years and</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:17.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:24.07%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">23
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">is not a perpetual form of leverage; there
can be no assurance that the Revolving Credit Facility will be available for renewal on acceptable terms, if at all. Bank loan fees and expenses included in the Statement of Operations include fees for the Revolving
Credit Facility as well as commitment fees for any portion of the Revolving Credit Facility not drawn upon at any time during the period. During the fiscal year ended September 30, 2025, the Fund incurred interest
expense of approximately $12,911,578.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The credit agreement
governing the Revolving Credit Facility includes usual and customary covenants for this type of transaction. These covenants impose on the Fund asset coverage requirements, Fund composition requirements and limits on
certain investments, such as illiquid investments, which are more stringent than those imposed on the Fund by the 1940 Act. The covenants or guidelines could impede the Investment Manager from fully managing the
Fund&#x2019;s portfolio in accordance with the Fund&#x2019;s investment objective and policies. Furthermore, non-compliance with such covenants or the occurrence of other events could lead to the cancellation of the
Revolving Credit Facility.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">9.&#xa0;&#xa0;Portfolio Investment
Risks</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">a.&#xa0;&#xa0;Concentration Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund&#x2019;s portfolio
may be more sensitive to, and possibly more adversely affected by, regulatory, economic or political factors or trends relating to the healthcare industries than a portfolio of companies representing a larger number
of industries. This risk is in addition to the risks normally associated with any strategy seeking capital appreciation by investing in a portfolio of equity securities. As a result of its concentration policy, the
Fund&#x2019;s investments may be subject to greater risk than a fund that has securities representing a broader range of investments and may cause the value of the Fund&#x2019;s shares to fluctuate significantly over
relatively short periods of time.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">b.&#xa0;&#xa0;Convertible Securities
Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Convertible securities
generally offer lower interest or dividend yields than nonconvertible debt securities of similar quality. The market value of convertible securities tends to decline as interest rates increase and, conversely, tends
to increase as interest rates decline. In addition, because of the conversion feature, the market value of convertible securities tends to vary with fluctuations in the market value of the underlying common stock.
Consequently, a unique feature of convertible securities is that as the market price of the underlying common stock declines, convertible securities tend to trade increasingly on a yield basis, and so may not
experience market value declines to the same extent as the underlying common stock. Investments in convertible securities generally entail less risk than investments in common stock of the same issuer but more risk
than the issuer&#x2019;s debt obligations.</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">c.&#xa0;&#xa0;Derivatives Risk (including Options,
Futures and Swaps):</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Derivatives are speculative
and may hurt the Fund&#x2019;s performance. The&#xa0;potential benefits to be derived from the Fund&#x2019;s options, futures and&#xa0;derivatives strategy are dependent upon the portfolio managers&#x2019;&#xa0;ability
to discern pricing inefficiencies and predict trends in these&#xa0;markets, which decisions could prove to be inaccurate.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">d.&#xa0;&#xa0;Emerging Markets
Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund is subject to
emerging markets risk. This is a magnification of the risks that apply to foreign investments. These risks are greater for securities of companies in emerging market countries because the countries may have less
stable governments, more volatile currencies and less established markets (see &#x201c;Foreign Securities Risk&#x201d; below).&#xa0;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">e.&#xa0;&#xa0;Equity Linked Notes:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund may invest in
equity-linked notes, which are generally subject to the same risks as the foreign equity securities or the basket of foreign securities they are linked to. If the linked security(ies) declines in value, the note may
return a lower amount at maturity. The trading price of an equity-linked note also depends on the value of the linked security(ies).</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">f.&#xa0;&#xa0;Equity Securities
Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The stock or other security
of a company may not perform as well as expected, and may decrease in value, because of factors related to the company (such as poorer than expected earnings or certain management decisions), to the industry in which
the company is engaged (such as a reduction in the demand for products or services in a particular industry) or to the market as a whole (such as periods of market volatility or instability, or general and prolonged
periods of economic decline). Holders of common stock generally are subject to more risks than holders of preferred stock or debt securities because the right to repayment of common shareholders' claims is
subordinated to that of preferred stock and debt securities upon the bankruptcy of the issuer.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">g.&#xa0;&#xa0;Foreign Securities
Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Foreign countries in which
the Fund may invest may have markets that are less liquid, less regulated and more volatile than U.S. markets. The value of the Fund's investments may decline because of factors such as unfavorable or unsuccessful
government actions, reduction of government or central bank support and political or financial instability. To the extent the Fund&#xa0;focuses its investments in a single country or only a few countries in a
particular geographic region, economic, political, regulatory or other conditions affecting such country or region may have a greater impact on Fund performance relative to a more geographically diversified fund.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:23.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">24
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">h.&#xa0;&#xa0;Key Personnel Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">There may be only a limited
number of securities professionals who have comparable experience to that of the Fund&#x2019;s existing portfolio management team in the area of healthcare companies. If one or more of the team members dies, resigns,
retires or is otherwise unable to act on behalf of the Adviser, there can be no assurance that a suitable replacement could be found immediately.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">i.&#xa0;&#xa0;Leverage Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund may use leverage
to purchase securities. Increases and decreases in the value of the Fund's portfolio will be magnified when the Fund uses leverage. Certain investments or trading strategies that involve leverage can result in losses
that greatly exceed the amount originally invested.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">j.&#xa0;&#xa0;Market Events Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Markets are affected by
numerous factors, including interest rates, the outlook for corporate profits, the health of the national and world economies, the fluctuation of other stock markets around the world, and financial, economic and other
global market developments and disruptions, such as those arising from war, terrorism, market manipulation, government interventions, trading and tariff arrangements, defaults and shutdowns, political changes or
diplomatic developments, public health emergencies and natural/environmental disasters. Such events can negatively impact the securities markets and cause the Fund to lose value.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Policy and legislative
changes in countries around the world are affecting many aspects of financial regulation, and governmental and quasi-governmental authorities and regulators throughout the world have previously responded to serious
economic disruptions with a variety of significant fiscal and monetary policy changes.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The impact of these changes
on the markets, and the practical implications for market participants, may not be fully known for some time. In addition, economies and financial markets throughout the world are becoming increasingly interconnected.
As a result, whether or not the Fund invests in securities of issuers located in or with significant exposure to countries or sectors experiencing economic and financial difficulties, the value and liquidity of the
Fund&#x2019;s investments may be negatively affected by such events.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">k.&#xa0;&#xa0;REIT and Real Estate
Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Investment in REITs and
real estate involves the risks that are associated with direct ownership of real estate and with the real estate industry in general. These risks include: declines in the value of real estate; risks related to local
economic conditions, overbuilding and increased competition; increases in property taxes and operating expenses; changes in zoning laws; casualty or condemnation losses; variations in rental income, neighborhood
values or the appeal of properties to tenants; changes in interest rates and changes in general</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">economic and market conditions; reduced
demand for commercial and office space; increased maintenance or tenant improvement costs to convert properties for other uses; default risk of tenants and borrowers; the financial condition of tenants, buyers and
sellers; and the inability to re-lease space on attractive terms or to obtain&#xa0;mortgage financing on a timely basis or at all. REITs&#x2019; share prices may decline because of adverse developments affecting the
real estate industry including changes in interest rates. The returns from REITs may trail returns from the overall market. Additionally, there is always a risk that a given REIT will fail to qualify for favorable tax
treatment. REITs may be leveraged, which increases risk.&#xa0;Certain REITs, like mutual funds, have expenses, including management and administration fees, that are paid by their shareholders. As a result,
shareholders will directly bear the expenses of their investment in the Fund and indirectly bear the expenses of the Fund&#x2019;s investments when the Fund invests in REITs.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">l.&#xa0;&#xa0;Restricted Securities
and Valuation Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Some of the Fund&#x2019;s
investments are subject to restrictions on resale and generally have no established trading market or are otherwise illiquid with little or no trading activity. The valuation process requires an analysis of various
factors. The Fund&#x2019;s fair value methodology includes the examination of, among other things, (i) the existence of any contractual restrictions on the disposition of the securities; (ii) information obtained from
the issuer which may include an analysis of the company&#x2019;s financial statements, the company&#x2019;s products or intended markets, or the company&#x2019;s technologies; and (iii) the price of a security sold at
arm&#x2019;s length in an issuer&#x2019;s subsequent completed round of financing. As there is typically no readily available market&#xa0;value for some of the Restricted Securities in the Fund&#x2019;s portfolio, such
Restricted Securities in the Fund&#x2019;s portfolio are valued at fair value as determined in good faith by or under the direction of the Board pursuant to the Fund&#x2019;s valuation policy and a consistently applied
valuation process. Because of the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Fund&#x2019;s investments determined in good
faith by the Board may differ significantly from the values that would have been used had a ready market existed for the investments, and the differences could be material.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">m.&#xa0;&#xa0;Risks Associated with
the Fund&#x2019;s Option Strategy:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The ability of the Fund to
achieve its investment objective is partially dependent on the successful implementation of its option strategy. There are several risks associated with transactions in options on securities used in connection with
the Fund's option strategy. For example, there are significant differences between the securities and options markets that could result in an imperfect correlation between these markets, causing a given transaction
not to achieve its objectives. A decision as to whether, when and how to use options</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:18.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:24.07%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">25
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">involves the exercise of skill and judgment,
and even a well-conceived transaction may be unsuccessful to some degree because of market behavior or unexpected events.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">As the writer of a call
option covered with a security held by the Fund, the Fund forgoes, during the option's life, the opportunities to profit from increases in the market value of the security covering the call option above the sum of the
premium and the strike price of the call but retains the risk of loss should the price of the underlying security decline. As the Fund writes such covered calls over more of its portfolio, its ability to benefit from
capital appreciation becomes more limited. To the extent the Fund writes call options that are not fully covered by securities in its portfolio (such as calls on an index or sector), it will lose money if the portion
of the security or securities underlying the option that is not covered by securities in the Fund's portfolio appreciate in value above the exercise price of the option by an amount that exceeds the premium received
on the option plus the exercise price of the option. The amount of this loss theoretically could be unlimited. The writer of an option has no control over the time when it may be required to fulfill its obligations as
a writer of the option.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">When the Fund writes put
options, it bears the risk of loss if the value of the underlying stock declines below the exercise price minus the put premium. If the option is exercised, the Fund could incur a loss if it is required to purchase
the stock underlying the put option at a price greater than the market price of the stock at the time of exercise plus the put premium the Fund received when it wrote the option. While the Fund's potential gain as the
writer of a covered put option is limited to the premium received from the purchaser of the put option, the Fund risks a loss equal to the entire exercise price of the option minus the put premium.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">n.&#xa0;&#xa0;Sector Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">To the extent that the Fund
has a significant portion of its assets invested in securities conducting business in a broadly related group of industries within an economic sector, the Fund may be more vulnerable to unfavorable developments in
that economic sector than funds that invest more broadly.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Biotechnology Industry
Risk.<font style="font-style:Normal"> The success of biotechnology companies is highly dependent on the development, procurement and/or marketing of drugs. The values of biotechnology companies are also dependent on the
development, protection and exploitation of intellectual property rights and other proprietary information, and the profitability of biotechnology companies may be significantly affected by such things as the
expiration of patents or the loss of, or the inability to enforce, intellectual property rights. The research and other costs associated with developing or procuring new drugs, products or technologies and the related
intellectual property rights can be significant, and the results of such research and expenditures are</font></div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">unpredictable. There can be no assurance
that those efforts or costs will result in the development of a profitable drug, product or technology.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The biotechnology sector is
also subject to rapid and significant technological change and competitive forces that may make drugs, products or technologies obsolete or make it difficult to raise prices and, in fact, may result in price
discounting. Companies in the biotechnology sector may also be subject to expenses and losses from extensive litigation based on intellectual property, product liability and similar claims. Companies in the
biotechnology sector may be adversely affected by government regulation and changes in reimbursement rates. Healthcare providers, principally hospitals, that transact with companies in the biotechnology industry,
often rely on third party payors, such as Medicare, Medicaid, private health insurance plans and health maintenance organizations to reimburse all or a portion of the cost of healthcare related products or services.
Biotechnology companies will continue to be affected by the efforts of governments and third-party payors to contain or reduce health care costs.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Pharmaceutical Sector
Risk<font style="font-style:Normal">. The success of companies in the pharmaceutical sector is highly dependent on the development, procurement and marketing of drugs. The values of pharmaceutical companies are also dependent
on the development, protection and exploitation of intellectual property rights and other proprietary information, and the profitability of pharmaceutical companies may be significantly affected by such things as the
expiration of patents or the loss of, or the inability to enforce, intellectual property rights. The research and other costs associated with developing or procuring new drugs and the related intellectual property
rights can be significant, and the results of such research and expenditures are unpredictable. There can be no assurance that those efforts or costs will result in the development of a profitable drug.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The pharmaceutical sector is
also subject to rapid and significant technological change and competitive forces that may make drugs obsolete or make it difficult to raise prices and, in fact, may result in price discounting. Companies in the
pharmaceutical sector may also be subject to expenses and losses from extensive litigation based on intellectual property, product liability and similar claims. Companies in the pharmaceutical sector may be adversely
affected by government regulation and changes in reimbursement rates. The ability of many pharmaceutical companies to commercialize and monetize current and any future products depends in part on the extent to which
reimbursement for the cost of such products and related treatments are available from third-party payors, such as Medicare, Medicaid, private health insurance plans and health maintenance organizations.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:19.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">26
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Managed Care Sector Risk.<font style="font-style:Normal"> Companies in the managed care sector often assume the risk of both medical and administrative costs for their customers in return for monthly premiums. The profitability of these products
depends in large part on the ability of such companies to predict, price for, and effectively manage medical costs. Managed care companies base the premiums they charge and their Medicare bids on estimates of future
medical costs over the fixed contract period; however, many factors may cause actual costs to exceed what was estimated and reflected in premiums or bids.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Managed care companies are
regulated at the federal, state, local and international levels. The evolution of the ACA and other regulatory reforms could materially and adversely affect the manner in which U.S. managed care companies conduct
business and their results of operations, financial position and cash flows. New laws or regulations could drive substantial change to the way healthcare products and services are currently delivered and paid for in
the United States. A transformative overhaul of the U.S. healthcare system could impact the financial viability of managed care companies in which the Fund may invest.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Life Science and Tools
Industry Risk.&#xa0; <font style="font-style:Normal">Life science industries are characterized by limited product focus, rapidly changing technology, extensive government regulation, and intense competition.&#xa0; In particular, technological
advances can render an existing product, which may account for a disproportionate share of a company&#x2019;s revenue, obsolete. Extensive regulation can delay cause delays in product development, which may
disadvantage a company in an intensely competitive environment. These various factors may result in abrupt advances and declines in the securities prices of particular companies, and, in some cases, may have a broad
effect on the prices of securities of companies in particular life science industries.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Technology Sector
Risk.<font style="font-style:Normal"> Companies in the healthcare technology sector may incur substantial cost related to product-related liabilities, interruptions at their data centers or client support facilities, claims for
infringement or misappropriation of intellectual property rights of others, or infringement or misappropriation of their intellectual property.&#xa0; Each of these may adversely impact the prices of securities of
companies in the healthcare technology sector.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Additionally, the success of
healthcare technology companies depends upon the recruitment and retention of key personnel. The failure to attract and retain qualified personnel could have a material adverse effect on healthcare technology
companies&#x2019; prospects for long-term growth.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Services Sector
Risk.<font style="font-style:Normal"> The operations of healthcare services companies are subject to extensive federal, state and local government regulations. A violation or departure from any of these legal requirements may
result in government audits, lower reimbursements, significant fines and penalties, the potential loss of</font></div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">certification, recoupment efforts or
voluntary repayments. If healthcare services companies fail to adhere to all of the complex government regulations that apply to their businesses, such companies could suffer severe consequences that would
substantially reduce revenues, earnings, cash flows and stock prices.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">A substantial percentage of a
healthcare services company&#x2019;s service revenues may be generated from patients who have state Medicaid or other non-Medicare government-based programs, such as coverage through the Department of Veterans Affairs
(&#x201c;VA&#x201d;), as their primary coverage. As state governments and other governmental organizations face increasing budgetary pressure, healthcare services companies may in turn face reductions in payment rates,
delays in the receipt of payments, limitations on enrollee eligibility or other changes to the applicable programs.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Supplies Sector
Risk. <font style="font-style:Normal">If healthcare supplies companies are unable to successfully expand their product lines through internal research and development and acquisitions or are unable to successfully grow their
business through marketing partnerships, their business may be materially and adversely affected.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Quality is extremely
important to healthcare supplies companies and their customers due to the serious and costly consequences of product failure. Quality certifications are critical to the marketing success of their products and
services. If a healthcare supplies company fails to meet these standards or fails to adapt to evolving standards, its reputation could be damaged, it could lose customers, and its revenue and results of operations
could decline.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Facilities Sector
Risk.<font style="font-style:Normal"> A healthcare facility&#x2019;s ability to negotiate favorable contracts significantly affects the revenues and operating results of such healthcare facilities. If a healthcare facility is
unable to enter into and maintain managed care contractual arrangements on acceptable terms, if it experiences material reductions in the contracted rates received from managed care payers, or if it has difficulty
collecting from managed care payers, its results of operations could be adversely affected.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Further changes in the
Medicare and Medicaid programs or other government health care programs could have an adverse effect on a healthcare facility&#x2019;s business. In addition to the changes affected by the ACA, the Medicare and Medicaid
programs are subject to other regulatory changes which could materially increase or decrease payments from government programs in the future, as well as affect the cost of providing services to patients and the timing
of payments to facilities, which could in turn adversely affect a healthcare facility&#x2019;s overall business, financial condition, results of operations or cashflows.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Equipment Sector
Risk. <font style="font-style:Normal">The medical device markets are highly competitive and characterized by rapid change, which may affect a company&#x2019;s ability to be competitive. They are also rigorously</font></div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:18.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:24.07%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">27
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">regulated and it is anticipated that
governmental authorities will continue to scrutinize this industry closely, and that additional regulation may increase compliance and legal costs, exposure to&#xa0;&#xa0;&#xa0; litigation, and other adverse effects
to operations.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare equipment
companies are substantially dependent on patent and other proprietary rights and failing to protect such rights or to be successful in litigation related to such rights may negatively impact the ability of healthcare
equipment companies to sell current or future products.&#xa0; Quality problems with the processes, goods and services of a healthcare equipment company could harm the company&#x2019;s reputation for producing
high-quality products and erode its competitive advantage, sales and market share. Quality certifications are critical to the marketing success of goods and services. If a healthcare equipment company fails to meet
these standards, its reputation could be damaged, it could lose customers, and its revenue and results of operations could decline.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Distributors
Sector Risk.<font style="font-style:Normal"> Companies in the healthcare distribution sector operate in markets that are highly competitive and in an industry that is highly regulated and often subject to legal proceedings. Due to the
nature of the business of healthcare distribution companies, each of the above may have an adverse impact on the securities prices of companies in the healthcare distribution sector.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare distribution
companies depend on the availability of various components, compounds, raw materials and energy supplied by others for their operations. Any of these supplier relationships could be interrupted due to events beyond
the control of such companies, including pandemics, epidemics or natural disasters, or could be terminated. A sustained supply interruption could have an adverse effect on business.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">o.&#xa0;&#xa0;Valuation Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The price that the Fund
could receive upon the sale of any particular portfolio investment may differ from the Fund's valuation of the investment, particularly for securities that trade in thin or volatile markets or that are valued using a
fair valuation methodology or a price provided by an independent pricing service. As a result, the price received upon the sale of an investment may be less than the value ascribed by the Fund, and the Fund could
realize a greater than expected loss or lower than expected gain upon the sale of the investment. The Fund's ability to value its investments may also be</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">impacted by technological issues and/or errors
by pricing services or other third-party service providers.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">p.&#xa0;&#xa0;Venture Capital
Investments Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund may occasionally
invest in venture capital opportunities. While these securities offer the opportunity for significant capital gains, such investments also involve a degree of risk that can result in substantial losses. Some of the
venture capital opportunities in which the Fund may invest are expected to be companies that are in a &#x201c;start-up&#x201d; stage of development, have little or no operating history, operate at a loss or with
substantial variations in operating results from period to period, have limited products, markets, financial resources or management depth, or have the need for substantial additional &#x201c;follow-on&#x201d; capital
to support expansion or to achieve or maintain a competitive position. Such additional investments may dilute the interests of prior investors, such as the Fund. Some of these companies may be emerging companies at
the research and development stage with no marketable or approved products or technology. There can be no assurance that securities of start-up or emerging growth companies will, in the future, yield returns
commensurate with their associated risks.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">These investments, which are
considered Restricted Securities, will be made primarily in convertible preferred stock. The Fund may also purchase non-convertible debt securities in connection with its venture capital investments, and otherwise
when the Adviser believes that such investments would be consistent with the Fund&#x2019;s investment objective. While these debt investments typically will not be rated, the Adviser believes that, in light of the risk
characteristics associated with investments in emerging growth companies, if such investments were to be compared with investments rated by S&amp;P or Moody&#x2019;s, they may be rated as low as &#x201c;C&#x201d; in the
rating categories established by S&amp;P and Moody&#x2019;s. Such securities are commonly referred to as &#x201c;junk bonds&#x201d; and are considered, on balance, as predominantly speculative.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">10.&#xa0;&#xa0;Contingencies</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">In the normal course of
business, the Fund may provide general indemnifications pursuant to certain contracts and organizational documents. The Fund's maximum exposure under these arrangements is dependent on future claims that may be made
against the Fund, and therefore, cannot be estimated; however, the Fund expects the risk of loss from such claims to be remote.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:110.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">28
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:17.5pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">11.&#xa0;&#xa0;Tax Information</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:left; text-decoration:none; text-transform:none">The U.S. federal income tax
basis of the Fund's investments (including derivatives, if applicable) and the net unrealized appreciation as of September 30, 2025, were as follows:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2pt; padding-left:6pt; padding-right:10.5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:19.76%">Tax Cost of<br>
Securities
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2pt; padding-left:10.5pt; padding-right:10.5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:28.70%">Unrealized<br>
Appreciation
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2pt; padding-left:10.5pt; padding-right:10.5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:29.43%">Unrealized<br>
Depreciation
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2pt; padding-left:10.5pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:29.57%">Net<br>
Unrealized<br>
Appreciation/<br>
(Depreciation)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:0pt; padding-right:10.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:19.76%; background-color: #F0F0F0;">$899,848,967
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:10.5pt; padding-right:10.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:28.70%; background-color: #F0F0F0;">$182,101,028
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:10.5pt; padding-right:10.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:29.43%; background-color: #F0F0F0;">$(116,642,768)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:10.5pt; padding-right:6pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:29.57%; background-color: #F0F0F0;">$65,458,260
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">The tax character of
distributions paid during the fiscal years ended September 30, 2025 and September 30, 2024 was as follows:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.63%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:9pt; padding-bottom:2pt; padding-right:5pt; padding-top:3pt; text-align:left; vertical-align:bottom; width:66.43%">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.29%">September 30, 2025
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2pt; padding-left:5pt; padding-right:6pt; padding-top:3pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.35%">September 30, 2024
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:66.43%; background-color: #F0F0F0;">Distributions paid from:
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:16.29%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:16.35%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:66.43%; background-color: #F0F0F0;">Ordinary Income
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.29%; background-color: #F0F0F0;">$<font style="padding-left:8.00pt"></font>3,979,432
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:5pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.35%; background-color: #F0F0F0;">$<font style="padding-left:1.40pt"></font>22,465,817
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:66.43%; background-color: #F0F0F0;">Net Long-Term Capital Gains
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:52.74pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.29%; background-color: #F0F0F0;">-
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:11.03pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.35%; background-color: #F0F0F0;">22,755,596
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:66.43%; background-color: #F0F0F0;">Return of Capital
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:12.17pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.29%; background-color: #F0F0F0;">85,399,220
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:11.19pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.35%; background-color: #F0F0F0;">32,941,565
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:2pt; padding-left:6pt; padding-right:5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:66.43%; background-color: #F0F0F0;">Total tax character of distributions
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:2pt; padding-left:5pt; padding-right:5pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.29%; background-color: #F0F0F0;">$89,378,652
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:2pt; padding-left:5pt; padding-right:6pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.35%; background-color: #F0F0F0;">$78,162,978
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:16pt; text-align:left; text-decoration:none; text-transform:none">Amounts listed as
 &#x201c;&#x2013;&#x201d; are $0 or round to $0.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">As of September 30, 2025, the
components of accumulated earnings on a tax basis were as follows:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.89%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:87.58%; background-color: #F0F0F0;">Undistributed Ordinary Income
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:3pt; padding-right:12pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.73%; background-color: #F0F0F0;">$<font style="padding-left:42.97pt"></font>-
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:6pt; padding-right:3pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:87.58%; background-color: #F0F0F0;">Undistributed Long-Term Capital Gains
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:50.94pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.73%; background-color: #F0F0F0;">-
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:6pt; padding-right:3pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:87.58%; background-color: #F0F0F0;">Total undistributed earnings
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:3pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.73%; background-color: #F0F0F0;">$<font style="padding-left:42.97pt"></font>-
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:3pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:87.58%; background-color: #F0F0F0;">Accumulated Capital and Other Losses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:3pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.73%; background-color: #F0F0F0;">$<font style="padding-left:42.97pt"></font>-
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:3pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:87.58%; background-color: #F0F0F0;">Capital loss carryforward
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:3pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.73%; background-color: #F0F0F0;">$<font style="padding-left:42.97pt"></font>-*
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:3pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:87.58%; background-color: #F0F0F0;">Other currency gains
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:50.94pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.73%; background-color: #F0F0F0;">-
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:3pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:87.58%; background-color: #F0F0F0;">Other Temporary Differences
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:50.94pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.73%; background-color: #F0F0F0;">-
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:6pt; padding-right:3pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:87.58%; background-color: #F0F0F0;">Unrealized Appreciation/(Depreciation)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:10.78pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.73%; background-color: #F0F0F0;">65,808,722
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:2pt; padding-left:6pt; padding-right:3pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:87.58%; background-color: #F0F0F0;">Total accumulated earnings/(losses) &#x2013; net
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:2pt; padding-left:3pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.73%; background-color: #F0F0F0;">$65,808,722**
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:16pt; text-align:left; text-decoration:none; text-transform:none">Amounts listed as
 &#x201c;&#x2013;&#x201d; are $0 or round to $0.</div>
<div style="text-align:center">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-right:auto; margin-top:11pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.22%">*
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.33%">During the fiscal year ended September 30, 2025, the Fund did not utilize a capital loss carryforward.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.22%">**
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.33%">The difference between book-basis and tax-basis unrealized appreciation/(depreciation) is attributable to the difference between the tax deferral of wash sales.
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">12.&#xa0;&#xa0;Segment Reporting</div>
</div>
<div style="margin-top:7pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">In this reporting period, the Fund adopted
FASB Accounting Standards Update 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures ("ASU 2023-07"). Adoption of the new standard impacted disclosures only and did not affect the
Fund&#x2019;s financial position nor the results of its operations. Operating segments are components of a public entity that engage in business activities from which it may recognize revenues and incur expenses, have
discrete financial information available, and have their operating results regularly reviewed by the public entity&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) when assessing segment performance and
making decisions about segment resources. The Chief Financial Officer</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">of the Fund acts as the Fund&#x2019;s CODM.
The CODM monitors the operating results of the Fund as a whole, and the Fund&#x2019;s asset allocation is managed in accordance with its Prospectus. The Fund operates as a single operating and reporting segment
pursuant to its investment objective and principal investment strategy. The Fund&#x2019;s portfolio composition, total returns, expense ratios and changes in net assets used by the CODM to assess segment performance
and make resource allocations are consistent with the information presented within the Fund's financial statements. Segment assets are reflected on the Fund&#x2019;s Statement of Assets and Liabilities as &#x201c;Total
Assets&#x201d; and</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:23.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:24.07%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">29
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(concluded)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">significant segment expenses are listed on the
Statement of Operations.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">13.&#xa0;&#xa0;Recent Accounting
Pronouncements</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">In December 2023, the FASB
issued Accounting Standards Update 2023-09 (&#x201c;ASU 2023-09&#x201d;), Income Taxes (Topic 740) Improvements to Income Tax Disclosures, which amends quantitative and qualitative income tax disclosure requirements in
order to increase disclosure consistency, bifurcate income tax information by jurisdiction and remove information that is no longer beneficial. ASU 2023-09 is effective for annual periods beginning after December 15,
2024, and early adoption is permitted. Fund Management is evaluating the impacts of these changes on the Fund&#x2019;s financial statements.</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">14.&#xa0;&#xa0;Subsequent Events</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Management has evaluated
the need for disclosures and/or adjustments resulting from subsequent events through the date the financial statements were issued.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Based on this evaluation, no
disclosures and/or adjustments were required to the financial statements as of September 30, 2025, other than as noted below.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">On October 9, 2025 and
November 11, 2025, the Fund announced that it will pay on October 31, 2025 and November 28, 2025 a distribution of $0.18 per share to all shareholders of record as of October 24, 2025 and November 21, 2025,
respectively.&#xa0;</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:491.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">30
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Report of Independent Registered Public Accounting
Firm<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;</font></div>
</div>
<div style="margin-top:13pt; width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:24.5pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">To&#xa0;the&#xa0;
Shareholders&#xa0;and&#xa0;Board&#xa0;of&#xa0;Trustees<br>
abrdn Healthcare Opportunities Fund:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Opinion on the Financial
Statements</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:5pt; text-align:justify; text-decoration:none; text-transform:none">We have audited the
accompanying statement of assets and liabilities of abrdn Healthcare Opportunities Fund (the Fund), including the portfolio of investments, as of September 30, 2025, the related statements of operations and cash flows
for the year then ended, the statements of changes in net assets for each of the years in the two-year period then ended, and the related notes (collectively, the financial statements) and the financial highlights for
each of the years in the three-year period then ended. In our opinion, the financial statements and financial highlights present fairly, in all material respects, the financial position of the Fund as of September 30,
2025, the results of its operations and its cash flows for the year then ended, the changes in its net assets for each of the years in the two-year period then ended, and the financial highlights for each of the years
in the three-year period then ended, in conformity with U.S. generally accepted accounting principles. The financial highlights for each of the years in the two-year period ended September 30, 2022 were audited by
other independent registered public accountants whose report, dated November 21, 2022, expressed an unqualified opinion on those financial highlights.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Basis for Opinion</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:5pt; text-align:justify; text-decoration:none; text-transform:none">These financial statements
and financial highlights are the responsibility of the Fund's management. Our responsibility is to express an opinion on these financial statements and financial highlights based on our audits. We are a public
accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Fund in accordance with the U.S. federal securities laws and
the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:12pt; text-align:justify; text-decoration:none; text-transform:none">We conducted our audits in
accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements and financial highlights are free of
material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements and financial highlights, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements and financial
highlights. Such procedures also included confirmation of securities owned as of September 30, 2025, by correspondence with the custodian, respective portfolio company, and brokers; when replies were not received from
brokers, we performed other auditing procedures. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the
financial statements and financial highlights. We believe that our audits provide a reasonable basis for our opinion.</div>
<div style="margin-left:40.19%; margin-top:9pt; text-align:Center; width:19.63%">
<img src="tm2527059d10thqreporti004.jpg" alt=" ">
</div>


<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">We have served as the auditor
of one or more abrdn investment companies since 2009.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Columbus, Ohio<br>
November 28, 2025&#xa0;</div>
</div>
<div style="margin-top:204pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:24.07%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">31
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Federal Tax Information: Dividends and
Distributions&#xa0;<font style="font-size:11pt; line-height:14pt"> (Unaudited)&#xa0;</font></div>
</div>
<div style="margin-top:8pt; width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:6.5pt; text-align:left; text-decoration:none; text-transform:none">Designation Requirements</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:left; text-decoration:none; text-transform:none">Of the distributions paid by the
Fund from ordinary income for the year ended September 30, 2025, the following percentages met the requirements to be treated as qualifying for the corporate dividends received deduction and qualified dividend income,
respectively.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:left; text-decoration:none; text-transform:none">Dividends Received Deduction
100.00%</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:left; text-decoration:none; text-transform:none">Qualified Dividend Income
100.00%</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:left; text-decoration:none; text-transform:none">.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:left; text-decoration:none; text-transform:none">The above amounts are based on
the best available information at this time. In early 2026, the Fund will notify applicable shareholders of final amounts for use in preparing 2025 U.S. federal income tax forms.&#xa0;</div>
</div>
<div style="margin-top:530pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">32
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Supplemental Information&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited)&#xa0;</font></div>
</div>
<div style="margin-top:8pt; width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:6.5pt; text-align:left; text-decoration:none; text-transform:none">Results of Annual Meeting of
Shareholders</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:left; text-decoration:none; text-transform:none">The Annual Meeting of
Shareholders was held on May 28, 2025. The description of the proposal and number of shares voted at the meeting are as follows:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:left; text-decoration:none; text-transform:none">To elect two Class B Trustees to
the Board of Trustees:</div>
</div>
<div style="margin-top:2.5pt; width:80.26%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:9.5pt; padding-bottom:3pt; padding-right:15pt; padding-top:3pt; text-align:left; vertical-align:bottom; width:64.98%">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:15pt; padding-right:15pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.12%">Votes For
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:15pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:19.56%">Votes Against/<br>
Withheld
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:15pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:64.98%; background-color: #F0F0F0;">Rose DiMartino
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:15.22pt; padding-right:15pt; padding-top:2.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.12%; background-color: #F0F0F0;">29,059,401
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:16.42pt; padding-right:6pt; padding-top:2.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.56%; background-color: #F0F0F0;">672,277
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:15pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:64.98%; background-color: #F0F0F0;">C. William Maher
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:15pt; padding-right:15pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.12%; background-color: #F0F0F0;">29,073,662
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:15pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.56%; background-color: #F0F0F0;">658,016
</td></tr></table>
</div>
</div>
<div style="margin-top:12.5pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:6.5pt; text-align:left; text-decoration:none; text-transform:none">Summary of Board Considerations in
Approving the Investment Advisory Agreement</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:justify; text-decoration:none; text-transform:none">At a regularly scheduled
meeting (the &#x201c;Meeting&#x201d;) of the Board of Directors (the &#x201c;Board&#x201d;) of abrdn Healthcare Opportunities Fund (&#x201c;THQ&#x201d; or the &#x201c;Fund&#x201d;) held on June 10, 2025, the Board, including
those Directors (the &#x201c;Independent Directors&#x201d;) who are not &#x201c;interested persons&#x201d; (as that term is defined in the Investment Company Act of 1940 (the &#x201c;1940 Act&#x201d;)) of the Fund, approved
the continuation of the investment advisory agreement (the &#x201c;Advisory Agreement&#x201d;) between abrdn Inc. (the &#x201c;Adviser&#x201d;) and the Fund. In connection with their consideration of whether to approve
the continuation of the Advisory Agreement, the Board members received and reviewed a variety of information provided by the Adviser relating to the Fund, the Advisory Agreement, and the Adviser. The information
provided to the Board members included (but was not limited to): comparative performance, fee and expense information (as well as information on the limitations of such comparable data) of a peer group of funds based
on the Fund&#x2019;s Morningstar Category (the &#x201c;Peer Funds&#x201d;), as selected by Institutional Shareholder Services Inc. (&#x201c;ISS&#x201d;), an independent third-party provider of investment company data and
other performance information. The Peer Funds presented for fee and expense data comparison consisted of a sub-set of the Morningstar Category as determined independently by ISS, and the Peer Funds presented for the
performance data comparison consisted of the Fund&#x2019;s Morningstar category, as determined by ISS. The Board also received information regarding relevant benchmark indices and information regarding the nature,
extent and quality of services provided by the Adviser under the Advisory Agreement.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:justify; text-decoration:none; text-transform:none">The materials provided to the
Board generally included, among other items: (i) information on the investment performance of the Fund, the performance of the Peer Funds, comparable funds, if any, and the Fund&#x2019;s performance benchmark;&#xa0;
(ii) reports prepared by the Adviser in response to requests submitted by the Independent Directors&#x2019; independent legal counsel on behalf of such Directors; (iii) information on the Fund&#x2019;s management fee
and other expenses, including information comparing the Fund&#x2019;s expenses to the Peer Funds, comparable funds, if any, and information about applicable fee &#x201c;breakpoints&#x201d; in the Fund&#x2019;s fee
structure and expense limitations, if any; (iv) information regarding the Adviser&#x2019;s revenues and costs of providing services to the funds and any compensation paid to affiliates of the Adviser; and (v) a
memorandum from the Independent Directors&#x2019; independent legal counsel on the responsibilities of the Board in considering the approval of the investment advisory arrangement under the 1940 Act and Massachusetts
law.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:justify; text-decoration:none; text-transform:none">The Independent Directors met
with representatives of the Adviser and separately in executive session with independent legal counsel on June 10, 2025 to discuss the continuation of the Advisory Agreement. The Independent Directors also met with
representatives of the Adviser and separately in executive session with independent legal counsel on May 29, 2025 to discuss the materials provided to the Board by the Adviser in response to a request for information
sent to them by the Independent Directors&#x2019; independent legal counsel.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:justify; text-decoration:none; text-transform:none">In evaluating whether to
renew the Advisory Agreement for the Fund, the Board considered numerous factors, including: (i) the nature, extent and quality of services provided to the Fund by the Adviser under the Advisory Agreement; (ii) the
costs of services provided to the Fund and the profits realized by the Adviser (and its affiliates) from its relationship with the Fund; (iii) the Fund&#x2019;s total expense ratio as well as the management fee paid by
the Fund pursuant to the Advisory Agreement relative to the total expense ratios of and the management fees charged to the Peer Funds and comparable accounts, if any; (iv) the investment performance of the Fund
relative to that of its benchmark index as well as the performance of the Peer Funds and comparable funds, if any; (v) any additional benefits (such as soft dollars, if any) received by the Adviser or its affiliates;
(vi) the extent to which economies of scale are being realized by shareholders and will be realized as the Fund&#x2019;s assets increase; (vii) the Adviser&#x2019;s compliance program; and (viii) any other
considerations deemed relevant by the Board.&#xa0; The Independent Directors also discussed the Advisory Agreement in an executive session with independent legal counsel at which no representatives of the Adviser were
present. No single factor reviewed by the Board was identified as the principal factor in determining whether to renew the Advisory Agreement, and individual Directors may have given different weight to various
factors.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:justify; text-decoration:none; text-transform:none">The discussion immediately
below outlines in greater detail certain of the materials and information presented to the Board by the Adviser in connection with the Board&#x2019;s consideration and approval of the continuation of the Advisory
Agreement, and the conclusions made by the Board at the Meeting when determining to renew the Advisory Agreement.</div>
</div>
<div style="margin-top:21.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:24.07%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">33
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Supplemental Information&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited)&#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:8pt; width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:20.5pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">The Nature, Extent and Quality of
Services Provided to the Fund Under the Advisory Agreement</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Directors considered the
nature, extent and quality of services provided by the Adviser to the Fund.&#xa0; They reviewed information about the resources dedicated to the Fund by the Adviser and its affiliates. Among other things, the Board
reviewed and discussed the background and experience of the Adviser&#x2019;s senior management personnel who serviced the Fund and the qualifications, background and responsibilities of the portfolio managers primarily
responsible for providing day-to-day portfolio management services for the Fund. The Directors also considered the financial condition of the Adviser and the Adviser&#x2019;s ability to provide quality service to the
Fund. Management representatives reported to the Board and responded to questions on, among other things, the Adviser&#x2019;s business plans and any current or proposed organizational changes. The Directors also took
into account the Adviser&#x2019;s experience as an asset manager and considered information regarding the Adviser&#x2019;s compliance with applicable laws and Securities and Exchange Commission (&#x201c;SEC&#x201d;) and
other regulatory agency inquiries or audits of the Fund, the Adviser and/or the Adviser&#x2019;s affiliates. The Board considered reports from the Adviser on its risk management processes. The Board noted that it
received information on a regular basis from the Fund&#x2019;s Chief Compliance Officer regarding the Adviser&#x2019;s compliance policies and procedures and information concerning the Adviser&#x2019;s brokerage policies
and practices. The Directors also noted that the Adviser had provided information and periodic reporting, including updates on its management of the Fund and the quality of its performance and had discussed these
matters with the Directors at meetings held regularly throughout the preceding year.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:justify; text-decoration:none; text-transform:none">Based on the totality of the
information considered, the Board concluded that the nature, extent and quality of the Adviser&#x2019;s services provided to the Fund were of high quality, and that the Adviser has provided and could reasonably be
expected to continue to provide these services on an ongoing basis based on its experience, operations and resources.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">The Costs of Services Provided
and Profits Realized by the Adviser and its Affiliates from their Relationships with the Fund</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Board reviewed
information compiled by ISS that compared the Fund&#x2019;s effective annual management fee rate with the fees paid by its Peer Funds. The Board reviewed with management the effective annual management fee rate paid by
the Fund to the Adviser for investment management services. The Board considered the Fund&#x2019;s management fee structure. The Directors also considered information from management about the fees charged by the
Adviser to other clients investing primarily in an asset class similar to that of the Fund. The Board considered the fee comparisons in light of the differences in resources and costs required to manage the different
types of accounts. In evaluating the Fund&#x2019;s management fee, the Board took into account the regulatory regimes, fund structure, level of services, complexity and quality of the investment management of the
Fund.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:justify; text-decoration:none; text-transform:none">In addition to the foregoing,
the Board considered the Fund&#x2019;s fees and expenses relative to the fees and expenses of the Peer Funds, as well as information on the limitations of such comparable data given differences between the Fund and the
Peer Funds presented. This information showed that the Fund&#x2019;s net management fee and total net expenses, exclusive of investment-related expenses, were below the median of the Peer Funds. The Board noted that
the Adviser manages the Fund&#x2019;s option writing strategy, as well as the Fund&#x2019;s structure, including any discount to the Fund&#x2019;s net asset value during market trading. The Board also reviewed the
profitability of the investment advisory relationship with the Fund to the Adviser.&#xa0; The Board concluded that the Fund&#x2019;s fees and expenses, as well as the Investment Adviser&#x2019;s profitability, were
reasonable in light of the nature, extent and quality of services provided.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Investment Performance of the
Fund</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Board received and
reviewed with the Fund&#x2019;s management, among other performance data, information that compared the Fund&#x2019;s return over the one-year period to the Peer Funds and discussed this information and other related
performance data with the Adviser. In addition, the Board received and reviewed information regarding the Fund&#x2019;s total return on a gross and net basis and relative to the Fund&#x2019;s benchmark. The Board also
considered information about the Fund&#x2019;s discount/premium ranking relative to its Peer Funds and the Adviser&#x2019;s discussion of the Fund&#x2019;s performance.&#xa0; The Directors noted that the Fund
outperformed the average of the Peer Funds for the one-year period ended March 31, 2025, and underperformed the benchmark for the 1-year period ended March 31, 2025. The Board noted that the Adviser began managing the
strategy in October 2023 and that prior performance is attributed to another adviser. The Board considered the Adviser&#x2019;s discussion of Fund performance, including distinguishing features between the benchmark
and the Funds and that the Peer Funds have varying investment objectives, strategies and policies, as well as varying exposures to the healthcare sector, which limits the comparability of Peer Fund performance to the
Fund. The Board also considered the Adviser&#x2019;s plans for the Fund, among other factors, in determining to continue the Advisory Agreement.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Direct and Indirect Benefits</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Board then considered
whether or the extent to which the Adviser derives any direct, ancillary or indirect benefits, such as reputational benefits, that could accrue to the Adviser from the Fund&#x2019;s operations as a result of the
Adviser&#x2019;s relationship with the Fund. The Board recognized the services provided to the Fund by affiliates of the Adviser and the related compensation paid by the Fund for those services.&#xa0; Based on the
totality of the information considered, the Board concluded that any benefits accruing to the Adviser by virtue of its relationship with the Fund appeared to be reasonable.</div>
</div>
<div style="margin-top:38.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">34
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Supplemental Information&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited)&#xa0;&#xa0;(concluded)</font></div>
</div>
<div style="margin-top:8pt; width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:20.5pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Economies of Scale</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Board next considered
management&#x2019;s discussion of the Fund&#x2019;s management fee structure and determined that the management fee structure was reasonable. The Board based its determination on various factors, including how the
Fund&#x2019;s management fee compared relative to the Peer Funds. The Board also considered that the Fund had an expense limitation agreement in place until October 27, 2025, pursuant to which the Adviser agreed to
waive a portion of its management fee and/or reimburse certain expenses as a means of limiting the Fund&#x2019;s total annual operating expenses. The Board concluded that the economies of scale shared with the Fund
were reasonable.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:center; text-decoration:none; text-transform:none">* * *</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:justify; text-decoration:none; text-transform:none">Based on the Board&#x2019;s
deliberations and its evaluation of the information described above and other factors and information the Directors deemed relevant in the exercise of their individual reasonable business judgment, the Board,
including the Independent Directors, with the assistance of fund counsel and independent legal counsel to the Independent Directors, unanimously determined that&#xa0; the fees charged pursuant to the Advisory
Agreement were fair and reasonable and approved the continuation of the Advisory Agreement.&#xa0;</div>
</div>
<div style="margin-top:520pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:24.07%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">35
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">RECENT CHANGES</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The following information is
a summary of certain changes during the fiscal year ended September 30, 2025. This information may not reflect all of the changes that have occurred since you purchased the Fund.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">During the applicable period,
there have been: (i) no material changes to the Fund&#x2019;s investment objectives and policies that constitute its principal portfolio emphasis that have not been approved by the Fund&#x2019;s shareholders (the
 &#x201c;Shareholders&#x201d;), (ii) no material changes to the Fund&#x2019;s principal risks, (iii) no changes to the persons primarily responsible for day-to-day management of the Fund; and (iv) no changes to the
Fund&#x2019;s charter or by-laws that would delay or prevent a change of control that have not been approved by Shareholders; except as follows:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Change in Non-Fundamental
Investment Policy</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Fund's Board of Trustees
approved, effective on or about January 28, 2026 (the &#x201c;Effective Date&#x201d;), to permit the Fund to employ leverage, both traditional and effective, up to the maximum extent permitted by the Investment Company
Act of 1940, as amended (the "Investment Company Act"), and to eliminate the following non-fundamental investment policy:&#xa0;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">&#x201c;The Fund will not
incur effective leverage (as such term is defined in this report) in an amount that exceeds 20% of its Managed Assets as measured at the time when leverage is incurred, except that effective leverage incurred through
the use of covered calls will not be counted toward the Fund's limit on the use of effective leverage.&#x201d;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">A summary of the Fund's
investment objectives, strategies, policies and risks, as of the Effective Date (inclusive of the change to the investment policy noted above), is set forth below.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">INVESTMENT OBJECTIVE, STRATEGIES AND
POLICIES</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Fund&#x2019;s investment
objective is to seek current income and long-term capital appreciation. The Fund&#x2019;s investment objective is a non-fundamental policy and may be changed by the Board of Trustees of the Fund (the
 &#x201c;Board&#x201d;) upon 60 days' notice to the Fund&#x2019;s shareholders (&#x201c;Shareholders&#x201d;).</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Under normal market
conditions, the Fund expects to invest at least 80% of its Managed Assets in U.S. and non-U.S. companies engaged in the healthcare industry("Healthcare Companies") including equity securities, debt securities, and
pooled investment vehicles. &#x201c;Managed Assets&#x201d; means the total assets of the Fund (including any assets attributable to borrowings for investment purposes) minus the sum of the Fund&#x2019;s accrued
liabilities (other than liabilities representing borrowings for investment purposes). The Fund&#x2019;s 80% policy may not be changed without&#xa0;60 days&#x2019; prior notice to the Fund&#x2019;s Shareholders.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">A company will be deemed to
be a Healthcare Company if, at the time the Fund makes an investment in the company, 50% or more of such</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">company&#x2019;s sales, earnings or assets
arise from or are dedicated to healthcare products or services or medical technology activities. healthcare companies may include companies in one or more of the following sub-sectors: pharmaceuticals, biotechnology
(with respect to which the Fund invests not more than 40% of its Managed Assets as measured at the time of investment), managed care, life science and tools, healthcare technology, healthcare services, healthcare
supplies, healthcare facilities, healthcare equipment, healthcare distributors and Healthcare REITs (as defined herein). The Investment Adviser determines, in its discretion, whether a company is a Healthcare
Company.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Fund expects to invest
55-90% of its Managed Assets in equity securities (which may include common stock, preferred stock, convertible securities, and warrants or other rights to acquire common or preferred stock) as measured at the time of
investment. Of the 55-90% of its Managed Assets that are invested in equity securities, the Fund will not invest more than 20%, as measured at the time of investment, in convertible securities, but in no event will
the Fund&#x2019;s investment in convertible securities exceed 30%. The Fund will not invest more than 20% of its Managed Assets as measured at the time of investment in debt securities, including corporate debt
obligations and debt securities that are rated non-investment grade (that is, rated Ba1 or lower by Moody&#x2019;s Investors Service, Inc. (&#x201c;Moody&#x2019;s&#x201d;), BB+ or lower by Standard &amp; Poor&#x2019;s
Ratings Group (&#x201c;S&amp;P&#x201d;), or BB by Fitch, Inc. (&#x201c;Fitch&#x201d;) or comparably rated by another nationally recognized statistical rating organization (&#x201c;NRSRO&#x201d;),or, if unrated, determined
by the Investment Adviser to be of comparable credit quality). In the event that a security receives different ratings from different NRSROs, the Adviser will treat the security as being rated in the highest rating
category received from an NRSRO.&#xa0;The Fund&#x2019;s investments in non-investment grade investments and those deemed to be of similar quality are considered speculative with respect to the issuer&#x2019;s capacity
to pay interest and repay principal and are commonly referred to as &#x201c;junk&#x201d; or &#x201c;high yield&#x201d; securities.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Fund will not invest more
than 30% of its Managed Assets (the total assets of the Fund (including any assets attributable to borrowings for investment purposes) minus the sum of the Fund&#x2019;s accrued liabilities (other than liabilities
representing borrowings for investment purposes)) as measured at the time of investment in derivatives, including but not limited to options, futures,options on futures, forwards, swaps, options on swaps and other
derivatives. Initially, the Fund employs a strategy of writing (selling) covered call options on a portion of the common stocks in its portfolio, writing (selling) put options on a portion of the common stocks in its
portfolio and, to a lesser extent, writing (selling) covered call and writing (selling) put options on indices of securities and sectors of securities generally within the healthcare industry. This option strategy is
intended to generate current income from option</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:15.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">36
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">premiums as a means to enhance distributions
payable to the Fund&#x2019;s Shareholders. As the Fund&#x2019;s portfolio becomes more seasoned, its ability to benefit from capital appreciation may become more limited, and the Fund will lose money to the extent that
it writes covered call options and the securities on which it writes the option appreciates above the exercise price of the option by an amount that exceeds the exercise price of the option. Therefore, the Investment
Adviser may choose to decrease its use of the option writing strategy to the extent that it may negatively impact the Fund&#x2019;s ability to benefit from capital appreciation. Other than the Fund&#x2019;s option
strategy, the Fund may invest up to 10% of its Managed Assets in derivatives. Derivative instruments can be illiquid, may disproportionately increase losses, and may have a potentially large adverse impact on Fund
performance.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Fund will not invest more
than 20% of its Managed Assets as measured at the time of investment in non-U.S. securities, which may include securities denominated in the U.S.dollars or in non-U.S. currencies or multinational currency units. The
Fund may invest in non-U.S. securities of so-called emerging market issuers. For purposes of the Fund, the Investment Adviser determines, in its discretion, whether a company is a non-U.S. company using an independent
analysis of one or more classifications assigned by third parties. These classifications are generally based on a number of criteria, including a company&#x2019;s country of domicile, the primary stock exchange on
which a company&#x2019;s securities trade, the location from which the majority of a company&#x2019;s revenue is derived, and a company&#x2019;s reporting&#xa0; currency. Non-U.S. securities markets generally are not as
developed or efficient as those in the United States. Securities of some non-U.S. issuers are less liquid and more volatile than securities of comparable U.S. issuers. Similarly, volume and liquidity in most
non-U.S.securities markets are less than in the United States and, at times, price volatility can be greater than in the United States.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Fund will not invest more
than 10% of its Managed Assets as measured at the time of investment in restricted securities, including private investments in public equity (&#x201c;PIPEs&#x201d;).</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Fund may invest up to 25%
of its Managed Assets as measured at the time of investment in real estate investment Funds that derive their income from the ownership,leasing, or financing of properties in the healthcare sector (&#x201c;Healthcare
REITs&#x201d;).</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">The Fund may from time-to-time
lend its portfolio securities but has terminated its Securities Lending program effective July 18, 2023.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">RISK FACTORS</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Investing in any investment
company security involves risk, including the risk that you may receive little or no return on your investment or even that you may lose part or all of your investment. Investors</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">should consider the following Risk Factors and
special considerations associated with investing in the Fund&#x2019;s shares.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Portfolio Market Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Fund is subject to market
risk&#x2014;the possibility that the prices of equity securities will decline over short or extended periods of time. As a result, the value of an investment in the Fund&#x2019;s shares will fluctuate with the market.
You could lose some or all of your investment over short or long periods of time.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Political and economic news
can influence market-wide trends and can cause disruptions in the U.S. or world financial markets. Other factors may be ignored by the market as a whole but may cause movements in the price of one company&#x2019;s
stock or the stock of companies in one or more industries. All of these factors may have a greater impact on initial public offerings and emerging company shares.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Market Events Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The market values of
securities or other assets will fluctuate, sometimes sharply and unpredictably, due to changes in general market conditions, overall economic trends or events, governmental actions or intervention, actions taken by
the US Federal Reserve or foreign central banks, market disruptions caused by trade disputes or other factors, political events within the U.S. and abroad, such as changes in the U.S. presidential administration and
Congress, investor sentiment and other factors that may or may not be related to the issuer of the security or other asset. Economies and financial markets throughout the world are increasingly interconnected.
Economic, financial or political events, imposition of sanctions and other measures, trading and tariff arrangements, actual or threatened war or armed conflicts, terrorism, social unrest, natural or environmental
disasters and other circumstances in one country or region could have profound impacts on global economies or markets. As a result, whether or not the Fund invests in securities of issuers located in or with
significant exposure to the countries directly affected, the value and liquidity of the Fund's investments may be negatively affected. In addition, public health emergencies (such as the spread of infectious diseases,
pandemics and epidemics) or similar issues could reduce consumer demand or economic output, result in market closures, travel restrictions or quarantines, and generally have a significant impact on the world economy,
which in turn could adversely affect the Fund's investments. The impact of the recent U.S. elections on such policies remains uncertain and policies supported by the new administration (or the reversal of policies
supported by the previous administration) could impact U.S. interest rates or inflation or otherwise impact the Fund.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:32.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:23.55%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">37
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">Security Market Risk - Discount to NAV</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">Shares of closed-end
investment companies frequently trade at a discount from their NAV. The risk that the Fund&#x2019;s common shares may trade at a discount is separate from the risk of a decline in the Fund&#x2019;s NAV as a result of
investment activities.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Whether Shareholders will
realize a gain or loss for federal income tax purposes upon the sale of their common shares depends upon whether the market value of the common shares at the time of sale is above or below the Shareholder&#x2019;s
basis in such common shares, taking into account transaction costs, and it is not directly dependent upon the Fund&#x2019;s NAV. Because the market price of the Fund&#x2019;s common shares will be determined by factors
such as the relative demand for and supply of the shares in the market, general market conditions and other factors beyond the Fund&#x2019;s control, the Fund cannot predict whether its common shares will trade at,
below or above the NAV, or at, below or above the public offering price for the Fund&#x2019;s common shares.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Equity Securities Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Fund expects to invest
55-90% of its Managed Assets in equity securities. Equity risk is the risk that equity securities held by the Fund will fall due to general market or economic conditions, perceptions regarding the industries in which
the issuers of securities held by the Fund participate, changes in interest rates, and the particular circumstances and performance of particular companies whose securities the Fund holds. The price of an equity
security of an issuer may be particularly sensitive to general movements in the stock market, or a drop in the stock market may depress the price of most or all of the equity securities held by the Fund. In addition,
equity securities held by the Fund may decline in price if the issuer fails to make anticipated distributions or dividend payments because,among other reasons, the issuer experiences a decline in its financial
condition.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Selection Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">Different types of equity
securities tend to shift into and out of favor with investors, depending on market and economic conditions. The performance of funds that invest in healthcare industry equity securities may at times be better or worse
than the performance of funds that focus on other types of securities or that have a broader investment style.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Concentration in the Healthcare
Industries</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">Under normal market
conditions, the Fund expects to invest at least 80% of its Managed Assets in securities of Healthcare Companies. As a result, the Fund&#x2019;s portfolio may be more sensitive to, and possibly more adversely affected
by, regulatory, economic or political factors or trends relating to the healthcare,agricultural and environmental technology industries than a portfolio of companies representing a</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">larger number of industries. This risk is in
addition to the risks normally associated with any strategy seeking capital appreciation by investing in a portfolio of equity securities. As a result of its concentration policy, the Fund&#x2019;s investments may be
subject to greater risk and market fluctuation than a fund that has securities representing a broader range of investments. The Fund may occasionally make investments in any company with the objective of controlling
or influencing the management and policies of that company, which could potentially make the Fund more susceptible to declines in the value of the company&#x2019;s stock. The Investment Adviser may seek control in
public companies only occasionally and most often in companies with a small capitalization.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare companies have in
the past been characterized by limited product focus, rapidly changing technology and extensive government regulation. In particular, technological advances can render an existing product, which may account for a
disproportionate share of a company&#x2019;s revenue, obsolete. Obtaining governmental approval from agencies such as the Food and Drug Administration (the &#x201c;FDA&#x201d;) for new products can be lengthy, expensive
and uncertain as to outcome. Such delays in product development may result in the need to seek additional capital, potentially diluting the interests of existing investors such as the Fund. In addition, governmental
agencies may, for a variety of reasons, restrict the release of certain innovative technologies of commercial significance. These various factors may result in abrupt advances and declines in the securities prices of
particular companies and, in some cases,may have a broad effect on the prices of securities of companies in particular healthcare industries.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">A concentration of
investments in any healthcare industry or in healthcare companies generally may increase the risk and volatility of an investment company&#x2019;s portfolio. Such volatility is not limited to the biotechnology
industry, and companies in other industries maybe subject to similar abrupt movements in the market prices of their securities. No assurance can be given that future declines in the market prices of securities of
companies in the industries in which the Fund may invest will not occur, or that such declines will not adversely affect the NAV or the price of the shares.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Intense competition exists
within and among certain healthcare industries, including competition to obtain and sustain proprietary technology protection, including patents,trademarks and other intellectual property rights, upon which healthcare
companies can be highly dependent for maintenance of profit margins and market exclusivity. Accordingly, such companies may be significantly affected by such things as the expiration of patents or the loss of , or the
inability to enforce, intellectual property rights. The complex nature of the technologies involved can lead to patent disputes, including litigation that maybe costly and that could result in a company losing an
exclusive right to a patent.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:11.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">38
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">With respect to healthcare industries, cost
containment measures already implemented by national governments, state or provincial governments and the private sector have adversely affected certain sectors of these industries. The implementation of the
Affordable Care Act (&#x201c;ACA&#x201d;) has created increased demand for healthcare products and services, but potential changes to the ACA and future healthcare laws and regulations may impact demand for healthcare
products and services and has had or may have an adverse effect on some companies in the healthcare industries, as discussed further below under &#x201c;Risks Associated with Regulatory and Policy Changes.&#x201d;
Increased emphasis on managed care in the United States and a shift toward value based payment models may put pressure on the price and usage of products sold by healthcare companies in which the Fund may invest and
may adversely affect the sales and revenues of healthcare companies.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Product development efforts
by healthcare companies may not result in commercial products for many reasons, including, but not limited to, failure to achieve acceptable clinical trial results, limited effectiveness in treating the specified
condition or illness, harmful side effects, failure to obtain regulatory approval, and high manufacturing costs. Even after a product is commercially released, governmental agencies may require additional clinical
trials or change the labeling requirements for products if additional product side effects are identified, which could have a material adverse effect on the market price of the securities of those healthcare
companies.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Certain healthcare companies
in which the Fund may invest may be exposed to potential product liability risks that are inherent in the testing, manufacturing, marketing and sale of pharmaceuticals, medical devices or other products. There can be
no assurance that a product liability claim would not have a material adverse effect on the business, financial condition or securities prices of a company in which the Fund has invested.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">All of these factors as well as
others may cause the value of the Fund&#x2019;s shares to fluctuate significantly over relatively short periods of time.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Pharmaceutical Sector Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The success of companies in
the pharmaceutical sector is highly dependent on the development, procurement and marketing of drugs. The values of pharmaceutical companies are also dependent on the development, protection and exploitation of
intellectual property rights and other proprietary information, and the profitability of pharmaceutical companies may be significantly affected by such things as the expiration of patents or the loss of, or the
inability to enforce, intellectual property rights.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The research and other costs
associated with developing or procuring new drugs and the related intellectual property rights can be significant, and the results of such research and expenditures are</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">unpredictable. There can be no assurance
that those efforts or costs will result in the development of a profitable drug. Pharmaceutical companies may be susceptible to product obsolescence. Many pharmaceutical companies face intense competition from new
products and less costly generic products. Moreover, the process for obtaining regulatory approval by the FDA or other governmental regulatory authorities is long and costly and there can be no assurance that the
necessary approvals will be obtained or maintained.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The pharmaceutical sector is
also subject to rapid and significant technological change and competitive forces that may make drugs obsolete or make it difficult to raise prices and, in fact, may result in price discounting. Companies in the
pharmaceutical sector may also be subject to expenses and losses from extensive litigation based on intellectual property,product liability and similar claims. Failure of pharmaceutical companies to comply with
applicable laws and regulations can result in the imposition of civil and criminal fines, penalties and, in some instances, exclusion of participation in government sponsored programs such as Medicare and Medicaid.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Companies in the
pharmaceutical sector may be adversely affected by government regulation and changes in reimbursement rates. The ability of many pharmaceutical companies to commercialize and monetize current and any future products
depends in part on the extent to which reimbursement for the cost of such products and related treatments are available from third party payors, such as Medicare, Medicaid, private health insurance plans and health
maintenance organizations. Third-party payors are increasingly challenging the price and cost-effectiveness of many medical products.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Significant uncertainty
exists as to the reimbursement status of health care products, and there can be no assurance that adequate third-party coverage will be available for pharmaceutical companies to obtain satisfactory price levels for
their products.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The international operations
of many pharmaceutical companies expose them to risks associated with instability and changes in economic and political conditions, foreign currency fluctuations, changes in foreign regulations and other risks
inherent to international business. Additionally, a pharmaceutical company&#x2019;s valuation can often be based largely on the potential or actual performance of a limited number of products. A pharmaceutical
company&#x2019;s valuation can also be greatly affected if one of its products proves unsafe, ineffective or unprofitable. Such companies also may be characterized by thin capitalization and limited markets, financial
resources or personnel, as well as dependence on wholesale distributors. The stock prices of companies in the pharmaceutical industry have been and will likely continue to be extremely volatile.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:19.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:23.55%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">39
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">Biotechnology Industry Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The success of biotechnology
companies is highly dependent on the development, procurement and/or marketing of drugs. The values of biotechnology companies are also dependent on the development, protection and exploitation of intellectual
property rights and other proprietary information, and the profitability of biotechnology companies may be significantly affected by such things as the expiration of patents or the loss of, or the inability to
enforce, intellectual property rights.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The research and other costs
associated with developing or procuring new drugs, products or technologies and the related intellectual property rights can be significant, and the results of such research and expenditures are unpredictable. There
can be no assurance that those efforts or costs will result in the development of a profitable drug, product or technology. Moreover, the process for obtaining regulatory approval by the FDA or other governmental
regulatory authorities is long and costly and there can be no assurance that the necessary approvals will be obtained or maintained.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The biotechnology sector is
also subject to rapid and significant technological change and competitive forces that may make drugs, products or technologies obsolete or make it difficult to raise prices and, in fact, may result in price
discounting. Companies in the biotechnology sector may also be subject to expenses and losses from extensive litigation based on intellectual property, product liability and similar claims. Failure of biotechnology
companies to comply with applicable laws and regulations can result in the imposition of civil and/or criminal fines, penalties and, in some instances, exclusion of participation in government sponsored programs such
as Medicare and Medicaid.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Companies in the
biotechnology sector may be adversely affected by government regulation and changes in reimbursement rates. Healthcare providers, principally hospitals, that transact with companies in the biotechnology industry,
often rely on third party payors, such as Medicare, Medicaid, private health insurance plans and health maintenance organizations to reimburse all or a portion of the cost of healthcare related products or services.
Biotechnology companies will continue to be affected by the efforts of governments and third party payors to contain or reduce health care costs. For example, certain foreign markets control pricing or profitability
of biotechnology products and technologies. In the United States, there has been, and there will likely continue to be, a number of federal and state proposals to implement similar controls.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">A biotechnology
company&#x2019;s valuation could be based on the potential or actual performance of a limited number of products and could be adversely affected if one of its products proves unsafe, ineffective or unprofitable. Such
companies may also be characterized by thin capitalization and limited markets, financial resources or personnel.</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">The stock prices of companies involved in the
biotechnology sector have been and will likely continue to be extremely volatile.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Managed Care Sector Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">Companies in the managed care
sector often assume the risk of both medical and administrative costs for their customers in return for monthly premiums. The profitability of these products depends in large part on the ability of such companies to
predict, price for, and effectively manage medical costs. Managed care companies base the premiums they charge and their Medicare bids on estimates of future medical costs over the fixed contract period; however, many
factors may cause actual costs to exceed what was estimated and reflected in premiums or bids. These factors may include medical cost inflation,increased use of services, increased cost of individual services, natural
catastrophes or other large-scale medical emergencies, epidemics, the introduction of new or costly treatments and technology, new mandated benefits (such as the expansion of essential benefits coverage) or other
regulatory changes and insured population characteristics. Relatively small differences between predicted and actual medical costs or utilization rates as a percentage of revenues can result in significant changes in
financial results.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Managed care companies are
regulated at the federal, state, local and international levels. Insurance and Health Maintenance Organization (&#x201c;HMO&#x201d;) subsidiaries must be licensed by and are subject to the regulations of the
jurisdictions in which they conduct business. U.S. health plans and insurance companies are also regulated under state insurance holding company regulations, and some of their activities may be subject to other health
care-related regulations. The health care industry is also regularly subject to negative publicity, including as a result of governmental investigations, adverse media coverage and political debate surrounding
industry regulation. Negative publicity may adversely affect stock price, damage the reputation of managed care companies in various markets or foster an increasingly active regulatory environment, which, in turn,
could further increase the regulatory burdens under which such companies operate and their costs of doing business.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The evolution of the ACA and
other regulatory reforms could materially and adversely affect the manner in which U.S. managed care companies conduct business and their results of operations, financial position and cash flows. The ACA includes
guaranteed coverage and expanded benefit requirements, eliminates pre-existing condition exclusions and annual and lifetime maximum limits, restricts the extent to which policies can be rescinded, establishes minimum
medical loss ratios, creates a federal premium review process, imposes new requirements on the format and content of communications (such as explanations of benefits) between health insurers and their members, grants
to members new and additional</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:18.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">40
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">appeal rights, and imposes new and significant
taxes on health insurers and health care benefits.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">New laws or regulations could
drive substantial change to the way healthcare products and services are currently delivered and paid for in the United States. Health plans and insurance companies could face meaningful disruption or
disintermediation if the U.S. migrates to a single payer healthcare system where the government acts as the sole payer of healthcare services for the entire population. A transformative overhaul of the U.S. healthcare
system could impact the financial viability of managed care companies in which the Fund may invest.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Managed care companies
contract with physicians, hospitals, pharmaceutical benefit service providers, pharmaceutical manufacturers, and other health care providers for services. Suchcompanies&#x2019; results of operations and prospects are
substantially dependent on their continued ability to contract for these services at competitive prices. Failure to develop and maintain satisfactory relationships with health care providers, whether in-network or
out-of network,could materially and adversely affect business, results of operations, financial position and cash flows.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Life Science and Tools Industry
Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">Life sciences industries are
characterized by limited product focus, rapidly changing technology and extensive government regulation. In particular, technological advances can render an existing product, which may account for a disproportionate
share of a company&#x2019;s revenue, obsolete. Obtaining governmental approval from agencies such as the FDA, the U.S. Department of Agriculture and other U.S. and non-U.S. governmental agencies for new products can be
lengthy, expensive and uncertain as to outcome. Such delays in product development may result in the need to seek additional capital, potentially diluting the interests of existing investors such as the Fund. In
addition,governmental agencies may, for a variety of reasons, restrict the release of certain innovative technologies of commercial significance, such as genetically altered material. These various factors may result
in abrupt advances and declines in the securities prices of particular companies and, in some cases, may have a broad effect on the prices of securities of companies in particular life sciences industries.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Intense competition exists
within and among certain life sciences industries, including competition to obtain and sustain proprietary technology protection. Life sciences companies can be highly dependent on the strength of patents, trademarks
and other intellectual property rights for maintenance of profit margins and market share. Accordingly, such companies may be significantly affected by such things as the expiration of patents or the loss of , or the
inability to enforce, intellectual property rights. The complex nature of the technologies involved can lead to patent disputes,</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">including litigation that could result in a
company losing an exclusive right to a patent. Competitors of life sciences companies may have substantially greater financial resources, more extensive development, manufacturing,marketing and service capabilities,
and a larger number of qualified managerial and technical personnel. Such competitors may succeed in developing technologies and products that are more effective or less costly than any that may be developed by life
sciences companies in which the Fund invests and may also prove to be more successful in production and marketing. Competition may increase further as a result of potential advances in health services and medical
technology and greater availability of capital for investment in these fields.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">With respect to healthcare,
cost containment measures already implemented by the federal government, state governments and the private sector have adversely affected certain sectors of these industries. Increased emphasis on managed care in the
United States may put pressure on the price and usage of products sold by life sciences companies in which the Fund may invest and may adversely affect the sales and revenues of life sciences companies.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Product development efforts
by life sciences companies may not result in commercial products for many reasons, including, but not limited to, failure to achieve acceptable clinical trial results, limited effectiveness in treating the specified
condition or illness, harmful side effects, failure to obtain regulatory approval, and high manufacturing costs. Even after a product is commercially released, governmental agencies may require additional clinical
trials or change the labeling requirements for products if additional product side effects are identified, which could have a material adverse effect on the market price of the securities of those life sciences
companies.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Certain life sciences
companies in which the Fund may invest may be exposed to potential product liability risks that are inherent in the testing, manufacturing, marketing and sale of pharmaceuticals, medical devices or other products.
There can be no assurance that a product liability claim would not have a material adverse effect on the business, financial condition or securities prices of a company in which the Fund has invested.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Healthcare Technology Sector
Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">Companies in the healthcare
technology sector may incur substantial costs related to product-related liabilities. Many of the software solutions,health care devices or services developed by such companies are intended for use in collecting,
storing and displaying clinical and health care-related information used in the diagnosis and treatment of patients and in related health care settings such as admissions,billing, etc. The limitations of liability set
forth in the companies&#x2019; contracts may not be enforceable or may not otherwise protect these companies from liability for damages. Healthcare technology companies may also be subject to claims that are not</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:12.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:23.55%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">41
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">covered by contract, such as a claim
directly by a patient. Although such companies may maintain liability insurance coverage, there can be no assurance that such coverage will cover any particular claim that has been brought or that may be brought in
the future, that such coverage will prove to be adequate or that such coverage will continue to remain available on acceptable terms, if at all.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare technology
companies may experience interruption at their data centers or client support facilities. The business of such companies often relies on the secure electronic transmission, data center storage and hosting of sensitive
information, including protected health information, financial information and other sensitive information relating to clients,company and workforce. In addition, such companies may perform data center and/or hosting
services for certain clients, including the storage of critical patient and administrative data and support services through various client support facilities. If any of these systems are interrupted, damaged or
breached by an unforeseen event or actions of a third party,including a cyber-attack, or fail for any extended period of time, it could have a material adverse impact on the results of operations for such
companies.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The proprietary technology
developed by healthcare technology companies may be subject to claims for infringement or misappropriation of intellectual property rights of others, or maybe infringed or misappropriated by others. Despite protective
measures and intellectual property rights, such companies may not be able to adequately protect against theft, copying,reverse-engineering, misappropriation, infringement or unauthorized use or disclosure of their
intellectual property, which could have an adverse effect on their competitive position. In addition, these companies are routinely involved in intellectual property infringement or misappropriation claims and it is
expected that this activity will continue or even increase as the number of competitors, patents and patent enforcement organizations in the healthcare technology market increases, the functionality of software
solutions and services expands, the use of open-source software increases and new markets such as health care device innovation, health care transactions, revenue cycle, population health management and life sciences
are entered into. These claims, even if not meritorious, are expensive to defend and are often incapable of prompt resolution.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The success of healthcare
technology companies depends upon the recruitment and retention of key personnel. To remain competitive, such companies must attract, motivate and retain highly skilled managerial, sales, marketing, consulting and
technical personnel, including executives, consultants, programmers and systems architects skilled in healthcare technology,health care devices, health care transactions, population health management, revenue cycle
and life sciences industries and the technical environments in which solutions, devices and services are needed. Competition for such</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">personnel in the healthcare technology
sector is intense in both the United States and abroad. The failure to attract additional qualified personnel could have a material adverse effect on healthcare technology companies&#x2019; prospects for long-term
growth.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Healthcare Services Sector
Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The operations of healthcare
services companies are subject to extensive federal, state and local government regulations, including Medicare and Medicaid payment rules and regulations, federal and state anti-kickback laws, the physician
self-referral law (&#x201c;Stark Law&#x201d;) and analogous state self-referral prohibition statutes, Federal Acquisition Regulations, the False Claims Act and federal and state laws regarding the collection, use and
disclosure of patient health information and the storage, handling and administration of pharmaceuticals. The Medicare and Medicaid reimbursement rules related to claims submission, enrollment and licensing
requirements, cost reporting, and payment processes impose complex and extensive requirements upon dialysis providers as well. A violation or departure from any of these legal requirements may result in government
audits,lower reimbursements, significant fines and penalties, the potential loss of certification,recoupment efforts or voluntary repayments. If healthcare services companies fail to adhere to all of the complex
government regulations that apply to their businesses, such companies could suffer severe consequences that would substantially reduce revenues, earnings, cash flows and stock prices.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">A substantial percentage of a
healthcare services company&#x2019;s service revenues may be generated from patients who have state Medicaid or other non-Medicare government-based programs, such as coverage through the Department of Veterans Affairs
(&#x201c;VA&#x201d;), as their primary coverage. As state governments and other governmental organizations face increasing budgetary pressure, healthcare services companies may in turn face reductions in payment rates,
delays in the receipt of payments, limitations on enrollee eligibility or other changes to the applicable programs.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Adverse economic conditions
could adversely affect the business and profitability of healthcare services companies. Among other things, the potential decline in federal, non-U.S. government and state revenues that may result from such conditions
may create additional pressures to contain or reduce reimbursements for services from Medicare, Medicaid and other government sponsored programs. Increasing job losses or slow improvement in the unemployment rate in
the United States and elsewhere as a result of adverse or recent economic conditions may result in a smaller percentage of patients being covered by an employer group health plan and a larger percentage being covered
by lower paying Medicare and Medicaid programs. Employers may also select more restrictive commercial plans with lower reimbursement rates. To the extent that payors are negatively impacted by a decline in the
economy, healthcare services</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:11.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">42
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">companies may experience further pressure on
commercial rates, a further slowdown in collections and a reduction in the amounts they expect to collect. In addition, uncertainty in the financial markets could adversely affect the variable interest rates payable
under credit facilities or could make it more difficult to obtain or renew such facilities or to obtain other forms of financing in the future, if at all. Any or all of these factors, as well as other consequences of
the adverse economic conditions which cannot currently be anticipated, could have a material adverse effect on a healthcare services company&#x2019;s revenues, earnings and cash flows and otherwise adversely affect its
financial condition.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Healthcare Supplies Sector
Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">If healthcare supplies
companies are unable to successfully expand their product lines through internal research and development and acquisitions, their business may be materially and adversely affected. In addition, if these companies are
unable to successfully grow their businesses through marketing partnerships and acquisitions, their business may be materially and adversely affected.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Consolidation of healthcare
providers has increased demand for price concessions and caused the exclusion of suppliers from significant market segments. It is expected that market demand, government regulation, third-party reimbursement
policies, government contracting requirements and societal pressures will continue to change the worldwide healthcare industry, resulting in further business consolidations and alliances among customers and
competitors. This may exert further downward pressure on the prices of healthcare suppliescompanies&#x2019; products and adversely impact their businesses, financial conditions or results of operations.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Quality is extremely
important to healthcare supplies companies and their customers due to the serious and costly consequences of product failure. Quality certifications are critical to the marketing success of their products and
services. If a healthcare supplies company fails to meet these standards or fails to adapt to evolving standards, its reputation could be damaged, it could lose customers, and its revenue and results of operations
could decline.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Healthcare Facilities Sector
Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">A healthcare facility&#x2019;s
ability to negotiate favorable contracts with HMOs, insurers offering preferred provider arrangements and other managed care plans significantly affects the revenues and operating results of such healthcare
facilities. In addition, private payers are increasingly attempting to control health care costs through direct contracting with hospitals to provide services on a discounted basis, increased utilization reviews and
greater enrollment in managed care programs, such as HMOs and Preferred Provider Organizations (&#x201c;PPOs&#x201d;). The trend toward consolidation among private managed care payers tends to increase their bargaining
power over prices and</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">fee structures. Non-government payers may
increasingly demand reduced fees. If a healthcare facility is unable to enter into and maintain managed care contractual arrangements on acceptable terms, if it experiences material reductions in the contracted rates
received from managed care payers, or if it has difficulty collecting from managed care payers, its results of operations could be adversely affected.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Further changes in the
Medicare and Medicaid programs or other government health care programs could have an adverse effect on a healthcare facility&#x2019;s business. In addition to the changes affected by the ACA, the Medicare and Medicaid
programs are subject to other statutory and regulatory changes, administrative rulings, interpretations and determinations concerning patient eligibility requirements, funding levels and the method of calculating
payments or reimbursements, among other things, requirements for utilization review, and federal and state funding restrictions. All of these could materially increase or decrease payments from government programs in
the future, as well as affect the cost of providing services to patients and the timing of payments to facilities, which could in turn adversely affect a healthcare facility&#x2019;s overall business, financial
condition, results of operations or cash flows.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare facilities are
adversely affected by uninsured and underinsured patients, as well as a growing mix of Medicare and Medicaid patients that typically have lower reimbursement rates than commercial managed care patients. As a result,
healthcare facilities continue to experience a shift in payer mix and a high level of uncollectible accounts, which could worsen if there is an increase in unemployment. Healthcare facilities may continue to
experience significant levels of bad debt expense and may have to provide uninsured discounts and charity care for undocumented immigrants who are not permitted to enroll in a health insurance exchange or government
health care program. The trend of higher co-pays and deductibles and a focus on migrating healthcare utilization to lower cost sites of care, may also pressure volumes and revenue at certain healthcare facilities
which could adversely impact the financial condition of hospitals and facilities with high fixed cost structures.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Healthcare Equipment Sector
Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The medical device markets
are highly competitive and a healthcare equipment company many be unable to compete effectively. These markets are characterized by rapid change resulting from technological advances and scientific discoveries.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Development by other
companies of new or improved products, processes, or technologies may make a healthcare equipment company&#x2019;s products or proposed products less competitive. In addition, these companies face competition from
providers of alternative medical therapies such as pharmaceutical companies.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:20.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:23.55%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">43
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Medical devices and related business
activities are subject to rigorous regulation, including by the FDA, U.S. Department of Justice (&#x201c;DOJ&#x201d;), and numerous other federal, state, and foreign governmental authorities. These authorities and
members of Congress have been increasing their scrutiny of the healthcare equipment industry. In addition, certain states have passed or are considering legislation restricting healthcare equipment companies&#x2019;
interactions with health care providers and requiring disclosure of certain payments to them. It is anticipated that governmental authorities will continue to scrutinize this industry closely,and that additional
regulation may increase compliance and legal costs, exposure to litigation, and other adverse effects to operations.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare equipment
companies are substantially dependent on patent and other proprietary rights and failing to protect such rights or to be successful in litigation related to such rights may result in the payment of significant
monetary damages and/or royalty payments, may negatively impact the ability of healthcare equipment companies to sell current or future products, or may prohibit such companies from enforcing their patent and other
proprietary rights against others.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Quality problems with the
processes, goods and services of a healthcare equipment company could harm the company&#x2019;s reputation for producing high-quality products and erode its competitive advantage, sales and market share. Quality is
extremely important to healthcare equipment companies and their customers due to the serious and costly consequences of product failure. Quality certifications are critical to the marketing success of goods and
services. If a healthcare equipment company fails to meet these standards, its reputation could be damaged, it could lose customers, and its revenue and results of operations could decline.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Healthcare Distributors Sector
Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">Companies in the healthcare
distribution sector operate in markets that are highly competitive. Because of competition, many of these companies face pricing pressures from customers and suppliers. If these companies are unable to offset margin
reductions caused by pricing pressures through steps such as effective sourcing and enhanced cost control measures, the financial condition of such companies could be adversely affected. In addition, the healthcare
industry has continued to consolidate. Further consolidation among customers and suppliers (including branded pharmaceutical manufacturers) could give the resulting enterprises greater bargaining power,which may
adversely impact the financial condition of companies in the health care distribution sector.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Fewer generic pharmaceutical
launches or launches that are less profitable than those previously experienced may have an adverse effect on the profits of companies in the healthcare distribution sector. Additionally, prices for existing generic
pharmaceuticals</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">generally decline over time, although this
may vary. Price deflation on existing generic pharmaceuticals may have an adverse effect on company profits. With respect to branded pharmaceutical price appreciation, if branded manufacturers increase prices less
frequently or by amounts that are smaller than have been experienced historically, healthcare distribution companies may profit less from branded pharmaceutical agreements.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The healthcare industry is
highly regulated, and healthcare distribution companies are subject to regulation in the United States at both the federal and state level and in foreign countries. If healthcare distribution companies fail to comply
with these regulatory requirements, the financial condition of such companies could be adversely affected.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Due to the nature of the
business of healthcare distribution companies, such companies may from time to time become involved in disputes or legal proceedings. For example, some of the products that these companies distribute may be alleged to
cause personal injury or violate the intellectual property rights of another party, subjecting such companies to product liability or infringement claims. Litigation is inherently unpredictable, and the unfavorable
resolution of one or more of these legal proceedings could adversely affect the cash flows and balance sheets of healthcare distribution companies. Pharmaceutical distributors currently face lawsuits related to the
abuse of opioid medications in the United States. The allegations include that pharmaceutical distributors failed to provide effective controls around the quantities of opioid medications distributed to certain
pharmacies, failed to properly prevent the diversion of medications and failed to report suspicious orders. Pharmaceutical distributors are in discussions with federal, state and local jurisdictions related to their
role in the distribution of opioid pharmaceuticals and it is possible that they will be required to pay multi-billion dollar settlements related to the ongoing litigation.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare distribution
companies depend on the availability of various components,compounds, raw materials and energy supplied by others for their operations. Any of these supplier relationships could be interrupted due to events beyond the
control of such companies, including pandemics, epidemics or natural disasters, or could be terminated. A sustained supply interruption could have an adverse effect on business.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Risks Associated with Regulatory
and Policy Changes</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">At any time after the date
hereof,-U.S. and non-U.S. governmental agencies and other regulators may implement additional regulations and legislators may pass new laws that affect the investments held by the Fund, the strategies used by the Fund
or the level of regulations or taxation applying to the Fund. These regulations and laws impact the investment strategies, performance, costs and operations of the Fund, as well as the way investments in, and
shareholders of, the Fund</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:12.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">44
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">are taxed. In particular, changes to U.S
healthcare policy could affect the Fund and its investments. The affordability of healthcare in the U.S. will remain a topic of debate, and proposals, laws and regulations to reduce the costs of healthcare products
and services could adversely impact healthcare companies that the Fund invests in.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Interest Rate Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">Prices of fixed-income
securities generally rise and fall in response to interest rate changes. Generally, the prices of fixed-rate instruments held by the Fund will tend to fall as interest rates rise. Conversely, when interest rates
decline, the value of fixed rate instruments held by the Fund can be expected to rise. Changing interest rates may have unpredictable effects on the markets, may result in heightened market volatility and may detract
from Fund performance. In addition, changes in monetary policy may exacerbate the risks associated with changing interest rates. The longer the duration, or price sensitivity to changes in interest rates, of the
security, the more sensitive the security is to this risk. In typical market interest rate environments, the prices of longer-term fixed-rate instruments tend to fluctuate more in price in response to changes in
market interest rates than prices of shorter-term fixed-rate instruments. A 1% increase in interest rates would reduce the value of a $100 note by approximately one dollar if it had a one-year duration. It is
difficult to predict the magnitude, timing or direction of interest rate changes and the impact these changes will have on the Fund&#x2019;s investments and the markets where it trades.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The risks attendant to
changing interest rate environments have been, and continue to be, magnified in the current economic environment. To combat rising inflation, the Board of Governors of the Federal Reserve System increased the federal
funds rate several times in 2022 and 2023; however, the Board of Governors of the Federal Reserve System decreased the federal funds rate in 2024, and the future of interest rates remain uncertain.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Credit/Default Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">Loans and other debt
obligation investments are subject to the risk of non-payment of scheduled principal and interest. Changes in economic conditions or other circumstances may reduce the capacity of the party obligated to make principal
and interest payments on such instruments and may lead to defaults. Such non-payments and defaults may reduce the value of the shares and income distributions. The value of loans and other income investments also may
decline because of concerns about the issuer&#x2019;s ability to make principal and interest payments. In addition, the credit ratings of loans or other income investments may be lowered if the financial condition of
the party obligated to make payments with respect to such instruments changes. Because the Fund invests in non-investment grade securities, it will be exposed to a greater amount of credit risk than a Fund which
invests solely in investment grade securities. The prices of</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">lower grade instruments are generally more
sensitive to negative developments, such as a decline in the issuer&#x2019;s revenues or a general economic downturn, than are the prices of higher grade instruments. Credit ratings assigned by rating agencies are
based on a number of factors and do not necessarily reflect the issuer&#x2019;s current financial condition or the volatility or liquidity of the security. In the event of bankruptcy of the issuer of loans or other
income investments, the Fund could experience delays or limitations with respect to its ability to realize the benefits of any collateral securing the instrument. In order to enforce its rights in the event of a
default,bankruptcy or similar situation, the Fund may be required to retain legal or similar counsel and incur additional costs.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">REIT Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">REITs whose underlying
properties are concentrated in a particular industry, such as the healthcare industry, or geographic region are subject to risks affecting such industries or regions. The securities of REITs involve greater risks than
those associated with larger,more established companies and may be subject to more abrupt or erratic price movements because of interest rate changes, economic conditions and other factors. Securities of such issuers
may lack sufficient market liquidity to enable the Fund to effect sales at an advantageous time or without a substantial drop in price.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Non-Investment Grade Securities
Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Fund may invest in
securities that are rated,at the time of investment, non-investment grade quality (rated &#x201c;Ba/BB&#x201d; or below), or securities that are unrated but determined to be of comparable quality by the Investment
Adviser. Securities of non-investment grade quality are regarded as having predominantly speculative characteristics with respect to the issuer&#x2019;s capacity to pay interest and repay principal, and are commonly
referred to as &#x201c;junk bonds.&#x201d; Non-investment grade securities and unrated securities of comparable credit quality are subject to the increased risk of an issuer&#x2019;s inability to meet principal and
interest payment obligations. The value of high yield,lower quality bonds is affected by the creditworthiness of the issuers of the securities and by general economic and specific industry conditions. These securities
may be subject to greater price volatility due to such factors as specific corporate or municipal developments, interest rate sensitivity, negative perceptions of the junk bond markets generally and less secondary
market liquidity. Issuers of high yield bonds are not as strong financially as those with higher credit ratings. These issuers are more vulnerable to financial setbacks and recession than more creditworthy issuers,
which may impair their ability to make interest and principal payments. Non-investment grade securities may be particularly susceptible to economic downturns, specific corporate or municipal developments, interest
rate sensitivity, negative perceptions of the junk bond markets generally and less secondary</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:13.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:23.55%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">45
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">market liquidity. An economic recession
could disrupt severely the market for such securities and may have an adverse impact on the value of such securities. In addition, any such economic downturn could adversely affect the ability of the issuers of such
securities to repay principal and pay interest thereon and increase the incidence of default for such securities. Non-investment grade securities, though higher yielding, are characterized by high risk. They may be
subject to certain risks with respect to the issuing entity and to greater market fluctuations than certain lower yielding, higher rated securities. The retail secondary market for non-investment grade securities may
be less liquid than that for higher rated securities. Adverse conditions could make it difficult at times for the Fund to sell certain securities or could result in lower prices than those used in calculating the
Fund&#x2019;s NAV. Because of the substantial risks associated with investments in non-investment grade securities, you could lose money on your investment in shares of the Fund, both in the short-term and the
long-term.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Derivatives Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Fund will invest no more
than 30% of its Managed Assets as measured at the time of investment in derivative instruments including options, futures,options on futures, forwards, swaps, options on swaps and other derivatives, although suitable
derivative instruments may not always be available to the Investment Adviser for these purposes. The Fund employs a strategy of writing (selling) covered call options on a portion of the common stocks in its
portfolio, writing (selling) put options on a portion of the common stocks in its portfolio and, to a lesser extent, writing (selling) covered call and writing (selling) put options on indices of securities and
sectors of securities generally within the healthcare industry. This option strategy is intended to generate current income from option premiums as a means to enhance distributions payable to the Fund&#x2019;s
Shareholders. Over time, as the Fund&#x2019;s portfolio becomes more seasoned, its ability to benefit from capital appreciation may become more limited and the Fund will lose money to the extent that it writes covered
call options and the securities on which it writes the option appreciates above the exercise price of the option by an amount that exceeds the exercise price of the option. To the extent the Fund writes a covered put
option, the Fund has assumed the obligation during the option period to purchase the security or securities from the put buyer at the option&#x2019;s exercise price if the put buyer exercises its option, regardless of
whether the value oft he underlying investment falls below the exercise price. This means that a Fund that writes a put option may be required make payment for such investment at the exercise price. This may result in
losses to the Fund and may result in the Fund holding securities for some period of time when it is disadvantageous to do so. Therefore, the Investment Adviser may choose to decrease its use of the option writing
strategy to the extent that it may negatively impact the Fund&#x2019;s ability to benefit from capital</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">appreciation. Other than the Fund&#x2019;s
option strategy, the Fund may invest up to 10% of its Managed Assets in derivatives. Derivative instruments can be illiquid, may disproportionately increase losses, and may have a potentially large adverse impact on
Fund performance.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Although both
over-the-counter (&#x201c;OTC&#x201d;) and exchange-traded derivatives markets may experience a lack of liquidity, OTC non-standardized derivative transactions are generally less liquid than exchange-traded instruments.
The illiquidity of the derivatives markets may be due to various factors, including congestion, disorderly markets, limitations on deliverable supplies, the participation of speculators or their withdrawal from the
markets, government regulation and intervention, and technical and operational or system failures. In addition, daily limits on price fluctuations and speculative position limits on exchanges on which the Fund may
conduct its transactions in derivative instruments may prevent the Fund from liquidating these positions at an advantageous time or price, subjecting the Fund to the potential of greater losses. Losses from
investments in derivative instruments can result from a lack of correlation between changes in the value of derivative instruments and the portfolio assets (if any) being hedged, the potential illiquidity of the
markets for derivative instruments, the failure of the counterparty to perform its contractual obligations, or the risks arising from margin requirements and related leverage factors associated with such transactions.
Losses may also arise if the Fund receives or posts cash collateral under the transactions and some or all of that collateral is invested in the market. To the extent that cash collateral is so invested, such
collateral will be subject to market depreciation or appreciation, and the Fund may be responsible for any loss that might result from the Fund's investment of the counterparty&#x2019;s cash collateral or for any loss
that might result from the investment of cash collateral that is an asset of the Fund. The use of these derivatives trading techniques also involves the risk of loss if the Investment Adviser is incorrect in its
expectation of the timing or level of fluctuations insecurities prices, interest rates or currency prices. Investments in derivative instruments maybe harder to value, subject to greater volatility and more likely
subject to changes in tax treatment than other investments. For these reasons, the Investment Adviser&#x2019;s use of derivative instruments may not be successful. Trading in derivative instruments can increase the
Fund&#x2019;s exposure to leverage. Thus, the leverage offered by trading in derivative instruments will magnify the gains and losses experienced by the Fund and could cause the Fund&#x2019;s net asset value to be
subject to wider fluctuations than would be the case if the Fund did not use the leverage feature in derivative instruments.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Derivatives markets have been
subject to increased regulation over the past several years,which may continue, and consequently, may make derivatives trading more costly, may limit the availability of and</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:17.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">46
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">reduce the liquidity of derivatives or may
otherwise adversely affect the value or performance of derivatives. Such potential adverse future developments could increase the risks reduce the effectiveness of the Fund&#x2019;s derivative transactions, and cause
the Fund to lose value.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Risks Associated with the
Fund&#x2019;s Option Strategy</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The ability of the Fund to
achieve its investment objective is partially dependent on the successful implementation of its option strategy. There are several risks associated with transactions in options on securities used in connection with
the Fund&#x2019;s option strategy. For example, there are significant differences between the securities and options markets that could result in an imperfect correlation between these markets, causing a given
transaction not to achieve its objectives. A decision as to whether, when and how to use options involves the exercise of skill and judgment, and even a well-conceived transaction may be unsuccessful to some degree
because of market behavior or unexpected events.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">As the writer of a call
option covered with a security held by the Fund, the Fund forgoes,during the option&#x2019;s life, the opportunities to profit from increases in the market value of the security covering the call option above the sum
of the premium and the strike price of the call but retains the risk of loss should the price of the underlying security decline. As the Fund writes such covered calls over more of its portfolio, its ability to
benefit from capital appreciation becomes more limited. To the extent the Fund writes call options that are not fully covered by securities in its portfolio (such as calls on an index or sector), it will lose money if
the portion of the security or securities underlying the option that is not covered by securities in the Fund&#x2019;s portfolio appreciate in value above the exercise price of the option by an amount that exceeds the
premium received on the option. The amount of this loss theoretically could be unlimited. The writer of an option has no control over the time when it may be required to fulfill its obligations as a writer of the
option.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">When the Fund writes put
options, it bears the risk of loss if the value of the underlying stock declines below the exercise price minus the put premium. If the option is exercised, the Fund could incur a loss if it is required to purchase
the stock underlying the put option at a price greater than the market price of the stock at the time of exercise plus the put premium the Fund received when it wrote the option. While the Fund&#x2019;s potential gain
as the writer of a covered put option is limited to the premium received from the purchaser of the put option,the Fund risks a loss equal to the entire exercise price of the option minus the put premium.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Counterparty Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">Many of the protections
afforded to participants on some organized exchanges, such as the performance guarantee of a clearing house, might not be available in connection with uncleared OTC</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">transactions. Therefore, in those instances
in which the Fund enters into uncleared OTC transactions, the Fund will be subject to the risk that its direct counterparty will not perform its obligations under the transactions and that the Fund will sustain
losses. Such risk is heightened in market environments where interest rates are changing, notably when rates are rising. If a counterparty becomes bankrupt, the Fund may experience significant delays in obtaining
recovery (if at all) under the derivative contract in bankruptcy or other reorganization proceeding; if the Fund&#x2019;s claim is unsecured, the Fund will be treated as a general creditor of such prime broker or
counterparty and will not have any claim with respect to the underlying security. The Fund may obtain only a limited recovery or may obtain no recovery in such circumstances. The counterparty risk for cleared
derivatives is generally lower than for uncleared OTC derivatives since generally a clearing organization becomes substituted for each counterparty to a cleared derivative and, in effect, guarantees theparties&#x2019;
performance under the contract as each party to a trade looks only to the clearinghouse for performance of financial obligations. However, there can be no assurance that the clearing house, or its members, will
satisfy its obligations to the Fund.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Regulation as a &#x201c;Commodity
Pool&#x201d;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Investment Adviser has
claimed an exclusion from the definition of the term &#x201c;commodity pool operator&#x201d; with respect to the Fund pursuant to Regulation 4.5 promulgated by the U.S. Commodity Futures Trading Commission
(the&#x201c;CFTC&#x201d;). For the Investment Adviser to continue to qualify for the exclusion under CFTC Regulation 4.5 with respect to the Fund, the aggregate initial margin and premiums required to establish our
positions in derivative instruments subject to the jurisdiction of the Commodity Exchange Act of 1936, as amended (&#x201c;CEA&#x201d;) (other than positions entered into for hedging purposes) may not exceed five
percent of the Fund&#x2019;s liquidation value or,alternatively. the net notional value of the Fund&#x2019;s aggregate investments in CEA-regulated derivative instruments (other than positions entered into for hedging
purposes) may not exceed 100% of the Fund&#x2019;s liquidation value. In the event the Investment Adviser fails to qualify for the exclusion with respect to the Fund and is required to register as a &#x201c;commodity
pool operator&#x201d;, it will become subject to additional disclosure, record keeping and reporting requirements with respect to the Fund, which may increase the Fund&#x2019;s expenses.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Failure of Futures Commission
Merchants and Clearing Organizations</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Fund may deposit funds
required to margin open positions in derivative instruments subject to the CEA with a clearing broker registered as a &#x201c;futures commission merchant&#x201d; (&#x201c;FCM&#x201d;). The CEA requires an FCM to segregate
all funds received from customers with respect to any orders for the purchase or sale of U.S. domestic futures contracts and cleared swaps from the FCM&#x2019;s proprietary assets.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:20.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:23.55%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">47
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Similarly, the CEA requires each FCM to hold
in a separate secure account all funds received from customers with respect to any orders for the purchase or sale of foreign futures contracts and segregate any such funds from the funds received with respect to
domestic futures contracts. However, all funds and other property received by a clearing broker from its customers are held by the clearing broker on a commingled basis in an omnibus account and may be freely accessed
by the clearing broker, which may also invest any such funds in certain instruments permitted under the applicable regulation. There is a risk that assets deposited by the Fund with any swaps or futures clearing
broker as margin for futures contracts or cleared swaps may, in certain circumstances, be used to satisfy losses of other clients of the Fund&#x2019;s clearing broker. In addition, the assets of the Fund may not be
fully protected in the event of the clearing broker&#x2019;s bankruptcy, as the Fund would be limited to recovering only a pro rata share of all available funds segregated on behalf of the clearing broker&#x2019;s
combined domestic customer accounts.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Similarly, the CEA requires a
clearing organization approved by the CFTC as a derivatives clearing organization to segregate all funds and other property received from a clearing member&#x2019;s clients in connection with domestic futures, swaps
and options contracts from any funds held at the clearing organization to support the clearing member&#x2019;s proprietary trading. Nevertheless, with respect to futures and options contracts, a clearing organization
may use assets of a non-defaulting customer held in an omnibus account at the clearing organization to satisfy payment obligations of a defaulting customer of the clearing member to the clearing organization. As a
result, in the event of a default or the clearing broker&#x2019;s other clients or the clearing broker&#x2019;s failure to extend its own funds in connection with any such default, the Fund would not be able to recover
the full amount of assets deposited by the clearing broker on its behalf with the clearing organization.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Liquidity Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">Illiquid securities include
securities the disposition of which is subject to substantial legal or contractual restrictions. The sale of illiquid securities often requires more time and results in higher brokerage charges or dealer discounts and
other selling expenses than does the sale of securities eligible for trading on national securities exchanges or in the over-the-counter markets. Restricted securities may sell at a price lower than similar securities
that are not subject to restrictions on resale. The continued liquidity of such securities may not be as well assured as that of publicly traded securities.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Convertible Securities Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The market value of
convertible securities tends to decline as interest rates increase and, conversely, tends to increase as interest rates decline. In addition,because of the conversion feature, the market value of convertible
securities tends to vary with fluctuations in the</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">market value of the underlying common stock.
A unique feature of convertible securities is that as the market price of the underlying common stock declines,convertible securities tend to trade increasingly on a yield basis, and so may not experience market value
declines to the same extent as the underlying common stock. When the market price of the underlying common stock increases, the prices of the convertible securities tend to rise as a reflection of the value of the
underlying common stock. While no securities investments are without risk, investments in convertible securities generally entail less risk than investments in common stock of the same issuer.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">PIPEs Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">PIPE transactions typically
involve the purchase of securities directly from a publicly traded company or its affiliates in a private placement transaction, typically at a discount to the market price of the company&#x2019;s common stock. In a
PIPE transaction, the Fund may bear the price risk from the time of pricing until the time of closing. Equity issued in this manner is often subject to transfer restrictions and is therefore less liquid than equity
issued through a registered public offering. In a PIPE transaction, the Fund may bear the price risk from the time of pricing until the time of closing. The Fund may be subject to lockup agreements that prohibit
transfers for a fixed period of time. In addition, because the offering of the securities in a PIPE transaction is not registered under the Securities Act, the securities are &#x201c;restricted&#x201d; and cannot be
immediately resold by the investors into the public markets. The Fund may enter into a registration rights agreement with the issuer pursuant to which the issuer commits to file a resale registration statement
allowing the Fund to publicly resell its securities. Accordingly, PIPE securities may be deemed illiquid. However, the ability of the Fund to freely transfer the shares is conditioned upon, among other things, the
Commission&#x2019;s preparedness to declare the resale registration statement effective covering the resale of the shares sold in the private financing and the issuer&#x2019;s right to suspend the Fund&#x2019;s use of
the resale registration statement if the issuer is pursuing a transaction or some other material non-public event is occurring. Accordingly, PIPE securities may be subject to risks associated with illiquid
securities.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Venture Capital Investments
Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Fund may occasionally
invest in venture capital opportunities. While these securities offer the opportunity for significant capital gains, such investments also involve a degree of risk that can result in substantial losses. Some of the
venture capital opportunities in which the Fund may invest are expected to be companies that are in a &#x201c;start-up&#x201d; stage of development, have little or no operating history, operate at a loss or with
substantial variations in operating results from period to period, have limited products, markets, financial resources or management depth, or have the need for substantial</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:13.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">48
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">additional &#x201c;follow-on&#x201d; capital
to support expansion or to achieve or maintain a competitive position. Such additional investments may dilute the interests of prior investors, such as the Fund. Some of these companies may be emerging companies at
the research and development stage with no marketable or approved products or technology. There can be no assurance that securities of start-up or emerging growth companies will, in the future, yield returns
commensurate with their associated risks.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">These investments, which are
considered Restricted Securities, will be made primarily in convertible preferred stock. The Fund may also purchase non-convertible debt securities in connection with its venture capital investments, and otherwise
when the Investment Adviser believes that such investments would be consistent with the Fund&#x2019;s investment objective. While these debt investments typically will not be rated, the Investment Adviser believes
that,in light of the risk characteristics associated with investments in emerging growth companies, if such investments were to be compared with investments rated by S&amp;P or Moody&#x2019;s, they may be rated as low
as &#x201c;C&#x201d; in the rating categories established by S&amp;P and Moody&#x2019;s. Such securities are commonly referred to as &#x201c;junk bonds&#x201d; and are considered, on balance, as predominantly
speculative.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Leverage Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Fund is permitted to have
financial leverage representing up to the maximum extent permitted by the Investment Company Act. The Investment Company Act generally prohibits the Fund from engaging in most forms of leverage representing
indebtedness other than preferred shares unless immediately after such incurrence the Fund's total assets less all liabilities and indebtedness not represented by senior securities (for these purposes, "total net
assets") is at least 300% of the aggregate senior securities representing indebtedness (i.e., the use of leverage through senior securities representing indebtedness may not exceed 33 1/3% of the Fund's total net
assets (including the proceeds from leverage)). Additionally, under the Investment Company Act, the Fund generally may not declare any dividend or other distribution upon any class of its capital shares, or purchase
any such capital shares, unless at the time of such declaration or purchase, this asset coverage test is satisfied. In addition, the Investment Company Act limits the extent to which the Fund may issue preferred
shares plus senior securities representing indebtedness to 50% of the Fund&#x2019;s total assets (less the Fund&#x2019;s liabilities and indebtedness not represented by senior securities). Indebtedness associated with
reverse repurchase agreements and similar financing transactions may be aggregated with any other senior securities representing indebtedness for this purpose or be treated as derivatives transactions under the
Investment Company Act and the rules and regulations thereunder, depending on the Fund&#x2019;s election under applicable SEC requirements.</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund uses financial leverage for
investment purposes. The Fund may issue preferred shares, borrow money and/or issue debt securities (&#x201c;traditional leverage&#x201d;). The Fund uses traditional leverage through a credit facility representing up to
20% of the Fund&#x2019;s Managed Assets as measured at the time when leverage is incurred. In addition, the Fund may enter into reverse repurchase agreements, swaps, futures, forward contracts, securities lending,
short sales, and other derivative transactions, that have similar effects as leverage (collectively referred to as &#x201c;effective leverage&#x201d;). Furthermore, at no time will the Fund&#x2019;s use of leverage,
either through traditional leverage or effective leverage, exceed the Investment Company Act limits as measured at the time when leverage is incurred. Notwithstanding the foregoing, effective leverage incurred through
the use of covered calls will not be counted toward the Fund's limit on the use of total leverage.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Fund&#x2019;s leveraged
capital structure creates special risks not associated with unleveraged funds having a similar investment objective and policies. These include the possibility of greater loss and the likelihood of higher volatility
of the NAV of the Fund and the asset coverage for preferred shares, if any. Such volatility may increase the likelihood of the Fund having to sell investments in order to meet its obligations to make distributions on
the preferred shares, or to redeem preferred shares when it may be disadvantageous to do so. Also, if the Fund is utilizing leverage, a decline in NAV could affect the ability of the Fund to make distributions and
such a failure to pay dividends or make distributions could result in the Fund ceasing to qualify as a regulated investment company under the Code, as amended.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Other risks and special
considerations include the risk that fluctuations in interest rates on borrowings and short-term debt or in the interest or dividend rates on any leverage that the Fund must pay will reduce the return to the
Shareholders; the effects of leverage in a declining market, which are likely to cause a greater decline in the NAV of the shares than if the Fund were not leveraged, which may result in a greater decline in the
market price of the shares; when the Fund uses financial leverage, the investment advisory fees payable to the Investment Adviser will be higher than if the Fund did not use leverage because the fees paid are
calculated based on Managed Assets, which includes assets purchased with leverage. Therefore, the Investment Adviser has a financial incentive to use leverage, which creates a conflict of interest between the
Investment Adviser and common shareholders, as only the Fund&#x2019;s common shareholders would bear the fees and expenses incurred through the Fund&#x2019;s use of leverage, including the issuance of Preferred shares,
if any. Leverage may increase operating costs, which may reduce total return.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:24.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:23.55%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">49
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">Effects of Leverage</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The following table is
furnished in response to requirements of the SEC. It is designed to, among other things, illustrate the effects of leverage through the use of senior securities, as that term is defined under Section 18 of the
Investment Company Act, on common share total return, assuming investment portfolio total returns (consisting of income and changes in the value of investments held in a Fund's portfolio) of -10%, -5%, 0%, 5% and 10%.
The table below reflects the Fund's continued use of the Revolving Credit Facility, as of September 30, 2025 as a percentage of total Managed Assets (including assets attributable to such leverage), and the annual
return that the Fund's portfolio must experience (net of expenses) in order to cover such costs. The information below does not reflect the Fund's use of certain other forms of economic leverage achieved through the
use of other instruments or transactions not considered to be senior securities under the Investment Company Act, such as covered reverse repurchase agreements or other derivative instruments, if any.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The assumed investment
portfolio returns in the table below are hypothetical figures and are not necessarily indicative of the investment portfolio returns experienced or expected to be experienced by the Fund. Your actual returns may be
greater or less than those appearing below. In addition, actual borrowing expenses associated with borrowings used by the Fund may vary frequently and may be significantly higher or lower than the rate used for the
example below.</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100.00%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; padding-bottom:2pt; padding-left:15pt; padding-right:6pt; padding-top:3pt; text-align:left; text-decoration:none; text-indent:-9pt; text-transform:none; vertical-align:bottom; width:30.35%; background-color: #F0F0F0;">Assumed<br>
annual<br>
returns on<br>
the Fund's<br>
portfolio<br>
(net of<br>
expenses)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; padding-bottom:2pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.89%; background-color: #F0F0F0;">(10%)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; padding-bottom:2pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.52%; background-color: #F0F0F0;">(5%)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; padding-bottom:2pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.88%; background-color: #F0F0F0;">0%
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; padding-bottom:2pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.52%; background-color: #F0F0F0;">5%
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; padding-bottom:2pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.52%; background-color: #F0F0F0;">10%
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:16pt; padding-right:6pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:30.35%; background-color: #F0F0F0;">Corresponding<br>
return of<br>
shareholder
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:6pt; padding-right:6pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.89%; background-color: #F0F0F0;">(14.7%)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:6pt; padding-right:6pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.52%; background-color: #F0F0F0;">(8.2%)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:6pt; padding-right:6pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.88%; background-color: #F0F0F0;">(1.7%)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:6pt; padding-right:6pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.52%; background-color: #F0F0F0;">4.8%
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:6pt; padding-right:6pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.52%; background-color: #F0F0F0;">11.4%
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Based on estimated
indebtedness of $225,000,000 (representing approximately 23.3% of the Fund's Managed Assets as of September 30, 2025), and a weighted average annual interest rate of 5.53% (effective weighted interest rate on the
Revolving Credit Facility as of September 30, 2025), the Fund's investment portfolio at fair value would have to produce an annual return of approximately 1.29% to cover annual interest payments on the estimated
debt.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Common share total return is
composed of two elements&#x2014;the distributions paid by a Fund to holders of common shares (the amount of which is largely determined by the net investment income of the Fund after paying dividend payments on any
preferred shares issued by the Fund and expenses on any forms of leverage outstanding) and gains or losses on the value of the securities and</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">other instruments the Fund owns. As required
by SEC rules, the table assumes that a Fund is more likely to suffer capital losses than to enjoy capital appreciation. For example, to assume a total return of 0%, a Fund must assume that the income it receives on
its investments is entirely offset by losses in the value of those investments. This table reflects hypothetical performance of a Fund's portfolio and not the actual performance of the Fund's shares, the value of
which is determined by market forces and other factors.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Should the Fund elect to add
additional leverage to its portfolio, any benefits of such additional leverage cannot be fully achieved until the proceeds resulting from the use of such leverage have been received by the Fund and invested in
accordance with the Fund's investment objective and policies. As noted above, the Fund's willingness to use additional leverage, and the extent to which leverage is used at any time, will depend on many factors,
including, among other things, the Adviser's assessment of the yield curve environment, interest rate trends, market conditions and other factors.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Restricted Securities and
Valuation Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">Some of the Fund&#x2019;s
investments are subject to restrictions on resale and generally have no established trading market or are otherwise illiquid with little or no trading activity. The valuation process requires an analysis of various
factors. The Fund&#x2019;s fair value methodology includes the examination of, among other things,(i) the existence of any contractual restrictions on the disposition of the securities;(ii) information obtained from
the issuer which may include an analysis of the company&#x2019;s financial statements, the company&#x2019;s products or intended markets, or the company&#x2019;s technologies; and (iii) the price of a security sold at
arm&#x2019;s length in an issuer&#x2019;s subsequent completed round of financing. As there is typically no readily available market value for some of the Restricted Securities in the Fund&#x2019;s portfolio, such
Restricted Securities in the Fund&#x2019;s portfolio are valued at fair value as determined in good faith by or under the direction of the Board pursuant to the Fund&#x2019;s valuation policy and a consistently applied
valuation process. Because of the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Fund&#x2019;s investments determined in good
faith by the Board may differ significantly from the values that would have been used had a ready market existed for the investments, and the differences could be material. There is no single standard for determining
fair value in good faith. As a result, determining fair value requires that judgment be applied to the specific facts and circumstances of each portfolio investment, while employing a consistently applied valuation
process for the types of investments the Fund makes.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Emerging Markets Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Fund may invest in
securities of issuers located in emerging countries (&#x201c;Emerging Markets&#x201d;). The risks of foreign investment are</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:13.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">50
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">heightened when the issuer is located in an
emerging country. Emerging countries are generally located in Africa,Asia, the Middle East, Eastern Europe and Central and South America. The Fund&#x2019;s purchase and sale of portfolio securities in Emerging Markets
may be constrained by limitations relating to daily changes in the prices of listed securities, periodic trading or settlement volume and/or limitations on aggregate holdings of foreign investors. Such limitations may
be computed based on the aggregate trading volume by or holdings of the Fund, the Investment Adviser, or its affiliates and respective clients and other service providers. The Fund may not be able to sell securities
in circumstances where price, trading or settlement volume limitations have been reached. The Fund will not invest more than 20% of its Managed Assets as measured at the time of investment in emerging market
countries.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Foreign investment in the
securities markets of certain emerging countries is restricted or controlled to varying degrees which may limit investment in such countries or increase the administrative costs of such investments. For example,
certain Asian countries require governmental approval prior to investments by foreign persons or limit investment by foreign persons to only a specified percentage of an issuer&#x2019;s outstanding securities or a
specific class of securities which may have less advantageous terms (including price) than securities of the issuer available for purchase by nationals. In addition, certain countries may restrict or prohibit
investment opportunities in issuers or industries deemed important to national interests. Such restrictions may affect the market price, liquidity and rights of securities that may be purchased by the Fund. The
repatriation of both investment income and capital from certain emerging countries is subject to restrictions such as the need for governmental consents. In situations where a country restricts direct investment in
securities (which may occur in certain Asian and other countries), the Fund may invest in such countries through other investment funds in such countries.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Many emerging countries have
recently experienced currency devaluations and substantial(and, in some cases, extremely high) rates of inflation. Other emerging countries have experienced economic recessions. These circumstances have had a negative
effect on the economies and securities markets of those emerging countries.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Economies in emerging
countries generally are dependent heavily upon commodity prices and international trade and, accordingly, have been and may continue to be affected adversely by the economies of their trading partners, trade barriers,
exchange controls, managed adjustments in relative currency values and other protectionist measures imposed or negotiated by the countries with which they trade.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Many emerging countries are
subject to a substantial degree of economic, political and social instability. Governments of some</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">emerging countries are authoritarian in
nature or have been installed or removed as a result of military coups, while governments in other emerging countries have periodically used force to suppress civil dissent. Disparities of wealth, the pace and success
of democratization, and ethnic, religious and racial disaffection, among other factors, have also led to social unrest, violence and/or labor unrest in some emerging countries. Unanticipated political or social
developments may result in sudden and significant investment losses. Investing in emerging countries involves greater risk of loss due to expropriation, nationalization, confiscation of assets and property or the
imposition of restrictions on foreign investments and on repatriation of capital invested. As an example, in the past, some Eastern European governments have expropriated substantial amounts of private property, and
many claims of the property owners have never been fully settled. There is no assurance that similar expropriations will not occur in other countries.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Fund&#x2019;s investment
in emerging countries may also be subject to withholding or other taxes, which may be significant and may reduce the return to the Fund from an investment in issuers in such countries.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Settlement procedures in
emerging countries are frequently less developed and reliable than those in the United States and may involve the Fund&#x2019;s delivery of securities before receipt of payment for their sale. In addition, significant
delays may occur in certain markets in registering the transfer of securities. Settlement or registration problems may make it more difficult for the Fund to value its portfolio securities and could cause the Fund to
miss attractive investment opportunities, to have a portion of its assets uninvested or to incur losses due to the failure of a counterparty to pay for securities the Fund has delivered or the Fund&#x2019;s inability
to complete its contractual obligations because of theft or other reasons.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The credit worthiness of the
local securities firms used by the Fund in emerging countries may not be as sound as the creditworthiness of firms used in more developed countries. As a result, the Fund may be subject to a greater risk of loss if a
securities firm defaults in the performance of its responsibilities.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The small size and
inexperience of the securities markets in certain emerging countries and the limited volume of trading in securities in those countries may make the Fund&#x2019;s investments in such countries less liquid and more
volatile than investments in countries with more developed securities markets (such as the United States, Japan and most Western European countries). The Fund&#x2019;s investments in emerging countries are subject to
the risk that the liquidity of a particular investment, or investments generally, in such countries will shrink or disappear suddenly and without warning as a result of adverse economic, market or political conditions
or adverse investor perceptions, whether or not accurate. Because of the lack of sufficient market liquidity, the Fund may incur losses because it will be required</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:18.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:23.55%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">51
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">to effect sales at a disadvantageous time
and only then at a substantial drop in price. Investments in emerging countries may be more difficult to value precisely because of the characteristics discussed above and lower trading volumes. In addition, the
impact of the economic and public health crisis in emerging market countries may be greater due to their generally less established healthcare systems and capabilities with respect to fiscal and monetary policies,
which may exacerbate other pre-existing political, social and economic risk.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Fund&#x2019;s use of
foreign currency management techniques in emerging countries may be limited. A significant portion of the Fund&#x2019;s currency exposure in emerging countries may not be covered by these techniques.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Foreign Securities Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Fund will not invest more
than 20% of its Managed Assets as measured at the time of investment in non-U.S. securities, which may include securities denominated in the U.S. dollars or in non-U.S. currencies or multinational currency units.
Foreign investments involve special risks that are not typically associated with U.S. dollar denominated or quoted securities of U.S. issuers. Foreign investments may be affected by changes in currency rates, changes
in foreign or U.S. laws or restrictions applicable to such investments and changes in exchange control regulations (e.g., currency blockage). A decline in the exchange rate of the currency (i.e., weakening of the
currency against the U.S. dollar)in which a portfolio security is quoted or denominated relative to the U.S. dollar would reduce the value of the portfolio security. In addition, if the currency in which the Fund
receives dividends, interest or other payments declines in value against the U.S. dollar before such income is distributed as dividends to Shareholders or converted to U.S. dollars, the Fund may have to sell portfolio
securities to obtain sufficient cash to pay such dividends.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Brokerage commissions,
custodial services and other costs relating to investment in international securities markets generally are more expensive than in the United States. In addition, clearance and settlement procedures may be different
in foreign countries and, in certain markets, such procedures have been unable to keep pace with the volume of securities transactions, thus making it difficult to conduct such transactions.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Foreign issuers are not
generally subject to uniform accounting, auditing and financial reporting standards comparable to those applicable to U.S. issuers. There may be less publicly available information about a foreign issuer than about a
U.S. issuer. In addition, there is generally less government regulation of foreign markets, companies and securities dealers than in the United States, and the legal remedies for investors may be more limited than the
remedies available in the United States. Foreign securities markets may have substantially less volume than U.S. securities markets and</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">securities of many foreign issuers are less
liquid and more volatile than securities of comparable domestic issuers. Furthermore, with respect to certain foreign countries, there is a possibility of nationalization, expropriation or confiscatory taxation,
imposition of withholding or other taxes on dividend or interest payments (or, in some cases, capital gains distributions), limitations on the removal of funds or other assets from such countries, and risks of
political or social instability or diplomatic developments which could adversely affect investments in those countries. Adverse diplomatic developments may include the imposition of economic or trade sanctions or
other measures by the U.S. or other governments and supranational organizations or changes in trade policies. These developments may, among other things, limit the ability of the Fund to invest in certain securities
require the disposition of the investment.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Management Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Fund&#x2019;s ability to
achieve its investment objective is directly related to the Investment Adviser&#x2019;s investment strategies for the Fund. The value of your investment in the Fund&#x2019;s common shares may vary with the effectiveness
of the research and analysis conducted by the Investment Adviser and its ability to identify and take advantage of attractive investment opportunities. If the investment strategies of the Investment Adviser do not
produce the expected results, the value of your investment could be diminished or even lost entirely, and the Fund could underperform the market or other funds with similar investment objective.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Key Personnel Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">There may be only a limited
number of securities professionals who have comparable experience to that of the Fund&#x2019;s existing portfolio management team in the area of healthcare companies. If one or more of the team members dies, resigns,
retires or is otherwise unable to act on behalf of the Investment Adviser, there can be no assurance that a suitable replacement could be found immediately.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Anti-Takeover Provisions Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Fund&#x2019;s Amended and
Restated Declaration of Trust(&#x201c;Declaration of Trust&#x201d;), dated June 11, 2014, as amended, has provisions that could have the effect of limiting the ability of other entities or persons to (1) acquire control
of the Fund, (2) cause it to engage in certain transactions, or (3) modify its structure. The By-Laws also contain provisions regarding qualifications for nominees for Trustee positions, advance notice of Shareholder
proposals, and requirements for the call of special Shareholder meetings. These provisions may be considered &#x201c;anti-takeover&#x201d; provisions.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:12.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">52
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">Related Party Transactions Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Fund may be subject to
certain potential conflicts of interest. Although the Fund has no obligation to do so, it may place brokerage orders with brokers who provide supplemental investment research and market and statistical information
about healthcare companies and the healthcare industries. In addition, other investment companies advised by the Investment Adviser may concurrently invest with the Fund in restricted securities under certain
conditions. The Fund also may invest, subject to applicable law, in companies in which the principals of the Investment Adviser or Trustees of the Fund have invested, or for which they serve as directors or executive
officers. The Investment Company Act prohibits the Fund from engaging in certain transactions involving its &#x201c;affiliates,&#x201d; including, among others, the Fund&#x2019;s Trustees, officers and employees, the
Investment Adviser and any &#x201c;affiliates&#x201d; of such affiliates except pursuant to an exemptive order or the provisions of certain rules under the Investment Company Act. In the view of the staff of the
Commission, other investment companies advised by the Investment Adviser may,in some instances, be viewed to be affiliates of the Fund. Such legal restrictions and delays and costs involved in obtaining necessary
regulatory approvals may preclude or discourage the Fund from making certain investments and no assurance can be given that any exemptive order sought by the Fund will be granted.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Government Intervention</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">Instability in the financial
markets has led the U.S. government and certain foreign governments to take a number of unprecedented actions designed to support certain financial institutions and segments of the financial markets that have
experienced extreme volatility, and in some cases a lack of liquidity, including through direct purchases of equity and debt securities, which can happen again in the future. Federal, state, and foreign governments,
their regulatory agencies or self-regulatory organizations may take actions that affect the regulation of the issuers in which the Fund invests in ways that are unforeseeable. Legislation or regulation may also change
the way in which the Fund is regulated. Such legislation or regulation could limit or preclude the Fund&#x2019;s ability to achieve its investment objective.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Market Disruption and
Geopolitical Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The value of your investment
in the Fund is based on the market prices of the securities the Fund holds. These prices change daily due to economic and other events that affect markets generally, as well as those that affect particular regions,
countries, industries, companies or governments. These price movements,sometimes called volatility, may be greater or less depending on the types of securities the Fund owns and the markets in which the securities
trade. The increasing interconnectivity between global economies and financial markets increases the likelihood that events or conditions in one region or</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">financial market may adversely impact
issuers in a different country, region or financial market. Securities in the Fund&#x2019;s portfolio may underperform due to inflation (or expectations for inflation), interest rates, global demand for particular
products or resources, natural/environmental disasters, pandemics, epidemics, cyber-attacks,terrorism, armed conflicts, regulatory events and governmental or quasi-governmental actions. The occurrence of global
events, such as terrorist attacks around the world, natural/environmental disasters,social and political discord or debt crises and downgrades, among others, may result in market volatility and may have long term
effects on both the U.S. and global financial markets. A disruption of financial markets or other terrorist attacks could adversely affect Fund service providers and/or the Fund&#x2019;s operations as well as interest
rates, secondary&#xa0; trading, credit risk, inflation and other factors relating to the shares. The Fund cannot predict the effects or likelihood of similar events in the future on the U.S. and world economies, the
value of the shares or the NAV of the Fund.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Social, political, economic
and other conditions and events, such as natural disasters, health emergencies (e.g., epidemics and pandemics such as COVID-19, avian influenza or HINI/09), cyber-attacks, terrorism, actual or threatened wars or other
armed conflicts (such as the Russia/Ukraine war and Middle East conflicts), may occur and could significantly impact issuers, industries,governments and other systems, including the financial markets. These impacts
could negatively affect the Fund&#x2019;s investments in securities and instruments that are economically tied to the applicable region, and include (but are not limited to) declines in value and reductions in
liquidity. In addition, to the extent new sanctions are imposed or previously relaxed sanctions are reimposed, complying with such restrictions may prevent the Fund from pursuing certain investments, cause delays or
other impediments with respect to consummating such investments or divestments, require divestment or freezing of investments on unfavorable terms, render divestment of underperforming investments impracticable,
negatively impact the Fund&#x2019;s ability to achieve its investment objective, prevent the Fund from receiving payments otherwise due it, increase diligence and other similar costs to the Fund, render valuation of
affected investments challenging, or require the Fund to consummate an investment on terms that are less advantageous than would be the case absent such restrictions. As global systems, economies and financial markets
are increasingly interconnected, events that once had only local impact are now more likely to have regional or even global effects. Events that occur in one country, region or financial market will, more frequently,
adversely impact issuers in other countries, regions or markets. These impacts can be exacerbated by failures of governments and societies to adequately respond to an emerging event or threat. These types of events
quickly and significantly impact markets in the U.S. and across the globe leading to extreme market</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:10.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:23.55%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">53
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">volatility and disruption. The extent and
nature of the impact on supply chains or economies and markets from these events is unknown, particularly if these types of events persist for an extended period of time. These types of events, could reduce consumer
demand or economic output, result in market closures, travel restrictions or quarantines, and generally have a significant impact on the economies and financial markets and the Investment Adviser&#x2019;s investments
advisory activities and services of other service providers, which in turn could adversely affect the Fund&#x2019;s investments and other operations. The value of the Fund&#x2019;s investments impact the operations and
effectiveness of the Investment Adviser or key service providers or if these events disrupt systems and processes necessary or beneficial to the investment advisory or other activities on behalf the Fund.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Systemic risk events and/or
resulting government actions in the financial markets can negatively impact the Funds, for example, through less credit being available to issuers or uncertainty regarding safety of deposits at other institutions.
These risks also may adversely affect financial intermediaries, such as clearing agencies, clearing houses, banks, securities firms, and exchanges, with which the Fund interacts.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Potential Conflicts of Interest
Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Investment
Adviser&#x2019;s investment team is responsible for managing the Fund as well as three other closed-end investment companies. In the future, the investment team may manage other funds and accounts, including
proprietary accounts, separate accounts and other pooled investment vehicles, such as unregistered hedge funds. In the future, a portfolio manager may manage a separate account or other pooled investment vehicle which
may have materially higher fee arrangements than the Fund and may also have a performance-based fee. The side-by-side management of these funds or accounts may raise potential conflicts of interest relating to cross
trading, the allocation of investment opportunities and the aggregation and allocation of trades.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Special Purpose Acquisition
Company Risk</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Fund may invest in SPACs.
SPACs are collective investment structures that pool funds in order to seek potential acquisition opportunities. Unless and until an acquisition is completed, a SPAC generally invests its assets (less an amount to
cover expenses) in U.S. Government securities, money market fund securities and cash. SPACs and similar entities may be blank check companies with no operating history or ongoing business other than to seek a
potential acquisition. Certain SPACs may seek acquisitions only in limited industries or regions. If an acquisition that meets the requirements for the SPAC is not completed within a predetermined period of time, the
invested funds are returned to the entity&#x2019;s shareholders, unless such</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">shareholders approve alternative arrangements.
Investments in SPACs may be illiquid and/or be subject to restrictions on resale.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">FUNDAMENTAL INVESTMENT
RESTRICTIONS</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Fund has adopted the
following fundamental restrictions, which may not be changed without the approval of the holders of a majority of the Fund's outstanding voting securities (which for this purpose and under the Investment Company Act,
means the lesser of (1) 67% of the voting shares present in person or by proxy at a meeting at which more than 50% of the outstanding voting shares are present in person or by proxy, or (2) more than 50% of the
outstanding voting shares).</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">For purposes of the following
limitations (except for the asset coverage requirement with respect to borrowings), all percentage limitations apply immediately after a purchase and any subsequent change in any applicable percentage resulting from
market conditions does not require any action. With respect to the limitations on the issuance of senior securities and in the case of borrowings, the percentage limitations apply at the time of issuance and on an
ongoing basis.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">The Fund may not:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:6pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:6.98%">1.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:justify; text-decoration:none; text-transform:none; vertical-align:top; width:93.02%">Purchase or sell commodities or commodities contracts. The prohibition on the purchase or sale of commodities applies to the purchase or sale of &#x201c;physical&#x201d; commodities; the Fund may invest
in currency and financial instruments and contracts in accordance with its investment objective and policies, including, without limitation, structured notes, futures contracts, swaps, options on commodities,
currencies, swaps and futures, ETFs, ETNs, investment pools and other instruments, regardless of whether such instrument is considered to be a commodity.
</td></tr></table>
</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:6pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:6.98%">2.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:justify; text-decoration:none; text-transform:none; vertical-align:top; width:93.02%">Purchase or sell real estate; although the Fund may purchase and sell securities or instruments that are secured by real estate or interests therein or that reflect the return of an index of real estate
values, securities of real estate investment trusts and mortgage-related securities, and may hold and sell real estate acquired by the Fund as a result of the ownership of securities.
</td></tr></table>
</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:6pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:6.98%">3.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:justify; text-decoration:none; text-transform:none; vertical-align:top; width:93.02%">Underwrite securities of other issuers, except to the extent that, in connection with the disposition of its portfolio securities, the Fund may be deemed an underwriter under federal or state securities
law.
</td></tr></table>
</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:6pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:6.98%">4.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:93.02%">Issue senior securities to the extent such issuance would violate applicable law.
</td></tr></table>
</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:6pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:6.98%">5.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:justify; text-decoration:none; text-transform:none; vertical-align:top; width:93.02%">Borrow money, except as permitted by the Investment Company Act, or interpretations or modifications by the Commission, Commission staff or other authority with appropriate jurisdiction.
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:14.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">54
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(concluded)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:6pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:6.98%">6.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:justify; text-decoration:none; text-transform:none; vertical-align:top; width:93.02%">Mortgage, pledge, hypothecate or in any manner transfer, as security for indebtedness, any securities owned or held by the Fund, except as may be necessary in connection with permitted borrowings under
6 above.
</td></tr></table>
</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:6pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:6.98%">7.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:justify; text-decoration:none; text-transform:none; vertical-align:top; width:93.02%">Make loans of money, except (a) by the purchase of debt obligations in which the Fund may invest consistent with its investment objective and policies, or (b) as may otherwise be permitted by the
Investment Company Act, as amended from time to time, the rules and regulation promulgated by the SEC under the Investment Company Act, as amended from time to time, or an exemption or other relief applicable to the
Fund from the provisions of the Investment Company Act, as amended from time to time.&#xa0; The Fund reserves the authority to enter into repurchase agreements, reverse repurchase agreements and to make loans of its
portfolio securities to qualified institutional investors, brokers, dealers, banks or other financial institutions, so long as the terms of the loans are not inconsistent with the requirements of the Investment
Company Act.
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">NON-FUNDAMENTAL INVESTMENT
RESTRICTIONS</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">In addition, the Fund has
adopted the following investment policies, which may be changed by the action of the Board without shareholder approval:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:6pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:6.98%">1.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:justify; text-decoration:none; text-transform:none; vertical-align:top; width:93.02%">The Fund, under normal circumstances, will have at least 80% of its Managed Assets invested in Healthcare Companies. This investment policy may not be changed without 60 days&#x2019; prior notice to
Shareholders.
</td></tr></table>
</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:6pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:6.98%">2.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:93.02%">The Fund will not invest more than 10% of the Fund&#x2019;s Managed Assets in Restricted Securities.
</td></tr></table>
</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:6pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:6.98%">3.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:justify; text-decoration:none; text-transform:none; vertical-align:top; width:93.02%">At no time will the Fund incur total leverage (whether through traditional leverage or effective leverage, as such terms are defined in this report) in an aggregate amount that exceeds the Investment
Company Act limits, except that effective leverage incurred through the use of covered calls will not be counted toward the Fund&#x2019;s limit on the use of total leverage.
</td></tr></table>
</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:6pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:6.98%">4.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:93.02%">The Fund will not invest more than 15% of the Fund&#x2019;s Managed Assets in debt securities that are rated non-investment grade.
</td></tr></table>
</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:6pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:6.98%">5.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:93.02%">The Fund will not invest more than 30% of the Fund&#x2019;s Managed Assets in derivatives for hedging purposes.
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Except as otherwise noted,
all percentage limitations set forth above apply immediately after a purchase and a subsequent change in the applicable percentage resulting from market fluctuations does not require elimination of any security from
the portfolio.&#xa0;</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:291.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:23.55%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">55
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Dividend Reinvestment and Optional Cash Purchase
Plan&#xa0;<font style="font-size:11pt; line-height:14pt"> (Unaudited)&#xa0;</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund intends to distribute to
shareholders substantially all of its net investment income and to distribute any net realized capital gains at least annually. Net investment income for this purpose is income other than net realized long-term and
short-term capital gains net of expenses. Pursuant to the Dividend Reinvestment and Optional Cash Purchase Plan (the &#x201c;Plan&#x201d;), shareholders whose shares of common stock are registered in their own names
will be deemed to have elected to have all distributions automatically reinvested by Computershare Trust Company N.A. (the &#x201c;Plan Agent&#x201d;) in the Fund shares pursuant to the Plan, unless such shareholders
elect to receive distributions in cash. Shareholders who elect to receive distributions in cash will receive such distributions paid by check in U.S. Dollars mailed directly to the shareholder by the Plan Agent, as
dividend paying agent. In the case of shareholders such as banks, brokers or nominees that hold shares for others who are beneficial owners, the Plan Agent will administer the Plan on the basis of the number of shares
certified from time to time by the shareholders as representing the total amount registered in such shareholders&#x2019; names and held for the account of beneficial owners that have not elected to receive
distributions in cash. Investors that own shares registered in the name of a bank, broker or other nominee should consult with such nominee as to participation in the Plan through such nominee and may be required to
have their shares registered in their own names in order to participate in the Plan. Please note that the Fund does not issue certificates so all shares will be registered in book entry form. The Plan Agent serves as
agent for the shareholders in administering the Plan. If the Trustees of the Fund declare an income dividend or a capital gains distribution payable either in the Fund&#x2019;s common stock or in cash, nonparticipants
in the Plan will receive cash and participants in the Plan will receive common stock, to be issued by the Fund or purchased by the Plan Agent in the open market, as provided below. If the market price per share (plus
expected per share fees) on the valuation date equals or exceeds NAV per share on that date, the Fund will issue new shares to participants at NAV; provided, however, that if the NAV is less than 95% of the market
price on the valuation date, then such shares will be issued at 95% of the market price. The valuation date will be the payable date for such distribution or dividend or, if that date is not a trading day on the NYSE,
the immediately preceding trading date. If NAV exceeds the market price of Fund shares at such time, or if the Fund should declare an income dividend or capital gains distribution payable only in cash, the Plan Agent
will, as agent for the participants, buy Fund shares in the open market, on the NYSE or elsewhere, for the participants&#x2019; accounts on, or shortly after, the payment date. If, before the Plan Agent has completed
its purchases, the market price exceeds the NAV of the Fund's share, the average per share purchase price paid by the Plan Agent may exceed the NAV of the Fund&#x2019;s shares, resulting in the acquisition of fewer
shares than if the distribution had been paid in shares issued by the Fund on the dividend payment date. Because of</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">the foregoing difficulty with respect to
open-market purchases, the Plan provides that if the Plan Agent is unable to invest the full dividend amount in open-market purchases during the purchase period or if the market discount shifts to a market premium
during the purchase period, the Plan Agent will cease making open-market purchases and will receive the uninvested portion of the dividend amount in newly issued shares at the close of business on the last purchase
date.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Participants have the option
of making additional cash payments of a minimum of $50 per investment (by check, one-time online bank debit or recurring automatic monthly ACH debit) to the Plan Agent for investment in the Fund&#x2019;s common stock,
with an annual maximum contribution of $250,000. The Plan Agent will wait up to three business days after receipt of a check or electronic funds transfer to ensure it receives good funds. Following confirmation of
receipt of good funds, the Plan Agent will use all such funds received from participants to purchase Fund shares in the open market on the 25th day of each month or the next trading day if the 25th is not a trading
day.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">If the participant sets up
recurring automatic monthly ACH debits, funds will be withdrawn from his or her U.S. bank account on the 20th of each month or the next business day if the 20th is not a banking business day and invested on the next
investment date. The Plan Agent maintains all shareholder accounts in the Plan and furnishes written confirmations of all transactions in an account, including information needed by shareholders for personal and tax
records. Shares in the account of each Plan participant will be held by the Plan Agent in the name of the participant, and each shareholder&#x2019;s proxy will include those shares purchased pursuant to the Plan. There
will be no brokerage charges with respect to common shares issued directly by the Fund. However, each participant will pay a per share fee of $0.02 incurred with respect to the Plan Agent&#x2019;s open market purchases
in connection with the reinvestment of dividends, capital gains distributions and voluntary cash payments made by the participant. Per share fees include any applicable brokerage commissions the Plan Agent is required
to pay.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Participants also have the
option of selling their shares through the Plan. The Plan supports two types of sales orders. Batch order sales are submitted on each market day and will be grouped with other sale requests to be sold. The price will
be the average sale price obtained by Computershare&#x2019;s broker, net of fees, for each batch order and will be sold generally within 2 business days of the request during regular open market hours. Please note that
all written sales requests are always processed by Batch Order. ($10 and $0.12 per share). Market Order sales will sell at the next available trade. The shares are sold real time when they hit the market, however an
available trade must be presented to complete this transaction. Market Order sales may only</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:16.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">56
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Dividend Reinvestment and Optional Cash Purchase
Plan&#xa0;<font style="font-size:11pt; line-height:14pt"> (Unaudited)&#xa0;&#xa0;(concluded)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">be requested by phone at 1-800-647-0584 or
using Investor Center through www.computershare.com/buyaberdeen. ($25 and $0.12 per share).</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The receipt of dividends and
distributions under the Plan will not relieve participants of any income tax that may be payable on such dividends or distributions. The Fund or the Plan Agent may terminate the Plan as applied to any voluntary cash
payments made and any dividend or distribution paid subsequent to notice of the termination sent to members of the Plan at least 30 days prior to the record date for such dividend or distribution. The Plan also may be
amended by</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">the Fund or the Plan Agent, but (except when
necessary or appropriate to comply with applicable law or the rules or policies of the Securities and Exchange Commission or any other regulatory authority) only by mailing a written notice at least 30 days prior to
the effective date to the participants in the Plan. All correspondence concerning the Plan should be directed to the Plan Agent by phone at 1-800-647-0584, using Investor Center through <font style="color:#0000FF; text-decoration:underline">www.computershare.com/buyaberdeen</font> or in writing to Computershare Trust Company N.A., P.O. Box 43006, Providence, RI 02940-3078.&#xa0;</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:517.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:23.55%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">57
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:Normal; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Management of the Fund&#xa0;<font style="font-size:11pt; line-height:14pt"> (Unaudited)&#xa0;</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of October 31, 2025<br>
</div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:18.5pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">The names, years of birth and
business addresses of the Board Members and officers of the Fund as of October 31, 2025, their principal occupations during at least the past five years, the number of portfolios each Board Member oversees and other
directorships they hold are provided in the tables below. Board Members that are deemed &#x201c;interested persons&#x201d; (as that term is defined in Section 2(a)(19) of the Investment Company Act of 1940, as amended)
of the Fund or the Fund's Advisers are included in the table below under the heading &#x201c;Interested Board Members.&#x201d; Board Members who are not interested persons, as described above, are referred to in the
table below under the heading &#x201c;Independent Board Members.&#x201d; abrdn Inc., its parent company Aberdeen Group plc, and its advisory affiliates are collectively referred to as &#x201c;Aberdeen&#x201d; in the
tables below.</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.28%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:6pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.53%; background-color: #D9D9D9;">Name, Address and<br>
Year of Birth
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.32%; background-color: #D9D9D9;">Position(s) Held<br>
with the Fund
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.31%; background-color: #D9D9D9;">Term of Office<br>
and Length of<br>
Time Served
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:22.06%; background-color: #D9D9D9;">Principal Occupation(s)<br>
During at Least the Past Five Years
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.16%; background-color: #D9D9D9;">Number of Registered<br>
Investment Companies<br>
("Registrants") consisting<br>
of Investment Portfolios<br>
("Portfolios") in<br>
Fund Complex*<br>
Overseen by<br>
Board Members
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:6pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.88%; background-color: #D9D9D9;">Other<br>
Directorships<br>
Held by<br>
Board Member**
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:17.53%; background-color: #F0F0F0;"><font style="text-decoration:underline">Interested Board Member</font>
</td><td style="line-height:0pt; padding-right:4pt; padding-top:2.25pt; text-align:left; vertical-align:top; width:13.32%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-right:4pt; padding-top:2.25pt; text-align:left; vertical-align:top; width:11.31%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-right:4pt; padding-top:2.25pt; text-align:left; vertical-align:top; width:22.06%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-right:4pt; padding-top:2.25pt; text-align:center; vertical-align:top; width:17.16%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-right:6pt; padding-top:2.25pt; text-align:left; vertical-align:top; width:17.88%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:17.53%; background-color: #F0F0F0;">Christian Pittard***<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1973
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:13.32%; background-color: #F0F0F0;">Class C Trustee and Vice President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Term expires 2026; Trustee since 2024
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:22.06%; background-color: #F0F0F0;">Mr. Pittard is Head of Closed End Funds for abrdn and is responsible for the US and UK businesses. Aberdeen is currently the 5th largest listed Closed-End Fund
manager in the world. &#xa0;He is also Managing Director of Corporate Finance, having done a significant number of closed end fund transactions in the US and UK since joining abrdn in 1999. Previously, he was Head of
the Americas and the North American Funds business for Aberdeen based in the US.
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:17.16%; background-color: #F0F0F0;">12 Registrants<br>
consisting of<br>
12 Portfolios
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:17.88%; background-color: #F0F0F0;">None.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:17.53%; background-color: #F0F0F0;"><font style="text-decoration:underline">Independent Board Members</font>
</td><td style="line-height:0pt; padding-right:4pt; padding-top:2.25pt; text-align:left; vertical-align:top; width:13.32%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-right:4pt; padding-top:2.25pt; text-align:left; vertical-align:top; width:11.31%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-right:4pt; padding-top:2.25pt; text-align:left; vertical-align:top; width:22.06%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-right:4pt; padding-top:2.25pt; text-align:center; vertical-align:top; width:17.16%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-right:6pt; padding-top:2.25pt; text-align:left; vertical-align:top; width:17.88%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:17.53%; background-color: #F0F0F0;">Jeffrey A. Bailey<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1962
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:13.32%; background-color: #F0F0F0;">Class C Trustee
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Term expires 2026; Trustee since 2020
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:22.06%; background-color: #F0F0F0;">Mr. Bailey was the CEO of IllummOss Inc from 2018-2020. He also served as the Board Chairman of Aileron Therapeutics Inc. 2017-2024 and Independent Board Chair of
Tekla Funds&#xa0;2020 - 2023.&#xa0; Most recently he served as the Director and CEO of BioDelivery Systems, Inc. from 2020-2022. He currently also serves on the board of Aurinia Pharmaceuticals.&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:17.16%; background-color: #F0F0F0;">4&#xa0;Registrants<br>
consisting of<br>
4 Portfolios
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:17.88%; background-color: #F0F0F0;">Aurinia Pharmaceuticals, Director since 2023.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:17.53%; background-color: #F0F0F0;">Rose DiMartino<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1952
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:13.32%; background-color: #F0F0F0;">Class B Trustee
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Term expires 2028; Trustee since 2023
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:22.06%; background-color: #F0F0F0;">Ms. DiMartino has been retired since 2019. Previously, she was Partner (1991-2017) and Senior Counsel (2017-2019) at the law firm of&#xa0;Willkie
Farr &amp; Gallagher LLP.
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:17.16%; background-color: #F0F0F0;">5 Registrants<br>
consisting of<br>
7 Portfolios
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:17.88%; background-color: #F0F0F0;">None.
</td></tr></table>
</div>
</div>
<div style="margin-top:142pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">58
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:Normal; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Management of the Fund&#xa0;<font style="font-size:11pt; line-height:14pt"> (Unaudited)&#xa0;&#xa0;(continued)</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of October 31, 2025<br>
</div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:82.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.28%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:6pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.53%; background-color: #D9D9D9;">Name, Address and<br>
Year of Birth
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.32%; background-color: #D9D9D9;">Position(s) Held<br>
with the Fund
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.31%; background-color: #D9D9D9;">Term of Office<br>
and Length of<br>
Time Served
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:22.06%; background-color: #D9D9D9;">Principal Occupation(s)<br>
During at Least the Past Five Years
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.16%; background-color: #D9D9D9;">Number of Registered<br>
Investment Companies<br>
("Registrants") consisting<br>
of Investment Portfolios<br>
("Portfolios") in<br>
Fund Complex*<br>
Overseen by<br>
Board Members
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:6pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.88%; background-color: #D9D9D9;">Other<br>
Directorships<br>
Held by<br>
Board Member**
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:17.53%; background-color: #F0F0F0;">Kathleen Goetz<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1966
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:13.32%; background-color: #F0F0F0;">Class A Trustee
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Term expires 2027; Trustee since 2021
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:22.06%; background-color: #F0F0F0;">Ms. Goetz is a healthcare advisor and biotech consultant since 2020. She brings over 30 years of biotech and pharma industry experience spanning commercial strategy,
business and product development, finance, operational effectiveness, corporate governance, and market access.She most recently served in multiple roles at Novartis Pharmaceuticals, including Vice President of Sales
(2017-2019) and Executive Director and Head of US Strategic Accounts (2014-2017). She currently serves on the board of Aurinia Pharmaceuticals.
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:17.16%; background-color: #F0F0F0;">4&#xa0;Registrants<br>
consisting of<br>
4 Portfolios
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:17.88%; background-color: #F0F0F0;">Aurinia Pharmaceuticals, Director, since &#xa0;2025.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:17.53%; background-color: #F0F0F0;">C. William Maher<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1961
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:13.32%; background-color: #F0F0F0;">Class B Trustee
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Term expires 2028; Trustee since 2023
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:22.06%; background-color: #F0F0F0;">Mr. Maher is a Co-founder of Asymmetric Capital Management LLC from May 2018 to September 2020. Formerly Chief Executive Officer of Santa Barbara
Tax Products Group ("SBTPG") from October 2014 to April 2016. Previously, he held senior financial leadership positions as CFO for SBTPG, CFO and Managing Director at LPL Financial, CFO and Managing Director at
Nicholas Applegate Capital Management and CFO at Mitchell Hutchins Asset Management.
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:17.16%; background-color: #F0F0F0;">7 Registrants<br>
consisting of<br>
7 Portfolios
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:17.88%; background-color: #F0F0F0;">None.
</td></tr></table>
</div>
</div>
<div style="margin-top:256pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:23.55%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">59
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:Normal; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Management of the Fund&#xa0;<font style="font-size:11pt; line-height:14pt"> (Unaudited)&#xa0;&#xa0;(continued)</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of October 31, 2025<br>
</div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:82.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.28%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:6pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.53%; background-color: #D9D9D9;">Name, Address and<br>
Year of Birth
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.32%; background-color: #D9D9D9;">Position(s) Held<br>
with the Fund
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.31%; background-color: #D9D9D9;">Term of Office<br>
and Length of<br>
Time Served
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:22.06%; background-color: #D9D9D9;">Principal Occupation(s)<br>
During at Least the Past Five Years
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.16%; background-color: #D9D9D9;">Number of Registered<br>
Investment Companies<br>
("Registrants") consisting<br>
of Investment Portfolios<br>
("Portfolios") in<br>
Fund Complex*<br>
Overseen by<br>
Board Members
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:6pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.88%; background-color: #D9D9D9;">Other<br>
Directorships<br>
Held by<br>
Board Member**
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:17.53%; background-color: #F0F0F0;">Todd Reit<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1968
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:13.32%; background-color: #F0F0F0;">Chair of the Board; Class A Trustee
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Term expires 2027; Trustee since 2023
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:22.06%; background-color: #F0F0F0;">Mr. Reit is a Managing Member of Cross Brook Partners LLC, a real estate investment and management company since 2017. Mr. Reit is also Director
and Financial Officer of Shelter Our Soldiers, a charity to support military veterans, since 2016. Mr. Reit was formerly a Managing Director and Global Head of Asset Management Investment Banking for UBS AG, where he
was responsible for overseeing all the bank&#x2019;s asset management client relationships globally, including all corporate security transactions, mergers and acquisitions. Mr. Reit retired from UBS in 2017 after an
over 25-year career at the company and its predecessor company, PaineWebber Incorporated (merged with UBS AG in 2000).
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:17.16%; background-color: #F0F0F0;">10 Registrants<br>
consisting of<br>
10 Portfolios
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:17.88%; background-color: #F0F0F0;">None.
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; text-align:center; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
<div style="text-align:center">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-right:auto; margin-top:11pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.61%">*
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:97.94%">As of October 31, 2025, the Fund Complex has a total of 17 Registrants with each Board member serving on the Boards of the number of Registrants listed. Each Registrant in the Fund Complex has one
Portfolio except for two Registrants that are open-end funds, abrdn Funds and abrdn ETFs, which each have multiple Portfolios. The Registrants in the Fund Complex are as follows: abrdn Asia-Pacific Income Fund, Inc.,
abrdn Global Income Fund, Inc., abrdn Australia Equity Fund, Inc., abrdn Emerging Markets ex-China Fund, Inc., The India Fund, Inc., abrdn Income Credit Strategies Fund, abrdn Global Dynamic Dividend Fund, abrdn
Global Premier Properties Fund, abrdn Total Dynamic Dividend Fund, abrdn Global Infrastructure Income Fund, abrdn National Municipal Income Fund, abrdn Healthcare Investors, abrdn Life Sciences Investors, abrdn
Healthcare Opportunities Fund, abrdn World Healthcare Fund, abrdn Funds (17 Portfolios), and abrdn ETFs (3 Portfolios).
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.61%">**
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:97.94%">Current directorships (excluding Fund Complex) as of the date of this report held in (1) any other investment companies registered under the 1940 Act, (2) any company with a class of securities
registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the &#x201c;1934 Act&#x201d;) or (3) any company subject to the requirements of Section 15(d) of the Exchange Act.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:3pt; padding-left:0pt; padding-right:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.61%">***
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:3pt; padding-left:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:97.94%">Mr. Pittard is deemed to be an interested person because of his affiliation with the Fund&#x2019;s investment adviser.
</td></tr></table>
</div>
</div>
<div style="margin-top:208pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">60
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:Normal; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Management of the Fund&#xa0;<font style="font-size:11pt; line-height:14pt"> (Unaudited)&#xa0;&#xa0;(continued)</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of October 31, 2025<br>
</div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:19.5pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; margin-top:10pt; text-align:left; text-decoration:none; text-transform:none">Officers of the Fund</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.28%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:6pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:18.42%; background-color: #D9D9D9;">Name, Address and<br>
Year of Birth
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.86%; background-color: #D9D9D9;">Position(s) Held<br>
with the Fund
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.31%; background-color: #D9D9D9;">Term of Office*<br>
and Length of<br>
Time Served
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:6pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:57.68%; background-color: #D9D9D9;">Principal Occupation(s) During at Least the Past Five Years
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Jason Akus**<br>
c/o&#xa0;abrdn Inc.<br>
28 State Street<br>
17th floor<br>
Boston, MA 02109<br>
Year of Birth: 1974&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Vice President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2023
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently Senior Investment Director. Dr. Akus joined abrdn Inc in October 2023 from Tekla Capital Management where he was employed as a Senior Vice President of
Research.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Joshua Duitz**<br>
c/o&#xa0;abrdn Inc.<br>
875 Third Ave<br>
4th Floor, Suite 403<br>
New York, NY 10022<br>
Year of Birth: 1970
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Vice President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2023
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently, Head of Global Income at abrdn Inc. Mr. Duitz joined abrdn Inc. in 2018 from Alpine Woods Capital Investors LLC where he was a Portfolio Manager.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Sharon Ferrari**<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1977
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Treasurer and Chief Financial Officer
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2023
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently, Director,&#xa0;Product Management for abrdn Inc. Ms. Ferrari joined abrdn Inc. as a Senior Fund Administrator in 2008.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Katie Gebauer**<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1986
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Chief Compliance Officer and Vice President - Compliance
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2025
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently, Ms. Gebauer is Head of US Registered Fund Compliance. She serves as the Chief Compliance Officer for Aberdeen's US closed end funds, open end funds and
ETFs. Ms. Gebauer joined abrdn Inc. in 2014.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Alan Goodson**<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1974
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.86%; background-color: #F0F0F0;">President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2023
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently, Executive Director and Head of Product &amp; Client Solutions &#x2013; Americas for abrdn Inc., overseeing Product Management &amp; Governance, Product
Development and Client Solutions for registered and unregistered investment companies in the U.S., Brazil and Canada. Mr. Goodson is Director and Vice President of abrdn Inc. and joined abrdn Inc. in 2000.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Heather Hasson**<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1982
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Vice President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2025
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently, Senior Product Development Manager. Previously, Senior Product Solutions and Implementation Manager, Product Governance US for abrdn Inc. Ms. Hasson
joined the company in November 2006.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Robert Hepp**<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1986
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Vice President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2025
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently, Senior Product Governance Manager &#x2013; US for abrdn Inc. Mr. Hepp joined abrdn Inc. as a Senior Paralegal in 2016.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Megan Kennedy**<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1974
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Secretary and Vice President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2023
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently, Senior Director, &#xa0;Product Governance for abrdn Inc. Ms. Kennedy joined abrdn Inc. in 2005.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Andrew Kim**<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1983
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Vice President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2025
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently, Senior Product Governance Manager &#x2013; Attorney for abrdn Inc. Mr. Kim joined abrdn Inc. as a Product Manager in 2013.
</td></tr></table>
</div>
</div>
<div style="margin-top:34pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:23.55%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Opportunities Fund
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.38%">61
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:Normal; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Management of the Fund&#xa0;<font style="font-size:11pt; line-height:14pt"> (Unaudited)&#xa0;&#xa0;(concluded)</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of October 31, 2025<br>
</div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:32.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.28%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:6pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:18.42%; background-color: #D9D9D9;">Name, Address and<br>
Year of Birth
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.86%; background-color: #D9D9D9;">Position(s) Held<br>
with the Fund
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.31%; background-color: #D9D9D9;">Term of Office*<br>
and Length of<br>
Time Served
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:6pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:57.68%; background-color: #D9D9D9;">Principal Occupation(s) During at Least the Past Five Years
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Michael Marsico**<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1980
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Vice President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2025
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently, Senior Product Manager &#x2013; US for abrdn Inc. Mr. Marsico joined abrdn Inc. as a Fund Administrator in 2014.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Ben Ritchie**<br>
c/o abrdn Investments Limited<br>
280 Bishopsgate<br>
London, EC2M 4AG<br>
Year of Birth: 1980&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Vice President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2023
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently Head of the Developed Markets Equity team at abrdn.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Kolotioloma Silue**<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1977
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Vice President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2024
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently, Senior Product Manager for abrdn Inc. Mr. Silue joined abrdn Inc in October 2023 from Tekla Capital Management where he was employed as a Senior Manager
of Fund Administration.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Lucia Sitar**<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1971
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Chief Legal Officer and Vice President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2023
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently, Vice President and U.S. Counsel - Head of Product Governance for&#xa0;abrdn Inc. Previously, Ms. Sitar was Head of Product Governance and Management and
Managing U.S. Counsel for abrdn Inc. She joined abrdn Inc. as U.S. Counsel in 2007.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Michael Taggart**<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1970&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Vice President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2023
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently, Head of Closed-End Fund Investor Relations at abrdn Inc since 2023. Prior to that, he was Vice President of Investment Research and Operations at Relative
Value Partners, LLC from June 2022. Prior to that, he was self-employed after having left Nuveen in November 2020, where he had served as Vice President of Closed-End Fund Product Strategy since November 2013.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Loretta Tse**<br>
c/o&#xa0;abrdn Inc.<br>
28 State Street<br>
17th floor<br>
Boston, MA 02109<br>
Year of Birth: 1967&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Vice President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2023
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently Investment Director at abrdn. Ms. Tse joined abrdn in October 2023 from Tekla Capital Management LLC where she was a Vice President investing in venture.
Previously, she worked for the Fred Hutchinson Cancer Research Center and Oxford Biosciences Partners.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Ashton Wilson**<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1986
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Vice President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2025
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently Senior Investment Director in healthcare portfolio management. Mr. Wilson joined abrdn in October 2023 from Tekla Capital Management
where he was a Senior Vice President. Previously, he worked for Goldman Sachs and Co.
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; text-align:left; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
<div style="text-align:center">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-right:auto; margin-top:11pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:1.92%">*
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.62%">Officers hold their positions with the Fund until a successor has been duly elected and qualifies. Officers are elected annually at a meeting of the Fund Board.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:3pt; padding-left:0pt; padding-right:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:1.92%">**
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:3pt; padding-left:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.62%">Each officer may hold officer position(s) in one or more other funds which are part of the Fund Complex.
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Further information about the
Fund's Board Members and Officers is available in the Fund's Statement of Additional Information, which can be obtained without charge by calling (800) 522-5465.&#xa0;</div>
</div>
<div style="margin-top:131pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">62
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Healthcare Opportunities Fund
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:10pt; font-style:Normal; font-weight:Normal; line-height:13pt; text-align:center; text-decoration:none; text-transform:none">[THIS PAGE INTENTIONALLY LEFT BLANK]</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:10pt; font-style:Normal; font-weight:Normal; line-height:13pt; text-align:center; text-decoration:none; text-transform:none">[THIS PAGE INTENTIONALLY LEFT BLANK]</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Corporate Information<font style="font-size:11pt; line-height:14pt">&#xa0;</font></div>
</div>
<div style="margin-top:2pt; width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:26.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48%">
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">Trustees</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">Todd Reit, <font style="font-style:italic">Chair<br>
</font>Jeffrey Bailey<br>
Rose DiMartino<br>
Kathleen Goetz<br>
C. William Maher<br>
Christian Pittard</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">Investment Adviser</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">abrdn Inc.<br>
1900 Market Street, Suite 200<br>
Philadelphia, PA&#xa0;19103</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">Custodian</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">State Street Bank and Trust Company<br>
John Adams Building<br>
1776 Heritage Drive<br>
North Quincy, MA 02171</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">Transfer Agent</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">Computershare Trust Company, N.A.<br>
P.O. Box 43006<br>
Providence, RI 02940-3078</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48%">
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">Independent Registered Public Accounting Firm</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">KPMG LLP<br>
191 West Nationwide Blvd., Suite 500<br>
Columbus, OH 43215</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">Legal Counsel</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">Dechert LLP<br>
1900 K Street N.W.<br>
Washington, D.C. 20006</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">Investor Relations</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">abrdn Inc.<br>
1900 Market Street, Suite 200<br>
Philadelphia, PA 19103<br>
1-800-522-5465<br>
Investor.Relations@aberdeenplc.com</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:212pt; width:100%">
<div style="margin-left:38.41%; margin-top:5pt; text-align:Center; width:23.19%">
<img src="tm2527059d10thqreporti005.jpg" alt=" ">
</div>


<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; margin-top:9pt; text-align:left; text-decoration:none; text-transform:none">Notice is hereby given in
accordance with Section 23(c) of the Investment Company Act of 1940, as amended, that the Fund may purchase, from time to time, shares of its common stock in the open market.</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Shares of abrdn
Healthcare Opportunities Fund are traded on the NYSE under the symbol &#x201c;THQ.&#x201d; Information about the Fund&#x2019;s net asset value and market price is available at www.aberdeenthq.com.</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">This report, including
the financial information herein, is transmitted to the shareholders of abrdn Healthcare Opportunities Fund for their general information only. It does not have regard to the specific investment objectives, financial
situation and the particular needs of any specific person. Past performance is no guarantee of future results.</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">THQ-ANNUAL</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<div style="font: 10pt Times New Roman, Times, Serif"><div style="Page-Break-Before: Always"></div><!-- BannerFile="tm2527059d10_items2-19.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2527059-10/tm2527059-10_ncsrseq1" -->

<p style="margin: 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left">(b)</td><td style="text-align: justify">Not applicable.</td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 2. Code of Ethics.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</font></td>
    <td style="text-align: justify; font-size: 10pt">As of September&#xa0;30, 2025, abrdn Healthcare Opportunities Fund (the &#x201c;Fund&#x201d;
or the &#x201c;Registrant&#x201d;) had adopted a Code of Ethics that applies to the Registrant&#x2019;s principal executive officer, principal
financial officer, principal accounting officer or controller, or persons performing similar functions, regardless of whether these individuals
are employed by the Registrant or a third party (the &#x201c;Code of Ethics&#x201d;).&#xa0;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</font></td>
    <td style="font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitional.</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</font></td>
    <td style="font-size: 10pt">There have been no amendments, during the period covered by this report, to a provision of
the Code of Ethics.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</font></td>
    <td style="font-size: 10pt">During the period covered by this report, there were no waivers to the provisions of the
Code of Ethics.&#xa0;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</font></td>
    <td style="font-size: 10pt">Not applicable</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</font></td>
    <td style="font-size: 10pt">A copy of the Code of Ethics has been filed as an exhibit to this Form&#xa0;N-CSR.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 3. Audit Committee Financial Expert.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Registrant's Board of Trustees has determined
that C. William Maher, a member of the Board of Trustees&#x2019; Audit Committee, possesses the attributes, and has acquired such attributes
through means, identified in instruction 2 of Item 3 to Form&#xa0;N-CSR to qualify as an &#x201c;audit committee financial expert,&#x201d;
and has designated Mr.&#xa0;Maher as the Audit Committee&#x2019;s financial expert. Mr.&#xa0;Maher is considered to be an &#x201c;independent&#x201d;
trustee, as such term is defined in paragraph (a)(2)&#xa0;of Item 3 to Form&#xa0;N-CSR.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 4. Principal Accountant Fees and Services.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">(a)&#xa0;&#x2013;
(d)&#xa0;Below is a table reflecting the fee information requested in Items 4(a)&#xa0;through (d):</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fiscal Year<br> Ended</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)<br> Audit Fees<sup>1</sup></b></font></td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)<br> Audit-Related Fees<sup>2</sup></b></font></td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)<br> Tax Fees<sup>3</sup></b></font></td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)<br> All Other Fees<sup>4</sup></b></font></td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">September&#xa0;30, 2025</td><td style="width: 2%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">91,100</td><td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">0</td><td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">0</td><td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">0</td><td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percentage
    approved pursuant to pre-approval exception<font style="font-style: normal; font-weight: normal"><sup>5</sup></font></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">September&#xa0;30, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">88,400</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percentage
    approved pursuant to pre-approval exception<font style="font-style: normal; font-weight: normal"><sup>5</sup></font></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><sup>1</sup> &#x201c;Audit Fees&#x201d; are the
aggregate fees billed for professional services for the audit of the Fund&#x2019;s annual financial statements and services provided in
connection with statutory and regulatory filings or engagements.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><sup>2</sup> &#x201c;Audit Related Fees&#x201d;
are the aggregate fees billed for assurance and related services reasonably related to the performance of the audit or review of financial
statements that are not reported under &#x201c;Audit Fees&#x201d;. These fees include offerings related to the Fund&#x2019;s common shares.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><sup>3</sup> &#x201c;Tax Fees&#x201d; are the aggregate
fees billed for professional services for tax advice, tax compliance, and tax planning. These fees include: federal and state income tax
returns, review of excise tax distribution calculations and federal excise tax return.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><sup>4</sup> &#x201c;All Other Fees&#x201d; are
the aggregate fees billed for products and services other than &#x201c;Audit Fees&#x201d;, &#x201c;Audit-Related Fees&#x201d; and &#x201c;Tax
Fees&#x201d;.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-style: normal; font-weight: normal"><sup>5</sup></font>
Pre-approval exception under Rule&#xa0;2-01 of Regulation S-X. The pre-approval exception for services provided directly to the Fund
waives the pre-approval requirement for services other than audit, review or attest services if: (A)&#xa0;the aggregate amount of all
such services provided constitutes no more than 5% of the total amount of revenues paid by the Fund to its accountant during the fiscal
year in which the services are provided; (B)&#xa0;the Fund did not recognize the services as non-audit services at the time of the engagement;
and (C)&#xa0;the services are promptly brought to the Audit Committee&#x2019;s attention, and the Committee (or its delegate) approves
the services before the audit is completed.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)(1)</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Registrant&#x2019;s Audit Committee (the &#x201c;Committee&#x201d;) has adopted a Charter that provides that the Committee shall annually select, retain or terminate, and recommend to the Independent Directors for their ratification, the selection, retention or termination, the Registrant&#x2019;s independent auditor and, in connection therewith, to evaluate the terms of the engagement (including compensation of the independent auditor) and the qualifications and independence of the independent auditor, including whether the independent auditor provides any consulting, auditing or tax services to the Registrant&#x2019;s investment adviser (the &#x201c;Adviser&#x201d;) or any sub-adviser, and to receive the independent auditor&#x2019;s specific representations as to their independence, delineating all relationships that may affect the independent auditor&#x2019;s independence, including the disclosures required by PCAOB Rule&#xa0;3526 or any other applicable auditing standard. PCAOB Rule&#xa0;3526 requires that, at least annually, the auditor: (1)&#xa0;disclose to the Committee in writing all relationships between the auditor and its related entities and the Registrant and its related entities that in the auditor&#x2019;s professional judgment may reasonably be thought to bear on independence; (2)&#xa0;confirm in the letter that, in its professional judgment, it is independent of the Registrant within the meaning of the Securities Acts administered by the SEC; and (3)&#xa0;discuss the auditor&#x2019;s independence with the audit committee. The Committee is responsible for actively engaging in a dialogue with the independent auditor with respect to any disclosed relationships or services that may impact the objectivity and independence of the independent auditor and for taking, or recommending that the full Board take, appropriate action to oversee the independence of the independent auditor. The Committee Charter also provides that the Committee shall review in advance, and consider approval of, any and all proposals by Management or the Adviser that the Registrant, the Adviser or their affiliated persons, employ the independent auditor to render &#x201c;permissible non-audit services&#x201d; to the Registrant and to consider whether such services are consistent with the independent auditor&#x2019;s independence. &#x201c;Permissible non-audit services&#x201d; include any professional services, including tax services, provided to the Registrant by the independent auditor, other than those provided to the Registrant in connection with an audit or a review of the financial statements of the Registrant. Permissible non-audit services may not include: (i)&#xa0;bookkeeping or other services related to the accounting records or financial statements of the Registrant; (ii)&#xa0;financial information systems design and implementation; (iii)&#xa0;appraisal or valuation services, fairness opinions or contribution-in-kind reports; (iv)&#xa0;actuarial services; (v)&#xa0;internal audit outsourcing services; (vi)&#xa0;management functions or human resources; (vii)&#xa0;broker or dealer, investment adviser or investment banking services; (viii)&#xa0;legal services and expert services unrelated to the audit; and (ix)&#xa0;any other service the PCAOB determines, by regulation, is impermissible.&#xa0;&#xa0;Pre-approval by the Committee of any permissible non-audit services is not required so long as: (i)&#xa0;the aggregate amount of all such permissible non-audit services provided to the Registrant constitutes not more than 5% of the total amount of revenues paid by the Registrant to its auditor during the fiscal year in which the permissible non-audit services are provided; (ii)&#xa0;the permissible non-audit services were not recognized by the Registrant at the time of the engagement to be non-audit services; and (iii)&#xa0;such services are promptly brought to the attention of the Committee and approved by the Committee or its Delegate(s)&#xa0;prior to the completion of the audit.
The Committee may delegate to one or more of its members (&#x201c;Delegates&#x201d;) authority to pre-approve permissible non-audit services to be provided to the Registrant. Any pre-approval determination of a Delegate shall be presented to the full Committee at its next meeting. Any pre-approval determination of a Delegate shall be presented to the full Committee at its next meeting. Pursuant to this authority, the Registrant&#x2019;s Committee delegates to the Committee Chair, subject to subsequent ratification by the full Committee, up to a maximum amount of $25,000, which includes any professional services, including tax services, provided to the Registrant by its independent registered public accounting firm other than those provided to the Registrant in connection with an audit or a review of the financial statements of the Registrant.&#xa0;&#xa0;The Committee shall communicate any pre-approval made by it or a Delegate to the Adviser, who will ensure that the appropriate disclosure is made in the Registrant&#x2019;s periodic reports required by Section&#xa0;30 of the Investment Company Act of 1940, as amended, and other documents as required under the federal securities laws.</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)(2)</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None of the services described in each of paragraphs (b)&#xa0;through (d)&#xa0;of this Item involved a waiver of the pre-approval requirement by the Audit Committee pursuant to Rule&#xa0;2-01 (c)(7)(i)(C)&#xa0;of Regulation S-X.</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not applicable.</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Audit Fees</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in">The following table shows the amount of fees that KPMG LLP
billed during the Fund&#x2019;s last two fiscal years for non-audit services to the Registrant, and to the Adviser, and any entity controlling,
controlled by or under common control with the Adviser that provides ongoing services to the Fund (&#x201c;Affiliated Fund Service Provider&#x201d;):</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Fiscal Year Ended</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total&#xa0;Non-Audit&#xa0;Fees<br> Billed to Fund</td><td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total&#xa0;Non-Audit&#xa0;Fees<br> billed to Adviser and<br> Affiliated&#xa0;Fund&#xa0;Service<br> Providers&#xa0;(engagements<br> related directly to the<br> operations and&#xa0;financial<br> reporting of the Fund)</td><td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total&#xa0;Non-Audit&#xa0;Fees<br> billed to Adviser and<br> Affiliated&#xa0;Fund&#xa0;Service<br> Providers (all other<br> engagements)</td><td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total</td><td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; font: 10pt Times New Roman, Times, Serif; text-indent: -12pt; padding-left: 12pt">September&#xa0;30, 2025</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 17%; font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 17%; font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 17%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,253,744</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 17%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,253,744</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -12pt; padding-left: 12pt">September&#xa0;30, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">629,124</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">629,124</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#x201c;Non-Audit Fees billed to Fund&#x201d; for both fiscal years represent
 &#x201c;Tax Fees&#x201d; and &#x201c;All Other Fees&#x201d; billed to Fund in their respective amounts from the previous table.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not applicable.</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left">(i)</td><td style="text-align: justify">Not applicable.</td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left">(j)</td><td style="text-align: justify">Not applicable.</td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 5. Audit Committee of Listed Registrants.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Registrant has a separately-designated standing Audit Committee established in accordance with Section&#xa0;3(a)(58)(A)&#xa0;of the Exchange Act (15 U.S.C. 78c(a)(58)(A)).</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of the fiscal year ended September&#xa0;30,
2025, the Audit Committee members were:</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Jeffrey Bailey</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Rose DiMartino</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Kathleen Goetz</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">C. William Maher</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Todd Reit</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not applicable.</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 6. Schedule of Investments.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a)&#xa0;Included as part of the Report to Shareholders
filed under Item 1 of this Form&#xa0;N-CSR.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b)&#xa0;Not applicable.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 7. Financial Statements and Financial Highlights for Open-End
Management Investment Companies.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 8. Changes in and Disagreements with Accountants for Open-End
Management Investment Companies.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9. Proxy Disclosures for Open-End Management Investment Companies.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 10. Remuneration Paid to Directors, Officers, and Others of
Open-End Management Investment Companies.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 11. Statement Regarding Basis for Approval of Investment Advisory
Contract.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The statement regarding the basis for approval of the investment advisory
contract is included in the response to Item 1, above.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 12. Disclosure of Proxy Voting Policies and Procedures for
Closed-End Management Investment Companies.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Registrant's Proxy Voting Policy
and Procedures, the Registrant has delegated responsibility for its proxy voting to its Adviser, provided that the Registrant's Board
of Trustees has the opportunity to periodically review the Adviser's proxy voting policies and material amendments thereto.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The proxy voting policies of the Registrant are
included herewith as Exhibit&#xa0;(d)&#xa0;and policies of the Adviser are included as Exhibit&#xa0;(e).</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 13. Portfolio Managers of Closed-End Management Investment
Companies.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(a)(1)&#xa0;PORTFOLIO MANAGER BIOGRAPHIES</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">As of the date of filing this report, Jason Akus, M.D./M.B.A.,
Ashton L. Wilson, Christopher Abbott, Robert Benson, Kelly Girskis, Ph.D., Richard Goss, and Loretta Tse, Ph.D. are members of a team
that analyzes investments on behalf of the Fund. Dr.&#xa0;Akus exercises ultimate decision-making authority with respect to investments.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24%; border: Black 1pt solid; padding-right: 4pt; padding-left: 4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual&#xa0;&amp; Position</font></td>
    <td style="width: 67%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 4pt; padding-left: 4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Past Business Experience&#xa0;&#xa0;</font></td>
    <td style="padding-left: 2pt; width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Served on the Fund Since</font></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 4pt; padding-left: 4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jason Akus, M.D./M.B.A</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Head of Healthcare Investments</p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 4pt; padding-left: 4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Head of Healthcare Investments of the investment adviser and is responsible for investment research and due diligence in the biotechnology, medical device, and diagnostic areas. He joined the predecessor investment adviser in 2001, where he was Senior Vice President, Research. Dr.&#xa0;Akus joined abrdn Inc. in October&#xa0;2023.</font></td>
    <td style="padding-left: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2014</font></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 4pt; padding-left: 4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ashton Wilson</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Senior Investments Director</p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 4pt; padding-left: 4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior Investments Director of the investment adviser. He joined the predecessor investment adviser in 2018, where he was Senior Vice President. He was previously a Vice President in equity derivative trading at Goldman Sachs and Co. and was an equity derivative trader at Bank of America Merrill Lynch. He joined abrdn Inc. in October&#xa0;2023</font></td>
    <td style="padding-left: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018</font></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 4pt; padding-left: 4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Christopher Abbott</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investment Director</p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 4pt; padding-left: 4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment Director of the investment adviser. He joined the predecessor investment adviser in 2016, where he was Vice President, Research. Previously, Mr.&#xa0;Abbott was at Leerink Partners where he was a Vice President on the Equity Research Team. He joined abrdn Inc. in October&#xa0;2023.</font></td>
    <td style="padding-left: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</font></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 4pt; padding-left: 4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Robert Benson</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investment Director</p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 4pt; padding-left: 4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment Director of the investment adviser. He joined the predecessor investment adviser in 2016, where he was Vice President. Previously, Mr.&#xa0;Benson was at State Street Global Advisors (SSgA) where he performed quantitative research for asset allocation, equities, and alternatives teams. He joined abrdn Inc. in October&#xa0;2023.</font></td>
    <td style="padding-left: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</font></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 4pt; padding-left: 4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kelly Girskis, Ph.D.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investment Director</p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 4pt; padding-left: 4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment Director of the investment adviser. She joined the predecessor investment adviser in 2021, where she was Vice President, Research. Previously, Dr.&#xa0;Girskis was an Equity Research Associate at SVB Leerink. She joined abrdn Inc. in October&#xa0;2023.</font></td>
    <td style="padding-left: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</font></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 4pt; padding-left: 4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Richard Goss</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investment Director</p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 4pt; padding-left: 4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment Director of the investment adviser. He joined the predecessor investment adviser in 2018, where he was Vice President, Research. Previously, Mr.&#xa0;Goss was at Leerink Partners where he was a Vice President on the Large Pharma and Biotech Equity Research Teams and a Healthcare Analyst at Datamonitor. He joined abrdn Inc. in October&#xa0;2023.</font></td>
    <td style="padding-left: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018</font></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 4pt; padding-left: 4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Loretta Tse, Ph.D.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investment Director</p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 4pt; padding-left: 4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment Director of the investment adviser. She joined the predecessor investment adviser in 2015, where she was Vice President. She previously ran a biotech consulting business and worked at various venture funds and start-up companies and was Managing Director at Fred Hutchinson Cancer Research Center. She joined abrdn Inc. in October&#xa0;2023.</font></td>
    <td style="padding-left: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)(2)&#xa0;OTHER ACCOUNTS
MANAGED BY PORTFOLIO MANAGERS.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following chart summarizes information regarding
other accounts for which each portfolio manager has day-to-day management responsibilities. Accounts are grouped into the following three
categories: (1)&#xa0;registered investment companies; (2)&#xa0;other pooled investment vehicles; and (3)&#xa0;other accounts. To the extent
that any of these accounts pay advisory fees that are based on account performance (&#x201c;performance-based fees&#x201d;), information
on those accounts is provided separately. The figures in the chart below for the category of &#x201c;registered investment companies&#x201d;
include the Fund. The &#x201c;Other Accounts Managed&#x201d; represents the accounts managed by the teams of which the portfolio manager
is a member. The information in the table below is as of September&#xa0;30, 2025.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;&#xa0;</p>


<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">Name of<br> Portfolio Manager</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">Type&#xa0;of&#xa0;Accounts</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Other Accounts Managed</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Total Assets ($M)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of<br> Accounts<br> Managed&#xa0;for<br> Which<br> Advisory<br> Fee is Based<br> on<br> Performance</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Total&#xa0;Assets&#xa0;for<br> Which<br> Advisory&#xa0;Fee&#xa0;is<br> Based&#xa0; on<br> Performance ($M)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: left; padding-bottom: 1pt">Jason Akus</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 31%; text-align: left; padding-bottom: 1pt">Registered Investment Companies</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">4</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">3,209.00</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Pooled Investment Vehicles</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other Accounts</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Ashton Wilson</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Registered Investment Companies</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,209.00</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Pooled Investment Vehicles</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other Accounts</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Christopher Abbot</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Registered Investment Companies</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,209.00</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Pooled Investment Vehicles</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other Accounts</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Robert Benson</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Registered Investment Companies</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,209.00</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Pooled Investment Vehicles</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other Accounts</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Kelly Girskis</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Registered Investment Companies</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,209.00</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Pooled Investment Vehicles</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other Accounts</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Richard Goss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Registered Investment Companies</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,209.00</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Pooled Investment Vehicles</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other Accounts</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Loretta Tse</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Registered Investment Companies</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,209.00</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Pooled Investment Vehicles</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other Accounts</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">POTENTIAL CONFLICTS OF INTEREST</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Adviser and its affiliates (collectively referred
to herein as &#x201c;Aberdeen&#x201d;) serve as investment advisers for multiple clients, including the Registrant and other investment
companies registered under the 1940 Act and private funds (such clients are also referred to below as &#x201c;accounts&#x201d;). The portfolio
managers&#x2019; management of &#x201c;other accounts&#x201d; may give rise to potential conflicts of interest in connection with their management
of the Registrant&#x2019;s investments, on the one hand, and the investments of the other accounts, on the other. The other accounts may
have the same investment objective as the Registrant. Therefore, a potential conflict of interest may arise as a result of the identical
investment objectives, whereby the portfolio manager could favor one account over another. However, the Adviser believes that these risks
are mitigated by the fact that: (i)&#xa0;accounts with like investment strategies managed by a particular portfolio manager are generally
managed in a similar fashion, subject to exceptions to account for particular investment restrictions or policies applicable only to certain
accounts, differences in cash flows and account sizes, and similar factors; and (ii)&#xa0;portfolio manager personal trading is monitored
to avoid potential conflicts. In addition, the Adviser has adopted trade allocation procedures that require equitable allocation of trade
orders for a particular security among participating accounts.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In some cases, another account managed by the
same portfolio manager may compensate Aberdeen based on the performance-based fees with qualified clients. The existence of such a performance-based
fee may create additional conflicts of interest for the portfolio manager in the allocation of management time, resources and investment
opportunities.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Another potential conflict could include instances
in which securities considered as investments for the Registrant also may be appropriate for other investment accounts managed by the
Adviser or its affiliates. Whenever decisions are made to buy or sell securities for the Registrant and one or more of the other accounts
simultaneously, the Adviser may aggregate the purchases and sales of the securities and will allocate the securities transactions in a
manner that it believes to be equitable under the circumstances. As a result of the allocations, there may be instances where the Registrant
will not participate in a transaction that is allocated among other accounts. While these aggregation and allocation policies could have
a detrimental effect on the price or amount of the securities available to the Registrant from time to time, it is the opinion of the
Adviser that the benefits from the policies outweigh any disadvantage that may arise from exposure to simultaneous transactions. The Registrant
has adopted policies that are designed to eliminate or minimize conflicts of interest, although there is no guarantee that procedures
adopted under such policies will detect each and every situation in which a conflict arises.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to non-discretionary model delivery
accounts (including UMA accounts) and discretionary SMA accounts, abrdn Inc. will utilize a third party service provider to deliver model
portfolio recommendations and model changes to the Sponsors. abrdn Inc. seeks to treat clients fairly and equitably over time, by delivering
model changes to our service provider and investment instructions for our other discretionary accounts to our trading desk, simultaneously
or approximately at the same time. The service provider will then deliver the model changes to each Sponsor on a when-traded, randomized
full rotation schedule. All Sponsors will be included in the rotation schedule, including SMA and UMA.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">UMA Sponsors will be responsible for determining
how and whether to implement the model portfolio or model changes and implementation of any client specific investment restrictions. The
Sponsors are solely responsible for determining the suitability of the model portfolio for each model delivery client, executing trades
and seeking best execution for such clients.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As it relates to SMA accounts, abrdn Inc. will
be responsible for managing the account on the basis of each client&#x2019;s financial situation and objectives, the day to day investment
decisions, best execution, accepting or rejecting client specific investment restrictions and performance. The SMA Sponsors will collect
suitability information and will provide a summary questionnaire for our review and approval or rejection. For dual contract SMAs, abrdn
Inc. will collect a suitability assessment from the client, along with the Sponsor suitability assessment. Our third party service provider
will monitor client specific investment restrictions on a day to day basis. For SMA accounts, model trades will be traded by the Sponsor
or may be executed through a &#x201c;step-out transaction,&#x201d;- or traded away- from the client&#x2019;s Sponsor if doing so is consistent
with Aberdeen&#x2019;s obligation to obtain best execution. When placing trades through Sponsor Firms (instead of stepping them out), we
will generally aggregate orders where it is possible and in the client&#x2019;s best interests. In the event we are not comfortable that
a Sponsor can obtain best execution for a specific security and trading away is infeasible, we may exclude the security from the model.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trading costs are not covered by the Wrap Program
fee and may result in additional costs to the client. In some instances, step-out trades are executed without any additional commission,
mark-up, or mark-down, but in many instances, the executing broker-dealer may impose a commission or a mark-up or mark-down on the trade.
Typically, the executing broker will embed the added costs into the price of the trade execution, making it difficult to determine and
disclose the exact added cost to clients. In this instance, these additional trading costs will be reflected in the price received for
the security, not as a separate commission, on trade confirmations or on account statements. In determining best execution for SMA accounts,
abrdn Inc. takes into consideration that the client will not pay additional trading costs or commission if executing with the Sponsor.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While UMA accounts are invested in the same strategies
as and may perform similarly to SMA accounts, there are expected to be performance differences between them. There will be performance
dispersions between UMAs and other types of accounts because Aberdeen does not have discretion over trading and there may be client specific
restrictions for SMA accounts.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aberdeen may have already commenced trading for
its discretionary client accounts before the model delivery accounts have executed Aberdeen&#x2019;s recommendations. In this event, trades
placed by the model delivery clients may be subject to price movements, particularly with large orders or where securities are thinly
traded, that may result in model delivery clients receiving less favorable prices than our discretionary clients. Aberdeen has no discretion
over transactions executed by model delivery clients and is unable to control the market impact of those transactions.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Timing delays or other operational factors associated
with the implementation of trades may result in non-discretionary and model delivery clients receiving materially different prices relative
to other client accounts. In addition, the constitution and weights of stocks within model portfolios may not always be exactly aligned
with similar discretionary accounts. This may create performance dispersions within accounts with the same or similar investment mandate.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(a)(3)</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529"><font style="text-decoration:underline">DESCRIPTION OF COMPENSATION STRUCTURE</font></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Aberdeen&#x2019;s remuneration policies are designed
to support its business strategy as a leading international asset manager.&#xa0; The objective is to attract, retain and reward talented
individuals for the delivery of sustained, superior returns for Aberdeen&#x2019;s clients and shareholders.&#xa0; Aberdeen operates in
a highly competitive international employment market, and aims to maintain its strong track record of success in developing and retaining
talent.</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Aberdeen&#x2019;s policy is to recognize corporate
and individual achievements each year through an appropriate annual bonus scheme. The bonus is a single, fully discretionary variable
pay award. The aggregate value of awards in any year is dependent on the group&#x2019;s overall performance and profitability.&#xa0; Consideration
is also given to the levels of bonuses paid in the market.&#xa0; Individual awards, which are payable to all members of staff, are determined
by a rigorous assessment of achievement against defined objectives.</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The variable pay award is composed of a mixture
of cash and a deferred award, the portion of which varies based on the size of the award.&#xa0; Deferred awards are by default Aberdeen
Group plc shares, with an option to put up to 50% of the deferred award into funds managed by Aberdeen. Overall compensation packages
are designed to be competitive relative to the investment management industry.</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><font style="text-decoration:underline">Base Salary</font></b></p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Aberdeen&#x2019;s policy is to pay a fair salary
commensurate with the individual&#x2019;s role, responsibilities and experience, and having regard to the market rates being offered for
similar roles in the asset management sector and other comparable companies. Any increase is generally to reflect inflation and is applied
in a manner consistent with other Aberdeen employees; any other increases must be justified by reference to promotion or changes in responsibilities.</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><font style="text-decoration:underline">Annual Bonus</font></b></p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Remuneration Committee determines the key performance
indicators that will be applied in considering the overall size of the bonus pool.&#xa0; In line with practices amongst other asset management
companies, individual bonuses are not subject to an absolute cap.&#xa0; However, the aggregate size of the bonus pool is dependent on
the group&#x2019;s overall performance and profitability.&#xa0; Consideration is also given to the levels of bonuses paid in the market.&#xa0;
Individual awards are determined by a rigorous assessment of achievement against defined objectives, and are reviewed and approved by
the Remuneration Committee.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Aberdeen has a deferral policy which is intended
to assist in the retention of talent and to create additional alignment of executives&#x2019; interests with Aberdeen&#x2019;s sustained
performance and, in respect of the deferral into funds managed by Aberdeen, to align the interest of portfolio managers with our clients.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


<!-- Field: Page; Sequence: 4 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Staff performance is reviewed formally at least
once a year. The review process evaluates the various aspects that the individual has contributed to Aberdeen, and specifically, in the
case of portfolio managers, to the relevant investment team. Discretionary bonuses are based on client service, asset growth and the performance
of the respective portfolio manager. Overall participation in team meetings, generation of original research ideas and contribution to
presenting the team externally are also evaluated.</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the calculation of a portfolio management team&#x2019;s
bonus, Aberdeen takes into consideration investment matters (which include the performance of funds, adherence to the company investment
process, and quality of company meetings) as well as more subjective issues such as team participation and effectiveness at client presentations
through key performance indicator scorecards.&#xa0; To the extent performance is factored in, such performance is not judged against any
specific benchmark and is evaluated over the period of a year - January&#xa0;to December. The pre- or after-tax performance of an individual
account is not considered in the determination of a portfolio manager&#x2019;s discretionary bonus; rather the review process evaluates
the overall performance of the team for all of the accounts the team manages.</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Portfolio manager performance on investment matters
is judged over all of the accounts the portfolio manager contributes to and is documented in the appraisal process.&#xa0; A combination
of the team&#x2019;s and individual&#x2019;s performance is considered and evaluated.</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Although performance is not a substantial portion
of a portfolio manager&#x2019;s compensation, Aberdeen also recognizes that fund performance can often be driven by factors outside one&#x2019;s
control, such as (irrational) markets, and as such pays attention to the effort by portfolio managers to ensure integrity of our core
process by sticking to disciplines and processes set, regardless of momentum and &#x2018;hot&#x2019; themes.&#xa0; Short-terming is thus
discouraged and trading-oriented managers will thus find it difficult to thrive in the Aberdeen environment.&#xa0; Additionally, if any
of the aforementioned undue risks were to be taken by a portfolio manager, such trend would be identified via Aberdeen&#x2019;s dynamic
compliance monitoring system.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In rendering investment management services, the
Adviser may use the resources of additional investment adviser subsidiaries of Aberdeen Group plc. These affiliates have entered into
a memorandum of understanding (&#x201c;MOU&#x201d;) pursuant to which investment professionals from each affiliate may render portfolio
management, research or trading services to Aberdeen clients. Each investment professional who renders portfolio management, research
or trading services under a MOU or personnel sharing arrangement (&#x201c;Participating Affiliate&#x201d;) must comply with the provisions
of the Advisers Act, the 1940 Act, the Securities Act of 1933, the Exchange Act, and the Employee Retirement Income Security Act of 1974,
and the laws of states or countries in which the Adviser does business or has clients. No remuneration is paid by the Fund with respect
to the MOU/personnel sharing arrangements.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">(a)(4)</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-spacing: 0px;">
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Dollar Range of Equity Securities in the <br> Registrant Beneficially Owned by the Portfolio<br> Manager as of September&#xa0;30, 2025</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 57%; font: 10pt Times New Roman, Times, Serif; text-align: justify">Jason Akus</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Ashton Wilson</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Christopher Abbot</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Robert Benson</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Kelly Girkskis</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Richard Goss</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Loretta Tse</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">(b)&#xa0; Not applicable.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 14. Purchases of Equity Securities by Closed-End Management
Investment Company and Affiliated Purchasers.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Period</b></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">(a)&#xa0;Total No.<br> of Shares<br> Purchased (1)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">(b)&#xa0;Average<br> Price Paid per<br> Share</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">(c)&#xa0;Total No.<br> of Shares<br> Purchased as<br> Part&#xa0;of<br> Publicly<br> Announced Plans<br> or Programs</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">(d)&#xa0;Maximum No.<br> of Shares that<br> May&#xa0;Yet Be<br> Purchased Under<br> the Plans or<br> Programs</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 44%; padding-bottom: 1pt">Month #1 (Oct.&#xa0;1, 2024 &#x2013; Oct.&#xa0;31, 2024)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">4,962,727</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Month #2 (Nov.&#xa0;1, 2024 &#x2013; Nov.&#xa0;30, 2024)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,962,727</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Month #3 (Dec.&#xa0;1, 2024&#x2013; Dec.&#xa0;31, 2024)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,962,727</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Month #4 (Jan.&#xa0;1, 2025 &#x2013; Jan.&#xa0;31, 2025)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,962,727</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Month #5 (Feb.&#xa0;1, 2025 &#x2013; Feb.&#xa0;28, 2025)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,962,727</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Month #6 (Mar.&#xa0;1, 2025 &#x2013; Mar.&#xa0;31, 2025)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,962,727</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Month #7 (Apr.&#xa0;1, 2025 &#x2013; Apr.&#xa0;30, 2025)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,962,727</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Month #8 (May&#xa0;1, 2025 &#x2013; May&#xa0;31, 2025)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,962,727</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Month #9 (June&#xa0;1, 2025 &#x2013; June&#xa0;30, 2025)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,962,727</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Month #10 (Jul.&#xa0;1, 2025 &#x2013; Jul.&#xa0;31, 2025)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,968,945</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Month #11 (Aug.&#xa0;1, 2025 &#x2013; Aug.&#xa0;31, 2025)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,968,945</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Month #12 (Sep.&#xa0;1, 2025&#x2013; Sep.&#xa0;30, 2025)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,968,945</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2013;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#xa0;</td>
    <td style="width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March&#xa0;19, 2015, the share repurchase program (the &#x201c;Program&#x201d;) was announced, which has been subsequently reviewed and approved by the Board of Trustees. In March&#xa0;2025, the Board approved the renewal of the repurchase program to allow the Fund to repurchase up to 12% of its outstanding shares in the open market for a one-year period ending July&#xa0;14, 2026. Prior to this renewal, in March&#xa0;2024, the Trustees approved the renewal of the share repurchase program to allow the Fund to repurchase up to 12% of its outstanding shares for a one-year period ending July&#xa0;14, 2025. In September&#xa0;2025, the Board approved a change to the Program allowing the Fund to purchase, in the open market for a one-year period from October&#xa0;1, 2025 to September&#xa0;30, 2026, up to 12% of its outstanding common shares as of September&#xa0;30, 2025, with the amount and timing of any repurchase determined at the discretion of the Fund's investment adviser.&#xa0;&#xa0;Such purchases may be made opportunistically at certain discounts to NAV per share in the reasonable judgment of management based on historical discount levels and current market conditions. If shares are repurchased, the Fund reports repurchase activity on its website on a monthly basis. For the fiscal year ended September&#xa0;30, 2025, the Fund did not repurchase any shares through the Program.&#xa0;&#xa0;</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 15. Submission of Matters to a Vote of Security Holders.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended September&#xa0;30, 2025, there were no material
changes to the procedures by which shareholders may recommend nominees to the Registrant&#x2019;s Board of Trustees.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 16. Controls and Procedures.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#xa0;</td>
    <td style="width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Registrant&#x2019;s principal executive and principal financial officers, or persons performing similar functions, have concluded that the Registrant&#x2019;s disclosure controls and procedures (as defined in Rule&#xa0;30a-3(c)&#xa0;under the Investment Company Act of 1940 (the &#x201c;Act&#x201d;) (17 CFR 270.30a-3(c)) are effective, as of a date within 90 days of the filing date of the report that includes the disclosure required by this paragraph, based on the evaluation of these controls and procedures required by Rule&#xa0;30a-3(b)&#xa0;under the Act (17 CFR 270.30a3(b)) and Rule&#xa0;13a-15(b)&#xa0;or 15d-15(b)&#xa0;under the Securities Exchange Act of 1934, as amended (17 CFR 240.13a-15(b)&#xa0;or 240.15d15(b)).</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p>


<!-- Field: Page; Sequence: 5 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#xa0;</td>
    <td style="width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were no changes in the Registrant&#x2019;s internal control over financial reporting (as defined in Rule&#xa0;30a-3(d)&#xa0;under the Act (17 CFR 270.30a-3(d))) that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the Registrant&#x2019;s internal control over financial reporting.</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 17. Disclosure of Securities Lending Activities for Closed-End
Management Investment Companies</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 18. Recovery of Erroneously Awarded Compensation.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 19. Exhibits.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
<tr style="vertical-align: top">
<td style="width: 14%; padding-left: 35pt"><a href="tm2527059d10_ex99-codeeth.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)(1)</font></a></td>
<td style="text-align: justify; width: 86%"><a href="tm2527059d10_ex99-codeeth.htm" style="-sec-extract: exhibit">Code of Ethics of the Registrant for the period covered by this report as required pursuant to Item 2 of this Form N-CSR.</a></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; padding-left: 42pt">&#xa0;</td>
<td style="text-align: justify; padding-left: 42pt">&#xa0;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; padding-left: 35pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)(2)</font></td>
<td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any policy required by the listing standards adopted pursuant to Rule&#xa0;10D-1 under the Exchange Act (17 CFR 240.10D-1) by the registered national securities exchange or registered national securities association upon which the registrant&#x2019;s securities are listed. Not applicable.</font></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; padding-left: 35pt">&#xa0;</td>
<td style="text-align: justify">&#xa0;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; padding-left: 35pt"><a href="tm2527059d10_ex99-cert.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)(3)</font></a></td>
<td style="text-align: justify"><a href="tm2527059d10_ex99-cert.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The certifications of the registrant as required by Rule&#xa0;30a-2(a)&#xa0;under the Act are exhibits to this Form&#xa0;N-CSR.</font></a></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; padding-left: 42pt">&#xa0;</td>
<td style="text-align: justify; padding-left: 42pt">&#xa0;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; padding-left: 35pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)(4)</font></td>
<td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any written solicitation to purchase securities under Rule&#xa0;23c-1 under the 1940 Act (17 CFR 270.23c-1) sent or given during the period covered by the report by or on behalf of the registrant to 10 or more persons. Not applicable.</font></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; padding-left: 35pt">&#xa0;</td>
<td style="text-align: justify">&#xa0;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; padding-left: 35pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)(5)</font></td>
<td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in Registrant&#x2019;s independent public accountant.&#xa0;&#xa0;Not applicable.</font></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; padding-left: 42pt">&#xa0;</td>
<td style="text-align: justify; padding-left: 42pt">&#xa0;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; padding-left: 35pt"><a href="tm2527059d10_ex99-906cert.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</font></a></td>
<td style="text-align: justify"><a href="tm2527059d10_ex99-906cert.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The certifications of the registrant as required by Rule&#xa0;30a-2(b)&#xa0;under the Act are exhibits to this Form&#xa0;N-CSR.</font></a></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; padding-left: 42pt">&#xa0;</td>
<td style="text-align: justify">&#xa0;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; padding-left: 35pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</font></td>
<td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A copy of the Registrant&#x2019;s notices to stockholders, which accompanied distributions paid, pursuant to the Registrant&#x2019;s Managed Distribution Policy since the Registrant&#x2019;s last filed N-CSR, are filed herewith as Exhibits <a href="tm2527059d10_ex99-xcx1.htm" style="-sec-extract: exhibit">(c)(1)</a>, <a href="tm2527059d10_ex99-xcx2.htm" style="-sec-extract: exhibit">(c)(2)</a>, <a href="tm2527059d10_ex99-xcx3.htm" style="-sec-extract: exhibit">(c)(3)</a>, <a href="tm2527059d10_ex99-xcx4.htm" style="-sec-extract: exhibit">(c)(4)</a>, <a href="tm2527059d10_ex99-xcx5.htm" style="-sec-extract: exhibit">(c)(5)</a>&#xa0;and <a href="tm2527059d10_ex99-xcx6.htm" style="-sec-extract: exhibit">(c)(6)</a>&#xa0;as required by the terms of the Registrant&#x2019;s SEC exemptive order.</font></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; padding-left: 42pt">&#xa0;</td>
<td style="text-align: justify">&#xa0;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; padding-left: 35pt"><a href="tm2527059d10_ex99-xd.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</font></a></td>
<td style="text-align: justify"><a href="tm2527059d10_ex99-xd.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proxy Voting Policy of Registrant</font></a></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; padding-left: 42pt">&#xa0;</td>
<td style="text-align: justify">&#xa0;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify; padding-left: 35pt"><a href="tm2527059d10_ex99-xe.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</font></a></td>
<td style="text-align: justify"><a href="tm2527059d10_ex99-xe.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proxy Voting Policies and Procedures of Adviser.</font></a></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


<!-- Field: Page; Sequence: 6; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="margin: 0">&#xa0;</p>


</div><div style="font: 10pt Times New Roman, Times, Serif"><div style="Page-Break-Before: Always"></div><!-- BannerFile="tm2527059d10_signaturepage.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2527059-10/tm2527059-10_ncsrseq1" -->

<p style="margin: 0">&#xa0;&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="text-transform: uppercase"><b><font style="text-decoration:underline">SIGNATURES</font></b></font></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934 and the Investment Company Act of 1940, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">abrdn Healthcare Opportunities Fund</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 3%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
    <td style="width: 47%; border-bottom: black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Alan Goodson</i></font></td>
    <td style="width: 50%">&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alan Goodson,</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Executive Officer of</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">abrdn Healthcare Opportunities Fund</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2">&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&#xa0;December&#xa0;8, 2025</font></td>
    <td>&#xa0;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the
Registrant and in the capacities and on the dates indicated.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 3%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
    <td style="width: 47%; border-bottom: black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Alan Goodson</i></font></td>
    <td style="width: 50%">&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alan Goodson,</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Executive Officer of</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">abrdn Healthcare Opportunities Fund</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2">&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&#xa0;December&#xa0;8, 2025</font></td>
    <td>&#xa0;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 3%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
    <td style="width: 47%; border-bottom: black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Sharon Ferrari</i></font></td>
    <td style="width: 50%">&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sharon Ferrari,</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Financial Officer of</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">abrdn Healthcare Opportunities Fund</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2">&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&#xa0;December&#xa0;8, 2025</font></td>
    <td>&#xa0;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;&#xa0;</p>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->


<p style="margin: 0"></p>


</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.CODEETH
<SEQUENCE>2
<FILENAME>tm2527059d10_ex99-codeeth.htm
<DESCRIPTION>EXHIBIT 99.CODEETH
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2527059d10_ex99-codeeth.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2527059-10/tm2527059-10_ncsrseq1/users" -->

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.CODEETH</B></P>


<P STYLE="margin: 0; text-align: right">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CODE OF ETHICS (PERSONAL TRADING)</U></B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>I.</B></TD><TD><B>Introduction</B></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Rule&nbsp;17j-1(b)&nbsp;under
the Investment Company Act of 1940, as amended (the &ldquo;1940 Act&rdquo;), makes it unlawful for any affiliated person, officer or Board
member of the Funds in connection with the purchase or sale by such person of a Security (as defined below) &ldquo;held or to be acquired&rdquo;
by the Funds:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">To employ any device, scheme or artifice to defraud the Funds;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">To make to the Funds any untrue statement of a material fact or omit to state to the Funds a material
fact necessary in order to make the statement made, in light of the circumstances under which they are made, not misleading;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">To engage in any act, practice, or course of business which operates or would operate as a fraud or deceit
upon the Funds; or</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">To engage in any manipulative practice with respect to the Funds&rsquo; investment portfolios.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>II.</B></TD><TD><B>Purpose of the Code of Ethics</B></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Funds expect that the
officers and Fund Board members will conduct their personal investment activities in accordance with (1)&nbsp;the duty at all times to
place the interests of the Funds&rsquo; shareholders first; (2)&nbsp;the requirement that all personal Securities transactions be conducted
consistent with this Code of Ethics and in such a manner as to avoid any actual or potential conflict of interest or any abuse of an individual&rsquo;s
position of trust and responsibility; and (3)&nbsp;the fundamental standard that investment company personnel should not take inappropriate
advantage of their positions.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In view of the foregoing,
the provisions of Section&nbsp;17(j)&nbsp;of the 1940 Act, Rule&nbsp;17j-1 under the 1940 Act, and various pronouncements by the Securities
and Exchange Commission (&ldquo;SEC&rdquo;) and the Investment Company Institute on personal investing by investment company personnel,<SUP>1</SUP>
the Funds have adopted this Code of Ethics to specify a code of conduct for certain types of personal Securities transactions that might
involve conflicts of interest or an appearance of impropriety, and to establish reporting requirements and enforcement procedures. This
Code does not attempt to identify all possible conflicts of interest, and literal compliance with each of its specific provisions will
not shield Fund personnel from liability for personal trading or other conduct that violates a fiduciary duty to Fund shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Code of Ethics does not
apply to any officer, Board member or employee of the Funds who is also an Access Person or Investment Personnel (as defined under Rule&nbsp;17j-1
under the 1940 Act) employed by the Funds&rsquo; investment adviser, investment sub-advisers or principal underwriter (&ldquo;Excluded
Advisory Personnel&rdquo;). Those individuals are covered by the Codes of Ethics that have been adopted by their respective entities and
approved by the Board of each of the Funds in accordance with the provisions of Rule&nbsp;17j-1 of the 1940 Act.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT></TD><TD STYLE="text-align: justify">See Investment Adviser Code of Ethics, SEC Release No. IC-26492
(July 9, 2004); Personal Investment Activities of Investment Company Personnel, SEC Release No. IC-23958 (August 24, 1999); Personal
Investment Activities of Investment Company Personnel, Report by the Securities and Exchange Commission (September 1994); and Report
of the Advisory Group on Personal Investing, Investment Company Institute (May 9, 1994).</TD>
</TR></TABLE>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>III.</B></TD><TD><B>Definitions</B></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">A.</TD><TD STYLE="text-align: justify">&ldquo;<B><U>Access Person</U></B>&rdquo; means (1)&nbsp;each Board member or officer of the Funds; and
(2)&nbsp;any Advisory Person of the Funds except Excluded Advisory Personnel.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">B.</TD><TD STYLE="text-align: justify">&ldquo;<B><U>Advisory Person</U></B>&rdquo; means (1)&nbsp;each Board member, officer, general partner
or employee of the Funds (or of any company in a control relationship to the Funds) who in connection with his or her regular functions
or duties, makes, participates in, or obtains information regarding the purchase or sale of a Reportable Security (as defined below) by
the Funds or whose functions relate to the making of any recommendations with respect to such purchases or sales; and (2)&nbsp;any natural
person in a control relationship to the Funds who obtains information concerning recommendations made to the Funds with regard to the
purchase or sale of a Reportable Security by the Funds.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">C.</TD><TD STYLE="text-align: justify">&ldquo;<B><U>Automatic Investment Plan</U></B>&rdquo; means a program in which regular periodic purchases
(or withdrawals) are made automatically in (or from) investment accounts in accordance with a predetermined schedule and allocation. An
Automatic Investment Plan includes a dividend reinvestment plan.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">D.</TD><TD STYLE="text-align: justify">&ldquo;<B><U>Beneficial Ownership</U></B>&rdquo; shall be interpreted in the same manner as it would be
in determining whether a person is considered a &ldquo;beneficial owner&rdquo; as defined in Rule&nbsp;16a-1(a)(2)&nbsp;under the Securities
Exchange Act of 1934, as amended (&ldquo;1934 Act&rdquo;), which generally speaking, encompasses those situations where the beneficial
owner has the right to enjoy some economic benefit from the ownership of the Reportable Security. You will be treated as a &ldquo;beneficial
owner&rdquo; of a Security under this Code only if you have a direct or indirect pecuniary interest in the Security. A direct pecuniary
interest is the opportunity, directly or indirectly, to profit, or to share the profit, from the transaction. An indirect pecuniary interest
is any nondirect financial interest, but is specifically defined in the rules&nbsp;to include, among other things, Securities held by
members of your immediate family sharing the same household; Securities held by a partnership of which you are a general partner; Securities
held by a trust of which you are the settlor if you can revoke the trust without the consent of another person, or a beneficiary if you
have or share investment control with the trustee; and equity Securities which may be acquired upon exercise of an option or other right,
or through conversion. For interpretive guidance on this test, you should consult your counsel. A person is normally regarded as the beneficial
owner of Reportable Securities held in the name of his or her spouse or minor children and adults living in his or her household.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">E.</TD><TD STYLE="text-align: justify">&ldquo;<B><U>Control</U></B>&rdquo; shall have the same meaning as set forth in Section&nbsp;2(a)(9)&nbsp;of
the 1940 Act. Generally, control is the power to exercise a controlling influence over the management or policies of a company unless
such power is solely the result of an official position with such company.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">F.</TD><TD STYLE="text-align: justify">&ldquo;<B><U>Exempt Transactions</U></B>&rdquo; means: (1)&nbsp;purchases or sales effected in any account
over which an Access Person or Investment Personnel has no direct or indirect influence or control; (2)&nbsp;purchases or sales which
are non-volitional<SUP>2</SUP> on the part of the Access Person,&nbsp;Investment Personnel or the Funds; (3)&nbsp;purchases which are
part of an Automatic Investment Plan; or (4)&nbsp;purchases effected upon the exercise of rights issued by an issuer pro-rata to all holders
of a class of its Reportable Securities, to the extent such rights were acquired from such issuer, and sales of such rights so acquired.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP></FONT></TD><TD STYLE="text-align: justify">Non-volitional purchases or sales include those transactions, which do not involve a willing act or conscious
decision on the part of the Board Member, officer or employee. For example, shares received or disposed of by Access Persons or Investment
Personnel in a merger, recapitalization or similar transaction are considered non-volitional.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">G.</TD><TD STYLE="text-align: justify">A Security is &ldquo;<B><U>held or to be acquired</U></B>&rdquo; if within the most recent 15 days it
(1)&nbsp;is or has been held by the Funds, (2)&nbsp;is being or has been considered by the Funds or the investment adviser or investment
sub-adviser for purchase by the Funds or (3)&nbsp;any option to purchase or sell and any Security convertible into or exchangeable for
a Reportable Security that is described in (1)&nbsp;or (2)&nbsp;of this definition.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">H.</TD><TD STYLE="text-align: justify">An Access Person&rsquo;s &ldquo;<B><U>immediate family</U></B>&rdquo; means a spouse, minor children and
adults living in the same household as the Access Person.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">I.</TD><TD STYLE="text-align: justify">&ldquo;<B><U>Independent Board Member</U></B>&rdquo; means each Board member who is not an &ldquo;interested
person&rdquo; of the Funds (as defined in Section&nbsp;2(a)(19) of the 1940 Act) and who would be required to make a report under Section&nbsp;V
of this Code solely by reason of being a Board member of the Funds.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">J.</TD><TD STYLE="text-align: justify">An &ldquo;<B><U>Initial Public Offering</U></B>&rdquo; means an offering of Securities registered under
the Securities Act of 1933, the issuer of which, immediately before the registration, was not subject to the reporting requirements of
Sections 13 or 15(d)&nbsp;of the 1934 Act.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">K.</TD><TD STYLE="text-align: justify">&ldquo;<B><U>Investment Personnel</U></B>&rdquo; of the Funds means (1)&nbsp;any employee of the Funds
(or of any company in a control relationship to the Funds) who, in connection with his or her regular functions or duties, makes or participates
in making recommendations regarding the purchase or sale of Securities by the Funds or (2)&nbsp;any natural person who controls the Funds
and who obtains information concerning recommendations made to the Funds regarding the purchase or sale of Securities by the Funds.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">L.</TD><TD STYLE="text-align: justify">A &ldquo;<B><U>Limited Offering</U></B>&rdquo; means an offering that is exempt from registration under
the Securities Act of 1933 pursuant to Section&nbsp;4(2)&nbsp;or Section&nbsp;4(6)&nbsp;or pursuant to Rule&nbsp;504, Rule&nbsp;505, or
Rule&nbsp;506 under the Securities Act of 1933.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">M.</TD><TD STYLE="text-align: justify">&ldquo;<B><U>Purchase or sale of a Reportable Security</U></B>&rdquo; includes, among other things, the
writing of an option to purchase or sell a Reportable Security.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">N.</TD><TD STYLE="text-align: justify">&ldquo;<B><U>Reportable Security</U></B>&rdquo; means a Security excluding (1)&nbsp;direct obligations
of the Government of the United States; (2)&nbsp;banker&rsquo;s acceptances; (3)&nbsp;bank certificates of deposit; (4)&nbsp;commercial
paper; (5)&nbsp;high quality short-term debt instruments (any instrument having a maturity at issuance of less than 366 days and that
is rated in one of the two highest rating categories by a nationally recognized statistical rating organization), including repurchase
agreements; and (6)&nbsp;shares of registered open-end investment companies other than those advised by an Aberdeen Adviser.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">O.</TD><TD STYLE="text-align: justify">&ldquo;<B><U>Security</U></B>&rdquo; means a security as defined in Section&nbsp;2(a)(36)of the 1940 Act
which is defined as any note, stock, treasury stock, security future, bond, debenture, evidence of indebtedness, certificate of interest
or participation in any profit-sharing agreement, collateral-trust certificate, preorganization certificate or subscription, transferable
share, investment contract, voting-trust certificate, certificate of deposit for a security, fractional undivided interest in oil, gas,
or other mineral rights, any put, call, straddle, option, or privilege on any security (including a certificate of deposit) or on any
group or index of securities (including any interest therein or based on the value thereof), or any put, call, straddle, option, or privilege
entered into on a national securities exchange relating to foreign currency, or, in general, any interest or instrument commonly known
as a &ldquo;security,&rdquo; or any certificate of interest or participation in, temporary or interim certificate for, receipt for, guarantee
of, or warrant or right to subscribe to or purchase, any of the foregoing.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>IV.</B></TD><TD><B>Policies of the Funds Regarding Personal Securities Transactions</B></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">A.</TD><TD STYLE="text-align: justify">General Policy</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No Access Person of the Funds
shall engage in any act, practice or course of business that would violate the provisions of Rule&nbsp;17j-1(b)&nbsp;set forth above,
or in connection with any personal investment activity, engage in conduct inconsistent with this Code of Ethics.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">B.</TD><TD STYLE="text-align: justify">Specific Policies</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify"><B>Restrictions on Personal Securities Transactions by Independent Board Members</B></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">The Funds recognize that an Independent
Board Member does not have on-going, day-to-day interaction with the operations of the Funds. In addition, it has been the practice of
the Funds to give information about Securities purchased or sold by the Funds or considered for purchase or sale by the Funds to Independent
Board Members in materials circulated more than 15 days after such Securities are purchased or sold by the Funds or are considered for
purchase or sale by the Funds. Accordingly, the Funds believe the following controls are appropriate for Independent Board Members:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">a.</TD><TD STYLE="text-align: justify">Personal Account Dealing in Fund Shares.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2.25in"></TD><TD STYLE="width: 0.5in">i.</TD><TD STYLE="text-align: justify">Independent Board Members are prohibited from buying or selling any Aberdeen-advised U.S. Registered Fund
(closed-end, open-end, and ETFs) shares during the two week period prior to or following Board meetings of which they are aware.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2.25in"></TD><TD STYLE="width: 0.5in">ii.</TD><TD STYLE="text-align: justify">Independent Board Members are required to pre-clear with the Fund CCO or his/her designee all Aberdeen-advised
U.S. Registered Fund buys or sells including funds for which an Independent Board Member does not serve as a director/trustee.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2.25in"></TD><TD STYLE="width: 0.5in">iii.</TD><TD STYLE="text-align: justify">The Fund CCO may waive this prohibition in exceptional circumstances and upon a determination that the
transaction does not violate any applicable laws or regulations. The Fund CCO will document any such waivers.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">b.</TD><TD STYLE="text-align: justify">Limited Pre-clearance. The Securities pre-clearance requirement contained in IV.B.2. below shall only
apply to an Independent Board Member if he or she knew that during the fifteen day period before the proposed transaction in a Reportable
Security (other than Exempt Transactions) or at the time of the transaction that the Reportable Security to be purchased or sold by him
or her (other than Exempt Transactions) was also purchased or sold by the Fund(s)&nbsp;or considered for the purchase or sale by the Fund(s)&nbsp;(i)&nbsp;for
which such Independent Board Member acts as a Director or Trustee or (ii)&nbsp;any Aberdeen-advised U.S. Registered Fund (closed-end,
open-end, and ETFs).<SUP>3</SUP></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">c.</TD><TD STYLE="text-align: justify">Pre-clearance Not Granted. When the securities pre-clearance requirement applies to an Independent Board
Member, no clearance will be given to the Independent Board Member to purchase or sell any Reportable Security (1)&nbsp;on a day when
any Fund has a pending &ldquo;buy&rdquo; or &ldquo;sell&rdquo; order in that same Reportable Security until that order is executed or
withdrawn or (2)&nbsp;when the Funds&rsquo; Chief Compliance Officer has been advised by the Funds&rsquo; investment adviser or investment
sub-adviser that the same Reportable Security is being considered for purchase or sale for any Fund.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify"><B>Restrictions on Initial Public Offering or Limited Offering Personal Securities Transactions by Access
Persons Who Are Not Independent Board Members</B></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">a.</TD><TD STYLE="text-align: justify">Pre-clearance. An Access Person who is not an Independent Board Member is prohibited from buying or selling
any Security through an Initial Public Offering or a Limited Offering for his or her personal portfolio or the portfolio of a member of
his or her immediate family without obtaining (i)&nbsp;email or other written authorization or (ii)&nbsp;oral authorization from a Funds
Chief Compliance Officer prior to effecting such Reportable Security transaction.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">A written authorization for such Security
transaction will be provided by the Funds&rsquo; Chief Compliance Officer or his/her delegate to the person receiving the oral authorization
(if granted). The written authorization will also be provided to the Funds&rsquo; administrator to memorialize the email and oral authorization
that was granted.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><U>Note</U>: If an Access Person has questions
as to whether purchasing or selling a Reportable Security for his or her personal portfolio or the portfolio of a member of his or her
immediate family requires prior oral authorization, the Access Person should consult the Funds&rsquo; Chief Compliance Officer for clearance
or denial of clearance to trade prior to effecting any Reportable Securities transition.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>3</SUP></FONT>&nbsp;</TD><TD STYLE="text-align: justify">Because monitoring the publication of the portfolio holdings
of series of abrdn ETFs and abrdn Funds that operate as ETFs is not construed to be within the ordinary course of fulfilling the duties
of a board member, the publication or availability of such portfolio holdings shall not be construed to impart actual or constructive
knowledge of such series&rsquo; portfolio transactions on an Independent Board Member.</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">b.</TD><TD STYLE="text-align: justify">Pre-clearance Expiration. Pre-clearance approval will expire at the close of business on the trading day
after the date on which written or oral authorization is received, and the Access Person is required to renew clearance for the transaction
if the trade is not completed before the authority expires.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">c.</TD><TD STYLE="text-align: justify">Pre-clearance Not Granted. No pre-clearance will be given to purchase or sell any Reportable Security
(1)&nbsp;on a day when any Fund has a pending &ldquo;buy&rdquo; or &ldquo;sell&rdquo; order in that same Reportable Security until that
order is executed or withdrawn or (2)&nbsp;when the Funds&rsquo; Chief Compliance Officer has been advised by the Funds&rsquo; investment
adviser or investment sub-adviser that the same Reportable Security is being considered for purchase or sale for any Fund.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify"><B>Additional Restrictions on Investment Personnel</B></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">a.</TD><TD STYLE="text-align: justify">Gifts. No investment personnel shall receive any gift or other thing of more than <I>de minimis</I> value
from any person or entity that does business with or on behalf of the Funds.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">b.</TD><TD STYLE="text-align: justify">Board Service. Investment Personnel shall not serve on the boards of directors of publicly traded companies
absent prior authorization by the Funds&rsquo; Chief Compliance Officer.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>V.</B></TD><TD><B>Procedures &ndash; Initial Holdings Reports, Annual Holdings Reports and Quarterly Transaction Reports</B></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">A.</TD><TD STYLE="text-align: justify">In order to provide the Funds with information to enable it to determine with reasonable assurance whether
the provisions of this Code of Ethics are being observed by its Access Persons:</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify"><B>Independent Board Members</B></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">a.</TD><TD STYLE="text-align: justify">Holdings Reports Not Required &ndash; Each Independent Board Member need not make initial or annual holdings
reports.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">b.</TD><TD STYLE="text-align: justify">Limited Quarterly Transaction Reporting &ndash; An Independent Board Member must submit the same quarterly
transaction report as required under paragraph V.A.2.d below to the Chief Compliance Officer of the Funds, but only for a transaction
in a Reportable Security where he or she knew at the time of the transaction or, in the ordinary course of fulfilling his or her official
duties as an Independent Board Member, should have known that during the 15-day period immediately preceding or after the date of the
transaction, such Reportable Security is or was purchased or sold, or considered by the Funds, its investment adviser or investment sub-adviser
for purchase or sale by the Fund (i)&nbsp;for which such Independent Board Member acts as a Director or Trustee or (ii)&nbsp;any Aberdeen-advised
U.S. Registered Fund (closed-end, open-end, and ETFs).</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify"><B>Access Persons Who Are Not Independent Board Members</B></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">a.</TD><TD STYLE="text-align: justify">Initial Holdings Reports &ndash; Each Access Person who is not an Independent Board Member will submit
to the Chief Compliance Officer or his/her designee of the Funds an Initial Holdings Report in the form attached hereto as <B>Exhibit&nbsp;A</B>
that lists all Reportable Securities in which the Access Person has Beneficial Ownership.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">The Initial Holdings Report must be submitted within ten days of becoming an Access Person and must contain
information current as of a date no more than 45 days prior to becoming an Access Person.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">The Initial Holdings Report must include the title of each Reportable Security, the number of shares held
(for equity securities), the principal amount (for debt securities) of each Reportable Security, the date the report is submitted as well
as a list of any Securities accounts maintained with any broker, dealer or bank in which any Securities were held for the direct or indirect
benefit of the Access Person as of the date the person became an Access Person of the Funds.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">An Access Person need not include in the report transactions effected for, and Reportable Securities held
in, any account over which the Access Person has no direct or indirect influence or control.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">The report may contain a statement that the report shall not be construed as an admission by the person
making such report that he or she has any direct or indirect beneficial ownership in the Reportable Security to which the report relates.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">b.</TD><TD STYLE="text-align: justify">Annual Holdings Reports &ndash; Each Access Person of the Funds who is not an Independent Board Member
will also submit to the Chief Compliance Officer or his/her designee of the Funds an Annual Holdings Report attached hereto as <B>Exhibit&nbsp;A</B>
no later than 30 days after the end of the calendar year.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">The information contained in the Annual Holdings Report must be current as of a date no more than 45 days
before the report is submitted.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">The Annual Holdings Report must list all Reportable Securities in which the Access Person has Beneficial
Ownership, the title of each Reportable Security, the number of shares held (for equity securities), the principal amount (for debt securities)
of the Reportable Security, and the date the report is submitted. The Report must also list any Securities accounts maintained with any
broker, dealer or bank in which any Securities were held for the direct or indirect benefit of the Access Person.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">An Access Person need not include in the report transactions effected for, and Reportable Securities held
in, any account over which the Access Person has no direct or indirect influence or control.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">The report may contain a statement that the report shall not be construed as an admission by the person
making such report that he or she has any direct or indirect beneficial ownership in the Reportable Security to which the report relates.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">c.</TD><TD STYLE="text-align: justify">Securities Confirmations &ndash; Each Access Person of the Funds who is not an Independent Board Member
shall direct his or her broker to supply to a Chief Compliance Officer or his/her designee of the Funds, on a timely basis, duplicate
copies of confirmation of all personal Securities transactions and copies of periodic statements for all Securities accounts in which
the Access Person has Beneficial Ownership.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">d.</TD><TD STYLE="text-align: justify">Quarterly Transaction Reports &ndash; Each Access Person of the Funds who is not an Independent Board
Member shall submit reports in the form attached hereto as <B>Exhibit&nbsp;B</B> to the Chief Compliance Officer or his/her designee of
the Funds, showing all transactions in Reportable Securities in which the person has, or by reason of such transaction acquires, any direct
or indirect Beneficial Ownership, as well as all accounts established with brokers, dealers or banks during the quarter in which any Securities
were held for the direct or indirect beneficial interest of the Access Person.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">Quarterly transaction reports shall be filed no later than 30 days after the end of each calendar quarter.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">The report shall include (a)&nbsp;the date of the transaction, (b)&nbsp;the title of the Reportable Security,
(c)&nbsp;the interest rate and maturity date (if applicable), (d)&nbsp;the number of shares (for equity securities), (e)&nbsp;the principal
amount of each Reportable Security involved; (f)&nbsp;the nature of the transaction (i.e., purchase, sale or any other type of acquisition
or disposition), (g)&nbsp;the price at which the transaction was effected, (h)&nbsp;the name of the broker, dealer or bank with or through
whom the transaction was effected; and (i)&nbsp;the date the report is submitted. In addition, with respect to any account established
by the Access Person in which any Reportable Securities were held during the quarter for the direct or indirect benefit of the Access
Person, the Access Person shall report the following information: (a)&nbsp;the name and address of the broker, dealer or bank with whom
the Access Person established the account; (b)&nbsp;the date the account was established; and (c)&nbsp;the date the report is submitted.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">An Access Person of the Funds need not make a quarterly transaction report with respect to (a)&nbsp;transactions
effected pursuant to an Automatic Investment Plan, (b)&nbsp;a transaction if all of the information required by paragraph (ii)&nbsp;above
is contained in the brokerage confirmations or account statements required to be submitted under paragraph (c)&nbsp;above, and (c)&nbsp;transactions
effected for, and Reportable Securities held in, any account over which the Access Person has no direct or indirect influence or control.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">The report may contain a statement that the report shall not be construed as an admission by the person
making such report that he or she has any direct or indirect beneficial ownership in the Reportable Security to which the report relates.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify"><B>Identification of Access Persons</B> &ndash; The Chief Compliance Officer or his/her designee of the
Funds shall notify each Access Person of the Funds who may be subject to the pre-clearance requirement or required to make reports pursuant
to this Code of Ethics that such person is subject to the pre-clearance or reporting requirements and shall deliver a copy of this Code
of Ethics to each such person.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify"><B>Compliance Review</B> &ndash; The Chief Compliance Officer or his/her designee of the Funds shall (i)&nbsp;with
regard to any Access Persons or Investment Personnel reporting directly under this Code of Ethics, review any initial holdings reports,
annual holdings reports, and quarterly transaction reports that are received by the Chief Compliance Officer or his/her designee under
this Code of Ethics, and as appropriate compare the reports with the pre-clearance authorization received; (ii)&nbsp;with regard to any
Excluded Advisory Personnel reporting under a Code of Ethics of the Funds&rsquo; investment adviser, sub-advisers or principal underwriter,
quarterly contact the compliance officer of such investment adviser, sub-advisers or principal underwriter regarding the compliance of
such Access Persons or Investment Personnel with their Code of Ethics and (iii)&nbsp;report to the Funds&rsquo; Board: (a)&nbsp;with respect
to any transaction that appears to evidence a violation of this Code or the investment adviser&rsquo;s, sub-advisers&rsquo; or principal
underwriter&rsquo;s Codes of Ethics; and (b)&nbsp;violations of the reporting requirement stated in such Codes of Ethics.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify"><B>Board Review</B> &ndash; The Board shall review the operation of this Code of Ethics at least once
a year.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify"><B>Service Provider Code of Ethics</B> &ndash; The investment adviser, any investment sub-advisers and
the principal underwriter shall adopt, maintain and enforce a separate code of ethics with respect to their personnel in compliance with
Rule&nbsp;17j-1 of the 1940 Act and Rule&nbsp;204A-1 of the Investment Advisers Act of 1940, as applicable. Any material changes to the
investment adviser&rsquo;s, investment sub-adviser&rsquo;s or principal underwriter&rsquo;s code will be approved by the Board no later
than six months after such change.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">7.</TD><TD STYLE="text-align: justify"><B>Board Reporting</B> &ndash; At each quarterly Board meeting, the Chief Compliance Officer of the Funds&rsquo;
investment adviser, any investment sub-adviser and the principal underwriter of the Funds shall provide a written report to the Funds&rsquo;
Board stating:</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">a.</TD><TD STYLE="text-align: justify">any reported Securities transaction that occurred during the prior quarter that materially violated (either
individually or in the aggregate) the provisions of the code of ethics adopted by the investment adviser, any investment sub-adviser or
principal underwriter; and</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">b.</TD><TD STYLE="text-align: justify">all disciplinary actions<SUP>4</SUP> taken in response to such violations.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify"><B>Annual Reports</B> &ndash; At least once a year, the Funds&rsquo; Chief Compliance Officer shall provide
to the Board a written report that contains any previously reported material violations of the code or procedures and sanctions imposed
in response to material violations, any recommended changes in the code or procedures, and a certification that the procedures which have
been adopted are those reasonably necessary to prevent Access Persons (as defined under Rule&nbsp;17j-1) from violating their respective
Codes of Ethics. The written report will also include an assessment of the effectiveness of the Service Providers&rsquo; Codes of Ethics
outlined in Section&nbsp;6 above.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">9.</TD><TD><B>Recordkeeping &ndash;</B> This Code, the codes of the investment adviser, any investment sub-adviser and principal underwriter,
a copy of each report by an Access Person, any record of any violation of this Code of Ethics and any action taken as a result thereof,
any written report hereunder by the Chief Compliance Officer of the investment adviser, investment sub-adviser or the principal underwriter,
records of approvals relating to Initial Public Offerings and Limited Offerings, lists of all persons required to make reports and a list
of all persons responsible for reviewing such reports shall be preserved with the Funds&rsquo; records for the period required by Rule&nbsp;17j-1
of the 1940 Act.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><B>IV. Certification</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Access Person, including
an Independent Board Member, will be required to certify annually that he or she has read and understood this Code of Ethics, and will
abide by it. Each Access Person, including an Independent Board Member, will further certify that he or she has disclosed or reported
all personal Securities transactions required to be disclosed or reported under the Code of Ethics. Certification of compliance with the
Code of Ethics by an Independent Board Member will occur annually.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>4</SUP></FONT></TD><TD STYLE="text-align: justify">Disciplinary action includes but is not limited to any action
that has a material financial effect upon the employee, such as fining, suspending, or demoting the employee, imposing a substantial
fine or requiring the disgorgement of profits.</TD>
</TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Code of Ethics</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Exhibit&nbsp;A</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>HOLDINGS REPORT</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the Year/Period Ended _____________________________________</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25in">(Month/day/year)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Wingdings">&#168;</FONT> &#8239;&#8239;Check here if
this is an Initial Holdings Report</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To: ___________________,
as the Chief Compliance Officer of [Name of Aberdeen Fund]</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From: ______________________</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the calendar year/period
referred to above,&nbsp;I have a direct or indirect beneficial ownership interest in the Securities listed below which are required to
be reported pursuant to the Code of Ethics of the Funds.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 95%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title of Security</B></FONT></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Shares</B></FONT></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principal Amount</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The name and address of any
broker, dealer or bank with whom I maintain an account in which my Securities are held for my direct or indirect benefit are as follows.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 95%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 70%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Address</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; text-indent: 0.5in">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; text-indent: 0.5in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; text-indent: 0.5in">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; text-indent: 0.5in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; text-indent: 0.5in">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; text-indent: 0.5in">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For Initial Holdings Reports:
This report contains information current as of a date no more than 45 days prior to the date of becoming an Access Person.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For Annual Holdings Reports:
This report contains information current as of a date no more than 45 days before the report is submitted.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This report (i)&nbsp;excludes
transactions with respect to which I had no direct or indirect influence or control, (ii)&nbsp;excludes other transactions not required
to be reported and (iii)&nbsp;is not an admission that I have or had any direct or indirect beneficial ownership in the Securities listed
above.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 5%">Date:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 44%"></TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 2%">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 8%">Signature:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 41%"> </TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Code of Ethics</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit&nbsp;B</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>QUARTERLY SECURITIES TRANSACTION REPORT</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the Calendar Quarter Ended _____________________________________</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.75in">(month/day/year)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To: ___________________,
Chief Compliance Officer</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From: ___________________</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the quarter referred
to above, the following transactions were effected in Securities of which I had, or by reason of such transaction acquired, direct or
indirect beneficial ownership, and which are required to be reported pursuant to the Code of Ethics of the Funds:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Security</B></FONT></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date of<BR>
 Transaction</B></FONT></TD>
    <TD STYLE="width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number <BR>
of <BR>
Shares</B></FONT></TD>
    <TD STYLE="width: 10%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 1.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principal<BR>
 Amount</B></FONT></TD>
    <TD STYLE="width: 12%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Interest <BR>
Rate and<BR>
 Maturity<BR>
 Rate (if<BR>
 applicable)</B></FONT></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nature of<BR>
 Transaction<BR>
 (Purchase, <BR>
Sale, or<BR>
 Other)</B></FONT></TD>
    <TD STYLE="width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price</B></FONT></TD>
    <TD STYLE="width: 21%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Broker/Dealer<BR>
 or Bank <BR>
Though Whom<BR>
 Effected</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the quarter referred
to above,&nbsp;I established the following accounts in which Securities were held during the quarter for my direct or indirect benefit:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 95%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name and address of the broker, dealer or bank <BR>
with which I established the account.</B></FONT></TD>
    <TD STYLE="width: 48%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The date the account was established.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This report (i)&nbsp;excludes
transactions with respect to which I had no direct or indirect influence or control, (ii)&nbsp;excludes other transactions not required
to be reported, and (iii)&nbsp;is not an admission that I have or had any direct or indirect beneficial ownership in the Securities listed
above.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 5%">Date:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 44%"></TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 2%">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 8%">Signature:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 41%"> </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.906CERT
<SEQUENCE>3
<FILENAME>tm2527059d10_ex99-906cert.htm
<DESCRIPTION>EXHIBIT 99.906CERT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2527059d10_ex99-906cert.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2527059-10/tm2527059-10_ncsrseq1/users" -->

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="text-align: right; margin: 0"><B>Exhibit&nbsp;99.906CERT</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>Certification
Pursuant to Rule&nbsp;30</U></B></FONT><B><U>a<FONT STYLE="text-transform: uppercase">-2(</FONT>b<FONT STYLE="text-transform: uppercase">)&nbsp;under
the 1940 Act and Section&nbsp;906 of the Sarbanes-Oxley Act</FONT></U></B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alan Goodson, Principal Executive Officer, and
Sharon Ferrari, Principal Financial Officer, of abrdn Healthcare Opportunities Fund (the &ldquo;Registrant&rdquo;), each certify that:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">The Registrant&rsquo;s periodic report on Form&nbsp;N-CSR for the period ended September&nbsp;30, 2025
(the &ldquo;Form&nbsp;N-CSR&rdquo;) fully complies with the requirements of Section&nbsp;13(a)&nbsp;or Section&nbsp;15(d)&nbsp;of the
Securities Exchange Act of 1934, as amended, as applicable; and</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">The information contained in the Form&nbsp;N-CSR fairly presents, in all material respects, the financial
condition and results of operations of the Registrant.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PRINCIPAL EXECUTIVE OFFICER</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">abrdn Healthcare Opportunities Fund</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-size: 10pt">/s/
    Alan Goodson</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Alan Goodson</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Date: December&nbsp;8, 2025</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PRINCIPAL FINANCIAL OFFICER</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">abrdn Healthcare Opportunities Fund</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-size: 10pt">/s/
    Sharon Ferrari</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Sharon Ferrari</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Date:  December&nbsp;8, 2025</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This certification is being furnished solely pursuant
to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 and is not being filed as part of Form&nbsp;N-CSR or as a separate disclosure document.
A signed original of this written statement, or other document authenticating, acknowledging, or otherwise adopting the signature that
appears in typed form within the electronic version of this written statement required by Section&nbsp;906, has been provided to the Registrant
and will be retained by the Registrant and furnished to the Securities and Exchange Commission or its staff upon request.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin: 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.CERT
<SEQUENCE>4
<FILENAME>tm2527059d10_ex99-cert.htm
<DESCRIPTION>EXHIBIT 99.CERT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2527059d10_ex99-cert.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2527059-10/tm2527059-10_ncsrseq1/users" -->

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><B>Exhibit&nbsp;99.CERT</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>Certification
Pursuant to Rule&nbsp;30</U></B></FONT><B><U>a<FONT STYLE="text-transform: uppercase">-2(</FONT>a<FONT STYLE="text-transform: uppercase">)&nbsp;under
the 1940 Act and Section&nbsp;302 of the Sarbanes-Oxley Act</FONT></U></B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Sharon Ferrari, certify that:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD>I have reviewed this report on Form&nbsp;N-CSR of abrdn Healthcare Opportunities Fund (the &ldquo;Registrant&rdquo;);</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to
state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the
financial statements are required to include a statement of cash flows) of the Registrant as of, and for, the periods presented in this
report;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">The Registrant&rsquo;s other certifying officer(s)&nbsp;and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Rule&nbsp;30a-3(c)&nbsp;under the Investment Company Act of 1940) and internal control
over financial reporting (as defined in Rule&nbsp;30a-3(d)&nbsp;under the Investment Company Act of 1940) for the Registrant and have:</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to
be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the Registrant&rsquo;s disclosure controls and procedures and presented
in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to
the filing date of this report based on such evaluation; and</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the Registrant&rsquo;s internal control over financial reporting
that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the
Registrant&rsquo;s internal control over financial reporting; and</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">The Registrant&rsquo;s other certifying officer(s)&nbsp;and I have disclosed to the Registrant&rsquo;s
auditors and the audit committee of the Registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the Registrant&rsquo;s ability to record, process, summarize, and
report financial information; and</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant
role in the Registrant&rsquo;s internal control over financial reporting.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: December&nbsp;8, 2025</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-size: 10pt">/s/
    Sharon Ferrari</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Sharon Ferrari</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Principal Financial Officer</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>Certification
Pursuant to Rule&nbsp;30</U></B></FONT><B><U>a<FONT STYLE="text-transform: uppercase">-2(</FONT>a<FONT STYLE="text-transform: uppercase">)&nbsp;under
the 1940 Act and Section&nbsp;302 of the Sarbanes-Oxley Act</FONT></U></B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Alan Goodson, certify that:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD>I have reviewed this report on Form&nbsp;N-CSR of abrdn Healthcare Opportunities Fund (the &ldquo;Registrant&rdquo;);</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to
state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the
financial statements are required to include a statement of cash flows) of the Registrant as of, and for, the periods presented in this
report;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">The Registrant&rsquo;s other certifying officer(s)&nbsp;and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Rule&nbsp;30a-3(c)&nbsp;under the Investment Company Act of 1940) and internal control
over financial reporting (as defined in Rule&nbsp;30a-3(d)&nbsp;under the Investment Company Act of 1940) for the Registrant and have:</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to
be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the Registrant&rsquo;s disclosure controls and procedures and presented
in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to
the filing date of this report based on such evaluation; and</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the Registrant&rsquo;s internal control over financial reporting
that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the
Registrant&rsquo;s internal control over financial reporting; and</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">The Registrant&rsquo;s other certifying officer(s)&nbsp;and I have disclosed to the Registrant&rsquo;s
auditors and the audit committee of the Registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the Registrant&rsquo;s ability to record, process, summarize, and
report financial information; and</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant
role in the Registrant&rsquo;s internal control over financial reporting.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: December&nbsp;8, 2025</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%">/s/ Alan Goodson</TD>
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Alan Goodson</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Principal Executive Officer</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(C)(1)
<SEQUENCE>5
<FILENAME>tm2527059d10_ex99-xcx1.htm
<DESCRIPTION>EXHIBIT 99.(C)(1)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2527059d10_ex99-xcx1.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2527059-10/tm2527059-10_ncsrseq1/users" -->

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.(c)(1)</B></P>


<P STYLE="margin: 0; text-align: right">&nbsp;</P>


<P STYLE="margin: 0; text-align: right"><IMG SRC="tm2527059d10_exc1img001.jpg" ALT="">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Press Release</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>FOR IMMEDIATE RELEASE</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For More Information Contact:</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Aberdeen Investments U.S. Closed-End Funds<BR>
Investor Relations&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1-800-522-5465 <BR>
Investor.Relations@aberdeenplc.com</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>ABERDEEN INVESTMENTS
U.S. CLOSED-END FUNDS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>ANNOUNCE DISTRIBUTION
PAYMENT DETAILS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Philadelphia, June&nbsp;30, 2025) - The <U>Aberdeen Investments U.S.
Closed-End Funds</U> (NYSE: ASGI, HQH, HQL,&nbsp;IFN, THQ), (NYSE American: IAF) (the &ldquo;Funds&rdquo; or individually the &ldquo;Fund&rdquo;),
today announced that the Funds paid the distributions noted in the table below on June&nbsp;30, 2025, on a per share basis to all shareholders
of record as of June&nbsp;23, 2025 (ex-dividend date June&nbsp;23, 2025). These dates apply to the Funds listed below with the exception
of abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Australia Equity Fund,&nbsp;Inc. (IAF) and the India
Fund Inc. (IFN) which paid on June&nbsp;30, 2025, to all shareholders of record as of May&nbsp;22, 2025 (ex-dividend date May&nbsp;22,
2025).</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Ticker</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif">Exchange</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif">Fund</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; padding-bottom: 1pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-bottom: 1pt">abrdn Global Infrastructure
    Income Fund</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0.2100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQH</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">abrdn Healthcare Investors</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.5400</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">abrdn Life Sciences Investors</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4300</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAF</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">NYSE American</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">abrdn Australia Equity Fund,&nbsp;Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFN</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">The India Fund,&nbsp;Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">abrdn Healthcare Opportunities Fund</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1800</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each Fund has adopted a distribution policy to provide investors with
a stable distribution out of current income, supplemented by realized capital gains and, to the extent necessary, paid-in capital.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors
(HQL), abrdn Australia Equity Fund,&nbsp;Inc. (IAF) and the India Fund Inc. (IFN) the stock distributions were automatically paid in
newly issued shares of the Fund unless otherwise instructed by the shareholder to be paid in cash. Shares of common stock were issued
at the lower of the net asset value (&ldquo;NAV&rdquo;) per share or the market price per share with a floor for the NAV of not less
than 95% of the market price on June&nbsp;17, 2025. The reinvestment prices per share for these distributions were as follows: $15.32
for abrdn Healthcare Investors (HQH); $12.60 for abrdn Life Sciences Investors (HQL); $4.44 for abrdn Australia Equity Fund,&nbsp;Inc.
(IAF) and $15.94 for the India Fund,&nbsp;Inc. (IFN). Fractional shares were generally settled in cash, except for registered shareholders
with book entry accounts at Computershare Investor Services who had whole and fractional shares added to their account.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To have received the abrdn Healthcare Investors (HQH), abrdn Life
Sciences Investors (HQL), abrdn Australia Equity Fund,&nbsp;Inc. (IAF) and the India Fund Inc. (IFN) quarterly distributions payable
in June&nbsp;2025 in cash instead of shares of common stock, for shareholders who hold shares in &ldquo;street name,&rdquo; the bank,
brokerage or nominee who holds the shares must have advised the Depository Trust Company as to the full and fractional shares for which
they want the distribution paid in cash by June&nbsp;16, 2025; and for shares that are held in registered form, written notification
for the election of cash by registered shareholders must have been received by Computershare Investor Services prior to June&nbsp;16,
2025.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Under applicable
U.S. tax rules, the amount and character of distributable income for each Fund&rsquo;s fiscal year can be finally determined only as
of the end of the Fund&rsquo;s fiscal year. However, under Section&nbsp;19 of the Investment Company Act of 1940, as amended (the &ldquo;1940
Act&rdquo;) and related rules, the Funds may be required to indicate to shareholders the estimated source of certain distributions to
shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The following
tables set forth the estimated amounts of the sources of the distributions for purposes of Section&nbsp;19 of the 1940 Act and the rules&nbsp;adopted
thereunder. The tables have been computed based on generally accepted accounting principles. The tables include estimated amounts and
percentages for the current distributions paid this month as well as for the cumulative distributions paid relating to fiscal year to
date, from the following sources: net investment income; net realized short-term capital gains; net realized long-term capital gains;
and return of capital. The estimated compositions of the distributions may vary because the estimated composition may be impacted by
future income, expenses and realized gains and losses on securities and currencies.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The Funds&rsquo;
estimated sources of the current distribution paid this month and for its current fiscal year to date are as follows:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="36" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Estimated
    Amounts of Current Distribution per Share</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Fund</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">Distribution<BR>
    Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">Net
    Investment <BR>
    Income</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">Net
    Realized Short- <BR>
    Term Gains**</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">Net
    Realized Long-<BR>
    Term Gains</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">Return
    of Capital</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>


<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.2100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.0252</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">12</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.0042</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.0861</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">41</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.0945</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">45</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQH</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.5400</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.2322</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">43</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0486</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.2592</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4300</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1986</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">46</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0916</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">21</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1398</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">33</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAF</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0120</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0264</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0816</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">68</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFN</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1800</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0126</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1674</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">93</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="36" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Estimated Amounts of Fiscal Year* to Date Cumulative
Distributions per Share</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Fund</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">Distribution<BR>
    Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">Net
    Investment <BR>
    Income</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">Net
    Realized Short- <BR>
    Term Gains**</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">Net
    Realized Long-<BR>
    Term Gains</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">Return
    of Capital</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>


<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">1.8100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.2172</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">12</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.0362</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.7421</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">41</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.8145</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">45</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQH</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.7300</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.7439</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">43</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1557</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.8304</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.4000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.6468</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">46</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.2982</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">21</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4550</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">33</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAF</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.3700</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0370</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0814</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.2516</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">68</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFN</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.8700</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.8700</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.6200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1134</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.5066</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">93</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">* ASGI, HQH,
HQL and THQ have a 9/30 fiscal year end. IAF has a 10/31 fiscal year end. IFN has a 12/31 fiscal year end.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">**includes
currency gains</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Where
the estimated amounts above show a portion of the distribution to be a &ldquo;Return of Capital,&rdquo; it means that Fund estimates
that it has distributed more than its income and capital gains; therefore, a portion of your distribution may be a return of capital.
A return of capital may occur for example, when some or all the money that you invested in a Fund is paid back to you. A return of capital
distribution does not necessarily reflect the Fund&rsquo;s investment performance and should not be confused with &ldquo;yield&rdquo;
or &ldquo;income.&rdquo;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of June&nbsp;20, 2025, after giving effect to this payment HQL
estimates it has a net deficit $2,445,453. of A net deficit results when the Fund has net unrealized losses that are in excess of any
net realized gains that have not yet been distributed.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The amounts and sources of distributions reported in this notice
are only estimates and are not being provided for tax reporting purposes. The final determination of the source of all distributions
for the current year will only be made after year-end. The actual amounts and sources of the amounts for tax reporting purposes will
depend upon the Fund&rsquo;s investment experience during the remainder of the fiscal year and may be subject to change based on tax
regulations. After the end of each calendar year, a Form&nbsp;1099-DIV will be sent to shareholders for the prior calendar year that
will tell you how to report these distributions for federal income tax purposes.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following tables provide the Funds&rsquo; total return performance
based on net asset value (NAV) over various time periods compared to the Funds&rsquo; annualized and cumulative distribution rates.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<TR STYLE="vertical-align: bottom">
<TD COLSPAN="16" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Fund Performance
and Distribution Rate Information</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Fund</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average
<BR> Annual Total<BR> Return on NAV<BR> for the 5 Year<BR> Period Ending<BR> 05/31/2025<SUP>1</SUP></B></FONT></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><B>Current
Fiscal<BR> Period&rsquo;s<BR>
Annualized<BR> Distribution<BR> Rate on NAV</B></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><B>Cumulative<BR>
Total Return <BR> on NAV<SUP>1</SUP></B></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><B>Cumulative<BR>
Distribution<BR> Rate on NAV<SUP>2</SUP></B></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI<B><SUP>3</SUP></B></FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right">9.96</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%<SUP>3</SUP></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right">11.35</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right">7.93</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right">7.54</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">THQ</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5.03</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12.22</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-16.81</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8.15</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>1</SUP> Return
data is net of all Fund expenses and fees and assumes the reinvestment of all distributions reinvested at prices obtained under the Fund&rsquo;s
dividend reinvestment plan.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><SUP>2</SUP> Based
on the Fund&rsquo;s NAV as of May&nbsp;31, 2025.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>3</SUP> The
Fund launched within the past 5 years; the performance and distribution rate information presented reflects data from inception (July&nbsp;29,
2020) through May&nbsp;31, 2025.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<TR STYLE="vertical-align: bottom">
<TD COLSPAN="16" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Fund Performance
and Distribution Rate Information</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 36%">Fund</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; width: 13%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average<BR>
Annual Total<BR> Return on NAV<BR> for the 5 Year<BR> Period Ending<BR> 04/30/2025<SUP>1</SUP></B></FONT></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; width: 13%"><B>Current
Fiscal<BR> Period&rsquo;s<BR> Annualized<BR> Distribution<BR> Rate on NAV</B></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; width: 13%"><B>Cumulative<BR>
Total Return <BR> on NAV<SUP>1</SUP></B></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; width: 13%"><B>Cumulative<BR>
Distribution<BR> Rate on NAV<SUP>2</SUP></B></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD></TR>


<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQH</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">4.82</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">13.01</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">-5.48</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">6.64</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.78</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13.45</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-6.93</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6.83</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAF</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12.39</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.40</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-0.50</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5.31</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFN</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14.16</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.68</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-3.10</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.67</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  </TABLE>
<P STYLE="margin: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>1</SUP> Return
data is net of all Fund expenses and fees and assumes the reinvestment of all distributions reinvested at prices obtained under the Fund&rsquo;s
dividend reinvestment plan.&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><SUP>2</SUP> Based
on the Fund&rsquo;s NAV as of April&nbsp;30, 2025.</FONT></P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Shareholders should not draw any conclusions about a Fund&rsquo;s
investment performance from the amount of the Fund&rsquo;s current distributions or from the terms of the distribution policy (the &ldquo;Distribution
Policy&rdquo;).</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">While NAV performance may be indicative of the Fund&rsquo;s investment
performance, it does not measure the value of a shareholder&rsquo;s investment in the Fund. The value of a shareholder&rsquo;s investment
in the Fund is determined by the Fund&rsquo;s market price, which is based on the supply and demand for the Fund&rsquo;s shares in the
open market.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to an exemptive order granted by the Securities and Exchange
Commission, the Funds may distribute any long-term capital gains more frequently than the limits provided in Section&nbsp;19(b)&nbsp;under
the 1940 Act and Rule&nbsp;19b-1 thereunder. Therefore, distributions paid by the Funds during the year may include net income, short-term
capital gains, long-term capital gains and/or a return of capital. Net income dividends and short-term capital gain dividends, while
generally taxable at ordinary income rates, may be eligible, to the extent of qualified dividend income earned by the Funds, to be taxed
at a lower rate not to exceed the maximum rate applicable to your long-term capital gains. Distributions made in any calendar year in
excess of investment company taxable income and net capital gain are treated as taxable ordinary dividends to the extent of undistributed
earnings and profits, and then as a return of capital that reduces the adjusted basis in the shares held. To the extent return of capital
distributions exceed the adjusted basis in the shares held, capital gain is recognized with a holding period based on the period the
shares have been held at the date such amount is received.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The payment of distributions in accordance with the Distribution Policy
may result in a decrease in the Fund&rsquo;s net assets. A decrease in the Fund&rsquo;s net assets may cause an increase in the Fund&rsquo;s
annual operating expense ratio and a decrease in the Fund&rsquo;s market price per share to the extent the market price correlates closely
to the Fund&rsquo;s net asset value per share. The Distribution Policy may also negatively affect the Fund&rsquo;s investment activities
to the extent that the Fund is required to hold larger cash positions than it typically would hold or to the extent that the Fund must
liquidate securities that it would not have sold, for the purpose of paying the distribution. Each Fund&rsquo;s Board has the right to
amend, suspend or terminate the Distribution Policy at any time. The amendment, suspension or termination of the Distribution Policy
may affect the Fund&rsquo;s market price per share. Investors should consult their tax advisor regarding federal, state, and local tax
considerations that may be applicable in their particular circumstances.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Circular 230 disclosure</U>: To ensure compliance with requirements
imposed by the U.S. Treasury, we inform you that any U.S. tax advice contained in this communication (including any attachments) is not
intended or written to be used, and cannot be used, for the purpose of (i)&nbsp;avoiding penalties under the Internal Revenue Code or
(ii)&nbsp;promoting, marketing or recommending to another party any transaction or matter addressed herein.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aberdeen Investments Global is the trade name of Aberdeen's investments
business, herein referred to as &quot;Aberdeen Investments&quot; or &quot;Aberdeen&quot;. In the United States, Aberdeen Investments
refers to the following affiliated, registered investment advisers: abrdn Inc., abrdn Investments Limited, and abrdn Asia Limited.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Closed-end funds are traded on the secondary market through one of
the stock exchanges. A Fund&rsquo;s investment return and principal value will fluctuate so that an investor&rsquo;s shares may be worth
more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a discount) the net asset value
(NAV) of the fund&rsquo;s portfolio. There is no assurance that a Fund will achieve its investment objective. Past performance does not
guarantee future results.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><U>Closed end funds | Aberdeen</U></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 176pt; text-indent: 2in"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">###</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="margin: 0"></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(C)(2)
<SEQUENCE>6
<FILENAME>tm2527059d10_ex99-xcx2.htm
<DESCRIPTION>EXHIBIT 99.(C)(2)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2527059d10_ex99-xcx2.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2527059-10/tm2527059-10_ncsrseq1/users" -->

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.(c)(2)</B></P>


<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="text-align: right; margin: 0"><IMG SRC="tm2527059d10_exc2img002.jpg" ALT="">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Press Release</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>FOR IMMEDIATE
RELEASE</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>For More
Information Contact:</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Aberdeen Investments U.S. Closed-End Funds<BR>
Investor Relations&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1-800-522-5465<BR>
Investor.Relations@aberdeenplc.com</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ABERDEEN INVESTMENTS
U.S. CLOSED-END FUNDS</B></P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ANNOUNCE DISTRIBUTION
PAYMENT DETAILS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(Philadelphia, July&nbsp;31, 2025) - The <U>Aberdeen Investments
U.S. Closed-End Funds</U> (NYSE: ASGI, THQ), (the &ldquo;Funds&rdquo; or individually the &ldquo;Fund&rdquo;), today announced that the
Funds paid the distributions noted in the table below on July&nbsp;31, 2025, on a per share basis to all shareholders of record as of
July&nbsp;24, 2025 (ex-dividend date July&nbsp;24, 2025).</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Ticker</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Exchange</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fund</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NYSE</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-bottom: 1pt">abrdn Global Infrastructure
    Income Fund</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0.2100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NYSE</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">abrdn Healthcare Opportunities Fund</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1800</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Each Fund
has adopted a distribution policy to provide investors with a stable distribution out of current income, supplemented by realized capital
gains and, to the extent necessary, paid-in capital.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Under applicable
U.S. tax rules, the amount and character of distributable income for each Fund&rsquo;s fiscal year can be finally determined only as
of the end of the Fund&rsquo;s fiscal year. However, under Section&nbsp;19 of the Investment Company Act of 1940, as amended (the &ldquo;1940
Act&rdquo;) and related rules, the Funds may be required to indicate to shareholders the estimated source of certain distributions to
shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The following
tables set forth the estimated amounts of the sources of the distributions for purposes of Section&nbsp;19 of the 1940 Act and the rules&nbsp;adopted
thereunder. The tables have been computed based on generally accepted accounting principles. The tables include estimated amounts and
percentages for the current distributions paid this month as well as for the cumulative distributions paid relating to fiscal year to
date, from the following sources: net investment income; net realized short-term capital gains; net realized long-term capital gains;
and return of capital. The estimated compositions of the distributions may vary because the estimated composition may be impacted by
future income, expenses and realized gains and losses on securities and currencies.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The Funds&rsquo;
estimated sources of the current distribution paid this month and for its current fiscal year to date are as follows:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="36" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Estimated
    Amounts of Current Distribution per Share</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Fund</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">Distribution<BR>
    Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">Net
    Investment <BR>
    Income</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">Net
    Realized Short- <BR>
    Term Gains**</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">Net
    Realized Long-<BR>
    Term Gains</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">Return
    of Capital</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>




<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.2100</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.0315</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">15</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.0063</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">3</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.0756</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">36</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.0966</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">46</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1800</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0180</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1620</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">90</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="margin: 0"></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="36" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Estimated
    Amounts of Fiscal Year* to Date Cumulative Distributions per Share</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Fund</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">Distribution<BR>
    Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">Net
    Investment <BR>
    Income</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">Net
    Realized Short- <BR>
    Term Gains**</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">Net
    Realized Long-<BR>
    Term Gains</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">Return
    of Capital</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>




<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">2.0200</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.3030</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">15</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.0606</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">3</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.7272</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">36</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.9292</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">46</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.8000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1800</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.6200</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">90</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">* ASGI and
THQ have a 9/30 fiscal year end</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">**includes currency gains</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Where the
estimated amounts above show a portion of the distribution to be a &ldquo;Return of Capital,&rdquo; it means that Fund estimates that
it has distributed more than its income and capital gains; therefore, a portion of your distribution may be a return of capital. A return
of capital may occur for example, when some or all the money that you invested in a Fund is paid back to you. A return of capital distribution
does not necessarily reflect the Fund&rsquo;s investment performance and should not be confused with &ldquo;yield&rdquo; or &ldquo;income.&rdquo;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>The amounts
and sources of distributions reported in this notice are only estimates and are not being provided for tax reporting purposes. The final
determination of the source of all distributions for the current year will only be made after year-end. The actual amounts and sources
of the amounts for tax reporting purposes will depend upon the Fund&rsquo;s investment experience during the remainder of the fiscal
year and may be subject to change based on tax regulations. After the end of each calendar year, a Form&nbsp;1099-DIV will be sent to
shareholders for the prior calendar year that will tell you how to report these distributions for federal income tax purposes.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The following
tables provide the Funds&rsquo; total return performance based on net asset value (NAV) over various time periods compared to the Funds&rsquo;
annualized and cumulative distribution rates.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<TR STYLE="vertical-align: bottom">
<TD COLSPAN="16" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Fund
Performance and Distribution Rate Information</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 36%">Fund</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 13%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average
<BR> Annual Total<BR> Return on NAV<BR> for the 5 Year<BR> Period Ending<BR> 06/30/2025<SUP>1</SUP></B></FONT></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 13%"><B>Current
Fiscal<BR> Period&rsquo;s<BR>
Annualized<BR> Distribution<BR> Rate on NAV</B></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 13%"><B>Cumulative<BR>
Total Return <BR> on NAV<SUP>1</SUP></B></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 13%"><B>Cumulative<BR>
Distribution<BR> Rate on NAV<SUP>2</SUP></B></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD></TR>


<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI<SUP>3</SUP></FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">10.29</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%<SUP>3</SUP></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">11.40</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">10.39</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">8.44</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5.85</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12.13</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-15.30</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9.10</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>
<P STYLE="margin: 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><SUP>1</SUP>
Return data is net of all Fund expenses and fees and assumes the reinvestment of all distributions reinvested at prices obtained under
the Fund&rsquo;s dividend reinvestment plan.&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><SUP>2</SUP> Based
on the Fund&rsquo;s NAV as of June&nbsp;30, 2025.&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><SUP>3</SUP>
The Fund launched within the past 5 years; the performance and distribution rate information presented reflects data from inception (July&nbsp;29,
2020) through June&nbsp;30, 2025.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Shareholders
should not draw any conclusions about a Fund&rsquo;s investment performance from the amount of the Fund&rsquo;s current distributions
or from the terms of the distribution policy (the &ldquo;Distribution Policy&rdquo;).</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">While NAV
performance may be indicative of the Fund&rsquo;s investment performance, it does not measure the value of a shareholder&rsquo;s investment
in the Fund. The value of a shareholder&rsquo;s investment in the Fund is determined by the Fund&rsquo;s market price, which is based
on the supply and demand for the Fund&rsquo;s shares in the open market.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to an exemptive order granted by the Securities and Exchange
Commission, the Funds may distribute any long-term capital gains more frequently than the limits provided in Section&nbsp;19(b)&nbsp;under
the 1940 Act and Rule&nbsp;19b-1 thereunder. Therefore, distributions paid by the Funds during the year may include net income, short-term
capital gains, long-term capital gains and/or a return of capital. Net income dividends and short-term capital gain dividends, while
generally taxable at ordinary income rates, may be eligible, to the extent of qualified dividend income earned by the Funds, to be taxed
at a lower rate not to exceed the maximum rate applicable to your long-term capital gains. Distributions made in any calendar year in
excess of investment company taxable income and net capital gain are treated as taxable ordinary dividends to the extent of undistributed
earnings and profits, and then as a return of capital that reduces the adjusted basis in the shares held. To the extent return of capital
distributions exceed the adjusted basis in the shares held, capital gain is recognized with a holding period based on the period the
shares have been held at the date such amount is received.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The payment of distributions in accordance with the Distribution Policy
may result in a decrease in the Fund&rsquo;s net assets. A decrease in the Fund&rsquo;s net assets may cause an increase in the Fund&rsquo;s
annual operating expense ratio and a decrease in the Fund&rsquo;s market price per share to the extent the market price correlates closely
to the Fund&rsquo;s net asset value per share. The Distribution Policy may also negatively affect the Fund&rsquo;s investment activities
to the extent that the Fund is required to hold larger cash positions than it typically would hold or to the extent that the Fund must
liquidate securities that it would not have sold, for the purpose of paying the distribution. Each Fund&rsquo;s Board has the right to
amend, suspend or terminate the Distribution Policy at any time. The amendment, suspension or termination of the Distribution Policy
may affect the Fund&rsquo;s market price per share. Investors should consult their tax advisor regarding federal, state, and local tax
considerations that may be applicable in their particular circumstances.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Circular 230 disclosure</U>: To ensure compliance with requirements
imposed by the U.S. Treasury, we inform you that any U.S. tax advice contained in this communication (including any attachments) is not
intended or written to be used, and cannot be used, for the purpose of (i)&nbsp;avoiding penalties under the Internal Revenue Code or
(ii)&nbsp;promoting, marketing or recommending to another party any transaction or matter addressed herein.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aberdeen Investments Global is the trade name of Aberdeen's investments
business, herein referred to as &quot;Aberdeen Investments&quot; or &quot;Aberdeen&quot;. In the United States, Aberdeen Investments
refers to the following affiliated, registered investment advisers: abrdn Inc., abrdn Investments Limited, and abrdn Asia Limited.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Closed-end funds are traded on the secondary market through one of
the stock exchanges. A Fund&rsquo;s investment return and principal value will fluctuate so that an investor&rsquo;s shares may be worth
more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a discount) the net asset value
(NAV) of the fund&rsquo;s portfolio. There is no assurance that a Fund will achieve its investment objective. Past performance does not
guarantee future results.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><U>Closed end funds | Aberdeen</U></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">###</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(C)(3)
<SEQUENCE>7
<FILENAME>tm2527059d10_ex99-xcx3.htm
<DESCRIPTION>EXHIBIT 99.(C)(3)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2527059d10_ex99-xcx3.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2527059-10/tm2527059-10_ncsrseq1/users" -->

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.(c)(3)</B></P>


<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="text-align: right; margin: 0"><IMG SRC="tm2527059d10_exc3img003.jpg" ALT="">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Press Release</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>FOR IMMEDIATE
RELEASE</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>For More
Information Contact:</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Aberdeen Investments U.S. Closed-End Funds<BR>
Investor Relations&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1-800-522-5465<BR>
Investor.Relations@aberdeenplc.com</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>ABERDEEN INVESTMENTS
U.S. CLOSED-END FUNDS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>ANNOUNCE DISTRIBUTION
PAYMENT DETAILS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">(Philadelphia,
August&nbsp;29, 2025) - The <U>Aberdeen Investments U.S. Closed-End Funds</U> (NYSE: ASGI, THQ), (the &ldquo;Funds&rdquo; or individually
the &ldquo;Fund&rdquo;), today announced that the Funds paid the distributions noted in the table below on August&nbsp;29, 2025, on a
per share basis to all shareholders of record as of August&nbsp;22, 2025 (ex-dividend date August&nbsp;22, 2025).</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif">Ticker</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif">Exchange</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif">Fund</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NYSE</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-bottom: 1pt">abrdn Global Infrastructure
    Income Fund</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0.2100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NYSE</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">abrdn Healthcare Opportunities Fund</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1800</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Each Fund
has adopted a distribution policy to provide investors with a stable distribution out of current income, supplemented by realized capital
gains and, to the extent necessary, paid-in capital.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Under applicable
U.S. tax rules, the amount and character of distributable income for each Fund&rsquo;s fiscal year can be finally determined only as
of the end of the Fund&rsquo;s fiscal year. However, under Section&nbsp;19 of the Investment Company Act of 1940, as amended (the &ldquo;1940
Act&rdquo;) and related rules, the Funds may be required to indicate to shareholders the estimated source of certain distributions to
shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">The following
tables set forth the estimated amounts of the sources of the distributions for purposes of Section&nbsp;19 of the 1940 Act and the rules&nbsp;adopted
thereunder. The tables have been computed based on generally accepted accounting principles. The tables include estimated amounts and
percentages for the current distributions paid this month as well as for the cumulative distributions paid relating to fiscal year to
date, from the following sources: net investment income; net realized short-term capital gains; net realized long-term capital gains;
and return of capital. The estimated compositions of the distributions may vary because the estimated composition may be impacted by
future income, expenses and realized gains and losses on securities and currencies.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">The Funds&rsquo;
estimated sources of the current distribution paid this month and for its current fiscal year to date are as follows:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="36" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Estimated
    Amounts of Current Distribution per Share</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Fund</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Distribution<BR>
    Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Net
    Investment <BR>
    Income</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Net
    Realized Short- <BR>
    Term Gains**</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Net
    Realized Long-<BR>
    Term Gains</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Return
    of Capital</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>


<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.2100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.0294</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">14</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.0063</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">3</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.0756</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">36</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.0987</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">47</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1800</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0036</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1764</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">98</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="36" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Estimated
    Amounts of Fiscal Year* to Date Cumulative Distributions per Share</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Fund</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Distribution<BR>
    Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Net
    Investment <BR>
    Income</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Net
    Realized Short- <BR>
    Term Gains**</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Net
    Realized Long-<BR>
    Term Gains</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Return
    of Capital</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>


<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">2.2300</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.3122</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">14</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.0669</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">3</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.8028</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">36</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">1.0481</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">47</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.9800</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0396</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.9404</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">98</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">* ASGI and
THQ have a 9/30 fiscal year end</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">**includes currency gains</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Where the
estimated amounts above show a portion of the distribution to be a &ldquo;Return of Capital,&rdquo; it means that Fund estimates that
it has distributed more than its income and capital gains; therefore, a portion of your distribution may be a return of capital. A return
of capital may occur for example, when some or all the money that you invested in a Fund is paid back to you. A return of capital distribution
does not necessarily reflect the Fund&rsquo;s investment performance and should not be confused with &ldquo;yield&rdquo; or &ldquo;income.&rdquo;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>The amounts
and sources of distributions reported in this notice are only estimates and are not being provided for tax reporting purposes. The final
determination of the source of all distributions for the current year will only be made after year-end. The actual amounts and sources
of the amounts for tax reporting purposes will depend upon the Fund&rsquo;s investment experience during the remainder of the fiscal
year and may be subject to change based on tax regulations. After the end of each calendar year, a Form&nbsp;1099-DIV will be sent to
shareholders for the prior calendar year that will tell you how to report these distributions for federal income tax purposes.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The following
tables provide the Funds&rsquo; total return performance based on net asset value (NAV) over various time periods compared to the Funds&rsquo;
annualized and cumulative distribution rates.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<TR STYLE="vertical-align: bottom">
<TD COLSPAN="16" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Fund
Performance and Distribution Rate Information</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 36%">Fund</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 13%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average
<BR> Annual Total<BR> Return on NAV<BR> for the 5 Year<BR> Period Ending<BR> 07/31/2025<SUP>1</SUP></B></FONT></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 13%"><B>Current
Fiscal<BR> Period&rsquo;s<BR>
Annualized<BR> Distribution<BR> Rate on NAV</B></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 13%"><B>Cumulative<BR>
Total Return <BR> on NAV<SUP>1</SUP></B></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 13%"><B>Cumulative<BR>
Distribution<BR> Rate on NAV<SUP>2</SUP></B></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD></TR>


<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">10.13</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">11.56</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">10.03</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">9.55</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.92</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-18.89</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.67</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>
<P STYLE="margin: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><SUP>1</SUP>
Return data is net of all Fund expenses and fees and assumes the reinvestment of all distributions reinvested at prices obtained under
the Fund&rsquo;s dividend reinvestment plan.&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><SUP>2</SUP> Based
on the Fund&rsquo;s NAV as of July&nbsp;31, 2025.</FONT></P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Shareholders
should not draw any conclusions about a Fund&rsquo;s investment performance from the amount of the Fund&rsquo;s current distributions
or from the terms of the distribution policy (the &ldquo;Distribution Policy&rdquo;).</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">While NAV
performance may be indicative of the Fund&rsquo;s investment performance, it does not measure the value of a shareholder&rsquo;s investment
in the Fund. The value of a shareholder&rsquo;s investment in the Fund is determined by the Fund&rsquo;s market price, which is based
on the supply and demand for the Fund&rsquo;s shares in the open market.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to an exemptive order granted by the Securities and Exchange
Commission, the Funds may distribute any long-term capital gains more frequently than the limits provided in Section&nbsp;19(b)&nbsp;under
the 1940 Act and Rule&nbsp;19b-1 thereunder. Therefore, distributions paid by the Funds during the year may include net income, short-term
capital gains, long-term capital gains and/or a return of capital. Net income dividends and short-term capital gain dividends, while
generally taxable at ordinary income rates, may be eligible, to the extent of qualified dividend income earned by the Funds, to be taxed
at a lower rate not to exceed the maximum rate applicable to your long-term capital gains. Distributions made in any calendar year in
excess of investment company taxable income and net capital gain are treated as taxable ordinary dividends to the extent of undistributed
earnings and profits, and then as a return of capital that reduces the adjusted basis in the shares held. To the extent return of capital
distributions exceed the adjusted basis in the shares held, capital gain is recognized with a holding period based on the period the
shares have been held at the date such amount is received.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The payment of distributions in accordance with the Distribution Policy
may result in a decrease in the Fund&rsquo;s net assets. A decrease in the Fund&rsquo;s net assets may cause an increase in the Fund&rsquo;s
annual operating expense ratio and a decrease in the Fund&rsquo;s market price per share to the extent the market price correlates closely
to the Fund&rsquo;s net asset value per share. The Distribution Policy may also negatively affect the Fund&rsquo;s investment activities
to the extent that the Fund is required to hold larger cash positions than it typically would hold or to the extent that the Fund must
liquidate securities that it would not have sold, for the purpose of paying the distribution. Each Fund&rsquo;s Board has the right to
amend, suspend or terminate the Distribution Policy at any time. The amendment, suspension or termination of the Distribution Policy
may affect the Fund&rsquo;s market price per share. Investors should consult their tax advisor regarding federal, state, and local tax
considerations that may be applicable in their particular circumstances.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Circular 230 disclosure</U>: To ensure compliance with requirements
imposed by the U.S. Treasury, we inform you that any U.S. tax advice contained in this communication (including any attachments) is not
intended or written to be used, and cannot be used, for the purpose of (i)&nbsp;avoiding penalties under the Internal Revenue Code or
(ii)&nbsp;promoting, marketing or recommending to another party any transaction or matter addressed herein.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aberdeen Investments Global is the trade name of Aberdeen's investments
business, herein referred to as &quot;Aberdeen Investments&quot; or &quot;Aberdeen&quot;. In the United States, Aberdeen Investments
refers to the following affiliated, registered investment advisers: abrdn Inc., abrdn Investments Limited, and abrdn Asia Limited.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Closed-end funds are traded on the secondary market through one of
the stock exchanges. A Fund&rsquo;s investment return and principal value will fluctuate so that an investor&rsquo;s shares may be worth
more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a discount) the net asset value
(NAV) of the fund&rsquo;s portfolio. There is no assurance that a Fund will achieve its investment objective. Past performance does not
guarantee future results.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><U>Closed end funds | Aberdeen</U></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 176pt; text-indent: 2in"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">###</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(C)(4)
<SEQUENCE>8
<FILENAME>tm2527059d10_ex99-xcx4.htm
<DESCRIPTION>EXHIBIT 99.(C)(4)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2527059d10_ex99-xcx4.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2527059-10/tm2527059-10_ncsrseq1/users" -->

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.(c)(4)</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><IMG SRC="tm2527059d10_exc4img001.jpg" ALT="">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Press Release</b></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>FOR IMMEDIATE RELEASE</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For More Information Contact:</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Aberdeen Investments U.S. Closed-End Funds<BR>
Investor Relations&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1-800-522-5465<BR>
Investor.Relations@aberdeenplc.com</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>ABERDEEN INVESTMENTS
U.S. CLOSED-END FUNDS</B>&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>ANNOUNCE DISTRIBUTION
PAYMENT DETAILS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Philadelphia, September&nbsp;30, 2025) - The <U>Aberdeen Investments
U.S. Closed-End Funds</U> (NYSE: ASGI, HQH, HQL,&nbsp;IFN, THQ), (NYSE American: IAF) (the &ldquo;Funds&rdquo; or individually the &ldquo;Fund&rdquo;),
today announced that the Funds paid the distributions noted in the table below on September&nbsp;30, 2025, on a per share basis to all
shareholders of record as of September&nbsp;23, 2025 (ex-dividend date September&nbsp;23, 2025). These dates apply to the Funds listed
below with the exception of abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Australia Equity Fund,&nbsp;Inc.
(IAF) and the India Fund Inc. (IFN) which paid on September&nbsp;30, 2025, to all shareholders of record as of August&nbsp;22, 2025 (ex-dividend
date August&nbsp;22, 2025).</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Ticker</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Exchange</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fund</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; padding-bottom: 1pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-bottom: 1pt">abrdn Global Infrastructure
    Income Fund</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0.2100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQH</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">abrdn Healthcare Investors</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.5100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">abrdn Life Sciences Investors</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAF</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">NYSE American</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">abrdn Australia Equity Fund,&nbsp;Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFN</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">The India Fund,&nbsp;Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4300</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">abrdn Healthcare Opportunities Fund</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1800</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each Fund has adopted a distribution policy to provide investors with
a stable distribution out of current income, supplemented by realized capital gains and, to the extent necessary, paid-in capital.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors
(HQL), abrdn Australia Equity Fund,&nbsp;Inc. (IAF) and the India Fund Inc. (IFN) the stock distributions were automatically paid in
newly issued shares of the Fund unless otherwise instructed by the shareholder to be paid in cash. Shares of common stock were issued
at the lower of the net asset value (&ldquo;NAV&rdquo;) per share or the market price per share with a floor for the NAV of not less
than 95% of the market price on September&nbsp;17, 2025. The reinvestment prices per share for these distributions were as follows: $16.50
for abrdn Healthcare Investors (HQH); $13.95 for abrdn Life Sciences Investors (HQL); $4.63 for abrdn Australia Equity Fund,&nbsp;Inc.
(IAF) and $15.14 for the India Fund,&nbsp;Inc. (IFN). Fractional shares were generally settled in cash, except for registered shareholders
with book entry accounts at Computershare Investor Services who had whole and fractional shares added to their account.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To have received the abrdn Healthcare Investors (HQH), abrdn Life
Sciences Investors (HQL), abrdn Australia Equity Fund,&nbsp;Inc. (IAF) and the India Fund Inc. (IFN) quarterly distributions payable
in September&nbsp;2025 in cash instead of shares of common stock, for shareholders who hold shares in &ldquo;street name,&rdquo; the
bank, brokerage or nominee who holds the shares must have advised the Depository Trust Company as to the full and fractional shares for
which they want the distribution paid in cash by September&nbsp;16, 2025; and for shares that are held in registered form, written notification
for the election of cash by registered shareholders must have been received by Computershare Investor Services prior to September&nbsp;16,
2025.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Under applicable
U.S. tax rules, the amount and character of distributable income for each Fund&rsquo;s fiscal year can be finally determined only as
of the end of the Fund&rsquo;s fiscal year. However, under Section&nbsp;19 of the Investment Company Act of 1940, as amended (the &ldquo;1940
Act&rdquo;) and related rules, the Funds may be required to indicate to shareholders the estimated source of certain distributions to
shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The following
tables set forth the estimated amounts of the sources of the distributions for purposes of Section&nbsp;19 of the 1940 Act and the rules&nbsp;adopted
thereunder. The tables have been computed based on generally accepted accounting principles. The tables include estimated amounts and
percentages for the current distributions paid this month as well as for the cumulative distributions paid relating to fiscal year to
date, from the following sources: net investment income; net realized short-term capital gains; net realized long-term capital gains;
and return of capital. The estimated compositions of the distributions may vary because the estimated composition may be impacted by
future income, expenses and realized gains and losses on securities and currencies.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The Funds&rsquo;
estimated sources of the current distribution paid this month and for its current fiscal year to date are as follows:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="36" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Estimated
    Amounts of Current Distribution per Share</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Fund</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Distribution<BR>
    Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Net
    Investment <BR>
    Income</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Net
    Realized Short- <BR>
    Term Gains**</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Net
    Realized Long-<BR>
    Term Gains</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Return
    of Capital</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>


<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.2100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.0252</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">12</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.0063</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">3</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.0714</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">34</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.1071</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">51</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQH</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.5100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">20</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4080</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.2461</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">59</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1739</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">41</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAF</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0132</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0348</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">29</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0720</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFN</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4300</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4300</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1800</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1782</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">99</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="36" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Estimated
    Amounts of Fiscal Year* to Date Cumulative Distributions per Share</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Fund</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Distribution<BR>
    Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Net
    Investment <BR>
    Income</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Net
    Realized Short- <BR>
    Term Gains**</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Net
    Realized Long-<BR>
    Term Gains</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Return
    of Capital</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>


<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">2.4400</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.2928</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">12</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.0732</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">3</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.8296</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">34</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">1.2444</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">51</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQH</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.2400</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4480</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">20</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.7920</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.8200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.0665</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">59</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.7535</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">41</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAF</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4900</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0539</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1421</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">29</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.2940</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFN</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.3000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.3000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.1600</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0216</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.1384</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">99</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">* ASGI, HQH,
HQL and THQ have a 9/30 fiscal year end. IAF has a 10/31 fiscal year end. IFN has a 12/31 fiscal year end.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">**includes
currency gains</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Where the
estimated amounts above show a portion of the distribution to be a &ldquo;Return of Capital,&rdquo; it means that Fund estimates that
it has distributed more than its income and capital gains; therefore, a portion of your distribution may be a return of capital. A return
of capital may occur for example, when some or all the money that you invested in a Fund is paid back to you. A return of capital distribution
does not necessarily reflect the Fund&rsquo;s investment performance and should not be confused with &ldquo;yield&rdquo; or &ldquo;income.&rdquo;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The amounts and sources of distributions reported in this notice
are only estimates and are not being provided for tax reporting purposes. The final determination of the source of all distributions
for the current year will only be made after year-end. The actual amounts and sources of the amounts for tax reporting purposes will
depend upon the Fund&rsquo;s investment experience during the remainder of the fiscal year and may be subject to change based on tax
regulations. After the end of each calendar year, a Form&nbsp;1099-DIV will be sent to shareholders for the prior calendar year that
will tell you how to report these distributions for federal income tax purposes.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following tables provide the Funds&rsquo; total return performance
based on net asset value (NAV) over various time periods compared to the Funds&rsquo; annualized and cumulative distribution rates.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<TR STYLE="vertical-align: bottom">
<TD COLSPAN="16" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Fund
Performance and Distribution Rate Information</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 36%">Fund</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 13%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average
<BR> Annual Total<BR> Return on NAV<BR> for the 5 Year<BR> Period Ending<BR> 08/31/2025<SUP>1</SUP></B></FONT></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 13%"><B>Current
Fiscal<BR> Period&rsquo;s<BR>
Annualized<BR> Distribution<BR> Rate on NAV</B></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 13%"><B>Cumulative<BR>
Total Return <BR> on NAV<SUP>1</SUP></B></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 13%"><B>Cumulative<BR>
Distribution<BR> Rate on NAV<SUP>2</SUP></B></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD></TR>


<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">9.97</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">11.61</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">10.68</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">10.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.64</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12.21</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-14.06</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11.19</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  </TABLE>
<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><SUP>1</SUP> Return
data is net of all Fund expenses and fees and assumes the reinvestment of all distributions reinvested at prices obtained under the Fund&rsquo;s
dividend reinvestment plan.&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><SUP>2</SUP> Based
on the Fund&rsquo;s NAV as of August&nbsp;31, 2025.</FONT></P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<TR STYLE="vertical-align: bottom">
<TD COLSPAN="16" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Fund
Performance and Distribution Rate Information</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Fund</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average<BR>
Annual Total<BR> Return on NAV<BR> for the 5 Year<BR> Period Ending<BR> 07/31/2025<SUP>1</SUP></B></FONT></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><B>Current
Fiscal<BR> Period&rsquo;s<BR> Annualized<BR> Distribution<BR> Rate on NAV</B></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><B>Cumulative<BR>
Total Return <BR> on NAV<SUP>1</SUP></B></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><B>Cumulative<BR>
Distribution<BR> Rate on NAV<SUP>2</SUP></B></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD></TR>


<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQH</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">3.44</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">13.11</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">-5.37</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">9.99</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.50</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12.55</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-1.18</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAF</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.33</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9.78</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8.69</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7.39</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFN</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.89</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.27</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-5.05</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5.29</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><SUP>1</SUP> Return
data is net of all Fund expenses and fees and assumes the reinvestment of all distributions reinvested at prices obtained under the Fund&rsquo;s
dividend reinvestment plan.&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><SUP>2</SUP> Based
on the Fund&rsquo;s NAV as of July&nbsp;31, 2025.</FONT></P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Shareholders should not draw any conclusions about a Fund&rsquo;s
investment performance from the amount of the Fund&rsquo;s current distributions or from the terms of the distribution policy (the &ldquo;Distribution
Policy&rdquo;).</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The value at which a closed-end fund stock may trade on a public
exchange is a function of external market factors that are not at the control of the Fund&rsquo;s Board or Investment Advisor. Closed-end
Fund shares may therefore trade at a premium or a discount to net asset value at any given time. Shareholders should be aware that a
fund trading at a premium to net asset value may not be sustainable and a fund&rsquo;s discount to net asset value, can widen as well
as narrow. Shareholders of a fund trading at a premium who participate in that fund&rsquo;s dividend reinvestment plan should note the
reinvestment of distributions may occur at a premium to net asset value.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">While NAV performance may be indicative of the Fund&rsquo;s investment
performance, it does not measure the value of a shareholder&rsquo;s investment in the Fund. The value of a shareholder&rsquo;s investment
in the Fund is determined by the Fund&rsquo;s market price, which is based on the supply and demand for the Fund&rsquo;s shares in the
open market.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to an exemptive order granted by the Securities and Exchange
Commission, the Funds may distribute any long-term capital gains more frequently than the limits provided in Section&nbsp;19(b)&nbsp;under
the 1940 Act and Rule&nbsp;19b-1 thereunder. Therefore, distributions paid by the Funds during the year may include net income, short-term
capital gains, long-term capital gains and/or a return of capital. Net income dividends and short-term capital gain dividends, while
generally taxable at ordinary income rates, may be eligible, to the extent of qualified dividend income earned by the Funds, to be taxed
at a lower rate not to exceed the maximum rate applicable to your long-term capital gains. Distributions made in any calendar year in
excess of investment company taxable income and net capital gain are treated as taxable ordinary dividends to the extent of undistributed
earnings and profits, and then as a return of capital that reduces the adjusted basis in the shares held. To the extent return of capital
distributions exceed the adjusted basis in the shares held, capital gain is recognized with a holding period based on the period the
shares have been held at the date such amount is received.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The payment of distributions in accordance with the Distribution Policy
may result in a decrease in the Fund&rsquo;s net assets. A decrease in the Fund&rsquo;s net assets may cause an increase in the Fund&rsquo;s
annual operating expense ratio and a decrease in the Fund&rsquo;s market price per share to the extent the market price correlates closely
to the Fund&rsquo;s net asset value per share. The Distribution Policy may also negatively affect the Fund&rsquo;s investment activities
to the extent that the Fund is required to hold larger cash positions than it typically would hold or to the extent that the Fund must
liquidate securities that it would not have sold, for the purpose of paying the distribution. Each Fund&rsquo;s Board has the right to
amend, suspend or terminate the Distribution Policy at any time. The amendment, suspension or termination of the Distribution Policy
may affect the Fund&rsquo;s market price per share. Investors should consult their tax advisor regarding federal, state, and local tax
considerations that may be applicable in their particular circumstances.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Circular 230 disclosure</U>: To ensure compliance with requirements
imposed by the U.S. Treasury, we inform you that any U.S. tax advice contained in this communication (including any attachments) is not
intended or written to be used, and cannot be used, for the purpose of (i)&nbsp;avoiding penalties under the Internal Revenue Code or
(ii)&nbsp;promoting, marketing or recommending to another party any transaction or matter addressed herein.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aberdeen Investments Global is the trade name of Aberdeen's investments
business, herein referred to as &quot;Aberdeen Investments&quot; or &quot;Aberdeen&quot;. In the United States, Aberdeen Investments
refers to the following affiliated, registered investment advisers: abrdn Inc., abrdn Investments Limited, and abrdn Asia Limited.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Closed-end funds are traded on the secondary market through one of
the stock exchanges. A Fund&rsquo;s investment return and principal value will fluctuate so that an investor&rsquo;s shares may be worth
more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a discount) the net asset value
(NAV) of the fund&rsquo;s portfolio. There is no assurance that a Fund will achieve its investment objective. Past performance does not
guarantee future results.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><U>Closed end funds | Aberdeen</U></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 176pt; text-indent: 2in"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">###</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(C)(5)
<SEQUENCE>9
<FILENAME>tm2527059d10_ex99-xcx5.htm
<DESCRIPTION>EXHIBIT 99.(C)(5)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2527059d10_ex99-xcx5.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2527059-10/tm2527059-10_ncsrseq1/users" -->

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.(c)(5)</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><IMG SRC="tm2527059d10_exc5img001.jpg" ALT="">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Press Release</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>FOR IMMEDIATE
RELEASE</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B>For More
Information Contact:</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Aberdeen Investments U.S. Closed-End Funds<BR>
Investor Relations</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1-800-522-5465<BR>
Investor.Relations@aberdeenplc.com</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>ABERDEEN INVESTMENTS
U.S. CLOSED-END FUNDS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>ANNOUNCE DISTRIBUTION
PAYMENT DETAILS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">(Philadelphia,
October&nbsp;31, 2025) - The <U>Aberdeen Investments U.S. Closed-End Funds</U> (NYSE: ASGI, THQ), (the &ldquo;Funds&rdquo; or individually
the &ldquo;Fund&rdquo;), today announced that the Funds paid the distributions noted in the table below on October&nbsp;31, 2025, on
a per share basis to all shareholders of record as of October&nbsp;24, 2025 (ex-dividend date October&nbsp;24, 2025).</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Ticker</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Exchange</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fund</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NYSE</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">abrdn
    Global Infrastructure Income Fund</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0.2100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NYSE</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">abrdn Healthcare Opportunities
    Fund</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1800</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Each Fund
has adopted a distribution policy to provide investors with a stable distribution out of current income, supplemented by realized capital
gains and, to the extent necessary, paid-in capital.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Under applicable
U.S. tax rules, the amount and character of distributable income for each Fund&rsquo;s fiscal year can be finally determined only as
of the end of the Fund&rsquo;s fiscal year. However, under Section&nbsp;19 of the Investment Company Act of 1940, as amended (the &ldquo;1940
Act&rdquo;) and related rules, the Funds may be required to indicate to shareholders the estimated source of certain distributions to
shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The following
tables set forth the estimated amounts of the sources of the distributions for purposes of Section&nbsp;19 of the 1940 Act and the rules&nbsp;adopted
thereunder. The tables have been computed based on generally accepted accounting principles. The tables include estimated amounts and
percentages for the current distributions paid this month as well as for the cumulative distributions paid relating to fiscal year to
date, from the following sources: net investment income; net realized short-term capital gains; net realized long-term capital gains;
and return of capital. The estimated compositions of the distributions may vary because the estimated composition may be impacted by
future income, expenses and realized gains and losses on securities and currencies.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The Funds&rsquo;
estimated sources of the current distribution paid this month and for its current fiscal year to date are as follows:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<P STYLE="margin: 0"></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="36" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Estimated
    Amounts of Current Distribution per Share</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Fund</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Distribution<BR>
    Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Net
    Investment <BR>
    Income</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Net
    Realized Short- <BR>
    Term Gains**</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Net
    Realized Long-<BR>
    Term Gains</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Return
    of Capital</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>




<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.2100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.1050</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">50</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.1050</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">50</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1800</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0396</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0396</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1008</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">56</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="36" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Estimated
    Amounts of Fiscal Year* to Date Cumulative Distributions per Share</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Fund</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Distribution<BR>
    Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Net
    Investment <BR>
    Income</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Net
    Realized Short- <BR>
    Term Gains**</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Net
    Realized Long-<BR>
    Term Gains</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Return
    of Capital</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>




<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.2100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.1050</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">50</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.1050</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">50</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1800</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0396</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0396</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1008</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">56</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">* ASGI and
THQ have a 9/30 fiscal year end</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">**includes
currency gains</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Where the
estimated amounts above show a portion of the distribution to be a &ldquo;Return of Capital,&rdquo; it means that Fund estimates that
it has distributed more than its income and capital gains; therefore, a portion of your distribution may be a return of capital. A return
of capital may occur for example, when some or all the money that you invested in a Fund is paid back to you. A return of capital distribution
does not necessarily reflect the Fund&rsquo;s investment performance and should not be confused with &ldquo;yield&rdquo; or &ldquo;income.&rdquo;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>The amounts
and sources of distributions reported in this notice are only estimates and are not being provided for tax reporting purposes. The final
determination of the source of all distributions for the current year will only be made after year-end. The actual amounts and sources
of the amounts for tax reporting purposes will depend upon the Fund&rsquo;s investment experience during the remainder of the fiscal
year and may be subject to change based on tax regulations. After the end of each calendar year, a Form&nbsp;1099-DIV will be sent to
shareholders for the prior calendar year that will tell you how to report these distributions for federal income tax purposes.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The following
tables provide the Funds&rsquo; total return performance based on net asset value (NAV) over various time periods compared to the Funds&rsquo;
annualized and cumulative distribution rates.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<TR STYLE="vertical-align: bottom">
<TD COLSPAN="16" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Fund
Performance and Distribution Rate Information</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 36%">Fund</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 13%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average
<BR> Annual Total<BR> Return on NAV<BR> for the 5 Year<BR> Period Ending<BR> 09/30/2025<SUP>1</SUP></B></FONT></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 13%"><B>Current
Fiscal<BR> Period&rsquo;s<BR>
Annualized<BR> Distribution<BR> Rate on NAV</B></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 13%"><B>Cumulative<BR>
Total Return <BR> on NAV<SUP>1</SUP></B></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 13%"><B>Cumulative<BR>
Distribution<BR> Rate on NAV<SUP>2</SUP></B></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD></TR>


<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">11.27</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">11.49</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">12.96</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">11.49</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5.73</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12.07</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-12.19</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12.07</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><SUP>1</SUP>
Return data is net of all Fund expenses and fees and assumes the reinvestment of all distributions reinvested at prices obtained under
the Fund&rsquo;s dividend reinvestment plan.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><SUP>2</SUP> Based
on the Fund&rsquo;s NAV as of September&nbsp;30, 2025.</FONT></P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Shareholders
should not draw any conclusions about a Fund&rsquo;s investment performance from the amount of the Fund&rsquo;s current distributions
or from the terms of the distribution policy (the &ldquo;Distribution Policy&rdquo;).</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>The value
at which a closed-end fund stock may trade on a public exchange is a function of external market factors that are not at the control
of the Fund&rsquo;s Board or Investment Advisor. Closed-end Fund shares may therefore trade at a premium or a discount to net asset value
at any given time. Shareholders should be aware that a fund trading at a premium to net asset value may not be sustainable and a fund&rsquo;s
discount to net asset value, can widen as well as narrow. Shareholders of a fund trading at a premium who participate in that fund&rsquo;s
dividend reinvestment plan should note the reinvestment of distributions may occur at a premium to net asset value.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">While NAV performance may be indicative of the Fund&rsquo;s investment
performance, it does not measure the value of a shareholder&rsquo;s investment in the Fund. The value of a shareholder&rsquo;s investment
in the Fund is determined by the Fund&rsquo;s market price, which is based on the supply and demand for the Fund&rsquo;s shares in the
open market.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to an exemptive order granted by the Securities and Exchange
Commission, the Funds may distribute any long-term capital gains more frequently than the limits provided in Section&nbsp;19(b)&nbsp;under
the 1940 Act and Rule&nbsp;19b-1 thereunder. Therefore, distributions paid by the Funds during the year may include net income, short-term
capital gains, long-term capital gains and/or a return of capital. Net income dividends and short-term capital gain dividends, while
generally taxable at ordinary income rates, may be eligible, to the extent of qualified dividend income earned by the Funds, to be taxed
at a lower rate not to exceed the maximum rate applicable to your long-term capital gains. Distributions made in any calendar year in
excess of investment company taxable income and net capital gain are treated as taxable ordinary dividends to the extent of undistributed
earnings and profits, and then as a return of capital that reduces the adjusted basis in the shares held. To the extent return of capital
distributions exceed the adjusted basis in the shares held, capital gain is recognized with a holding period based on the period the
shares have been held at the date such amount is received.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The payment of distributions in accordance with the Distribution Policy
may result in a decrease in the Fund&rsquo;s net assets. A decrease in the Fund&rsquo;s net assets may cause an increase in the Fund&rsquo;s
annual operating expense ratio and a decrease in the Fund&rsquo;s market price per share to the extent the market price correlates closely
to the Fund&rsquo;s net asset value per share. The Distribution Policy may also negatively affect the Fund&rsquo;s investment activities
to the extent that the Fund is required to hold larger cash positions than it typically would hold or to the extent that the Fund must
liquidate securities that it would not have sold, for the purpose of paying the distribution. Each Fund&rsquo;s Board has the right to
amend, suspend or terminate the Distribution Policy at any time. The amendment, suspension or termination of the Distribution Policy
may affect the Fund&rsquo;s market price per share. Investors should consult their tax advisor regarding federal, state, and local tax
considerations that may be applicable in their particular circumstances.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Circular 230 disclosure</U>: To ensure compliance with requirements
imposed by the U.S. Treasury, we inform you that any U.S. tax advice contained in this communication (including any attachments) is not
intended or written to be used, and cannot be used, for the purpose of (i)&nbsp;avoiding penalties under the Internal Revenue Code or
(ii)&nbsp;promoting, marketing or recommending to another party any transaction or matter addressed herein.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aberdeen Investments Global is the trade name of Aberdeen's investments
business, herein referred to as &quot;Aberdeen Investments&quot; or &quot;Aberdeen&quot;. In the United States, Aberdeen Investments
refers to the following affiliated, registered investment advisers: abrdn Inc., abrdn Investments Limited, and abrdn Asia Limited.&quot;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Closed-end funds are traded on the secondary market through one of
the stock exchanges. A Fund&rsquo;s investment return and principal value will fluctuate so that an investor&rsquo;s shares may be worth
more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a discount) he net asset value
(NAV) of the fund&rsquo;s portfolio. There is no assurance that a Fund will achieve its investment objective. Past performance does not
guarantee future results.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><U>Closed end funds | Aberdeen</U></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 176pt; text-indent: 2in"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">###</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(C)(6)
<SEQUENCE>10
<FILENAME>tm2527059d10_ex99-xcx6.htm
<DESCRIPTION>EXHIBIT 99.(C)(6)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2527059d10_ex99-xcx6.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2527059-10/tm2527059-10_ncsrseq1/users" -->

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.(c)(6)</B></P>


<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="margin: 0; text-align: right"><IMG SRC="tm2527059d10_exc6img001.jpg" ALT="">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Press Release</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>FOR IMMEDIATE
RELEASE</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>For More
Information Contact:</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Aberdeen Investments U.S. Closed-End Funds<BR>
Investor Relations</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1-800-522-5465<BR>
Investor.Relations@aberdeenplc.com</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>ABERDEEN INVESTMENTS
U.S. CLOSED-END FUNDS</B>&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>ANNOUNCE DISTRIBUTION
PAYMENT DETAILS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">(Philadelphia,
November&nbsp;28, 2025) - The <U>Aberdeen Investments U.S. Closed-End Funds</U> (NYSE: ASGI, THQ), (the &ldquo;Funds&rdquo; or individually
the &ldquo;Fund&rdquo;), today announced that the Funds paid the distributions noted in the table below on November&nbsp;28, 2025, on
a per share basis to all shareholders of record as of November&nbsp;21, 2025 (ex-dividend date November&nbsp;21, 2025).</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Ticker</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Exchange</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fund</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NYSE</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-bottom: 1pt">abrdn Global Infrastructure
    Income Fund</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0.2100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NYSE</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">abrdn Healthcare Opportunities Fund</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1800</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Each Fund
has adopted a distribution policy to provide investors with a stable distribution out of current income, supplemented by realized capital
gains and, to the extent necessary, paid-in capital.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Under applicable
U.S. tax rules, the amount and character of distributable income for each Fund&rsquo;s fiscal year can be finally determined only as
of the end of the Fund&rsquo;s fiscal year. However, under Section&nbsp;19 of the Investment Company Act of 1940, as amended (the &ldquo;1940
Act&rdquo;) and related rules, the Funds may be required to indicate to shareholders the estimated source of certain distributions to
shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The following
tables set forth the estimated amounts of the sources of the distributions for purposes of Section&nbsp;19 of the 1940 Act and the rules&nbsp;adopted
thereunder. The tables have been computed based on generally accepted accounting principles. The tables include estimated amounts and
percentages for the current distributions paid this month as well as for the cumulative distributions paid relating to fiscal year to
date, from the following sources: net investment income; net realized short-term capital gains; net realized long-term capital gains;
and return of capital. The estimated compositions of the distributions may vary because the estimated composition may be impacted by
future income, expenses and realized gains and losses on securities and currencies.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The Funds&rsquo;
estimated sources of the current distribution paid this month and for its current fiscal year to date are as follows:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="36" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Estimated
    Amounts of Current Distribution per Share</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Fund</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Distribution<BR>
    Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Net
    Investment <BR>
    Income</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Net
    Realized Short- <BR>
    Term Gains**</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Net
    Realized Long-<BR>
    Term Gains</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Return
    of <BR>
    Capital</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>


<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.2100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.0042</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.1029</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">49</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.1029</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">49</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1800</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0306</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">17</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1494</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">83</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="36" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Estimated
    Amounts of Fiscal Year* to Date Cumulative Distributions per Share</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Fund</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Distribution<BR>
    Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Net
    Investment <BR>
    Income</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Net
    Realized Short- <BR>
    Term Gains**</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Net
    Realized Long-<BR>
    Term Gains</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Return
    of<BR>
    Capital</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>


<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.4200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.0084</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.2058</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">49</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.2058</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">49</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1800</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0612</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">17</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.2988</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">83</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">* ASGI and
THQ have a 9/30 fiscal year end</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">**includes
currency gains</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Where the
estimated amounts above show a portion of the distribution to be a &ldquo;Return of Capital,&rdquo; it means that Fund estimates that
it has distributed more than its income and capital gains; therefore, a portion of your distribution may be a return of capital. A return
of capital may occur for example, when some or all the money that you invested in a Fund is paid back to you. A return of capital distribution
does not necessarily reflect the Fund&rsquo;s investment performance and should not be confused with &ldquo;yield&rdquo; or &ldquo;income.&rdquo;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>The amounts
and sources of distributions reported in this notice are only estimates and are not being provided for tax reporting purposes. The final
determination of the source of all distributions for the current year will only be made after year-end. The actual amounts and sources
of the amounts for tax reporting purposes will depend upon the Fund&rsquo;s investment experience during the remainder of the fiscal
year and may be subject to change based on tax regulations. After the end of each calendar year, a Form&nbsp;1099-DIV will be sent to
shareholders for the prior calendar year that will tell you how to report these distributions for federal income tax purposes.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The following
tables provide the Funds&rsquo; total return performance based on net asset value (NAV) over various time periods compared to the Funds&rsquo;
annualized and cumulative distribution rates.&nbsp;&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<TR STYLE="vertical-align: bottom">
<TD COLSPAN="16" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Fund
Performance and Distribution Rate Information</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 36%">Fund</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 13%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average
<BR> Annual Total<BR> Return on NAV<BR> for the 5 Year<BR> Period Ending<BR> 10/31/2025<SUP>1</SUP></B></FONT></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 13%"><B>Current
Fiscal<BR> Period&rsquo;s<BR>
Annualized<BR> Distribution<BR> Rate on NAV</B></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 13%"><B>Cumulative<BR>
Total Return <BR> on NAV<SUP>1</SUP></B></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 13%"><B>Cumulative<BR>
Distribution<BR> Rate on NAV<SUP>2</SUP></B></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center; width: 1%">&nbsp;</TD></TR>


<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">11.58</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">12.09</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">-0.08</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">1.01</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7.26</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.32</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.98</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>1</SUP>
Return data is net of all Fund expenses and fees and assumes the reinvestment of all distributions reinvested at prices obtained under
the Fund&rsquo;s dividend reinvestment plan.&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><SUP>2</SUP> Based
on the Fund&rsquo;s NAV as of October&nbsp;31, 2025.</FONT></P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Shareholders
should not draw any conclusions about a Fund&rsquo;s investment performance from the amount of the Fund&rsquo;s current distributions
or from the terms of the distribution policy (the &ldquo;Distribution Policy&rdquo;).</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>The value
at which a closed-end fund stock may trade on a public exchange is a function of external market factors that are not at the control
of the Fund&rsquo;s Board or Investment Advisor. Closed-end Fund shares may therefore trade at a premium or a discount to net asset value
at any given time. Shareholders should be aware that a fund trading at a premium to net asset value may not be sustainable and a fund&rsquo;s
discount to net asset value, can widen as well as narrow. Shareholders of a fund trading at a premium who participate in that fund&rsquo;s
dividend reinvestment plan should note the reinvestment of distributions may occur at a premium to net asset value.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">While NAV performance may be indicative of the Fund&rsquo;s investment
performance, it does not measure the value of a shareholder&rsquo;s investment in the Fund. The value of a shareholder&rsquo;s investment
in the Fund is determined by the Fund&rsquo;s market price, which is based on the supply and demand for the Fund&rsquo;s shares in the
open market.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to an exemptive order granted by the Securities and Exchange
Commission, the Funds may distribute any long-term capital gains more frequently than the limits provided in Section&nbsp;19(b)&nbsp;under
the 1940 Act and Rule&nbsp;19b-1 thereunder. Therefore, distributions paid by the Funds during the year may include net income, short-term
capital gains, long-term capital gains and/or a return of capital. Net income dividends and short-term capital gain dividends, while
generally taxable at ordinary income rates, may be eligible, to the extent of qualified dividend income earned by the Funds, to be taxed
at a lower rate not to exceed the maximum rate applicable to your long-term capital gains. Distributions made in any calendar year in
excess of investment company taxable income and net capital gain are treated as taxable ordinary dividends to the extent of undistributed
earnings and profits, and then as a return of capital that reduces the adjusted basis in the shares held. To the extent return of capital
distributions exceed the adjusted basis in the shares held, capital gain is recognized with a holding period based on the period the
shares have been held at the date such amount is received.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The payment of distributions in accordance with the Distribution Policy
may result in a decrease in the Fund&rsquo;s net assets. A decrease in the Fund&rsquo;s net assets may cause an increase in the Fund&rsquo;s
annual operating expense ratio and a decrease in the Fund&rsquo;s market price per share to the extent the market price correlates closely
to the Fund&rsquo;s net asset value per share. The Distribution Policy may also negatively affect the Fund&rsquo;s investment activities
to the extent that the Fund is required to hold larger cash positions than it typically would hold or to the extent that the Fund must
liquidate securities that it would not have sold, for the purpose of paying the distribution. Each Fund&rsquo;s Board has the right to
amend, suspend or terminate the Distribution Policy at any time. The amendment, suspension or termination of the Distribution Policy
may affect the Fund&rsquo;s market price per share. Investors should consult their tax advisor regarding federal, state, and local tax
considerations that may be applicable in their particular circumstances.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Circular 230 disclosure</U>: To ensure compliance with requirements
imposed by the U.S. Treasury, we inform you that any U.S. tax advice contained in this communication (including any attachments) is not
intended or written to be used, and cannot be used, for the purpose of (i)&nbsp;avoiding penalties under the Internal Revenue Code or
(ii)&nbsp;promoting, marketing or recommending to another party any transaction or matter addressed herein.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aberdeen Investments Global is the trade name of Aberdeen's investments
business, herein referred to as &quot;Aberdeen Investments&quot; or &quot;Aberdeen&quot;. In the United States, Aberdeen Investments
refers to the following affiliated, registered investment advisers: abrdn Inc., abrdn Investments Limited, and abrdn Asia Limited.&quot;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Closed-end funds are traded on the secondary market through one of
the stock exchanges. A Fund&rsquo;s investment return and principal value will fluctuate so that an investor&rsquo;s shares may be worth
more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a discount) the net asset value
(NAV) of the fund&rsquo;s portfolio. There is no assurance that a Fund will achieve its investment objective. Past performance does not
guarantee future results.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><U>Closed end funds | Aberdeen</U></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 176pt; text-indent: 2in">###</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin: 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(D)
<SEQUENCE>11
<FILENAME>tm2527059d10_ex99-xd.htm
<DESCRIPTION>EXHIBIT 99.(D)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2527059d10_ex99-xd.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2527059-10/tm2527059-10_ncsrseq1/users" -->

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.(d)</B></P>


<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Appendix A - Proxy Voting Policies and Procedures</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Aberdeen Investments
U.S. Registered Advisers (the &ldquo;Advisers&rdquo;)</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Proxy Voting Guidelines<BR>
</B><I>Effective as of March&nbsp;2025</I></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Rule&nbsp;206(4)-6 under the Investment
Advisers Act of 1940, as amended (the &ldquo;Advisers Act&rdquo;) requires the Advisers to vote proxies in a manner consistent with clients&rsquo;
best interest and must not place its interests above those of its clients when doing so. It requires the Advisers to: (i)&nbsp;adopt and
implement written policies and procedures that are reasonably designed to ensure that the Advisers vote proxies in the best interest of
the clients, and (ii)&nbsp;to disclose to the clients how they may obtain information on how the Advisers voted proxies. In addition,
Rule&nbsp;204-2 requires the Advisers to keep records of proxy voting and client requests for information. As of August&nbsp;31, of each
year, investment managers that are required to file reports under Section&nbsp;13(f)&nbsp;are required to report their proxy voting records
on Form&nbsp;N-PX for the twelve-month period ended June&nbsp;30, with respect to certain shareholder advisory votes on executive compensation
(those required by Section&nbsp;14A of the Exchange Act). As registered investment advisers, the Advisers have an obligation to vote proxies
with respect to securities held in its client portfolios in the best interests of the clients for which it has proxy voting authority.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">The Advisers are committed to exercising
responsible ownership with a conviction that companies adopting best practices in corporate governance will be more successful in their
core activities and deliver enhanced returns to shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">The Advisers have adopted a proxy voting
policy. The proxy voting policy is designed and implemented in a way that is reasonably expected to ensure that proxies are voted in the
best interests of clients.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Resolutions are analysed by a member
of our regional investment teams or our Active Ownership Team and votes instructed following consideration of our policies, our views
of the company and our investment insights. To enhance our analysis, we will often engage with a company prior to voting to understand
additional context and explanations, particularly where there is a deviation from what we believe to be best practice.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Where contentious issues arise in relation
to motions put before a shareholders&rsquo; meeting, Advisers will usually contact the management of the company to exchange views and
give management the opportunity to articulate its position. The long-term nature of the relationships that we develop with investee company
boards should enable us to deal with any concerns that we may have over strategy, the management of risk or governance practices directly
with the chairman or senior independent director. In circumstances where this approach is unsuccessful, Advisers are prepared to escalate
their intervention by expressing their concerns through the company&rsquo;s advisers, through interaction with other shareholders or attending
and speaking at General Meetings.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">In managing third party money on behalf
of clients, there are a limited number of situations where potential conflicts of interest could arise in the context of proxy voting.
One case is where funds are invested in companies that are either clients or related parties of clients. Another case is where one fund
managed by Aberdeen Investments invests in other funds managed by Aberdeen Investments.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">For cases involving potential conflicts
of interest, Advisers have implemented procedures to ensure the appropriate handling of proxy voting decisions. The guiding principle
of the Advisers&rsquo; conflicts of interest policy is simple &ndash; to exercise our right to vote in the best interests of the clients
on whose behalf we are managing funds.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">We employ ISS as a service provider
to facilitate electronic voting. We require ISS to provide recommendations based on our own set of parameters to tailored Aberdeen&rsquo;s
assessment and approach but remain conscious that all voting decisions, where we have been given voting authority, are our own on behalf
of our clients. We consider ISS&rsquo;s recommendations and those based on our custom parameters as input to our voting decisions. We
make use of the ISS standard research and recommendations and those based on our own custom policy as input to our voting decisions. Where
our analysts make a voting decision that is different from the recommendations based on our custom policy they will provide a rationale
for such decisions which will be made available upon request.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">In order to make proxy voting decisions,
an Aberdeen Investments analyst will assess the resolutions at general meetings of companies held in our active investment portfolios.
This analysis will be based on our knowledge of the company, but will also make use of the custom and standard recommendations provided
by ISS as described above. The product of this analysis will be a final voting decision instructed through ISS and applied to all funds
for which Aberdeen have been appointed to vote. For funds managed by a sub-adviser, we may delegate to the sub-adviser the authority to
vote proxies; however, the sub-adviser will be required to either follow our policies and procedures or to demonstrate that their policies
and procedures are consistent with ours, or otherwise implemented in the best interest of clients.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">There may be certain circumstances where
Aberdeen may take a more limited role in voting proxies. We will not vote proxies for client accounts in which the client contract specifies
that Aberdeen will not vote. We may abstain from voting a client proxy if the voting is uneconomic or otherwise not in clients&rsquo;
best interests. For companies held only in passively managed portfolios the Aberdeen custom recommendations provided by ISS will be used
to automatically apply our voting approach; we have scope to intervene to test that this delivers appropriate results and will on occasions
opt to instruct a vote differently from custom recommendations if we consider this to be in clients&rsquo; best interests. If voting securities
are part of a securities lending program, we may be unable to vote while the securities are on loan. However, we have the ability to recall
shares on loan or to restrict lending when required, in order to ensure all shares have voted. In addition, certain jurisdictions may
impose share-blocking restrictions at various times which may prevent Aberdeen from exercising our voting authority.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">We recognize that there may be situations
in which we vote at a company meeting where we encounter a conflict of interest. Such situations include:</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.3in"></TD><TD STYLE="text-align: left; width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">where a portfolio manager owns the holding in a personal account</TD></TR></TABLE>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.3in"></TD><TD STYLE="text-align: left; width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">An investee company that is also a segregated client</TD></TR></TABLE>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.3in"></TD><TD STYLE="text-align: left; width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">An investee company where an executive director or officer of our company is also a director of that company</TD></TR></TABLE>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.3in"></TD><TD STYLE="text-align: left; width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">An investee company where an employee of Aberdeen is a director of that company</TD></TR></TABLE>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.3in"></TD><TD STYLE="text-align: left; width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">A significant distributor of our products</TD></TR></TABLE>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.3in"></TD><TD STYLE="text-align: left; width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Any other companies which may be relevant from time to time</TD></TR></TABLE>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">In order to manage such conflicts of
interests, we have established procedures to escalate decision-making so as to ensure that our voting decisions are based on our clients&rsquo;
best interests and are not impacted by any conflict.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">The implementation of this policy, along
with conflicts of interest, will be reviewed periodically by the Active Ownership team. Aberdeen Investments&rsquo; Listed Company Sustainable
Investment Principles and Voting Policies are published on our website.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">To the extent that an Adviser may rely
on sub-advisers, whether affiliated or unaffiliated, to manage any client portfolio on a discretionary basis, the Adviser may delegate
responsibility for voting proxies to the sub-adviser. However, such sub-advisers will be required either to follow these Policies and
Procedures or to demonstrate that their proxy voting policies and procedures are consistent with these Policies and Procedures or otherwise
implemented in the best interests of the Adviser&rsquo;s clients. Clients that have not granted Aberdeen voting authority over securities
held in their accounts will receive their proxies in accordance with the arrangements they have made with their service providers.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">As disclosed in Part&nbsp;2A of each
Adviser&rsquo;s Form&nbsp;ADV, a client may obtain information on how its proxies were voted by requesting such information from its Adviser.
Unless specifically requested by a client in writing, and other than as required for the Funds, the Advisers do not generally disclose
client-specific proxy votes to third parties.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Our proxy voting records are available
per request and on the SEC&rsquo;s website at SEC.gov.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">On occasions when it is deemed to be a fiduciary for an ERISA
client&rsquo;s assets, Aberdeen will vote the Plan assets in accordance with Aberdeen Investments&rsquo; Listed Company Sustainable Investment
Principles and Voting Policies and in line with DOL guidance.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B>Listed Company ESG Principles&nbsp;&amp; Voting Policies
March&nbsp;2024</B></P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Active Ownership and Environmental, Social&nbsp;&amp; Governance
(ESG) considerations are a driver of our investment process, our investment activity, our client journey and our corporate influence.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Through engagement with the companies in which we invest,
and by exercising votes on behalf of our clients, we seek to improve the financial resilience and performance of our clients&rsquo; investments.
Where we believe change is needed, we endeavour to catalyse this through our stewardship capabilities.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B>Our expectations</B></P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">As global investors, we are particularly aware that ESG structures
and frameworks vary across regions. Furthermore, what we expect of the companies in which we invest varies between different stages of
business development and the underlying history and nature of the company in question. We seek to understand each company&rsquo;s individual
circumstances and so evaluate how it can best be governed and overseen. As such, we strive to apply the principles and policies set out
on these pages&nbsp;in response to the needs of that individual company at that particular time. Our heritage as a predominantly active
fund manager helps drive this bespoke approach to understanding good governance and risk management.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">We have a clear perception of what we consider to be best
practice globally &ndash; as set out in this document. However we will reflect the nature of the business, our close understanding of
individual companies and regional considerations, where appropriate, in our approach to applying these policies, which are not exhaustive.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">The principles and voting policies noted
herein reflect our current position. We are monitoring and contributing to the many reform agendas and consultations underway in the governance
arena, particularly in the UK, on areas such as market competitiveness, listing rules, the approval of corporate transactions and greater
flexibility in remuneration practices, including wider use of restricted stock. We are actively involved in these discussions, both as
a corporate issuer and an investor, and our position will evolve as rules, guidance and practice develops.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">This document has received approval from the Head of Public
Markets and the Chief Sustainability Officer - Investments following consultation with various internal stakeholders.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B>Our approach to stewardship</B></P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">We seek to integrate and appraise environmental, social and
governance factors in our investment process. Our aim is to generate the best long-term outcomes for our clients, proportionate to the
risk preference they have accepted, and we will actively take steps as stewards and owners to protect and enhance the value of our clients&rsquo;
assets.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Stewardship is a reflection of this bespoke approach to good
governance and risk management. We seek to understand each company&rsquo;s specific approach to governance, how value is created through
business success and how investors&rsquo; interests are protected through the management of risks that materially impact business success.
This requires us to play our part in the governance process by being active stewards of companies, involved in dialogue with management
and non-executive directors where appropriate, understanding the material risks and opportunities &ndash; including those relating to
environmental and social factors and helping to shape the future success of the business.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">We will:</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.3in"></TD><TD STYLE="text-align: left; width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Take into consideration, in our investment process, the policies and practices on environmental, social and governance matters of
the companies in which we invest.</TD></TR></TABLE>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.3in"></TD><TD STYLE="text-align: left; width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Seek to enhance long-term shareholder value through constructive engagement with the companies in which we invest.</TD></TR></TABLE>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.3in"></TD><TD STYLE="text-align: left; width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Actively engage with companies and assets in which we invest where we believe we can influence or gain insight.</TD></TR></TABLE>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.3in"></TD><TD STYLE="text-align: left; width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Seek to exercise voting rights, where held, in a manner consistent with our clients&rsquo; long-term best interests.</TD></TR></TABLE>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.3in"></TD><TD STYLE="text-align: left; width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Seek to influence the development of appropriately high standards
of corporate governance and corporate responsibility in relation to environmental and social factors for the benefit of our clients.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Communicate our Listed Company ESG Principles and Voting Policies to clients, companies and other interested parties.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Be accountable to clients within the constraints of professional confidentiality and legislative and regulatory requirements.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Be transparent in reporting our engagement and voting activities.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">abrdn is committed to exercising responsible
ownership with a conviction that companies seeking to upgrade their practices in corporate governance and risk management will be more
successful in their core activities and deliver enhanced long-term returns to shareholders. As owners of companies, the process of stewardship
is a natural part of our investment approach as we seek to benefit from their long-term success on our clients&rsquo; behalf.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B>Engagement</B></P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">It is a central tenet of our active
investment approach that we strive to meet with the management and directors of our investee companies on a regular basis. We will concentrate
that engagement on investee companies undergoing transformation or facing exceptional challenges or opportunities. The discussions we
have cover a wide range of topics, including: strategic, operational, and ESG issues and consider the long-term drivers of value.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Engagement with<IMG SRC="image_001.gif" ALT="" STYLE="width: 5px; height: 1px">
companies on ESG risks an opportunities is a fundamental part of our investment process. It is a process through which we can discuss
how a company identifies, prioritises and mitigates its key risks and optimises outcomes from its most significant opportunities. As such,
we regard engagement as:</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.3in"></TD><TD STYLE="text-align: left; width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Important to understanding investee companies holistically.</TD></TR></TABLE>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.3in"></TD><TD STYLE="text-align: left; width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Helpful when conducting comprehensive ESG analysis.</TD></TR></TABLE>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.3in"></TD><TD STYLE="text-align: left; width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Useful to maintaining open dialogue and constructive relationships with companies.</TD></TR></TABLE>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.3in"></TD><TD STYLE="text-align: left; width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">An opportunity to generate positive change on a company&rsquo;s holistic risk management programme&ndash;be active with our holdings
rather than activist.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Proxy Voting</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Proxy voting is an integral part of our active stewardship
approach and we seek to exercise voting rights in a manner in line with our clients&rsquo; best interests. We seek to ensure that voting
reflects our understanding of the companies in which we invest on behalf of our clients. We believe that voting is a vital mechanism for
holding boards and management teams to account, and is an important tool for escalation and shareholder action.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">This document includes our process and overarching policy
guidelines which we apply when voting at general meetings. These policies are not exhaustive and we evaluate our voting on a case by case
basis. As a global investment firm we recognise the practical necessity of adopting a regional approach, taking into account differing
and developing market practices. Where a policy is specific to one region this is denoted.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We endeavour to engage with companies regarding our voting
decisions to maintain a dialogue on matters of concern.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Voting Process</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In line with our active ownership approach, we review the
majority of general meeting agendas convened by companies which are held in our active equity portfolios. Analysis is undertaken by a
member of our regional investment teams or our Active Ownership team and votes instructed following consideration of our policies, our
views of the company and our investment insights. To enhance our analysis we may engage with a company prior to voting to understand additional
context and explanations, particularly where there is deviation from what we believe to be best practice.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">To supplement our own analysis we make use of the benchmark
research and recommendations provided by ISS, a provider of proxy voting services. In the UK we also make use of the Investment Association&rsquo;s
(IA) Institutional Voting Information Service. We have implemented regional voting policy guidelines with ISS which ISS applies to all
meetings in order to produce customised vote recommendations. These custom recommendations help identify resolutions which deviate from
our expectations. They are also used to determine votes where a company is held only in passive funds. Within our custom policies, however,
we do specify numerous resolutions which should be referred to us for active review. For example we will analyse all proposals marked
by ISS as environmental or social proposals.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">While it is most common for us to vote in line with a board&rsquo;s
voting recommendation we will vote our clients&rsquo; shares against resolutions which we believe are not consistent with their best interests.
We may also vote against resolutions which conflict with local governance guidelines, such as the IA in the UK. Although we seek to vote
either in favour or against a resolution we do make use of an abstain vote where this is considered appropriate. For example we may use
an abstention to acknowledge some improvement, but as a means to reserve our position in expectation that further improvement is needed
before we can vote in favour. Where we vote against a resolution we endeavour to inform companies of our rationale.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In exceptional circumstances we may attend and speak at a
shareholder meeting to reinforce our views to the company&rsquo;s board.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We endeavour to vote all shares for which we have voting
authority. We may not vote when there are obstacles to do so, for example those impacting liquidity, such as shareblocking, or where there
is a significant conflict of interest. We use the voting platform of ISS to instruct our votes. Where we lend stock on behalf of clients,
and subject to the terms of client agreements, we hold the right to recall shares where it is in clients&rsquo; interests to do so and
where we take the view that to maintain full voting weight on a particular meeting or resolution may impact the final vote.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Our votes are disclosed publicly on our website one day after
a general meeting has taken place.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Strategy</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We invest in companies that will create the best outcome
for our clients in line with their investment mandates. Companies must be clear about the drivers of their business success and their
strategy for maintaining and enhancing it. Investment is a forward-looking process; we seek to understand the opportunity for a business
and its scope for future value-creation over the long term. In order to do this, we need clarity on past business delivery and its drivers,
and on the effective track record of management; we require honest and open reporting to build confidence in that track record. We seek
confidence that companies and their management can maintain their competitive positioning and operational performance and subsequently
enhance returns for investors. A clear strategy and clarity about the drivers of operational success provides the lens through which we
will consider most corporate issues, not least assessing performance and risk management.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will consider voting against executive or non-executive directors if we have serious concerns regarding the oversight or implementation
of strategy.</TD></TR></TABLE>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Board of Directors</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We believe effective board governance promotes the long-term
success and value creation of the company. The board should be responsible for establishing the company&rsquo;s purpose and strategy,
overseeing management in their implementation of strategy and performance against objectives. The board should ensure a strong framework
of control and risk oversight, including material ESG risks. The board should assess and monitor culture and be engaged with the workforce,
shareholders and wider society.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Board Composition</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Effective decision making requires a mix of skills around
the table and constructive debate between diverse and different-minded individuals. A range of skills, experience and perspectives should
be drawn together on the board. These include industry knowledge, experience from other sectors and relevant geographical knowledge. Independence
of thought plays a crucial role in the ability of a board to generate the debate and discussion that will challenge management, help enhance
business performance and improve decision-making. Board assessments will help the board ensure it has the necessary mix of skills, diversity
and quality of individuals to address the risks and opportunities the company faces. Unitary boards should comprise an appropriate combination
of executive and non-executive directors such that no group of individuals dominates decision-making. We expect the size of the board
to reflect the size, nature and complexity of the business. We also expect regular internal and external board evaluations which include
an assessment of board composition and effectiveness.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Leadership</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Running businesses effectively for the long term requires
effective collaboration and cooperation, with no individual or small group having unfettered powers. Nor should any individual or small
group have dominant influence over the way a business is run or over major decisions about its operations or future. There should be a
division of responsibility between board leadership and executive leadership of the business. We believe that there should be a division
of roles at the top of the organisation, typically between a Chief Executive Officer (CEO) and an independent Chair.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will consider supporting the re-election of an existing Chair&nbsp;&amp; CEO role combination, recognising that this remains common
in certain geographies. In reviewing this on a case by case basis we will take account of the particular circumstances of the company
and consider what checks and balances are in place, such as the presence of a strong Senior Independent Director with a clear scope of
responsibility.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will generally oppose any re-combination of the roles of CEO and Chair, unless the move is on a temporary basis due to exceptional
circumstances or other mitigating factors.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will generally oppose any move of a retiring CEO to the role of Chair.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Independence</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Companies should be led and overseen by genuinely independent
boards. When looking at board composition we generally expect to see a majority of independent directors, with boards identifying their
independence classifications in the Annual Report. It is preferable to see an identified Senior Independent Director (SID) on the board,
who will lead the appraisal of and succession planning for the Chair. We expect SIDs to meet with investors and be a point of contact
for escalating concerns if required.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In assessing a director&rsquo;s independence we will have
due regard for whether a director:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in">i.</TD><TD>Has been an employee of the company within the last five years.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in">ii.</TD><TD>Has had within the last three years a material business relationship with the company.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in">iii.</TD><TD>Has received remuneration in addition to director fees or participates in the company&rsquo;s option or variable incentive schemes,
or is a member of the company&rsquo;s pension scheme.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in">iv.</TD><TD>Has close family ties with any of the company&rsquo;s advisers, directors or senior employees.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in">v.</TD><TD>Holds cross-directorships or has significant links with other directors through involvement in other companies or bodies.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in">vi.</TD><TD>Represents a significant shareholder.</TD></TR></TABLE>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in">vii.</TD><TD>Has served on the board for more than 12 years (or 9 for UK companies).</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will consider voting against the re-election of non-independent directors if the board is not majority independent (excluding employee
representatives). In doing so we will have regard for whether a company is controlled and the nature of the non-independence &ndash; for
example, we are unlikely to vote against shareholder representatives unless their representation is disproportionate to their shareholding</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Succession Planning&nbsp;&amp; Refreshment</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Regular refreshment of the non-executive portion of a board
helps draw in fresh perspectives, not least in the context of changes to business and emerging opportunities and risks. It also helps
limit the danger of group-think. Thoughtful and proactive succession planning is therefore needed for board continuity, to ensure that
a board is populated by individuals with an appropriate mix of skills, experience and perspective. We expect the board to implement a
formal process for the recruitment and appointment of new directors, and to provide transparency of this in the Annual Report.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will vote against non-executive directors where there are concerns regarding board refreshment or excessive tenure. Where there
are directors who have served for over 12 years on a board which has seen no refreshment in 3 years (2 in UK), we will generally vote
against their re-election. If a director has served for over 15 years we will generally vote against their re-election. We will, however,
consider the impact on board continuity and the company&rsquo;s succession planning efforts prior to doing so. We may also not apply the
tenure limit to directors who are founders or shareholder representatives where we believe this is appropriate.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Diversity</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We
believe that companies that make progress in diversity, equity and inclusion (DEI) are better positioned for long-term sustainability
and outperformance. Diversity of thought, paired with a culture of inclusion, can help companies to tackle increasingly complex challenges
and markets. We expect boards to report on how they promote DEI throughout the business and believe that setting targets is important
to addressing imbalances. We recognise the necessity of adopting a regional approach to diversity, equity and inclusion, allowing us to
press for progress with appropriate consideration for the starting point. We have for several years, actively encouraged progress in gender
diversity at all levels, and have expanded our scope in relation to diversity, equity and inclusion across geographies. In respect of
ethnic diversity, this is coming increasingly into focus as we encourage boards to progress in ensuring that their composition reflects
their employee and customer bases. Our regional specific policies are below. In determining our votes we will take account of mitigating
factors, such as the sudden departure of a female board member. We will also consider any clear progress being made by the company on
diversity and any assurance that diversity shortfalls will soon be addressed.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Gender Diversity.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>UK: We will generally vote against the Nomination Committee Chair of FTSE 350 companies if the board is not comprised of at least
one third female directors. We expect companies to seek to comply with the FCA&rsquo;s diversity targets and may vote against the Chair
of the Nomination Committee if we have concerns regarding the Committee&rsquo;s efforts in succession planning to achieve the gender diversity
target of 40% female members. For smaller companies, we will take action if the board does not include at least one female director.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Europe: We will generally vote against the Nomination Committee Chair of LargeCap companies if the supervisory board is not comprised
of at least 30% female directors, or is not in line with the local standard if higher. For smaller companies, we will take this action
if the supervisory board does not include at least one female director.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Australia: We will generally vote against the Nomination Committee Chair of ASX300 companies if the board is not comprised of at least
30% female directors.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>North America: We will generally vote against the Nomination Committee Chair of LargeCap companies if the board is not comprised of
at least 30% female directors. For smaller companies, we will take this action if the board does not include at least one female director</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Ethnic Diversity</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>UK: We will generally vote against the Nomination Committee Chair at the boards of FTSE 100 companies, if the board does not include
at least one member from an ethnic minority background. This is in line with targets set up by the Parker Review.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>US: We will generally vote against the Nomination Committee Chair at the boards of S&amp;P 1500&nbsp;&amp; Russell 3000 companies
if the board does not include at least one member from a racial or ethnic minority background.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Directors&rsquo; Time Commitment</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Individual directors need sufficient time to carry out their
role effectively and therefore we seek to ensure that all directors maintain an appropriate level of overall commitments such that allows
them to be properly diligent.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will consider opposing the election or re-election of any director where there is a concern regarding their ability to dedicate
sufficient time to the role. In making this assessment we will have regard to the ISS classification of &lsquo;overboarding&rsquo;.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will generally oppose the re-election of any director who has attended fewer than 75% of board meetings in two consecutive years.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Board Committees</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Boards should establish committees, populated by independent
and appropriately skilled non-executive directors, to oversee (as a minimum) the nomination, audit and remuneration processes. It may
also be appropriate for additional committees to be established, such as a risk or sustainability committee. These committees should report
openly on an annual basis about their activities and key decisions taken.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We will consider voting against committee members if we have
concerns regarding the composition of a committee in relation to independence or skills.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Nomination Committee</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">This committee has responsibility for leading the process
for orderly non-executive and senior management succession planning and recruitment, and for overseeing the composition of the board including
skillset, experience and diversity. We expect the committee to be comprised of a majority of independent directors with an independent
Chair.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We will consider voting against the re-election of the Nomination Committee Chair if we have concerns regarding the composition of
the board or concerns regarding poor succession planning.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Audit Committee</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">This committee has responsibility for monitoring the integrity
of the financial statements, reviewing the company&rsquo;s internal financial controls and risk management systems, reviewing the effectiveness
of the company&rsquo;s internal audit function and appointing and overseeing the quality of the work done by external auditors. We prefer
the committee to be wholly independent, and expect this at UK and US companies in view of general market practice and board composition.
In other regions, as a minimum, we expect the committee to be comprised of a majority of independent directors with an independent Chair.
Furthermore we expect at least one member of the committee to have recent and relevant financial experience.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>UK&nbsp;&amp; US: We will generally vote against the re-election of non-independent members of the Audit Committee..</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Europe: We will generally vote against the re-election of non-independent members of the Audit Committee if the Committee is not majority
independent. We will also generally vote against a non-independent Chair of the Audit Committee.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will generally vote against the re-election of the Audit Committee Chair if at least one member of the Committee does not have
recent and relevant financial experience.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Remuneration Committee</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The
committee is responsible for determining the policy and setting remuneration levels for executive and nonexecutive directors. The committee
should ensure that directors&rsquo; remuneration is aligned with strategy and company performance and should clearly demonstrate that
outcomes have had regard to the experience of the company&rsquo;s employees and wider society. Remuneration policy should be cognisant
of the company&rsquo;s licence to operate and the potential overall level of remuneration. We expect remuneration committees to be robust
in their approach to developing and implementing remuneration policies, with formal and transparent procedures for developing policies
and for determining remuneration packages. Remuneration committees should be comprised of a majority of independent directors with an
independent Chair and we expect members to have appropriate experience and knowledge of the business and remuneration practices in the
jurisdiction in which they operate. No executive should be involved in setting their own remuneration..</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Where we have significant concerns regarding the company&rsquo;s remuneration policy or reward outcomes we may escalate these concerns
through a vote against the Chair or members of the Remuneration Committee.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Director Accountability</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We expect to be able to hold boards to account through engagement
and regular director re-elections and directors should feel that they are accountable to investors. We encourage individual, rather than
bundled, director elections. While our preference is for directors to be subject to re- election annually, we expect re-elections to take
place at least every three years. Lengthier board mandates, while not uncommon in some markets, risk divorcing directors from an appropriate
sense of accountability. Directors and management should make themselves available for discussions with major shareholders as we expect
to have open dialogue to share our perspectives and gain confidence that the individuals are carrying out their roles with appropriate
vigour and diligence. A further important element of director accountability to shareholders is that investors should have the right,
both formal and informal, to propose and promote individual directors to be considered for election to the board by all shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will generally oppose the re-election of nonindependent NEDs who are proposed for a term exceeding three years. We may not apply
this to directors who are shareholder representatives.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Where we have significant concerns regarding a board member&rsquo;s performance, actions or inaction to address issues raised we may
vote against their re-election.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><IMG SRC="image_001.gif" ALT="" STYLE="width: 5px; height: 1px">We may vote against directors who decline appropriate requests for
meetings without a clear justification.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Where a director has held a position of responsibility at a company which has suffered a material governance failure, we will consider
whether we are comfortable to support their re-election at other listed companies.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will generally support resolutions to discharge the supervisory board or management board members from legal liability unless we
have serious concerns regarding actions taken during the year under review. Where there is insufficient information regarding allegations
of misconduct, we may prefer to abstain. In exceptional circumstances we may vote against the discharge resolution to reflect serious
ESG concerns if there is not another appropriate resolution.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will not support the election of directors who are not personally identified but are proposed as corporations.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Reporting</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">A company&rsquo;s board should present a fair, balanced and
understandable assessment of the company&rsquo;s position and prospects &ndash; financial and non- financial &ndash; and of how it has
fulfilled its responsibilities. We support the principle of full disclosure of relevant and useful information, subject to issues of commercial
confidentiality and prejudice. Boilerplate disclosure should be avoided. We encourage companies to consider using the appropriate globally
developed standards and would particularly encourage the use of those created by the Taskforce for Climate related Financial Disclosures
(TCFD), the International Integrated Reporting Council (IIRC), the Sustainability Accounting Standards Board (SASB) and the Global Reporting
Initiative (GRI).</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Audited reporting and financial numbers should be published
ahead of any relevant shareholder meetings. We continue to monitor the evolving reporting landscape and consider new reporting developments
as they emerge, either voluntary or regulatory.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We may consider voting against a company&rsquo;s Annual Report&nbsp;&amp; Accounts if we have concerns regarding timely provision
or adequacy of disclosure.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Political Donations&nbsp;&amp; Lobbying</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Companies should be consistent in their public statements
and not undermine these in private commentary to market participants or to politicians and regulators. We welcome transparency from companies
about their lobbying activities and believe that good companies have nothing to hide in this respect. Similarly we encourage transparency
of any political donations that companies deem appropriate &ndash; and we expect a clear explanation of why such donations are an appropriate
use of corporate funds.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Risk&nbsp;&amp; Audit</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The board is responsible for determining the company&rsquo;s
risk appetite, establishing procedures to manage risk and for monitoring the company&rsquo;s internal controls. We expect boards to conduct
robust assessments of the company&rsquo;s material risks and report to shareholders on risks, controls and effectiveness. The introduction
of global accounting standards has led to much greater investor confidence in the accounts produced by companies around the world. It
has also assisted in creating consistency of reporting across companies, enabling fairer comparisons between different operating businesses.
We therefore encourage companies seeking international investment to report under International Financial Reporting Standards (IFRS) or
US GAAP. As a firm abrdn supports the continued development of high quality global accounting standards.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">An independent audit, delivered by a respected audit firm,
is a required element for investor confidence in reporting by companies. We strongly favour meaningful, transparent and informative auditor
reports, giving us additional insights into the audit process and accounting outcomes. Audit fees must be sufficient to pay for an appropriately
in-depth assurance process. We would be concerned if a company sought to make unjustified savings in this respect as the cost in terms
of damage to audit effectiveness and confidence in the company&rsquo;s accounts would be much more substantial.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The independence of the auditor and the standard of their
work, particularly in challenging management, should be subject to regular assessment that is appropriately disclosed. Even when individuals
carrying out the audit are refreshed, we believe that the independence of the audit firm erodes over time and we will encourage a tender
process and change of audit firm where an engagement has lasted for an extended period. In order to demonstrate the level of independence,
companies should not have the same audit firm in place for more than 20 years.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The relationship with the auditor should be mediated through
the audit committee. Where we are significant shareholders, we expect to be consulted on plans to tender and replace auditors.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will generally vote against the re-election of an auditor which has a tenure of 20 years or over, if there are no plans for rotation
in the near term.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will consider voting against the auditors if we have concerns regarding the accounts presented or the audit procedures used.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will vote against the approval of auditor fees if we have concerns regarding the level of fees or the balance of non-audit and
audit fees.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Remuneration</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Remuneration policies and the overall levels of pay should
be aligned with strategy, attracting and retaining talent and incentivising the decisions and behaviours needed to create long-term value.
The component parts of remuneration should be structured so as to link rewards to corporate and individual performance and they should
be considered in the context of the remuneration policies when taken as a whole. We recognise the benefits of simplicity in forming the
policy, which should clearly link outcomes and expectations for those receiving the remuneration, as well as external stakeholders. The
structure should be transparent and understandable.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">A company&rsquo;s annual report should contain an informative
statement of remuneration policy which communicates clearly to stakeholders how it has developed and evolved. This should include details
of any stress testing that may have been undertaken to understand the policy outcomes for different business scenarios. The remuneration
committee should provide a clear description of the application of policy and the outcomes achieved.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Base
salary should be set at a level appropriate for the role and responsibility of the executive. We discourage increases which are driven
solely by peer benchmarking, and expect increases to be aligned with the wider workforce. Consideration should also be given to the knock-on
impact to variable remuneration potential. Pension arrangements and benefits should be clearly disclosed. We generally expect pension
structures to be aligned with the wider workforce.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">A company should structure variable, performancerelated pay
to incentivise and reward management in a manner that is aligned with the company&rsquo;s sustainable performance and risk appetite over
the long term. We expect all variable pay to be capped, preferably with reference to base salary. In the UK we expect variable pay to
be capped with reference to base salary. In other markets, if variable pay is capped at a number of shares, we expect the value of grants
to be kept under review annually to ensure the value remains appropriate and is not excessive.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Performance metrics used to determine variable pay should
be clearly disclosed and aligned with the company&rsquo;s strategy. A significant portion of performance metrics should seek to measure
significant improvements in the underlying financial performance of the company. We also encourage the inclusion of non-financial metrics
linked to targets which are aligned with the company&rsquo;s progress on its ESG strategy. Where possible we expect these targets to be
quantifiable and disclosed.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Variable
pay arrangements should incentivise participants to achieve above-average performance through the use of challenging targets. We encourage
sliding-scale performance measures and expect performance target ranges to be disclosed to enable shareholders to assess the level of
challenge and pay for performance alignment. We expect annual bonus targets to be disclosed retrospectively and encourage the disclosure
of long term incentive (LTI) targets at the beginning of the performance period, but at minimum we expect retrospective disclosure. Where
bonus or LTI targets are not disclosed due to commercial sensitivity we expect an explanation of why the targets continue to be considered
sensitive retrospectively and expect some detail regarding the level of achievement vs target. Where a share price metric is being used,
we expect this to be underpinned by a challenging measure of underlying performance. We encourage settlement of a portion of the annual
bonus in shares which are deferred for at least one year. We expect settlement of long term incentives to be in shares, with rationale
provided for any awards settled in cash. Long term incentives should have a performance period of no less than three years. In the UK
we expect a further holding period of two years to be applied, and we encourage this in other markets. We do not generally support value
creation plans. We will consider supporting the use of restricted share plans in the UK which have been structured consistent with the
guidelines of the Investment Association. We expect appropriate malus and clawback provisions to be applied to variable remuneration plans.
We expect shareholding guidelines to be adopted for executive directors and encourage the adoption of postdeparture shareholding guidelines.
We expect details of any use of discretion to be disclosed and its use should be justifiable, appropriate and clearly explained. We would
expect policies to be sufficiently robust so that discretion is only necessary in exceptional circumstances. We do not generally support
exceptional awards, and are particularly sensitive to such awards being granted to reward a corporate transaction. We expect executive
service contracts to provide for a maximum notice period of 12 months. We will consider local best practice provisions related to severance
arrangements when voting. Non-executive fees should reflect the role&rsquo;s level of responsibility and time commitment. We do not support
NED&rsquo;s participation in option or performance-related arrangements. However we do support the payment of fees in shares, particularly
where conservation of cash is an issue. In the UK our expectations of companies are aligned with the Investment Association&rsquo;s Principles
of Remuneration. Where significant changes to remuneration arrangements are being considered, we would expect remuneration committees
to consult with their largest shareholders prior to finalising any changes. Where any increase to variable remuneration is proposed, we
would expect this to be accompanied by a demonstrable increase in the stretch of the targets. Furthermore we expect any increases to remuneration
to be subject to shareholder approval.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In response to the issues arising from the cost of living
crisis being experienced by many people in the UK, we expect companies to focus additional capacity towards those members of the workforce
who need it most. We expect Remuneration Committees to take into account factors arising from the cost of living crisis when deliberating
over executive pay outcomes. We would be concerned by reputational issues arising from decisions made in these unusual circumstances and
may make this a factor in our voting decisions at relevant AGMs.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In line with the expectations set out above we will generally
vote against the appropriate resolution(s)&nbsp;where:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We consider the overall reward potential or outcome to be excessive.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A significant increase to salary has been granted which is not aligned with the workforce or is not sufficiently justified.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A significant increase to performance-related pay has been granted which is not sufficiently justified, is not accompanied by an increase
in the level of stretch required for achievement or results in the potential for excessive reward.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>There is no appropriate cap on variable incentive schemes.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Performance targets for annual bonus awards are not disclosed retrospectively and the absence of disclosure is not explained.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Performance targets for long term incentive awards are not disclosed up front and there is no compelling explanation regarding the
absence of disclosure or a commitment to disclose retrospectively.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Performance targets are not considered sufficiently challenging, either at threshold, target or maximum.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Relative performance targets allow vesting of awards for below median performance.. Retesting provisions apply.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Incentives that have been conditionally awarded have been repriced or performance conditions changed part way through a performance
period.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We have concerns regarding the use of discretion or the grant of exceptional awards.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Pension arrangements are excessive.. Pension arrangements are not aligned with the wider workforce (UK).</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Investor Rights</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The interests of minority shareholders must be protected
and any major, or majority, investor should not enjoy preferential treatment. The structure of ownership or control should minimise the
potential for abuse of public shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Corporate Transactions</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Companies should not make significant changes to their structure
or nature without being fully transparent to their investors. Shareholders should have the opportunity to vote on significant corporate
activity, such as mergers and acquisitions. Where a transaction is with a related party, only independent shareholders should have a vote.
Even in markets where no vote is given to shareholders in these circumstances, investors need transparent disclosure of the reasons for
any such major change. Companies should expect that shareholders may want to discuss and debate proposed developments</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Diversification beyond the core skills of the business needs
to be justified as it is more often than not a distraction from operational performance. All major deals need to be clearly explained
and justified in the context of the preexisting strategy and be subject to shareholder approval.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will vote on corporate transactions on a case by case basis.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="text-indent: 0.6in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Dividends</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: left; text-indent: 0">We will generally support the payment of dividends but will
scrutinise the proposed level where it appears excessive given the company&rsquo;s financial position.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0.6in"><B>Share Capital</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: left; text-indent: 0">The board carries responsibility for prudent capital management
and allocation.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0.6in"><B>Share Issuance</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: left; text-indent: 0">We will consider capital raises which are proposed for a specific
purpose on a case by case basis but recognise that it can be beneficial for companies to have some general flexibility to issue shares
to raise capital. However we expect issuances to be limited to the needs of the business and companies should not issue significant portions
of shares unless offering these on a pro-rata basis to existing shareholders to protect against inappropriate dilution of investments.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Where a company seeks a general authority to issue shares we generally expect this to be limited to 25% of the company&rsquo;s share
capital for pre- emptive issuances. In the UK we are aligned with the guidance of the Investment Association Share Capital Management
Guidelines.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Where a company seeks a general authority to issue shares we generally expect this to be limited to 10% of the company&rsquo;s share
capital for non- pre-emptive issuances. In the UK we are aligned with the guidance of the Investment Association Share Capital Management
Guidelines and those of the Pre-Emption Group.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will not generally support share issuances at investment trusts unless there is a commitment that shares would only be issued at
a price at or above net asset value.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">When considering our votes we will, however, take account
of the company&rsquo;s circumstances and any further detail regarding proposed capital issuance authorities prior to voting.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Following changes to the UK&rsquo;s Pre-Emption Group Guidelines
in November&nbsp;2022, which reflect an increase on previous limits, we will hold the Chair of the company accountable for any perceived
misuse of the increased flexibility through a vote against their re-election.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Buyback</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We recognise that share buybacks can be a flexible means
of returning cash to shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will generally support buyback authorities of up to 10% of the issued share capital. In the UK we will generally support authorities
which are in line with the levels permitted under the Listing Rules.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Related Party Transactions</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The nature of relations &ndash; particularly any related
party transactions (RPTs) &ndash; with parent or related companies, or other major investors, must be disclosed fully. Related party transactions
must be agreed on arm&rsquo;s length terms and be made fully transparent. Where they are material, they should be subject to the approval
of independent shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will vote against RPTs where there is insufficient transparency of the nature of the transaction, the rationale, the terms or the
views and assessment of directors and advisors.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Article/Bylaw amendments</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">While it is standard to see proposals from companies to amend
their articles of association or bylaws, we will review these on a case by case basis. When doing so we expect full transparency of the
proposed changes to be disclosed.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will vote against amendments which will reduce shareholder rights.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Anti-Takeover Defences</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">There should be no artificial structures put in place to
entrench management and protect companies from takeover. The best defence from hostile takeover is strong operational delivery.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will generally vote against anti-takeover/&lsquo;poison pill&rsquo; proposals.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Voting Rights</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We are strong supporters of the principle of &lsquo;one share,
one vote&rsquo; and therefore favour equal voting rights for all shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will generally vote against proposals which seek to introduce or continue capital structures with multiple voting rights.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will consider voting against proposals to raise new capital at companies with multiple share classes and voting rights.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>General Meetings</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Shareholder meetings provide an important
opportunity to hold boards to account not only through voting on the proposed resolutions but also by enabling investors the opportunity
to raise questions, express views and emphasise concerns to the entire board. We may make a statement at a company&rsquo;s AGM as a means
of escalation to reinforce our views to a company&rsquo;s board.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We welcome the opportunity to attend meetings virtually,
being of the view that this can increase participation given obstacles such as location or meeting concentration. However we are not supportive
of companies adopting virtual-only meetings as we believe this format reduces accountability. Our preference is for a hybrid meeting format
to balance the flexibility of remote attendance with the accountability of an in-person meeting.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We will generally support resolutions seeking approval to shorten the EGM notice period to minimum 14 days, unless we have concerns
regarding previous inappropriate use of this flexibility.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will generally support proposals to enable virtual meetings to take place as long as there is confirmation that the format will
be hybrid, with physical meetings continuing to take place (unless prohibited by law). We expect virtual attendees to have the same rights
to speak and raise questions as those attending in-person. We will generally vote against proposals which permit wholly virtual general
meetings.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>As part of strategic planning, boards need to have oversight
of, and clearly articulate, the key opportunities and risks affecting the sustainability of the business model. This includes having a
process for, and transparent disclosure of, potential and emerging opportunities and risks and the actions being taken to address them.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The effective management of risks extends to long-term issues
that are hard to measure and whose timeframe is uncertain and will include the management of environmental and social issues. We use the
UN Global Compact&rsquo;s four areas of focus in assessing how companies are performing in this area.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Specifically we expect companies to be able to demonstrate
how they manage their exposures under the following headings.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>The Environment</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">It is generally accepted that companies are responsible for
the effects of their operations and products on the environment. The steps they take to assess and reduce those impacts can lead to cost
savings and reduce potential reputational damage. Companies are held responsible for their impact on the climate and they face increased
regulation from world governments on activities that contribute to climate change.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We expect that companies will</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Identify, manage and reduce their environmental impacts.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Understand the impact of climate change along the company value chain.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Develop group-level climate policies and, where relevant, set targets to manage the impact, report on policies, practices and actions
taken to reduce carbon and other environmental risks within their operations.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Comply with all environmental laws and regulations, or recognised international best practice as a minimum.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Where we have serious concerns regarding a board&rsquo;s
actions, or inaction, in relation to the environment we will consider taking voting action on an appropriate resolution.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We will use the indicators within the Carbon Disclosure Project
to identify companies which are not fulfilling their climate commitments. Where appropriate we will take voting action to encourage better
practice among companies which we deem to be laggards.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Labour and employment</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Companies that respect internationally recognised labour
rights and provide safe and healthy working environments for employees are likely to reap the benefits. This approach is likely to foster
a more committed and productive workforce, and help reduce damage to reputation and a company&rsquo;s license to operate. We expect companies
to comply with all employment laws and regulations and adopt practices in line with the International Labour Organization&rsquo;s core
labour standards. a minimum.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In particular, companies will:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Take affirmative steps to ensure that they uphold decent labour standards.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Adopt strong health and safety policies and programmes to implement such policies.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Adopt equal employment opportunity and diversity policies and a programme for ensuring compliance with such policies.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Adopt policies and programmes for investing in employee training and development.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Adopt initiatives to attract and retain talented employees, foster higher productivity and quality, and encourage in their workforce
a commitment to achieving the company&rsquo;s purpose.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Ensure policies are in place for a company&rsquo;s suppliers that promote decent labour standards, and programmes are in place to
ensure high standards of labour along supply chains.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Report regularly on its policy and implementation of managing human capital.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Where we have serious concerns regarding a board&rsquo;s
actions, or inaction, in relation to labour and employment we will consider taking voting action on an appropriate resolution.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Human rights</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We recognise the impact that human-rights issues can have
on our investments and the role we can play in stimulating progress. We draw upon a number of international, legal and voluntary agreements
for guidance on human-rights responsibilities and compliance. Our primary sources are the International Bill of Rights and the core conventions
of the International Labour Organisation (ILO), which form the list of internationally agreed human rights, and the UN Guiding Principles
on Business and Human Rights (UNGPs), which clarifies the roles of states and businesses. We encourage companies to use the UNGPs Reporting
Framework and encourage disclosure in line with this guidance.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We expect companies to:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Continually work to understand their actual and potential impacts on human rights.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Establish systems that actively ensure respect for human rights.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Take appropriate action to remedy any infringements on human rights.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Where we have serious concerns regarding a board&rsquo;s
actions, or inaction, in relation to human rights we will consider taking voting action on an appropriate resolution.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Business ethics</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">As institutions of wealth and influence, companies have a
significant impact on the prosperity of their local communities and the wider world. Having a robust code of ethics and ensuring professional
conduct mean companies operate more effectively, particularly when it comes to ethical principles governing decision- making. A company&rsquo;s
failure to conform to internationally recognised standards of business ethics on matters such as bribery and corruption, can increase
its risk of facing investigation, litigation and fines. This could undermine its license to operate, and affect its reputation and image.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We expect companies to have policies in place to support
the following:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Ethics at the heart of the organisation&rsquo;s governance.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A zero-tolerance policy on bribery and corruption.. How people are rewarded, as pay can influence behaviour.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Respect for human rights.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Tax transparency.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Ethical training for employees.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Where we have serious concerns regarding a board&rsquo;s
actions, or inaction, related to business ethics we will consider taking voting action on an appropriate resolution.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>We will review any resolution at company meetings we have
identified as covering environmental and social factors. The following will detail our overarching approach and expectations.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Our approach to vote analysis is consistent across active
and quantitative investment strategies <B>Review </B>the resolution, proponent and board statements, existing disclosures, and external
research. <B>Engage </B>with the company, proponents, and other stakeholders as required.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Involve </B>thematic experts, regional specialists, and
investment analysts in decision-making to harness a wide range of expertise and include all material factors in our analysis.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Ensure </B>consistency by using our own in-house guidance
to frame case-by-case analysis.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Monitor </B>the outcomes of votes.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Follow-up </B>with on-going engagement as required.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Given the nature of the topics covered by these resolutions
we do not apply binary voting policies. We adopt a nuanced approach to our voting research and outcomes and will consider the specific
circumstances of the company concerned. Our objective is not to vote in favour of all shareholder resolutions but to determine the best
outcome for the company in the context of the best outcome for our clients. There are instances where we are supportive of the spirit
of a resolution however there may be a reason which prevents our support for the proposal. For example, where the purpose of the resolution
is unclear, where the wording is overly prescriptive, when suggested implementation is overly burdensome or where the proposal strays
too closely to the board&rsquo;s responsibility for setting the company&rsquo;s strategy.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Management Proposals</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We
are supportive of the steps being taken by companies to provide transparent, detailed reporting of their ESG strategies and targets. While
shareholder proposals on environmental and social topics have been common on AGM agendas for several years, an increasing number of companies
are presenting management proposals, such as so called &lsquo;say on climate&rsquo; votes, for shareholder approval. While we welcome
the intention of accountability behind these votes, we have reservations about the potential for them to limit the scope for subsequent
investor challenge and diminish the direct responsibility and accountability of the board and individual directors. We believe it is the
role of the board and the executive to develop and apply strategy, including ESG strategies, and we will continue to use existing voting
items to hold boards to account on the implementation of these strategies. As active investors we also regularly engage with investee
companies on ESG topics and find this dialogue to be the best opportunity to provide feedback.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We will review the appropriateness of &lsquo;say on climate&rsquo;
votes and consider if other voting mechanisms should be applied to ensure both Boards and Executives apply the appropriate rigour to initiate
and deliver strategies to support the climate transition.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Shareholder Proposals</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The number of resolutions focused on environmental and social
(E&amp;S) issues filed by shareholders continues to grow rapidly. The following provides an overview of some of the factors we consider
when assessing the most prevalent themes for shareholder proposals.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Climate Change</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We are members of the Net Zero Asset Managers Initiatives
and this is reflected in our Active Ownership approach. We encourage the companies in which we invest to demonstrate a robust methodology
underpinning Paris aligned goals and targets and are supportive of resolutions that will help companies to achieve this. Once a credible
climate strategy is in place, we prioritise evidence of implementation over requests to re-draft strategies and targets after only a year
or two.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">A growing number of resolutions call on companies to increase
the transparency of their reporting on climaterelated lobbying. These proposals typically encompass direct lobbying undertaken by the
company and indirect lobbying undertaken by trade associations and other organisations of which it is a member or supporter. Lobbying
contrary to the objectives of the Paris Agreement is effective in creating climate policy inertia and impeding the transition to net zero
economies.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We do not evaluate resolutions in isolation. Our approach
recognises the links between corporate governance, strategy and climate approach. Where a company&rsquo;s operational response to climate
change is inadequate, the effectiveness of board oversight and corporate governance may also be called into question.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We expect and encourage companies to:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Demonstrate that a robust methodology underpins Paris aligned, net zero goals and targets.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Set targets for absolute emission reduction, not just carbon intensity, to show a clear pathway to net zero.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Report in alignment with the TCFD framework.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Link targets to remuneration and ensure they are reflected in capital expenditure and R&amp;D plans.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Carefully manage climate-related lobbying by ensuring appropriate oversight, transparent disclosure of activities, and alignment of
activities with the company&rsquo;s strategy and publicly stated positions.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Diversity&nbsp;&amp; Inclusion</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Diversity, Equity&nbsp;&amp; Inclusion (DEI) is an important
and growing theme for shareholder resolutions. In recent years resolutions have focussed on racial equity audits, pay gap reporting, transparent
disclosure of DEI metrics and assessments of the efficacy of DEI programmes.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">A racial equity audit is an independent analysis of a company&rsquo;s
business practices designed to identify practices that may have a discriminatory effect. We are supportive of racial equity audits in
relation to internal and external DEI programmes. It is appropriate that these programmes should have KPIs and audit mechanisms in place
to measure and evaluate outcomes. Some proposals request racial equity audits of provision of services. We are aware that measuring provision
of service is challenging and gathering racial data on customers can be difficult and inappropriate. There are also multiple different
factors that can influence service provision and which could be misconstrued as being racially motivated. We will however, support resolutions
which are not unduly prescriptive and allow companies to carry out audits within a reasonable timeframe, at a reasonable cost, and excluding
confidential or proprietary information.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We consider standardised gender pay gap disclosure to be
an important tool for assessing how companies are addressing gender inequality. Reporting on gender pay gaps across global operations
can help companies to remain ahead of the regulatory curve. It also enables them to offer better opportunities and remuneration for women
around the world. We are therefore supportive of resolutions which are likely to deliver these benefits.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Proposals must be carefully drafted
to achieve these outcomes. For instance, in the past we have been unable to support resolutions which called for global median gender
and racial pay gap reporting as it was unclear how this would reveal potential pay disparities at a local level and how it could be implemented
by companies with operations in jurisdictions where collection of racial identity data is illegal.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In the US market we support public disclosure of EEO-1 forms
by companies. The EEO-1 form details a comprehensive breakdown of workforce by race and gender according to ten employment categories.
The form is submitted privately to the US Equal Employment Opportunity Commission on an annual basis. When publicly disclosed, it offers
investors and other stakeholders data in a standardised and comparable form. We have used our engagement programme to ask the companies
in which we invest to disclose this form for their US operations while making it central to our D&amp;I voting approach and supporting
resolutions that request it.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Human rights</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">As a supporter of the UN Guiding Principles on Business and
Human Rights (UNGPs), we expect companies to demonstrate how human rights due diligence is conducted across operations, services, product
use and the supply chain. Companies can have a significant impact on human rights directly through operations and provision of services,
and indirectly through product use and the supply chain. In recent years the sale and end-use of controversial technologies, such as facial
recognition software, has emerged as a prominent theme.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We expect and encourage companies to:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Have robust due diligence processes to assess the actual and potential human rights impacts of their operations, services, product
use and supply chain.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Conduct customer and supplier vetting processes commensurate with the risk of human rights abuse.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Publicly disclose information about the operation of these processes and utilise the UNGPs&rsquo; Reporting Framework. This will improve
the standard and consistency of human rights reporting and enable more informed investment decision making.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Corporate Lobbying&nbsp;&amp; Political Contributions</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Corporate lobbying and political contributions are a recurrent
theme of shareholder resolutions, particularly in the US. These proposals typically encompass direct lobbying undertaken by the company
and indirect lobbying undertaken by trade associations and other organisations of which it is a member or supporter. Proposals may also
request the disclosure of more information regarding the process and rationale for political contributions. We expect companies to make
transparent, consolidated disclosures of direct and indirect lobbying and political expenditure. This disclosure should be underpinned
by a coherent policy that: explains public policy priorities and the rationale for associated expenditure, identifies the management positions
responsible for public policy engagement, and provides appropriate mechanisms for board oversight. These measures should mitigate the
risks associated with corporate lobbying and political contributions, protecting the interest of shareholders and other stakeholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Nuclear Energy</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In the Japanese market nuclear energy is a recurrent theme
of shareholder resolutions. The Japanese government is seeking to reduce the nation&rsquo;s reliance on coal and its energy strategy presents
safe nuclear power generation as an important source of base-load power. In this context, resolutions which seek to limit or cease the
nuclear operations of an individual company do not appear to be in the best interests of shareholders and other stakeholders. The health&nbsp;&amp;
safety risks associated with nuclear energy are high, must be managed carefully across the industry, and are an important consideration
in our voting.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Important Information</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">This document is strictly for information purposes only and
should not be considered as an offer, investment recommendation, or solicitation, to deal in any of the investments or funds mentioned
herein and does not constitute investment research. abrdn does not warrant the accuracy, adequacy or completeness of the information and
materials contained in this document and expressly disclaims liability for errors or omissions in such information and materials.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Any research or analysis used in the preparation of this
document has been procured by abrdn for its own use and may have been acted on for its own purpose. The results thus obtained are made
available only coincidentally and the information is not guaranteed as to its accuracy. Some of the information in this document may contain
projections or other forward looking statements regarding future events or future financial performance of countries, markets or companies.
These statements are only predictions and actual events or results may differ materially. The reader must make their own assessment of
the relevance, accuracy and adequacy of the information contained in this document and make such independent investigations, as they may
consider necessary or appropriate for the purpose of such assessment. This material serves to provide general information and is not meant
to be investment, legal or tax advice for any particular investor. No warranty whatsoever is given and no liability whatsoever is accepted
for any loss arising whether directly or indirectly as a result of the reader, any person or group of persons acting on any information,
opinion or estimate contained in this document. abrdn reserves the right to make changes and corrections to any information in this document
at any time, without notice. This material is not to be reproduced in whole or in part without the prior written consent of abrdn.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Applying ESG and sustainability criteria in the investment
process may result in the exclusion of securities within the universe of potential investments. The interpretation of ESG and sustainability
criteria is subjective meaning that products may invest in companies which similar products do not (and thus perform differently) and
which do not align with the personal views of any individual investor. Furthermore, the lack of common or harmonized definitions and labels
regarding ESG and sustainability criteria may result in different approaches by managers when integrating ESG and sustainability criteria
into investment decisions. This means that it may be difficult to compare strategies within ostensibly similar objectives and that these
strategies will employ different security selection and exclusion criteria. Consequently, the performance profile of otherwise similar
vehicles may deviate more substantially than might otherwise be expected. Additionally, in the absence of common or harmonized definitions
and labels, a degree of subjectivity is required and this will mean that a product may invest in a security that another manager or an
investor would not.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">abrdn plc is registered in Scotland (SC286832) at 1 George
Street, Edinburgh EH2 2LL.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>


<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(E)
<SEQUENCE>12
<FILENAME>tm2527059d10_ex99-xe.htm
<DESCRIPTION>EXHIBIT 99.(E)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2527059d10_ex99-xe.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2527059-10/tm2527059-10_ncsrseq1/users" -->

<P STYLE="margin: 0pt">&nbsp;</P>


<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 99.(e)</B></P>


<P STYLE="margin: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>U.S. Registered Advisers</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Summary of Proxy Voting Guidelines</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>as of October 26, 2022</I></B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Where clients appoint abrdn Inc. to vote proxies on their behalf, policies
have been established to vote these proxies in the best interests of our clients.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We employ
ISS as a service provider to facilitate electronic voting. We require ISS to provide recommendations based on our own set of parameters
tailored to abrdn</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s assessment and approach, but remain conscious
that all voting decisions are our own on behalf of our clients. We consider ISS</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
recommendations and those based on our custom parameters as input to our voting decisions. We make use of the ISS standard research and
recommendations and those based on our own custom policy as input to our voting decisions. Where our analysts make a voting decision that
is different from the recommendations based on our custom policy they will provide a rationale for such a decisions which will be made
publicly available in our voting disclosures.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order to make proxy voting decisions, an abrdn analyst assesses
the resolutions at general meetings in our active investment portfolios. This analysis will be based on our knowledge of the company,
but will also make use of the custom and standard recommendations provided by ISS as described above. The product of this analysis will
be a final voting decision instructed through ISS and applied to all funds for which abrdn have been appointed to vote. For funds managed
by a sub-adviser, we may delegate to the sub-adviser the authority to vote proxies; however, the sub-adviser will be required to either
follow our policies and procedures or to demonstrate that their policies and procedures are consistent with ours, or otherwise implemented
in the best interest of clients.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">There may
be certain circumstances where abrdn Inc. may take a more limited role in voting proxies. We will not vote proxies for client accounts
in which the client contract specifies that abrdn Inc. will not vote. We may abstain from voting a client proxy if the voting is uneconomic
or otherwise not in clients</FONT>&rsquo; <FONT STYLE="font-family: Times New Roman, Times, Serif">best interests. For companies held
only in passively managed portfolios, abrdn Inc. custom recommendations provided by ISS will be used to automatically apply our voting
approach; we have scope to intervene to test that this delivers appropriate results, and will on occasions intrude to apply a vote more
fully in clients</FONT>&rsquo; <FONT STYLE="font-family: Times New Roman, Times, Serif">best interests. If voting securities are part
of a securities lending program, we may be unable to vote while the securities are on loan. However, we have the ability to recall shares
on loan or to restrict lending when required, in order to ensure all shares have voted. In addition, certain jurisdictions may impose
share-blocking restrictions at various times which may prevent abrdn Inc. from exercising our voting authority.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recognize that there may be situations in which we vote at a company
meeting where we encounter a conflict of interest. Such situations include:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt; width: 0in"></TD><TD STYLE="padding-bottom: 10pt; width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Where a portfolio manager owns the holding in a personal account.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt"></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">An investee company that is also a segregated client.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt"></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">An investee company where an Executive Director or Officer of our company
or that of abrdn plc or another affiliate is also a Director of that company.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt"></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">An investee company where an employee of abrdn plc or an affiliate or subsidiary
is a Director of that company.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt"></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">A significant distributor of our products.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Any other companies which may be relevant from time to time.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have adopted
procedures within our proxy voting process to identify where a conflict exists. These procedures are designed to ensure that our voting
decisions are based on our client</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s best interests and are not impacted
by any conflict.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The implementation
of this policy, along with conflicts of interest, will be reviewed periodically by the Active Ownership team. abrdn</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
Global ESG Principles &amp; Voting Policies are published on our website.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Clients may
obtain a free copy of abrdn Inc.</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s proxy voting policies and procedures
and/or proxy voting records for their account by contacting us at (215) 405-5700. abrdn publishes ESG Principles &amp; Voting Policies,
which describe our approach to investment analysis, shareholder engagement and proxy voting across companies worldwide. There are published
on our website.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Clients that have not granted abrdn Inc. voting authority over securities
held in their accounts will receive their proxies in accordance with the arrangements they have made with their service providers.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Listed Company ESG Principles &amp; Voting Policies</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>February 2023</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Introduction</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Active Ownership and Environmental, Social &amp; Governance (ESG) considerations
are a driver of our investment process, our investment activity, our client journey and our corporate influence.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Through engagement
with the companies in which we invest, and by exercising votes on behalf of our clients, we seek to improve the financial resilience and
performance of our clients</FONT>&rsquo; <FONT STYLE="font-family: Times New Roman, Times, Serif">investments. Where we believe change
is needed, we endeavour to catalyse this through our stewardship capabilities.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our expectations</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">As global
investors, we are particularly aware that ESG structures and frameworks vary across regions. Furthermore, what we expect of the companies
in which we invest varies between different stages of business development and the underlying history and nature of the company in question.
We seek to understand each company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s individual circumstances and
so evaluate how it can best be governed and overseen. As such, we strive to apply the principles and policies set out on these pages in
response to the needs of that individual company at that particular time. Our heritage as a predominantly active fund manager helps drive
this bespoke approach to understanding good governance and risk management.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have a
clear perception of what we consider to be best practice globally </FONT>&ndash; <FONT STYLE="font-family: Times New Roman, Times, Serif">as
set out in this document. However we will reflect the nature of the business, our close understanding of individual companies and regional
considerations, where appropriate, in our approach to applying these policies, which are not exhaustive.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">This document
has received approval from the Head of Public Markets and the Investment Vector</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
Chief Sustainability Officer following consultation with various internal stakeholders.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our approach to stewardship</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We seek to
integrate and appraise environmental, social and governance factors in our investment process. Our aim is to generate the best long-term
outcomes for our clients and we will actively take steps as stewards and owners to protect and enhance the value of our clients</FONT>&rsquo;
<FONT STYLE="font-family: Times New Roman, Times, Serif">assets.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stewardship
is a reflection of this bespoke approach to good governance and risk management. We seek to understand each company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
specific approach to governance, how value is created through business success and how investors</FONT>&rsquo; <FONT STYLE="font-family: Times New Roman, Times, Serif">interests
are protected through the management of risks that materially impact business success. This requires us to play our part in the governance
process by being active stewards of companies, involved in dialogue with management and non-executive directors where appropriate, understanding
the material risks and opportunities </FONT>&ndash; <FONT STYLE="font-family: Times New Roman, Times, Serif">including those relating
to environmental and social factors and helping to shape the future success of the business.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt; width: 0in"></TD><TD STYLE="padding-bottom: 10pt; width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Take into consideration, in our investment process, the policies and practices
on environmental, social and governance matters of the companies in which we invest.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt"></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Seek to enhance long-term shareholder value through constructive engagement
with the companies in which we invest.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt"></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Actively engage with the companies and assets in which we invest where we
believe we can influence or gain insight.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt"></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Seek to exercise voting rights, where held, in a manner consistent with our
clients</FONT>&rsquo; <FONT STYLE="font-family: Times New Roman, Times, Serif">long-term best interests.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt"></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Seek to influence the development of high standards of corporate governance
and corporate responsibility in relation to environmental and social factors for the benefit of our clients.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt"></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Communicate our Listed Company ESG Principles and Voting Policies to clients,
companies and other interested parties.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt"></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Be accountable to clients within the constraints of professional confidentiality
and legislative and regulatory requirements.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Be transparent in reporting our engagement and voting activities.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">abrdn is committed
to exercising responsible ownership with a conviction that companies adopting improving practices in corporate governance and risk management
will be more successful in their core activities and deliver enhanced returns to shareholders. As owners of companies, the process of
stewardship is a natural part of our investment approach as we seek to benefit from their long-term success on our clients</FONT>&rsquo;
<FONT STYLE="font-family: Times New Roman, Times, Serif">behalf.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Engagement</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">It is a central tenet of our active investment approach that we strive
to meet with the management and directors of our investee companies on a regular basis. The discussions we have cover a wide range of
topics, including: strategic, operational, and ESG issues and consider the long-term drivers of value. Engagement with companies on ESG
risks and opportunities is a fundamental part of our investment process. It is a process by which we can discuss how a company identifies,
prioritises and mitigates its key risks and optimises its most significant opportunities. As such, we regard engagement as:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Important to understanding investee companies as a whole.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Helpful when conducting proper ESG analysis.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Useful to maintaining open dialogue and solid relationships with companies.</FONT></TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">An opportunity to inflect positive change on a company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
holistic risk management programme </FONT>&ndash; <FONT STYLE="font-family: Times New Roman, Times, Serif">be active with our holdings
rather than activist.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Proxy Voting</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proxy voting
is an integral part of our active stewardship approach and we seek to exercise voting rights in a manner in line with our clients</FONT>&rsquo;
<FONT STYLE="font-family: Times New Roman, Times, Serif">best interests. We seek to ensure that voting reflects our understanding of the
companies in which we invest on behalf of our clients. We believe that voting is a vital mechanism for holding boards and management teams
to account, and is an important tool for escalation and shareholder action.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This document includes our process and overarching policy guidelines
which we apply when voting at general meetings. These policies are not exhaustive and we evaluate our voting on a case by case basis.
As a global investment firm we recognise the importance of adopting a regional approach, taking into account differing and developing
market practices. Where a policy is specific to one region this is denoted.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We endeavour to engage with companies regarding our voting decisions
to maintain a dialogue on matters of concern.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Voting Process</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In line with our active ownership approach, we review the majority
of general meeting agendas convened by companies which are held in our active equity portfolios. Analysis is undertaken by a member of
our regional investment teams or our Active Ownership team and votes instructed following consideration of our policies, our views of
the company and our investment insights. To enhance our analysis we may engage with a company prior to voting to understand additional
context and explanations, particularly where there is deviation from what we believe to be best practice.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">To supplement
our own analysis we make use of the benchmark research and recommendations provided by ISS, a provider of proxy voting services. In the
UK we also make use of the Investment Association</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s (IA) Institutional
Voting Information Service. We have implemented regional voting policy guidelines with ISS which ISS applies to all meetings in order
to produce customised vote recommendations. These custom recommendations help identify resolutions which deviate from our expectations.
They are also used to determine votes where a company is held only in passive funds. Within our custom policies, however, we do specify
numerous resolutions which should be referred to us for active review. For example we will analyse all proposals marked by ISS as environmental
or social proposals.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">While it is
most common for us to vote in line with a board</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s voting recommendation
we will vote our clients</FONT>&rsquo; <FONT STYLE="font-family: Times New Roman, Times, Serif">shares against resolutions which are not
consistent with their best interests. We may also vote against resolutions which conflict with local governance guidelines, such as the
IA in the UK. Although we seek to vote either in favour or against a resolution we do make use of an abstain vote where this is considered
appropriate. For example we may use an abstention to acknowledge some improvement, but as a means to reserve our position in expectation
that further improvement is needed before we can vote in favour. Where we vote against a resolution we endeavour to inform companies of
our rationale.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">In exceptional
circumstances we may attend and speak at a shareholder meeting to reinforce our views to the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
board.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We endeavour
to vote all shares for which we have voting authority. We may not vote when there are obstacles to do so, for example those impacting
liquidity, such as share- blocking, or where there is a significant conflict of interest. We use the voting platform of ISS to instruct
our votes. Where we lend stock on behalf of clients, and subject to the terms of client agreements, we hold the right to recall shares
where it is in clients</FONT>&rsquo; <FONT STYLE="font-family: Times New Roman, Times, Serif">interests and we take the view that it will
impact the final vote to maintain full voting weight on a particular meeting or resolution.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our votes are disclosed publicly on our website one day after a general
meeting has taken place.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Strategy</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We invest in companies to create the best outcome for our clients.
Companies must be clear about the drivers of their business success and their strategy for maintaining and enhancing it. Investment is
a forward-looking process; we seek to understand the opportunity for a business and its scope for future value-creation over the long
term. In order to do this, we need clarity on past business delivery and its drivers, and on the effective track record of management;
we require honest and open reporting to build confidence in that track record. We seek confidence that companies and their management
can maintain their competitive positioning and operational performance and subsequently enhance returns for investors. A clear strategy
and clarity about the drivers of operational success provides the lens through which we will consider most corporate issues, not least
assessing performance and risk management.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will consider voting against executive or non-executive directors if we
have serious concerns regarding the oversight or implementation of strategy.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Board of Directors</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We believe
effective board governance promotes the long-term success and value creation of the company. The board should be responsible for establishing
the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s purpose and strategy, overseeing management in their
implementation of strategy and performance against objectives. The board should ensure a strong framework of control and risk oversight,
including material ESG risks. The board should assess and monitor culture and be engaged with the workforce, shareholders and wider society.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Board Composition</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective decision making requires a mix of skills around the table
and constructive debate between diverse and different-minded individuals. A range of skills, experience and perspectives should be drawn
together on the board. These include industry knowledge, experience from other sectors and relevant geographical knowledge. Independence
of thought plays a crucial role in the ability of a board to generate the debate and discussion that will challenge management, help enhance
business performance and improve decision-making. Board assessments will help the board ensure it has the necessary mix of skills, diversity
and quality of individuals to address the current risks and opportunities the company faces. Unitary boards should comprise an appropriate
combination of executive and non- executive directors such that no group of individuals dominates decision-making. We expect the size
of the board to reflect the size, nature and complexity of the business. We also expect regular internal and external board evaluations
which include an assessment of board composition and effectiveness.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Leadership</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Running businesses effectively for the long term requires effective
collaboration and cooperation, with no individual or small group having unfettered powers. Nor should they have dominant influence over
the way a business is run or over major decisions about its operations or future. There should be a division of responsibility between
board leadership and executive leadership of the business. We believe that there should be a division of roles at the top of the organisation,
typically between a Chief Executive Officer (CEO) and an independent Chair.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will consider supporting the re-election of an existing Chair &amp; CEO
role combination, recognising that this remains common in certain geographies. In reviewing on a case by case basis we will take account
of the particular circumstances of the company and consider what checks and balances are in place, such as the presence of a strong Senior
Independent Director with a clear scope of responsibility.</FONT></TD></TR></TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will generally oppose any re-combination of the roles of CEO and Chair,
unless the move is on a temporary basis due to exceptional circumstances or other mitigating factors.</FONT></TD></TR></TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will generally oppose any move of a retiring CEO to the role of Chair.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Independence</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Companies should be led and overseen by genuinely independent boards.
When looking at board composition we generally expect to see a majority of independent directors, with boards identifying their independence
classifications in the Annual Report. It is preferable to see an identified Senior Independent Director (SID) on the board, who will lead
the appraisal of and succession planning for the Chair. We expect SIDs to meet with investors and be a point of contact for escalating
concerns if required.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">In assessing
a director</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s independence we will have due regard for whether a
director:</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt; width: 0in"></TD><TD STYLE="padding-bottom: 10pt; width: 0.3in">(I)</TD><TD STYLE="padding-bottom: 10pt">Has been an employee of the company within the last five years.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt"></TD><TD STYLE="padding-bottom: 10pt">(II)</TD><TD STYLE="padding-bottom: 10pt">Has had within the last three years a material business relationship with the company.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt"></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(III)</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Has received remuneration in addition to director fees or participates in
the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s option or variable incentive schemes, or is a member
of the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s pension scheme.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt"></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(IV)</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Has close family ties with any of the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
advisers, directors or senior employees.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt"></TD><TD STYLE="padding-bottom: 10pt">(V)</TD><TD STYLE="padding-bottom: 10pt">Holds cross-directorships or has significant links with other directors through involvement in other companies or bodies.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt"></TD><TD STYLE="padding-bottom: 10pt">(VI)</TD><TD STYLE="padding-bottom: 10pt">Represents a significant shareholder.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt"></TD><TD STYLE="padding-bottom: 10pt">(VII)</TD><TD STYLE="padding-bottom: 10pt">Has served on the board for more than 12 years (or 9 for UK companies).</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will consider voting against the re-election of non-independent directors
if the board is not majority independent (excluding employee representatives). In doing so we will have regard for whether a company is
controlled and the nature of the non-independence </FONT>&ndash; <FONT STYLE="font-family: Times New Roman, Times, Serif">for example,
we are unlikely to vote against shareholder representatives unless their representation is disproportionate to their shareholding.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Succession Planning &amp; Refreshment</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Regular refreshment of the non-executive portion of a board helps draw
in fresh perspectives, not least in the context of changes to business and emerging opportunities and risks. It also helps limit the danger
of group-think. Thoughtful and proactive succession planning is therefore needed for board continuity, to ensure that a board is populated
by individuals with an appropriate mix of skills, experience and perspective. We expect the board to implement a formal process for the
recruitment and appointment of new directors, and to provide transparency of this in the Annual Report.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will vote against non-executive directors where there are concerns regarding
board refreshment or excessive tenure. Where there are directors who have served for over 12 years on a board which has seen no refreshment
in 3 years (2 in UK), we will generally vote against their re-election. If a director has served for over 15 years we will generally vote
against their re-election. We will, however, consider the impact on board continuity and the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
succession planning efforts prior to doing so. We may not apply the tenure limit to directors who are founders or shareholder representatives.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Diversity</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe that companies that make progress in diversity and inclusion
(D&amp;I) are better positioned for long-term sustainability and outperformance. Diversity of thought, paired with a culture of inclusion,
can help companies to tackle increasingly complex challenges and markets. We expect boards to report on how they promote D&amp;I throughout
the business and believe that setting targets is important to addressing imbalances. We recognise the importance of adopting a regional
approach to diversity and inclusion, allowing us to press for progress with appropriate consideration for the starting point. We have
for several years, actively encouraged progress in gender diversity at all levels, and have expanded our scope in relation to diversity
and inclusion across geographies. In respect of ethnic diversity, this is coming increasingly into focus as we encourage boards to progress
in ensuring that their composition reflects their employee and customer bases.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our regional specific policies are below. In determining our votes
we will take account of mitigating factors, such as the sudden departure of a female board member. We will also consider any clear progress
being made by the company on diversity and any assurance that diversity shortfalls will soon be addressed.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gender Diversity</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">UK: We will generally vote against the Nomination Committee Chair of FTSE
350 companies if the board is not comprised of at least one third female directors. For smaller companies, we will take this action if
the board does not include at least one female director.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Europe: We will generally vote against the Nomination Committee Chair of
LargeCap companies if the supervisory board is not comprised of at least 30% female directors, or is not in line with the local standard
if higher. For smaller companies, we will take this action if the supervisory board does not include at least one female director.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Australia: We will generally vote against the Nomination Committee Chair
of ASX300 companies if the board is not comprised of at least 30% female directors.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">North America: We will generally vote against the Nomination Committee Chair
of LargeCap companies if the board is not comprised of at least 30% female directors. For smaller companies, we will take this action
if the board does not include at least one female director</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ethnic Diversity</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">UK: We will generally vote against the Nomination Committee Chair at the
boards of FTSE 100 companies, if the board does not include at least one member from an ethnic minority background. This is in line with
targets set up by the Parker Review.</FONT></TD></TR></TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">US: We will generally vote against the Nomination Committee Chair at the
boards of S&amp;P 1500 &amp; Russell 3000 companies if the board does not include at least one member from a racial or ethnic minority
background.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Directors</B></FONT><B>&rsquo;
<FONT STYLE="font-family: Times New Roman, Times, Serif">Time Commitment</FONT></B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Individual directors need sufficient time to carry out their role effectively
and therefore we seek to ensure that all directors maintain an appropriate level of overall commitments such that allows them to be properly
diligent.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will consider opposing the election or re-election of any director where
there is a concern regarding their ability to dedicate sufficient time to the role. In making this assessment we will have regard for
the ISS classification of </FONT>&lsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">overboarding</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will generally oppose the re-election of any director who has attended
fewer than 75% of board meetings in two consecutive years.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Board Committees</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Boards should establish committees, populated by independent and appropriately
skilled non-executive directors, to oversee (as a minimum) the nomination, audit and remuneration processes. It may also be appropriate
for additional committees to be established, such as a risk or sustainability committee. These committees should report openly on an annual
basis about their activities and key decisions taken.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will consider voting against committee members if we have concerns regarding
the composition of a committee.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Nomination Committee</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This committee has responsibility for leading the process for orderly
non-executive and senior management succession planning and recruitment, and for overseeing the composition of the board including skillset,
experience and diversity. We expect the committee to be comprised of a majority of independent directors with an independent Chair.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will consider voting against the re-election of the Nomination Committee
Chair if we have concerns regarding the composition of the board or concerns regarding poor succession planning.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Audit Committee</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">This committee
has responsibility for monitoring the integrity of the financial statements, reviewing the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
internal financial controls and risk management systems, reviewing the effectiveness of the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
internal audit function and appointing auditors. While we prefer the committee to be wholly independent, at minimum we expect the committee
to be comprised of a majority of independent directors with an independent Chair and at least one member having recent and relevant financial
experience.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will generally vote against the re-election of the Audit Committee Chair
if at least one member of the Committee does not have recent and relevant financial experience.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Remuneration Committee</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">This committee
is responsible for determining the policy and setting remuneration for executive and non-executive directors. The committee should ensure
that remuneration is aligned with strategy and company performance and should clearly demonstrate regard for the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
employees, for wider society and be cognisant of the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s licence
to operate when considering policy and the overall level of remuneration. We expect remuneration committees to be robust in their approach
to developing and implementing remuneration policies, with formal and transparent procedures for developing policies and for determining
remuneration packages. Remuneration committees should be comprised of a majority of independent directors with an independent Chair and
we expect members to have appropriate experience and knowledge of the business. No executive should be involved in setting their own remuneration.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Where we have significant concerns regarding the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
remuneration policy or reward outcomes we may escalate these concerns through a vote against the Chair or members of the Remuneration
Committee.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Director Accountability</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect to be able to hold boards to account through engagement and
regular director re-elections and directors should feel that they are accountable to investors. We encourage individual, rather than bundled,
director elections. While our preference is for directors to be subject to re-election annually, we expect re-elections to take place
at least every three years. Lengthier board mandates, while not uncommon in some markets, risk divorcing directors from an appropriate
sense of accountability. Directors and management should make themselves available for discussions with major shareholders as we expect
to have open dialogue to share our perspectives and gain confidence that the individuals are carrying out their roles with appropriate
vigour and diligence. A further important element of director accountability to shareholders is that investors should have the right,
both formal and informal, to propose and promote individual directors to be considered for election to the board by all shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt; width: 0in"></TD><TD STYLE="padding-bottom: 10pt; width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">We will generally oppose the re-election of non- independent NEDs who are
proposed for a term exceeding three years. We may not apply this to directors who are shareholder representatives.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt"></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Where we have significant concerns regarding a board member</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
performance, actions or inaction to address issues raised we may vote against their re-election.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt"></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">We may vote against directors who decline appropriate requests for meeting
without a clear justification.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt"></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Where a director has held a position of responsibility at a company which
has suffered a material governance failure, we will consider whether we are comfortable to support their re-election at other listed companies.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt"></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">We will generally support resolutions to discharge the supervisory board
or management board members unless we have serious concerns regarding actions taken during the year under review. Where there is insufficient
information regarding allegations of misconduct, we may prefer to abstain. In exceptional circumstances we may vote against the discharge
resolution to reflect serious ESG concerns if there is not another appropriate resolution.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will not support the election of directors who are not personally identified
but are proposed as corporations.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Reporting</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">A company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
board should present a fair, balanced and understandable assessment of the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
position and prospects </FONT>&ndash; <FONT STYLE="font-family: Times New Roman, Times, Serif">financial and non-financial </FONT>&ndash;
<FONT STYLE="font-family: Times New Roman, Times, Serif">and of how it has fulfilled its responsibilities. We support the principle of
full disclosure of relevant and useful information, subject to issues of commercial confidentiality and prejudice. Boilerplate disclosure
should be avoided. We encourage companies to consider using the appropriate globally developed standards and would particularly encourage
the use of those created by the Taskforce for Climate related Financial Disclosure (TCFD), the International Integrated Reporting Council
(IIRC), the Sustainability Accounting Standards Board (SASB) and the Global Reporting Initiative (GRI). Audited reporting and financial
numbers should be published ahead of any relevant shareholder meetings. We continue to monitor the evolving reporting landscape and consider
new reporting developments as they emerge, either voluntary or regulatory.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We may consider voting against a company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
Annual Report &amp; Accounts if we have concerns regarding timely provision or disclosure.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Political Donations &amp; Lobbying</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Companies
should be consistent in their public statements and not undermine these in private commentary to market participants or to politicians
and regulators. We welcome transparency from companies about their lobbying activities and believe that good companies have nothing to
hide in this respect. Similarly we encourage transparency of any political donations that companies deem appropriate </FONT>&ndash; <FONT STYLE="font-family: Times New Roman, Times, Serif">and
we expect a clear explanation of why such donations are an appropriate use of corporate funds.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risk &amp; Audit</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The board
is responsible for determining the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s risk appetite, establishing
procedures to manage risk and for monitoring the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s internal
controls. We expect boards to conduct robust assessments of the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
material risks and report to shareholders on risks, controls and effectiveness. The introduction of global accounting standards has led
to much greater investor confidence in the accounts produced by companies around the world. It has also assisted in creating consistency
of reporting across companies, enabling fairer comparisons between different operating businesses. We therefore encourage companies seeking
international investment to report under International Financial Reporting Standards (IFRS) or US GAAP. As a firm abrdn supports the continued
development of high quality global accounting standards.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">An independent
audit, delivered by a respected audit firm, is a required element for investor confidence in reporting by companies. We strongly favour
meaningful, transparent and informative auditor reports, giving us additional insights into the audit process and accounting outcomes.
Audit fees must be sufficient to pay for an appropriately in-depth assurance process. We would be concerned if a company sought to make
savings in this respect as the cost in terms of damage to audit effectiveness and confidence in the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
accounts would be much more substantial.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The independence of the auditor and the standard of their work, particularly
in challenging management, should be subject to regular assessment that is appropriately disclosed. Even when individuals carrying out
the audit are refreshed, we believe that the independence of the audit firm erodes over time and we will encourage a tender process and
change of audit firm where an engagement has lasted for an extended period. In order to demonstrate the level of independence, companies
should not have the same audit firm in place for more than 20 years.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The relationship with the auditor should be mediated through the audit
committee. Where we are significant shareholders, we expect to be consulted on plans to tender and replace auditors.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will generally vote against the re-election of an auditor which has a
tenure of 20 years or over, if there are no plans for rotation in the near term.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will consider voting against the auditors if we have concerns regarding
the accounts presented or the audit procedures used.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will vote against the approval of auditor fees if we have concerns regarding
the level of fees or the balance of non-audit and audit fees.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Remuneration</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Remuneration policies and the overall levels of pay should be aligned
with strategy, attracting and retaining talent and incentivising the decisions and behaviours needed to create long-term value. The component
parts of remuneration should be structured so as to link rewards to corporate and individual performance and they should be considered
in the context of the remuneration policies when taken as a whole. We recognise the benefits of simplicity in forming the policy, which
should clearly link outcomes and expectations for those receiving the remuneration, as well as external stakeholders. The structure should
be transparent and understandable.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">A company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
annual report should contain an informative statement of remuneration policy which communicates clearly to stakeholders how it has developed
and evolved. This should include details of any stress testing that may have been undertaken to understand the policy outcomes for different
business scenarios. The remuneration committee should provide a clear description of the application of policy and the outcomes achieved.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Base salary should be set at a level appropriate for the role and responsibility
of the executive. We discourage increases which are driven by peer benchmarking, and expect increases to be aligned with the wider workforce.
Consideration should also be given to the knock on impact to variable remuneration potential. Pension arrangements and benefits should
be clearly disclosed. We generally expect pension structures to be aligned with the wider workforce.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">A company
should structure variable, performance- related pay to incentivise and reward management in a manner that is aligned with the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
sustainable performance and risk appetite over the long term. We expect all variable pay to be capped, preferably as a proportion of base
salary. In the UK we expect variable pay to be capped as a proportion of salary. In other markets, if variable pay is capped at a number
of shares, we expect the value of grants to be kept under review annually to ensure the value remains appropriate and is not excessive.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Performance
metrics used to determine variable pay should be clearly disclosed and aligned with the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
strategy. A significant portion of performance metrics should seek to measure significant improvements in the underlying financial performance
of the company. We also encourage the inclusion of non-financial metrics linked to targets which are aligned with the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
progress on its ESG strategy. Where possible we expect these targets to be quantifiable and disclosed.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Variable pay arrangements should incentivise participants to achieve
above-average performance through the use of challenging targets. We encourage sliding-scale performance measures and expect performance
target ranges to be disclosed to enable shareholders to assess the level of challenge and pay for performance alignment. We expect annual
bonus targets to be disclosed retrospectively and encourage the disclosure of long term incentive (LTI) targets at the beginning of the
performance period, but at minimum we expect retrospective disclosure. Where bonus or LTI targets are not disclosed due to commercial
sensitivity we expect an explanation of why the targets continue to be considered sensitive retrospectively and expect some detail regarding
the level of achievement vs target. Where a share price metric is being used, we expect this to be underpinned by a challenging measure
of underlying performance.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We encourage settlement of a portion of the annual bonus in shares
which are deferred for at least one year.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect settlement of long term incentives to be in shares, with
rationale provided for any awards settled in cash. Long term incentives should have a performance period of no less than three years.
In the UK we expect a further holding period of two years to be applied, and we encourage this in other markets.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We do not generally support restricted share schemes or value creation
plans. We will consider supporting the use of restricted share plans which have been structured consistent with the guidelines of the
Investment Association.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect appropriate malus and clawback provisions to be applied to
variable remuneration plans.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect shareholding guidelines to be adopted for executive directors
and encourage the adoption of post- departure shareholding guidelines.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect details of any use of discretion to be disclosed and its
use should be justifiable, appropriate and clearly explained. We would expect policies to be sufficiently robust so that discretion is
only necessary in exceptional circumstances. We do not generally support exceptional awards, and are particularly sensitive to such awards
being granted to reward a corporate transaction.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect executive service contracts to provide for a maximum notice
period of 12 months. We will consider local best practice provisions related to severance arrangements when voting.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non-executive
fees should reflect the role</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s level of responsibility and time
commitment. We do not support NED</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s participation in option or performance-related
arrangements. However we do support the payment of fees in shares, particularly where conservation of cash is an issue.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">In the UK
our expectations of companies are aligned with the Investment Association</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
Principles of Remuneration.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Where significant changes to remuneration arrangements are being considered,
we would expect remuneration committees to consult with their largest shareholders prior to finalising any changes. Where any increase
to variable remuneration is proposed, we would expect this to be accompanied by a demonstrable increase in the stretch of the targets.
Furthermore we expect any increases to remuneration to be subject to shareholder approval.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In response to the issues arising from the cost of living crisis being
experienced by many people in the UK, we expect companies to focus any additional help towards those members of the workforce who need
it most. We expect Remuneration Committees to take into account factors arising from the cost of living crisis when deliberating over
executive pay outcomes. We would be concerned by reputational issues arising from decisions made in these unusual circumstances and may
make this a factor in our voting decisions at relevant AGMs.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In line with the expectations set out above we will generally vote
against the appropriate resolution(s) where:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt; width: 0in"></TD><TD STYLE="padding-bottom: 10pt; width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">We consider the overall reward potential or outcome to be excessive.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt"></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">A significant increase to salary has been granted which is not aligned with
the workforce or is not sufficiently justified.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt"></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">A significant increase to performance-related pay has been granted which
is not sufficiently justified, is not accompanied by an increase in the level of stretch required for achievement or results in the potential
for excessive reward.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt"></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">There is no appropriate cap on variable incentive schemes.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt"></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Performance targets for annual bonus awards are not disclosed retrospectively
and the absence of disclosure is not explained.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt"></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Performance targets for long term incentive awards are not disclosed up front
and there is no compelling explanation regarding the absence of disclosure or a commitment to disclose retrospectively.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt"></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Performance targets are not considered sufficiently challenging, either at
threshold, target or maximum.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Relative performance targets allow vesting of awards for below median performance.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt; width: 0in"></TD><TD STYLE="padding-bottom: 10pt; width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Retesting provisions apply.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt"></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Incentives that have been conditionally awarded have been repriced or performance
conditions changed part way through a performance period.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt"></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have concerns regarding the use of discretion or the grant of exceptional
awards.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt"></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pension arrangements are excessive.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Pension arrangements are not aligned with the wider workforce (UK).</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Rights</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The interests of minority shareholders must be protected and any major,
or majority, investor should not enjoy preferential treatment. The structure of ownership or control should minimise the potential for
abuse of public shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Transactions</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Companies should not make significant changes to their structure or
nature without being fully transparent to their investors. Shareholders should have the opportunity to vote on significant corporate activity,
such as mergers and acquisitions. Where a transaction is with a related party, only independent shareholders should have a vote. Even
in markets where no vote is given to shareholders in these circumstances, investors need transparent disclosure of the reasons for any
such major change. Companies should expect that shareholders may want to discuss and debate proposed developments</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Diversification beyond the core skills of the business needs to be
justified as it is more often than not a distraction from operational performance. All major deals need to be clearly explained and justified
in the context of the pre- existing strategy and be subject to shareholder approval.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will vote on corporate transactions on a case by case basis.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dividends</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We will generally
support the payment of dividends but will scrutinise the proposed level where it appears excessive given the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
financial position.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Share Capital</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The board carries responsibility for prudent capital management and
allocation.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Share Issuance</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will consider capital raises which are proposed for a specific purpose
on a case by case basis but recognise that it can be beneficial for companies to have some general flexibility to issue shares to raise
capital. However we expect issuances to be limited to the needs of the business and companies should not issue significant portions of
shares unless offering these on a pro-rata basis to existing shareholders to protect against inappropriate dilution of investments.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Where a company seeks a general authority to issue shares we generally expect
this to be limited to 25% of the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s share capital for pre-
emptive issuances. In the UK we are aligned with the guidance of the Investment Association Share Capital Management Guidelines.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Where a company seeks a general authority to issue shares we generally expect
this to be limited to 10% of the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s share capital for non-pre-emptive
issuances. In the UK we are aligned with the guidance of the Investment Association Share Capital Management Guidelines and those of the
Pre-Emption Group.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will not generally support share issuances at investment trusts unless
there is a commitment that shares would only be issued at a price at or above net asset value.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">When considering
our votes we will, however, take account of the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s circumstances
and any further detail regarding proposed capital issuance authorities prior to voting.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Following
changes to the UK</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s Pre-Emption Group Guidelines in November 2022,
which reflect an increase on previous limits, we will hold the Chair of the company accountable for any perceived misuse of the increased
flexibility through a vote against their re-election.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Buyback</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recognise that share buybacks can be a flexible means of returning
cash to shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will generally support buyback authorities of up to 10% of the issued
share capital.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Related Party Transactions</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The nature
of relations </FONT>&ndash; <FONT STYLE="font-family: Times New Roman, Times, Serif">particularly any related party transactions (RPTs)
</FONT>&ndash; <FONT STYLE="font-family: Times New Roman, Times, Serif">with parent or related companies, or other major investors, must
be disclosed fully. Related party transactions must be agreed on arm</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
length terms and be made fully transparent. Where they are material, they should be subject to the approval of independent shareholders.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.15in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will vote against RPTs where there is insufficient transparency of the
nature of the transaction, the rationale, the terms or the views and assessment of directors and advisors.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Article/Bylaw amendments</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">While it is standard to see proposals from companies to amend their
articles of association or bylaws, we will review these on a case by case basis. When doing so we expect full transparency of the proposed
changes to be disclosed.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will vote against amendments which will reduce shareholder rights.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Anti-Takeover Defences</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There should be no artificial structures put in place to entrench management
and protect companies from takeover. The best defence from hostile takeover is strong operational delivery.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will generally vote against anti-takeover/</FONT>&lsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">poison
pill</FONT>&rsquo; <FONT STYLE="font-family: Times New Roman, Times, Serif">proposals.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Voting Rights</U></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We are strong
supporters of the principle of </FONT>&lsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">one share, one vote</FONT>&rsquo;
<FONT STYLE="font-family: Times New Roman, Times, Serif">and therefore favour equal voting rights for all shareholders.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will generally vote against proposals which seek to introduce or continue
capital structures with multiple voting rights.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will consider voting against proposals to raise new capital at companies
with multiple share classes and voting rights.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General Meetings</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shareholder
meetings provide an important opportunity to hold boards to account not only through voting on the proposed resolutions but also by enabling
investors the opportunity to raise questions, express views and emphasise concerns to the entire board. We may make a statement at a company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
AGM as a means of escalation to reinforce our views to a company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
board.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We welcome the opportunity to attend meetings virtually, being of the
view that this can increase participation given obstacles such as location or meeting concentration. However we are not supportive of
companies adopting virtual-only meetings as we believe this format reduces accountability. Our preference is for a hybrid meeting format
to balance the flexibility of remote attendance with the accountability of an in-person meeting.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will generally support resolutions seeking approval to shorten the EGM
notice period to minimum 14 days, unless we have concerns regarding previous inappropriate use of this flexibility.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will generally support proposals to enable virtual meetings to take place
as long as there is confirmation that the format will be hybrid, with physical meetings continuing to take place (unless prohibited by
law). We expect virtual attendees to have the same rights to speak and raise questions as those attending in-person.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>As part of strategic planning, boards need to have oversight of,
and clearly articulate, the key opportunities and risks affecting the sustainability of the business model. This includes having a process
for, and transparent disclosure of, potential and emerging opportunities and risks and the actions being taken to address them.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The effective
management of risks extends to long-term issues that are hard to measure and whose timeframe is uncertain and will include the management
of environmental and social issues. We use the UN Global Compact</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
four areas of focus in assessing how companies are performing in this area.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Specifically we expect companies to be able to demonstrate how they
manage their exposures under the following headings.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The Environment</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">It is generally accepted that companies are responsible for the effects
of their operations and products on the environment. The steps they take to assess and reduce those impacts can lead to cost savings and
reduce potential reputational damage. Companies are responsible for their impact on the climate and they face increased regulation from
world governments on activities that contribute to climate change.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect that companies will</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Identify, manage and reduce their environmental impacts.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Understand the impact of climate change along the company value chain.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Develop group-level climate policies and, where relevant, set targets to
manage the impact, report on policies, practices and actions taken to reduce carbon and other environmental risks within their operations.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Comply with all environmental laws and regulations, or recognised international
best practice as a minimum.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Where we have
serious concerns regarding a board</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s actions, or inaction, in relation
to the environment we will consider taking voting action on an appropriate resolution.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will use the indicators within the Carbon Disclosure Project to
identify companies which are not fulfilling their climate commitments. Where appropriate we will take voting action to encourage better
practice among companies which we deem to be laggards.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Labour and employment</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Companies
that respect internationally recognised labour rights and provide safe and healthy working environments for employees are likely to reap
the benefits. This approach is likely to foster a more committed and productive workforce, and help reduce damage to reputation and a
company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s license to operate. We expect companies to comply with
all employment laws and regulations and adopt practices in line with the International Labour Organization</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
core labour standards. a minimum.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In particular, companies will:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Take affirmative steps to ensure that they uphold decent labour standards.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Adopt strong health and safety policies and programmes to implement such
policies.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Adopt equal employment opportunity and diversity policies and a programme
for ensuring compliance with such policies.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Adopt policies and programmes for investing in employee training and development.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Adopt initiatives to attract and retain talented employees, foster higher
productivity and quality, and encourage in their workforce a commitment to achieving the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
purpose.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Ensure policies are in place for a company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
suppliers that promote decent labour standards, and programmes are in place to ensure high standards of labour along supply chains.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Report regularly on its policy and implementation of managing human capital.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Where we have
serious concerns regarding a board</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s actions, or inaction, in relation
to labour and employment we will consider taking voting action on an appropriate resolution.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Human rights</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recognise the impact that human-rights issues can have on our investments
and the role we can play in stimulating progress. We draw upon a number of international, legal and voluntary agreements for guidance
on human-rights responsibilities and compliance. Our primary sources are the International Bill of Rights and the core conventions of
the International Labour Organisation (ILO), which form the list of internationally agreed human rights, and the UN Guiding Principles
on Business and Human Rights (UNGPs), which clarifies the roles of states and businesses. We encourage companies to use the UNGPs Reporting
Framework and encourage disclosure in line with this guidance.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect companies to:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Continually work to understand their actual and potential impacts on human
rights.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Establish systems that actively ensure respect for human rights.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Take appropriate action to remedy any infringements on human rights.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Where we have
serious concerns regarding a board</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s actions, or inaction, in relation
to human rights we will consider taking voting action on an appropriate resolution.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Business ethics</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">As institutions
of wealth and influence, companies have a significant impact on the prosperity of their local communities and the wider world. Having
a robust code of ethics and ensuring professional conduct mean companies operate more effectively, particularly when it comes to ethical
principles governing decision- making. A company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s failure to conform
to internationally recognised standards of business ethics on matters such as bribery and corruption, can increase its risk of facing
investigation, litigation and fines. This could undermine its license to operate, and affect its reputation and image.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect companies to have policies in place to support the following:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Ethics at the heart of the organisation</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
governance.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">A zero-tolerance policy on bribery and corruption.. How people are rewarded,
as pay can influence behaviour.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Respect for human rights.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Tax transparency.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Ethical training for employees.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Where we have
serious concerns regarding a board</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s actions, or inaction, related
to business ethics we will consider taking voting action on an appropriate resolution.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We will review any resolution at company meetings which ISS has
identified as covering environmental and social factors. The following will detail our overarching approach and expectations.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our approach to vote analysis is consistent across active and quantitative
investment strategies</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Review</B> the resolution, proponent and board statements, existing
disclosures, and external research.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Engage</B> with the company, proponents, and other stakeholders
as required.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Involve</B> thematic experts, regional specialists, and investment
analysts in decision-making to harness a wide range of expertise and include all material factors in our analysis.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Ensure</B> consistency by using our own in-house guidance to frame
case-by-case analysis.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Monitor</B> the outcomes of votes.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Follow-up</B> with on-going engagement as required.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Given the
nature of the topics covered by these resolutions we do not apply binary voting policies. We adopt a nuanced approach to our voting research
and outcomes and will consider the specific circumstances of the company concerned. Our objective is not to vote in favour of all shareholder
resolutions but to determine the best outcome for the company in the context of the best outcome for our clients. There are instances
where we are supportive of the spirit of a resolution however there may be a reason which prevents our support for the proposal. For example,
where the purpose of the resolution is unclear, where the wording is overly prescriptive, when suggested implementation is overly burdensome
or where the proposal strays too closely to the board</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s responsibility
for setting the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s strategy.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Management Proposals</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We are supportive
of the steps being taken by companies to provide transparent, detailed reporting of their ESG strategies and targets. While shareholder
proposals on environmental and social topics have been common on AGM agenda for several years, an increasing number of companies are presenting
management proposals, such as so called </FONT>&lsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">say on climate</FONT>&rsquo;
<FONT STYLE="font-family: Times New Roman, Times, Serif">votes, for shareholder approval. While we welcome the intention of accountability
behind these votes, we have reservations about the potential for them to limit the scope for subsequent investor challenge and diminish
the direct responsibility and accountability of the board and individual directors. We believe it is the role of the board and the executive
to develop and apply strategy, including ESG strategies, and we will continue to use existing voting items to hold boards to account on
the implementation of these strategies. As active investors we also regularly engage with investee companies on ESG topics and find this
dialogue to be the best opportunity to provide feedback.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We will review
the appropriateness of </FONT>&lsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">say on climate</FONT>&rsquo; <FONT STYLE="font-family: Times New Roman, Times, Serif">votes
and consider if other voting mechanisms should be applied to ensure both Boards and Executives apply the appropriate rigour to initiate
and deliver strategies to support the climate transition.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Shareholder Proposals</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The number of resolutions focused on environmental and social (E&amp;S)
issues filed by shareholders continues to grow rapidly. The following provides an overview of some of the factors we consider when assessing
the most prevalent themes for shareholder proposals.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Climate Change</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are members of the Net Zero Asset Manager Initiatives and this is
reflected in our Active Ownership approach. We encourage the companies in which we invest to demonstrate a robust methodology underpinning
Paris aligned goals and targets and are supportive of resolutions that will help companies to achieve this. Once a credible climate strategy
is in place, we prioritise evidence of implementation over requests to re-draft strategies and targets after only a year or two.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A growing number of resolutions call on companies to increase the transparency
of their reporting on climate- related lobbying. These proposals typically encompass direct lobbying undertaken by the company and indirect
lobbying undertaken by trade associations and other organisations of which it is a member or supporter. Lobbying contrary to the objectives
of the Paris Agreement is effective in creating climate policy inertia and impeding the transition to net zero economies.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We do not
evaluate resolutions in isolation. Our approach recognises the links between corporate governance, strategy and climate approach. Where
a company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s operational response to climate change is inadequate,
the effectiveness of board oversight and corporate governance may also be called into question.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect and encourage companies to:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Demonstrate that a robust methodology underpins Paris aligned, net zero goals
and targets.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Set targets for absolute emission reduction, not just carbon intensity, to
show a clear pathway to net zero.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Report in alignment with the TCFD </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">framework.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Link targets to remuneration and ensure they are reflected in capital expenditure
and R&amp;D plans.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Carefully manage climate-related lobbying by ensuring appropriate oversight,
transparent disclosure of activities, and alignment of activities with the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
strategy and publicly stated positions.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Diversity &amp; Inclusion</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Diversity &amp; Inclusion (D&amp;I) is an important and growing theme
for shareholder resolutions. In recent years resolutions have focussed on racial equity audits, pay gap reporting, transparent disclosure
of D&amp;I metrics and assessments of the efficacy of D&amp;I programmes.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">A racial
equity audit is an independent analysis of a company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s business
practices designed to identify practices that may have a discriminatory effect. We are supportive of racial equity audits in relation
to internal and external D&amp;I programmes. It is appropriate that these programmes should have KPIs and audit mechanisms in place to
measure and </FONT>evaluate outcomes. Some proposals request racial equity audits of provision of services. We are aware that measuring
provision of service is challenging and gathering racial data on customers can be difficult and inappropriate. There are also multiple
different factors that can influence service provision and which could be misconstrued as being racially motivated. We will however,
support resolutions which are not unduly prescriptive and allow companies to carry out audits within a reasonable timeframe, at a reasonable
cost, and excluding confidential or proprietary information.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We consider standardised gender pay gap disclosure to be an important
tool for assessing how companies are addressing gender inequality. Reporting on gender pay gaps across global operations can help companies
to remain ahead of the regulatory curve. It also enables them to offer better opportunities and remuneration for women around the world.
We are therefore supportive of resolutions which are likely to deliver these benefits. Proposals must be carefully drafted to achieve
these outcomes. For instance, in the past we have been unable to support resolutions which called for global median gender and racial
pay gap reporting as it was unclear how this would reveal potential pay disparities at a local level and how it could be implemented by
companies with operations in jurisdictions where collection of racial identity data is illegal.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the US market we support public disclosure of EEO-1 forms by companies.
The EEO-1 form details a comprehensive breakdown of workforce by race and gender according to ten employment categories. The form is submitted
privately to the US Equal Employment Opportunity Commission on an annual basis. When publicly disclosed, it offers investors and other
stakeholders data in a standardised and comparable form. We have used our engagement programme to ask the companies in which we invest
to disclose this form for their US operations while making it central to our D&amp;I voting approach and supporting resolutions that request
it.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Human rights</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a supporter of the UN Guiding Principles on Business and Human Rights
(UNGPs), we expect companies to demonstrate how human rights due diligence is conducted across operations, services, product use and the
supply chain. Companies can have a significant impact on human rights directly through operations and provision of services, and indirectly
through product use and the supply chain. In recent years the sale and end-use of controversial technologies, such as facial recognition
software, has emerged as a prominent theme.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect and encourage companies to:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Have robust due diligence processes to assess the actual and potential human
rights impacts of their operations, services, product use and supply chain.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Conduct customer and supplier vetting processes commensurate with the risk
of human rights abuse.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Publicly disclose information about the operation of these processes and
utilise the UNGPs</FONT>&rsquo; <FONT STYLE="font-family: Times New Roman, Times, Serif">Reporting Framework. This will improve the standard
and consistency of human rights reporting and enable more informed investment decision making.</FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Lobbying &amp; Political Contributions</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Corporate lobbying and political contributions are a recurrent theme
of shareholder resolutions, particularly in the US. These proposals typically encompass direct lobbying undertaken by the company and
indirect lobbying undertaken by trade associations and other organisations of which it is a member or supporter. Proposals may also request
the disclosure of more information regarding the process and rationale for political contributions. We expect companies to make transparent,
consolidated disclosures of direct and indirect lobbying and political expenditure. This disclosure should be underpinned by a coherent
policy that: explains public policy priorities and the rationale for associated expenditure, identifies the management positions responsible
for public policy engagement, and provides appropriate mechanisms for board oversight. These measures should mitigate the risks associated
with corporate lobbying and political contributions, protecting the interest of shareholders and other stakeholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Nuclear Energy</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">In the Japanese
market nuclear energy is a recurrent theme of shareholder resolutions. The Japanese government is seeking to reduce the nation</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
reliance on coal and its energy strategy presents safe nuclear power generation as an important source of base-load power. In this context,
resolutions which seek to limit or cease the nuclear operations of an individual company do not appear to be in the best interests of
shareholders and other stakeholders. The health &amp; safety risks associated with nuclear energy are high, must be managed carefully
across the industry, and are an important consideration in our voting.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Important Information</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This document is strictly for information purposes only and should
not be considered as an offer, investment recommendation, or solicitation, to deal in any of the investments or funds mentioned herein
and does not constitute investment research. abrdn does not warrant the accuracy, adequacy or completeness of the information and materials
contained in this document and expressly disclaims liability for errors or omissions in such information and materials.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any research or analysis used in the preparation of this document
has been procured by abrdn for its own use and may have been acted on for its own purpose. The results thus obtained are made
available only coincidentally and the information is not guaranteed as to its accuracy. Some of the information in this document may
contain projections or other forward looking statements regarding future events or future financial performance of countries,
markets or companies. These statements are only predictions and actual events or results may differ materially. The reader must make
their own assessment of the relevance, accuracy and adequacy of the information contained in this document and make such independent
investigations, as they may consider necessary or appropriate for the purpose of such assessment. This material serves to provide
general information and is not meant to be investment, legal or tax advice for any particular investor. No warranty whatsoever is
given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of the reader, any
person or group of persons acting on any information, opinion or estimate contained in this document. abrdn reserves the right to
make changes and corrections to any information in this document at any time, without notice. This material is not to be reproduced
in whole or in part without the prior written consent of abrdn.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Applying ESG and sustainability criteria in the investment process
may result in the exclusion of securities within the universe of potential investments. The interpretation of ESG and sustainability criteria
is subjective meaning that products may invest in companies which similar products do not (and thus perform differently) and which do
not align with the personal views of any individual investor. Furthermore, the lack of common or harmonized definitions and labels regarding
ESG and sustainability criteria may result in different approaches by managers when integrating ESG and sustainability criteria into investment
decisions. This means that it may be difficult to compare strategies within ostensibly similar objectives and that these strategies will
employ different security selection and exclusion criteria. Consequently, the performance profile of otherwise similar vehicles may deviate
more substantially than might otherwise be expected. Additionally, in the absence of common or harmonized definitions and labels, a degree
of subjectivity is required and this will mean that a product may invest in a security that another manager or an investor would not.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">abrdn plc is registered in Scotland (SC286832) at 1 George Street,
Edinburgh EH2 2LL.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tm2527059d10thqreporti001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2527059d10thqreporti001.gif
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MZ.?HZ>OL[._O\._P\//T]/?W^/?X^/[^_@
M
M
M                                                 "'Y!
M+     !K SH#  ?^@$Z"@X2%AH>(B8J#38F-34Q.3$V-DI27F)!,DTM-2Y^?
M3*!*2Z1)2DJGJ$FL2$E(KK"R1TBT1[=&N;E%1D6^O[Y$0\/$0T)"PL?*QT%!
M0LU"0,W3S3]!0#] V#_6W-[?W#[>/N3EYN0]/3[I[.D\[CP^\3ST[/3W^#L\
M^O@Z]_X\_ $4&% '08$Z=B@T6-"@0X,Y=.2(Z)#BQ(@8)T*\R+'C11P30>8
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M"H52:%9."K"I:R]<^(6O%&/Z,H9DB%<0^[ YAF\;N3#)V:9LRKN%M2"]9\;
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MF&&WL=BDB6U<I<2>^X_10;J;5RZC=(6R&;#UDJ6FAYOX\=D!$]H& MJ>'=K
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MUG33S3;9?+,D-^<\"8XY)K1CPCKK5*D.EOO8$P\^^O@#9D#\##20F 815%!
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MPV),F0]#2S1;1C.]["7UI/5+T:!&SG2V<YW/%S[:,"=]S.0S_'[^YZ#_63N
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M1$5$_$1#_T.$"!PX$$@0( @1_EBXT,>/'CYZ2.31@X?%BQ9U\-#!L6/''#I
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MPTPU?:I33CO]]!-1J :E%%)-+26#4U/-\&H,4LE@ZU958:7K5F*5-19::+U
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M CYG.Q##C@*]HS&.6:QC)'!/!,DCP?.43&0AHX\&-_@>E:D,9O_AC\ST$R
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MP6-+\8XGY]':,I><O8M?]%Q,O0#SF(!6YC);BZW6SE::Y\(M^]BE+MWN]K?
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M,+.5,(W&EG 90(T6EW)Y0*LI(+ZUFOKXFDXHHWU)1(%IH_8()*50F*$@C;U
M"H.0C=VX--BH- -U4HYP";@F:T#S7\8P"</F73F8@Y69#.VXFP-FI;LY15MZ
MD#ZH=X,'F89W"=)5(K)@"O'%(/RXCPBRFASHIJX)7/NX3@GDFHT74AH4A:[V
M"$,SCND(4\N0D,$IG NY>ETTAA+V>O$V)Q59>QBYAANY1FLTG6\8DD_^56+8
M"7Q3)7S=N4<[4"DL&1.?4P/+QWS.9YYL=9,X23L7-Q8K@'V>!#QW 8E"*1A5
M1F73$QFXFG[2PG(O]QJB"#XU9Z#GTF8)RG_'A)7Q<R_0 1X1:EJO6(#1Z@%H
MR4VX>&AN2:*X13'@E*(3$R 88X'[^*9MRIHP"FVQ.4_+%0OJVEPGN&P7%3/8
MJ O:V'8\4J3WNI@JI$)=XU^2^5"]UFWF:(54JH-7:C;AAK!<^ P2T%*_:7K@
M=I"<&7C&9B.4<#/UB%]B5WDBDT#D>C%SZK$A^W5J2FU_V30B!(,^@U+*T&L]
MR)E8XB7)P$5>I 3TX&X4!GNPYP_*67MGI)'^:<1&DTJI(3E'(XEB'D&'*]9B
M>:22G_H2H4H3HYH3@ @49G6JJY*>6&%)<U4K:&$7CL@K\RE^B>$7EI&?Y8<9
MT9.)U:.)V:,]O0J*P I,EU65Z9*5= 9:[_.5>L8=TT1-UO1:X>$!!#.X^U.X
MLF4>#KB+*)I;5?>+WHI.Y;0Q&F.,+:I.&=@@J)FY22A!_WAY&E)$[?JN@2FO
MB%D(0;HU0DJD1:JG+YA",X1>4R)KP  TM3LEY0A>@#>E!-L,@-J;!Q9N61J<
M6FAZ#+NP9L.P$I!@XQ:S7CJQ-G)X^J5!0N2/J?FBW^JF&^.BP"BR+TJR=OJY
M0X*RMLFG-529,+O^4KPY >G ;F\"1F"$#V;(J,LY. 5!./?6)VQ$G7#H.$!P
MJ9%SM(RBM$M[ATWKM% ;2%+[AU5[5JV#M:]B?=?GJE\;2D$IE")GB8Q1?KF:
M&951+=>S/:B12_/G&L":9G0[K)NEPL?$<\?J?ZZ8H:M%EOCC6K UN MHN 5C
M'R%PPPKC3;XX'R!@'T(<E^!*(+\UN<!%N1WSO1R;CRBS:2 8@LMX"Z)[HU"8
M0:@+4(1IF/A*7?G*F IE4$QJ7C7$4 #;:TSJ>06YNWEGF<X[#5DJQ\1+Q^,F
M <D+4PR;Q\C[4ERX)5KZ=U!J7O18CU7L"B<#>1NHQ""3=16X6[V%,0?^8KGD
M*J=,6*/.59OD6S0LJU(^&'H&IC>'6@_OQ@_V8 3Q6T;T6[\<EA#ZJWO[9IU"
M@!&RK!$HUA$>L9U6Q:G>&6,Y\$<NN2FE$Y-EE3K1%V345Q9<>Q9I$:OR&92$
M@3R+\1C1TQB=T;;8PW[>(Z E+%GS=\+UIV;XYUGL<QSSTG_V\DS+NJ'>H:&#
M1I;4BI:R=1X\_# \''4' X$2"#'=2C%(K,06Z%L*4J[Z"&V.5[(T>D%"<L7O
MFG9YN@ORZHU;P[I@C FWRZ2+,)!\JE!$TZ0,!5%@ZIGOJ%+$X+Q9LIG0\+ (
M6<=UK+P3T-(4D+QZ?,=YW-(MS;P&]K+!1K'^2,.Z,7-M'! +7.>QD\;/YF34
MYN2]QX7(LTF-$9T(1@-13QK5G3Q@7DH!H0PGB5K*RJG*A'._1M5AN?>1($EB
MM#R2<_@1N4S >&A\W]F2,A&U.E$ZQ%S,J(J3.CG!L3JK&'R4KG1^2XE++P=9
MWV,"]5?8K"%,-M<NZM-_P(%G0Y?.[!RM[_Q:9TFM[L%-BAM N/6612U.EG8@
M;5JG,*J7ED>C/S0BS@6%,H.C(L+%$JTB74S1.T.%Z67;MBLT:MQK'4U#,%0,
M$17(E-G&EGDE"(F%?8Q@6\C2+KW'-3W3=PS=T>W2SDW'I4=ZO6N.W&4T8]I>
M1 +4&*+(+"J,GFW^=49,ERWZFK+97'D:)4\J"!!U#2V;CF/3CJ3L4[)W)VAH
M1CT[$%]=$$<5UOE&UH;ROR0I.8V"RYO*M,97? >,P'PH.G--UX-HS%=A29F4
M*[U"2GT5?AB<JUFVG]?,+7";2[M46:-(BFR6BHSMPLF!SJWXK/*SSAMJEF.I
MEO"\3;E('XMV'YT]0(\[3L,8K@TB7$Z\N4H->7OYN7T)-7^)-0W-=E'N=B-$
MY8O)1&HLQCY3V_YJ;-[EQE+]I;SKLLI@I>G;)>*6W"O-W&NNO&T>W<X-TS =
MT\\]W6M.QYN)=\/&TSJ$L>NJN0LBL@*B6X_+K4 ^,7-)R>E],IAG(J[^1FLT
M M\?36!6 F]QDK-TTIQJN"<9=GO_/=9O.. CUF^7>N#:.< ]L -85<!ZE .>
MBGQO_3DT$,R?0M=%(7&O<N'M"4JR&HE/AL&4D9\?_L'9W'Z2)7^(?=@U5[?I
MHCX^USXO_-@Q');1.HNM%<\*0ULBBKA4]TV=K1^&#HS^(<D?2XQ%3MI'CH_+
M^-U2L] W^B/0%4*L!MO;F*^PQJ^UNZ2W.R7ER^7$ + R M_@)=+G:Y#%3>;C
M5MRCI]QJ;M,VO<=U+MUO+O$2S^9UC-U^!Z:@65'V.%*P:;W_7$Z.)O)PN<_A
M=%N^".Z4)FFC[;F8+-$P6 &1 -^^3; ^M0_^F"YO&';*F[[*]A;6;336C!/J
MH^Z_MKPH/Z"TE+-BJ;[JQ/>I,L8Y,Y%PGT)65DOA=JVU&,X[W/=]0#DLT+Q*
ME>C!@#UF+0=_-%=_=9M_>?OBK0B60M?. "/WEKV 'IJX H/MNCBM0ZP?0HRB
MGNVB'OL?@$[:R/51[U0RS<;N]W5V3Y.C-NK:@RGE?/[R%,U$5X[O<:?&-OCO
M=P=LGS?<(2WFOLN;6.)2%:"\51INRBMZ+TW';?[P;#[QLT_[M0_[#D]Z?\IW
MVIU"%TL+X*VY'3L@A[[/*+\PFOV Z['/1$SRDCOD,:K0U#BO*X)=,9\,+2O?
M\DWI9&3*L\?5F>[^L_Y=.&W4RI^^.!$A1[),$=<YAR:I],*'ZJF.ARL)GN$9
MM39 ]:&2.HYDB)4T2<H,""R"*X0J+(8JB8J)*2J-*9"1*2<I*"B3)YF:FR<F
M)IV=GJ*CI)XD)B4EIR2JJB2OL+&R)".T([>XN;<B(KN\O[PA(L+$(<;'R,DA
M(,S,RR#+RQ\?S=0@U-/9VMH>V]D>X!_@X^3@'./GXQWH'N<<'?#Q\O+O'/8<
M&_?Z]_GX_1L  PK4X ^@!@T"-R!<J!!AP(,;,C0\2#'#08L9,F+4J,%B1PP9
M,'S4@*&D1I 909HLR;*ERY<8+%@H.3,F398S<]:4R9-G3)X5>LH,.M3^0@6B
M1H\:34I4Z=&G4*%2D'ITZM0*5I]FK2 !*P4*$[!. #NAK%D)9\F"_6IV EH)
M<-VZC4L7;EV[>//JQ2MW+MJV;"N$?2I4YH7#+#5J5)@0G[T.[^25Z]9-G&7+
ME;==VSSMFK=OVIB%FUQNW;IZ_ H:G-A1<<B6B%E>J##[<-2J1Y$8T6WDB.XC
MP(T([UW$2/'C19(K7YY\2!'G0X@,F4Y]B)#KV(4$$0+D.I#OX'\ ^4&^O(_S
M/GJH[\&CO?L=\'?HT)&#?H[[./+GOV'#1HW__]% PPPTR&"@@3$D",.",+S@
MX(,M1"AA"X)4J (A*RRBX2.23 ())2">@ +^)R26D$DIHI2 "BJKO&)"+*[,
M\DHML-2B"RXAY&(,CCL6$XPPPQ@3I#+(0..,,]A4@\UG3'I#&673D"8E.Q\\
MEHX][6#ISCV0Q;,!//8 !%D_CI7IV#\)I9DF1&Q*9%%$$K%Y448=M4911:YQ
MA-)K)(64DDJ)P21H2SGA1)-,-NU4V**,-@K44I Z11A3MU6*%6Z77OJ55U5]
MY:E7FP[&%5A<C556J6V910%<J_HUUZMEW:677WO5*D$$MO[5EZJ90B54;*\I
MUI% ^\P3CY2845.9DDLR8\TT(3SK;&?.>K8D-Y.MTXX'](S)ST (G?3:2Q=@
M4$%)MM$V&VU1]>;^6W##Q6N<<,@QIQQT^%8W77;\=L<=$$& %UYYY*%WWGKJ
MN<=#?/#-9U\.^N%@@\3]5=R?@!C/, .""<; X((N0/C"A()0R *&A6BH"(>2
M@/BAB"1RD@HHJ)R@HB<JIJ)S*ZW $F,L-MYHBR\C_')+CB3D>,P(2O=(Y#'0
M&!/U,U$[&^W5TUK;Y&<=<!/EE.B<(TZ6VUYI#MG[I*UVVFCFH^::#JWFT)T+
M553GG!?9F>?>*;F&$J PC3OHH#7=9.A/B?;TDZ.,(O7H4D%9*OGDO6**VZ>;
M>JKYYIZ6Q9:JJ8;N5JN>X[7JJGF]FKI=$.3:N@2OVTJK7;&B=7KF7T'^RE-L
M)G$$$4 <$$2F.\<BZTTSR"-O3?+,5]O\LTY^35ID8.[C-K@'_3WH88<)U911
MO0U77+S+&6=O<D04D7YR0N1KW;[6\<O=OP(/3+#!Z;''WL+M,2S??/?!3\0H
M9C$;8$Q &SM0QSSV,1<X<&0D8X')!I$AE77H0QBD!"9BM@D3K4@3/-M9SV1$
MPAKA8D:Z (8*C?:T%DJM&2]$'M6F!:VM@69L'^C:-+K&0QW&(X?:.L=IRL8.
M(FII;4@,$_#0I)J -/%M!ID;W:9(18[P[8I]4XF?!-<2+@YN<(4J7*$0QSC&
M.>Y[A*%<Y"IUE:A<!7>9REP<.4?'.G[.5'C^%%U<8@66O[SE=JFK'>URE9?8
MZ:5UKS-D(.6RELT%95,]X5YBMD@1Q@QO2^#0UF2TEHW--.](T8#AU$ I2N9!
M+S/)*@VWXL&E)M8-3R(A%V+4%:FBR,M\N#R?<M9'A%X600C2J4[[XB>_[=3O
M.^09#\%^@+_U*&P'"VN8P^A#GXC=0&+\L=@!!Z0QCC&P@2]PH LB6"%!J(P1
M%[P$S$+$B4]DPD0VJYDH3G *>KZ"9R6LT2M$,#0:Z2)I3%OA, 8ZI"&YT$@S
M_"0-;8@M<HPM6SW,(1"-!8],5G1+2<RHF88'137%K:,-84W>[#8G+.ZM=Y,$
MG.#^]$5TP:1P9$3^E$R-LK@R-@HID:/4;72JQC;Z5"N8VHH=065'MFPN57<4
MG:I:]1:Y_%$"J#/=Z@A92$3B!0*Q2R1?WD([P&C.5[LKETKIQ!"%J TRI+$,
M)SES)%&&\JVCK)K40JE0Z&UC-! %4Y:^%<6*Q/*OL.'>!;R7%'H=QWSG<P[Z
MU#>=7A)!"+]LGV3YM9T@6-:RQQ3/_9AI,(6]QW__"^  KYG-BM7 /QGK)L<^
MUB 8C+,%KY50.1%A04E<HA*8V"")1G$SFZ4"%:IX$8SRN4]8\+,7_,P1CXIV
MM*8%PZ#%<"'4H&:DNGHR>D\"&VE,LTJ*&@LUX-7H)=VFFC.!U*-19(S^1"*2
M-SC!B6X;L:)B]M2W+&8Q4%U\"4Q=ZE*Q<F\F@TW<3&OJ$]W=%')#F1Q/@7J;
M-H***I<KJH0E[+DZXO%S?B1+Z+A:*C]R-2]?&215X:+50\*.Q">^ZEZ<NM1/
M8<4"% BK8"?Y)DL.;UM3^HQGVIH\Z2IC:D6*QC,2RBQL/32380OO]?I*-T$)
MMGN13 YBE[.^Q3HV.M$!YG7V5<S+>MFRFETFP=23'O1X%K34I.9H;\#F;)XV
M0 A,H#=9^\ )26@%%CK$RAQQP4F,R!*[#44I1*@SXN;S%_LL&C"81HNF)8-I
M/D9H=4W)UFN)!@0>$(WTCJS=Z9VM'9+I$BO^-6J]C3;QB5!D4YK62R?VWLEW
M&,F;2>^[1?RV='NRP4"Y=E*N[M$$RKO324\<][BB>$]R"^YII<+R4TT]&'<3
M#HRGNK(YJ![5<WG$ME*W'19=D<XM7'FJM:4ZXA2CV-RPP^JYTRV[T&%.*3&V
MP& E>8'Z5M*)^RA-E+Z1M0\,6=(^#G@+)5VUY#%)2L3KDA('PAJ1L%0VB!'L
M4G2I/O4Y-IC!Y++\KE/9+P,,S$%8I@\X2V9G/C.:\I'/?>PS0!RTV<T!J@$"
M"W0@&2@(9*X-IYU-U@(,U182MP5TS-PI:%*HZ)ZL^!EQCTL"7C0]!/L\KD %
M/MU_*_2Z#,5,I[/^Q2T<:VFO>RT69$A-IK:=][P,N=-$TMOJC924;RL15]SG
M[J=;PX90Z'IR]_Z;D\$RRN]F-'94DJW&!E-.<V$9S%C60M3.-1[Q1ET\8$;U
M> JW&'3;;JKJ-L_5VD65583,JHD3J>X3DYYULX+5XC<%5L/T.B/U)NM'';,M
MM*H#E=;:S-7@ZL(@$11(SQVHD([QW&04W."?J4QI1LU7QMQI3^32-=]E@K[T
M7?S*5Q;FQK7S92^'6>3XR]_^/NN_- M0/R\W+8 R1G.;WYR!+W#MSGM^,I\O
M A*.N(0Z=0N*HHOB%*-P3THG"S:"0L@U=;\ ),07:7-52LJ#?-=R5Q+^N'45
MQ77?=0]A1W9J0U[Y(#P+EQ ?%1$@^!"55()V,VNSIA*M$2R XD72YQ+[93@V
M@1@ )F]/)F\X:%-%<49HE!0^Z"N%=WA:\481)AA&:%288Q71)F&"X3GA9FUU
M]!=JD53<IGJI\A;AACJQXA> 5&Z*A&ZB1WI6=6ZXXF%(I815$4G[)2R-D6_E
MP"3,TX"])R3!MR/# &D^\B,,^#P[=AEY!29C]X&OY#> HG<XN%C1T4OZ$C_$
MM'W<]W$!$W)B5C &XTP)<W+21$VB%3$VT&;]L7[;1" *=',,(D[S5W\94D$K
M W25('3MA"+"Q2*&E@M#(U!3MX#2Y6]!1F3^6I-[J(1#>+5U2%:!JY2!J$$/
M:\-194)>Y>5$JQ$\SL=PO[->(I@1<.(FLD96*&A?6L2"+FAW\O:",I4XBQ,3
MP!9L@#=L!_8H.$4IA!>$A@=4BC<6E2='6=%(2^A(%09Y:C$6U#9M !DJ2&4[
M[I9Y6ZAY3M5YLF(7GT=566556#6&HH=N*^95;61LB-([PO([9#)VGY9)Q^-6
M0!9=P =\ML@+S$4TSZ5HO@==QD=DR2<]W64]<#-?+BAQ%G!EP 0_&[<='(=9
MW5$_WW<_(W<P".-9[C%- !1 FZ@?%G-:J'5 &B-GI @RX62*$5(A]H=.D6 )
M7HD"1 >+.],BLQ#^-$%#"RAI-,"@@"ZYBT"FBZ!D#/Z6)'?%2<((-MIB++4G
M:AB51,QH)JF!:JG&&DQ&15/D)MLH+EM4:[8F5BWE7_T5F7D7<3@I;(91&'XW
M6,3&CFO4F4 (CXEW%*+2A% QFHH78<SV;IS#*?Q(1Y)W;:_92-AFA(FG*M0&
MA:7S.1HV;9FG*WYT%@?)%U$U.WI1AK8BD:U3ANH6D1$  <HI8L Y& [V*[RC
M$+$4-V$2&5CR)"$)0T(672U)AR?)7+U GB;)DK?8EB\T9$F2:<H7C,2C#PEA
MC7#'7X*U+[WDB-C1?0$C,)-8E,UTB4G) SK0'DK)E.>7'Q-30#(7BG+^9G.L
M!3(.9&>HF#*K"'1?23-B25S^9):^@( D.7 Q5"TUU!GB$ +CP&]0DEV3P6E=
M=WM=MP'=15'U$(ALLXQGLE%+5E8<*3<,%R>O9)BO]GPKB$5TUS?UIE)VYU]Z
MUU^(4B[J0AO2IQ335QAK=&P[Z)F14BGO6#F4,YI&^!3SJ"GW2*9)F(^NN7JQ
MN7KXR'AF09LAUCF8=T=]-&[8IBM*M54L]F$?UI"N0V(/J54167J%I*?>)D=*
ML12\ S@]&A"2D:+A0"UN]30$M9(KM N*UG286IY2=X G68<_1C4)U5#E($2!
M&1#4*'=^TFO<HY_:H1W?<5D ,Q[()'+,] /^/2!^ HJ42ODP#]-R!.0?H'A
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M./3>-XA^^C;SR'\!!CR,APCV0HHNL\"R H80UV]_PPCC0DN#'EX\L(@G*$$
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M1L1 T2$+.79"\R,F,I5I3 @MT[(KJ&PS)^1,_@6C0_\SAB0P0< "JDB!W?2
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MF9/H$=@<P310^R(9"7WHVN!_ MAS>!8C=F9G,'* 2J=TX," #8AT3^= $?A
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MG<DR>Z31>NT&2$M52>U626?%>^7Y>]-!? !G/0%W? ;7GLKWJ9XZ/0[0  Z
M<*>D+NI!8HM!1>+E5QM EX-@"/G!']KG'P$T(*G86 73E&1&<E2IE1$:K,(Z
MK VZH, J9D_)JP_#<0FRH9B@##5G<XRP(OEA+R.Z<R.J6MH  B3J =Q:,B6J
MK> J(RHJKG Y'T)GEP086WA69^($6W_YKK-$F($IF##3(\V(F FQ3T;^&H(D
M%"4G%'9.4W;\U(W3=["8.5YO,D2TUFHWV#5@,YH2FX,F=6M]QQ4LE5_N9823
M8BB,$RG">6SZJ#@%1BEWT1=DY*:2]YN0AWEU6AA^ZJ?%F2LP6QJB,X:IA[.!
MBE7,PI&%E%6P\52L-V*KESO/,GNS(:G (Y[+03S\]K3]!AU[6'S7@TH!)ST_
M=G"E.HCMB7"CVGS485;VZ3<^01#I\ 'HJEKW@GV,((FV*D";D*N/Q:OG!ZS&
M.JPMH')Y2ZQ\ZZ#'Q)7CIZP-HR$3(TT!1'.%U3&,D AR)J+86J+<B@V/NZTB
MJK;:BJW=ZDTDLZ*T6!_:ZJ($J&=U>9<V:J/^R6A.NG6O]31"^U0/*?2Z"I6D
MB?EIT"BPSK5<:2>E+S1>$G43Y!6:=Q<G>T)K'?6.</-$\,)29 H65>1W6Z2Q
M9]%K*Q6;>I-?M8E?7Q%@G!*RVYN$;\JR=%H8LEEYP_FR,(LY%394<21Z8ZBS
M:<AAJEJHA_1'A[JHM#=52PLLM*<;Q?&=,0:IE I\PS? S?%)\_E6X4)P/E9P
MHTJJU<.U-?G \'F(P=&39I%$*:0.FKNVB$"K #I:T90*WU<_8+:)?=N@>]L"
M>ZNW*JS"4[G")]R@8G9^#<-,S!IS93DBK:BXMA0"DAM8]^*M:FNM*.JMW12N
M)+-SF2NN;5FN0V?^'^N:KB_Z?WA)NNSJ6HF&:#)RNBP#3XVF=?1 I)-6I$H*
MF0;QC,6U0RNHQE*C)E,Z@V)C7F$S=TJ$7JC&1#FHFH."4G(CIBI%4H S;'03
MO9;R-\()*:)"O8>#*>.;O<<V>=^[LI8S*N5K>6W4D,8I1[(2L[3"'G8$J+(!
M+-!Y+-QY58I4J+J7'*4L+*I,58L*?8@T8I3:M.1)/ 6,'6N5J>5R?'5U<%SK
MP%R[M1'<M3D9MA7<1VB$P1G, 6A+HMA0<4WF# ':?;H:"TUYH H*K"P PRZL
MM]N<M^ ,SBSLPN+LS3 LK#,\9B7W?F4V(3?LK,E06LT0 B30PXB #2W^DL^R
MB,_7L,_[3,1##-!$?*W7:KGUTJT(O:+6-[I7W-#R.FBH6R,9J'4EU#-38L:R
M:Q!20FD[!#0@X8T$=;"W.Z5 5%%B<]*O)K%VG%YT@YKP>'B PFN+XEYHX5Y>
M$<@@JQ4?RQ?-EIMM,9L!9D8INWB/DVR2,[[D&YS5=J<1*;,RFSE\"F'MXKZ@
M;"Q794BB;!N_H;^NW,KLMM6FO'O;6<'MQK1IY9)[F,O9X5;KJ<"^W*GQJ;6D
M^K6EZLLYV8?%8\%P 7$[@K8;C,\='(E.)D!PFY0&XUC8W(F=F'[EO,V.W<+E
M3,Z0W<V3O<*23=G">I5@27[MW'*^8+BLB'_^*"(") "+A,!-_:S/JJW/00S$
M/QQ8 9W$0VS0SNRYM%V+4%RC,9JN,=K;6'R,._J7+..C1P+&BQEI&DW&KKN8
MKGLT,52P5<-099*P)&VE-1%$*%VELA8GV:VE3L17@R=2@UR/DA)%O!8X7/0W
M6T2]U1N;-[6$<9J]?=&]</J$WUO4/D7)Y@O5ZUM4_FVSG[RG[,NG@%J&L<<Z
M()EN>16TDJ2H9KC5B71[_$O6=GA)FH2':KW6H;2I<_5C0.8 (![,,UE*(0[B
M-6FJS$-CB2@X?;4D1/+7^I$(;FNKAEU,D*6@BYV5CEV5C_W8E?WC/_[-XSS9
M/=[8Q9KC9A:XIIC^"SD,,)30BO1,VM1:"#[<N#G7(E>NVOR<S_R\MJ\=N0,=
MY@+-Q)KKS$_<EM9G'U)LHP=X=%!7:$*ZNORJ3V1\I,4UC4D3N]_()3.TYY:Y
MNT44L3;!L$SDW1[U7FZ#Z#TX-[BF16M!IAVKA(C<%R"[A#)E8+=9%[>91@/)
M4R5;>8U\1ONMR0Q)A764IYU,X* \2++#X(2T5*XS8J[!U6!=+4G;X+E3ZV4%
MGI ZJ6@%?'F(8SJ6P+Q,/?%9/2#>P+\LXJ/ZM0],+MO!2=^YJA=,=XIF9_92
ME(,]S6L&<S7\B8K]PB@LSD!>[BW@ I.-[BVL[N%<V4+NV!&JV4?>?DK^SED5
M(UJ9(,_UO"(*1.7]*:NHG7-9OMI<3O".*^8 _:V&(,3?"B,-/[FVG=!47,5]
M":_D=$XQ@Z]Q3J1T/D^M*\;\M'7\Q&F>9D-8HS0K\5!MTB:^BUVT]O*@6:42
MFP&Z!A6!@E+J55+JM19?=-,\[YIGH5^$3%^5?LBS25,OE5_Z]>F8(NI/&!C*
M-AB6WNE2/^IRY&!OE/7(V:>;L^I!BYV+&IVP+O;^NYVSCAR0!,N\H\J16N&5
MRI+!%P$/D$ES[U;&9R[/?N+,/HC*_N'-'N)V+1ZJA%>/5!=L\Q!"XM?<$*N(
M0 W1;$T9IPL.<N/JI^,KH,*7+^3F7MDNP.[^ZZ["GN\"WPSZGP_9HP_.F07#
M.![N,^R4P)2* G)_'?,,L%@(U,KO%2=8]FP-:XG:!I_/54X(PG\OPX\-1LRM
MR,_P0IS$ ^VB<"F 5*QGL05UA\9;K"MI%JWGQTV-$I'!F.9/+;3&+B@0<8P3
M)\W=&X445RJ:*MT4[RA?@.*\T7L4,$TW^>6QKZELLCGIU(N]KBD8@'!A43$X
M6$&(:*%(6)C(B'AQ>!@IZ7BX6$E9N4FQ*=E9T2EZ"$IA"AH:>IIJJGKZ"OLJ
M83I!46MK*G%+.W%;VPL<+!Q,,8LKH6N[FWN*;#RAV^OL##WM'!$AD;V-W1T!
M >']  X^#O& GJ[^OMZ WM[0_@ _[S!O;^^07_\>WWX>#HY:+4F*+&# D"&#
M!@T;-G!PR.&#AP\?0( ( 4*$B!$C2'0L 1+DB9$H2JI(H2*ERA4L6ZY@ 7-%
M"Q8R6<QL@3.GSA8N>/KLR;.GBZ$XAPHUNM.G4IXVD]:<21.F5!4L5+ALJ5)E
M"A0G4:08>:+$"1,A27C<*")$6HQJ0[A5>_$BV[=TZ\Z5:Y%MWKP8Y5(,\0$P
MX, 4"UOT8+'B88L@$$^46)CBQ,>1)UOV@#ES!\R;.W3V##IT!PZC.9@^[3#U
MZ8>I&[I^O8%A;-@,:S>LC7LA[M@98MO>D)!WP][#@2<\CARY!H7+FR/^7(CP
MH 8,RZ-GD#[](/7LU*U?/_A=N_CQXR^0/WC!/ ;UYMNK7V\00WQ"\@\6%(2A
M@GB#_ _J7Q])>NE5,*" D2@B2$'W$93?@ @BDL@B$A;22"*:: (AA(9(@B&!
MGGS(RB>IA%B**R.>& LIL:QX2B\M_K(+,,K .$R-L.B"S#&SY+AC,<W4$@V.
MMEA#I#;6>---.$G^\T\ZYZPC3SQ1\@.//%/>,P\#^] SCY52/O!-. *A4I!V
MS#6T&F:&J:711AV1$-)8)I#D%4HK7<625%+=E%1.0BD%%%)$&?4G4D$%VJ=.
M325E$TPSL025GEA9E95*7IWP%5AAA56"61[^C=#F6FRF)4)&;;*)JEUMT157
MJ6_)I1>L;@4&6%Z$N<488Q0MMEADOOY:V&429>;!9IIQY@$'FH5&VFBEK68:
M1*VQ]A!KL%U[FVR_V29;MK-YF]!"Q@%G7'"]$7?NN JM&ZY"VTT'';S2=3==
M>-7->QYYX9F9KW;LB9?>>OX&;*!]X\UG<'WY'9)?PPSK9V"  EHP(($**J@?
M?19Z>#$CAGQ<(8495JS)AI68#&+**9=(2LLNF[A**Z*\X@J+L?B""XW*\%)C
M,-%4 PLPLPC-S(X\XFCT-,44>8TVW(2)#4 1C#,U.>-<K<Z75J;3#Y;V,.!U
MV.^H0TXVT;1"87S^X;H6[;"[9F0J1V^&)!:===II59Z0ON1H3HLF6BBA1PE.
M^*!&O= 3XBT@[L(+?@*ETTM0M5"35'Q71=-5>9^4TE:9:AJ2"9YV=.JHH9Y.
MJENDCN 6ZW2)6E=&JM)UJZJ!Y8I[[B!$EABPP0X[&?#$3N19L<6"=KQHHI$&
M;;6HJ08;M=A>*V[UN\U6O6_ ,70<N>B6&^YRRHE_G&[7E;\=O?6"9QV_Y^V[
M;[_R^SLPP>;%)QY]!\_W7YD.Y]^?!%%,0?*Y6,<F= F+><AB(HO0A"1D"8*<
MC" ;0MF'4 &B4;!"@R.:F<P^",*8B?!F+((1+4Y(C)X)0TC(D(8QF@'^0Q_E
MPFA+<T8-D=:T;4!  DKJ83>N5C5T/.EJ3>+:V*ATI7N 36SVN)([I*2D:=SB
M$O@+G_-, QG&O$5N<Q/+G.RVE:RTA":4*V/?_E84/_VD<&QLHQO_]!.=0&YR
MC9+)Y2R')TI9JDZ:&DD)R.*I3X%J+:$:Y*E0IY&WA&I5BR05(6=GNUD)IB]]
MT5TE,?(VW_TJ>,"3C/$\2:S.)$]YGFE>M$XYK6I-[S:OZ19ML+>MV1!G>^3R
MWKF"HQONM8LYZ^H.NZY3'7G5*R'T>DYVB!D=][%/?O_*5WL ]B_\Z$\^_]$/
M?_"'S4'8!Q'45) @%'BQ J:M3!XKQ($<] C^"(8L@8T(D 37.8E')%!E]%R9
MRT91HE9L4$7X#.$KEO&C%+IH1C2"A@IC-,.E,4.A#.41D'!X)!XZ8X<\1%*8
M>D@.JY5CB%QC1Y0^JL2P+3%+]YB2.K[1C18.I)S@80Y#L!B1Q\B%=6XR"]V^
M6!*OB/$J4;%CHG8RN#<V;B@O0!SCA#JXQ0DNCCMIBDTJIZ>8Q&12G4/)I?KX
M1]&-;I%<1*0AVS3(K[J.JZE2W2-A![O9P2HN6L1=)2]"F$WZ+GAJJNMEAE>\
MY9726<UJ'II4"=A5NL:5WXJEN- EFULNQY;E\DV[>-.;YN22?-@1)G7.E\S,
M?N=\\1-/9\D3,/K^B19@ $)/ 1/6,-0R+#Z*\$\U3RN(B1FH3 :L[<4DYJ$$
M41%CXVQ$.P=QH JBS! 8LJ#*6":S#L+,GS6K62EH%D.;M8@7U!4&07TV#"'=
M2*$]\M'0;EC#:B##;,@("#:TH224?@-,4S,'$3D*)2-NC8DAA<>6Q/;$DY+7
M1;M56[A421%EO:UU<K.I2'!:DC#>R8XRX=-/BR)4QAV5<$:5\% ;9^&B3EA0
MAYICWVX253RZ)"LI*/$)4-!'0)I JV@!*T?<Q,47GXYU7T7D(5&G.E0]$I(\
MQA5;W1H9P6A2,K^#3+&$%\IEC5)YIC1E:YYLK<%*&7M3YA8KR;78Q*;^*SCE
MRJ5RF%/,YKAT7N'R)3"[D[YE;M:S\SM/,Y]I6H$9[#VHS0]__E,?<FKGM0U*
MSP!C*TX#"K"VD""$.\LYSW1&*-' I>#)C%O/EXD(N??T1')5!#/GR@*ZU-WT
M0&>T,U^LT$8#-49W96CJHK40HDR3Z'C1J]Z+1BVCZVU2$;\DI2KI&DLC'6D#
M&  V7X=M'>FEAC[]%[Z7GL8PM&(31^ $DA6#)<$Z3<D8]883-!9JC10FJH2+
MBF$-5QC<Y"8WAH-:N#0R*MMTM*.(5T#B$F\EIR-9\8H#28)3<?%3@I1;FSZE
MD7S'&"TUMG$B;ZSC'*M*5G6IR*S8.AC![&[^R,"RJV4^4#R\)F_)?'4R*E')
MMBB_\EN#U1:5)YLN\0U'S.);2+++!_/DR#S,XLD.=VRN'>ZTN5^A;0\V%98P
MVFKGFGG.LT%>V]JCPP=!]VFZ !,T:-[V%F/E!%E_)0BABLT3THF.M*0_V,'G
MGJAE^%2%V0%Z0NE.5X8Z.Z@*@V10:1@4U45;6MQ7/0VSD==LX/!&1C4*1"%B
MS1U> ND1OU9?+?V:I/ 0=A.=U'>58K"UQOPK%GEG5B[&2=HG3O!.H[(GH$(8
MW8<;JK@UO+C3JW[UXC[WA5]/%$#)T5%[HOU47\*2>)>8WO6^]^@XHI88"[\C
MQ!=!OXWO[ZZ"RM_^;C+XJ-KB2$*>;E4]?M5;XCJ8Q$R\(A6'3"<S,RQC?8:4
MH&GR*5%C+9&CZ<I1MK+VWF^^E3O6-]QSN?U;3CZ9YS\YEI579O'U/COW'CV7
M+S]79TEG']?$6JQE34;7,-Y$,4\W0+<5=5,'00XT=9: ,930(1O"@?'4(5['
M"?8T=FIG=B.D=C;S7;N0#*#F=B]X70\U0W#G0E+4:A*U0SFX)-A@#F$B1/ 5
M7U!"7TM$A(UGA$4X;%\2>9*W6V:R$,[S 1$Q8,[V$=!6-YW'%95B%;3G8')$
M>J[G;:SW C @AF6H8>%VAK!'*!"6;4#1*'0$>F-4%54U;RCF1V-! EK^918R
M]B;XYA$"AWQFH1'/-GS#UWPRUF+Y1@*F<W"EDTC05WVXPA9_,4G8MSN],U?>
MYWU'AF3&LW'EYRP=YW'/HWX<T"V_07)31G_B,B[;(UDNQTOL HO[)W/'D4S(
M]"XY-R\XAV8[!UJ_.( &PUKV06<*,XRG51_5U!_X R"R-8%^-H&V)76V147]
M51 >LV@<V($3E GR)((O<VD:%#,;I$\T<X(H& O/L% K4E#MB%TX(C39E5T)
MM2,N9(\WN'<X"&O_$#55\R3E$(3SE5\BM7A$V&O!AGB.5R60=UYGPR M11P:
M$(7,(X5Y,8AR$SK3YGG6EB=ZTB=L9&%H:(;^9%A4)#F&)VF&JO=Z&Q842@$3
M0]$HMF<YF6-M=+@5)P8Z]O9[H+*'@O2'?OB3/TE\A4B4814J^19P(8"4!M=(
MJ=-C#%<[MZ-%<<4[B*&)%G<LG#%^H%A^?04MI<$VT#,MZ\>*5W:*UB-+PI%R
M7F8^^0>+_%>+Z',ONNB+^?)9]--,<H9G^V%:ZM$?QEATVI2 XD1-"^.,3 =U
MT5B!A(:-TBA/UY@VA0:"'U@R*<-U(G)<+%,)^72"FG:.*9B.:?<+,?B"-?(S
MHP8DS3 T>"=>K491YY5>4",.YW!10P2$'45?B+=XNZEX7Z.0"TDV?6<VO7 R
M"A,^L7%Y:T*%=./^11JI8'ES1A_9;:97DJ='DB8I;F2HG:NWG:T7;M3)1GYB
M$SWQ89$2*;B7)Y4B;R:F*?>FAP4&E/$9G\37DW\XE/U&.CP9<*A3<$S9B*X3
MB1('5V^%.]QGH+ZB)IUX+!+1 1A'?GME2AT@+1L@H2+W$!J@2J^D+:ZT6-YS
M6"@G6;\DBW%9BV36B\=4<^.Q/@(X6FVV@$$'F$!'=$KW@$F'@,\8@3D*7+$E
MC3UZ0%4'F8K&" %B7!^S"16"==^XF2AB=F2'(K# 3YKV3]LUI:+FCJ59:@)5
M#41C0W9G4#=87A-E)-_@-'U7-N;PCT0D>$+(#TEDA%D2;+U6D,#V:_7^@(2/
M]X,4Y9",X%D*L1I1B'G+^1%9A84FH1)1)4<=1E2+JGHPL)V/.H:.6I+=B9TQ
MD)(55GIMQ(9]0D8AAGMSJ!6[5Q)@86]Z>!;&!R?RJ:HV-0(ET(>M.I3W*8CU
M:7RHNA$ MY0#YY\A "H)IU:4%"NY<Z#==U=XA3P<!XI>&2T2ZAFI-%CJIXHD
MESW=$EFKF&4A:CZ_1(O)@1#N8B\H^G]UR:($(S#XP8Q\23'":'3+^)<-2%O>
M%#&(&5N'V70^VJ/L=(U;1UR30 E&6D$9LD DF$$8Y*2?T$^9-C/+I6EHMW8N
M@C/M2)KO2%T"X3-4^J5P!Z;C1:8H9::T:37^5$,V0DAXA+=K"5F$<3JGC$>G
M7K,U9:-2 ^$_QO2$6-2@#C<J&'E@./6<T,DW0$4H1S5N9?BH)GF=U8F=U:F2
MX&ENA)-&+]E43A5B,5&3G%.'=B@G6O6>QM<IJ<JU@;2UGO*U?EB%\SFK9=N'
M O=B2)E\+89CO/I\^K9PK\(7NL-]VX>@1D97&.>@XK>57.E7Z <]&4I8(R>M
MB55R9]*6+O5E;TFBW I,-P<O:]:+XAIG @*,<(:NI.6 @QF8ZIJ E">O?B:Z
M?V:N3#>-#T1U",1;5Q=/' )/ZV1!EZF9([BDJ#".G':[4IJ"5GH+S\"[Q^!V
M+]0S=/>R4M2:T[#^0V2:@^6UO.'@7GWW7B([7UWB-2=;D+^&LG&*D(R'IV@Z
MG,3)4MTZL\FI&)G'$7331X;*D:'GA:4WDD4KJ2<IJ8XZO_![J=XI5$'! C#9
MA3$I5: 'JB<A;Z/:>Z7J*1O1*2"1JG0#;6#[M0G<JJX*$F>[JH&$JHJXA_0I
M2,BGG\L'8XC8B*U#?6KU8[J2*Q2'M\7:H,C*9*<Q&A !<ND7+81+?X7;99.%
MP]@JHB3J'6<F+YUE+W09KN**'W(V6@VX'_<#HYN;=-8TH^(T6PB2F#PJC8L)
MF;?56]68KP\""96YKQJR"2$8:;/+05$:(I.FN[BK=I^6FCDC(PZ+77'^K%"H
MR5W/4+S4@(]&0@X\))RU29N#UU%9,[U4PKUTBI"&C)#[ &R_J35+F P30$40
MB:$0 :@#YF(2+!)VHP)92!4=J48_2YV-&K_U&ZGRJYU#FYW<66[G9E3I9A3[
M*Q1.Q6Y\(BDI :KK.6^D*B>!1#H-G(>_W"EDD< *7!9EX<!P\A&M6L&K&HCV
M691RX[8T%LUN:U:0M!>Z<\**T7TU2SP:1TK'PSRE]+<P+*%B23VMA,Z[ :+8
M*F8QU[C(T:W="C_Q/,1L1KD':,24M\0T:HQ$%YC+"&@#1" 1([I3[$[0"(WV
MRD!7C+J/^9B8 -%8%]$ ^XT85';[=,8>U*3^4 J:[/@B5\HS\?AV=M<C/%+'
M/\-J^#AK?M>Q'PO(TKN0O.:;<*J]O&F]*[N;P)FG E&<X,&*IN$9AC%3SV9@
M5]AY"N827:BH(CFIX4:_D K51BN_2'MZWYEAB[I41[&_G#K+37$Y5*&%-VFU
M5YO !\S ?_3+HC/,9[VUQ5S6S$G,-K7,]?DF1!VKSTQCKC-6!Y=C:(47!%J@
MFO08X#<\:B)*>B7.Y@=8&1J6M+&AN9'#UAH^N/3.\HQ9FW79Q"2YD\O9;9:7
MF&O$17<P^W&,RQB83CROS3C0_#IH5!R!/'I.U&A UMB8J LRM_UH'-)U2@J.
M(VB[YYC1G<E<);3^##$R#*%&##&H#/ H0T.R#"_4(UL:)"D]IMR0O"L-$%CS
MQR$+TX0,IXVWR#<=WHN,O7.JD R9#<$0OFL#U*2AG*K319F,A26VOI#R.#_;
MJ!I&OZ4<J4,[RO![M&5HU:T<GD2!1B#V*%/UO_ 6JIY#P+NLP'LH F2A8G!M
MX6]MA7"]P+[LUO@6MJIZUW@M?+SZ5;YJ%VN!%]ALMYLTV(/MH'O[H,_B5^8L
MEM J9:RH&_2G$*ZHN.]LBV7&698-D?P2/]!QSSRGN3\'NL<8='])0 @('U!'
MT+,UK\]8@4!Z0 LR@8@F,KYU@2:C3IXPT;R=04NZF<^5L.:87*#9NYW^IMP1
MBUUN+"/-O6JHEC1XQS3;X#3GU8]_-VM4X[SM)<AN.H2\B;T&*:?9F]/=2S4O
M"[-55*V75[,VNV]QHI&<PY$--IX=%K12W=^HC)*G?,I3?;2A',I+JZF&TM7L
MYB@-YF[PQN "+*J94JK&?+Y_%&TW=>%9)3HKMNN_OL#%[+5SW9.$6(@D#GQ&
M25/0]XAJE19TJWW#2F2AQ* -:NTLW'&E\2PPG'Z"A>/;LN.0K;A>5MG I-GA
M@5GN<Y>46XS%B)>B/73Q?G1.SL0_!S%3CN]47.5.E]#1*&C8J&A9OL5=?HW]
MFDZ09C*'YG7Z!-SE2(X;#4*0W-&;YH)72FK^XB4CT9TC,'0T%YNQ&ENF.FBF
M@@Z0 1G(7B(V!YF]X5W>Y'W(UXNGPOFR%.2$(1?4N[)%1&WI\[U@#<:&ITZT
MHF[*HCZ_^DW51F^&%W;5;;3I;N@W(/:&>=3@F))BOAZVK4KAH9/UN([KPDSA
M6\_UPOSKQ,R<<MW68"O70$G4^%E@ Y?LO,K73QFLPBK8X4<1-6OMB!W.,@ZX
M#_'"@G7.B94;LD3NC.OCWMK#[(/9+=4^['X>YSI:S"CY?^D?R$CO3&P@ YWY
M$A.OL#W% VVOJQND5^P(/[K;8+[;'R+&EL8)FFG1:\Y/9>=!'DU";"Q0N6 C
M;CPTT, ,%TN/SCW^W2G]-!RKO!G5@WEJ\FW*1(A^Z#4]WHALWF_Z>"ZK4OTE
MSZX1&E,(GU9XZ9P\1NT[5"2)8:->O^0_RD.ORE6-J:T\;FK(87#D-UPH*60T
M8J%*]>WIG@<\X;YN;[R>A_P/""8F)8.#)8>$B(J)AX*-BY"+)"63E"27F)F7
M(R,DG)V?H:$AG"(C(2*IJ*DBJ"&OL"(@(+(AL[>X(!^[O!\>'KT='QW"Q,+#
MO\;$'!W,',_/S<P;'1O3U1P;VMO<&AO>&N$:&1D;Y./BZ1GAZ^CD[_#D&/ :
M\_,9]O@8&/7[_OOZ_@D<B.%"08(6#AH\F!!#0X<#$SZ4*!&BA8L7]UW^O,#1
M(<>/(#]:N#"R)$F,'#=:J$ R)<:7&RN@/ E3)D:9.%>NO, 2)\T*0"_F#$H4
MJ-&C2(U22%IA*5*G39U2D!IUZ=2I5;%>W<IUZP0*7[]*"/MUZH2R9].F'7N6
M@H2Q;MVFG2K!;=VX;R>,?<NWKX0(;R, E@!!L&$(A1$K?O @ N/'D!\W:/!@
M<N7)F#$SF+RYP>;/#$*+%NUYM.?2GSEGAJQ8<-ZS01^NTY;MV"X0KUIQNH3H
MA(D3*%"D0*&BN(H5*UHD;]'"A?/G+UR\F#[=!8SIUV%<?Z%=._?OV:F#'R^^
MO'CIT:4_7\^^N0OF\./'9\&B!7WE]I$C-Z[^(H7_%"<$&* @)I!0("8B3$*@
M(PLV2" A#!92"(04_O9()(Q@>,@D'!ZHR8>=>!*B*"2F,@(KK+B"XBNXV>*B
M+;GHTHLOO7C0 3#$(..+,,D08Z,R'D0C#3394+---=9PT\TWWFSC33GD,,G.
ME/'$<P\^[P"4CSSZ!*2E/UX2).:8 BVT4$06I9F11O]4E-%))%DT$D@LM62G
M27?B.:=+,-VDDU!_]@GHGS:-E!1)."5JE$Y#&<K4HT!!156D35%*J59857I5
M5EUY5999;84*%EABJ44J6VJ=!==6=>G5ZEMVP>KJ7G[5"IAK$226JV*(-288
M8[TR1AEDPPI+F6;^F74&&F>C-<LL:J:EUIEEK W65FQK1JG-,KS,DMMNE0@2
M8'#!&:=??<R]MUYTXG7W'7G;=>=N>-Z9MYUYYCE7'7KL/9<N?._!AZY]]=%G
ML'+Z[5<<<?\%)Z!O@AB(X @.1BBAQ1 VF+'&AYS0FR$>/V*(AHA<4F"!E%CR
MX2:;D%C*RZ:<LJ(KJ[18B[<PQBCCC+L ,\R.Q?CXHS)##@E--=C49DV12WZC
MS3CFE/,-E%%/2665668]3CY<8\G/UU]^&2:9_IP)T3\&+301FVV>O29%::89
MYYXA@41W2W/NN:=,?-*$DDHJV23XH"\);A-/'!TUJ.$K0>KXXY<RE:G^595&
MQ2GEG5[U*:E<A2IJJ*BF.I>JK>H%JEAUW<767K/6^M>MM_Z5V&*Y,N:88XU%
M5IEDQV:F66JH01M\L\Z&5MIITV+V&&*#H1H;F%+7EN,'+:+R2;B_ 4<N?PG'
MU^]Y,%C'77;SAH?=O>69CV]U[)>G7GK]NA>P?,P=;#\+*^"?<'$I].??"0 2
M$($TT0D1E, W'@M0(L3UFXI!C($:LQC(%!$A1!AB9!CB$")"E#).E"!$F0"A
M)Q)T(E.8B!6G6$4L<@,+6.#FA;B@GB]FX0$0_*)GOOB%#GLT-&4P0QI#6MK2
MF,:!)C'-24R2TM/2(8YU.+$=]Z@'UN1QCRW^53%,7AO(V,@FD+6US1]N8MO9
MU)21,+JMC'V:6]KP!">1  Z->(O)1^I$1\3UI' E*=3@&N63HR2.*8V#W*.@
M\I1)*>525DGDIA1IELPU\I&J.MU=2"6ZUXA.5:Y22^CRPA>]M*XOL#-,KG;%
M*P@\(%BGU!VQ+K,[WSUK <8[7K2(1QKBG099#7  :R#0R:\\#R!-HH9MJ)<;
M$_&F$;\1SG_Z=QS]R,<Y+: .>J@3K_&=[U[R$I]UQ%<O]+EOFNQZ7[^@J2Z!
MO8<%+C@8P92#/X0E; 7\&0Z _C>@!A$08@<4UX!"]L '.@AB -4G@?B9P I%
M4&222.B&*L&;E5W^@H0B$M$G8O:)5:BB%31SH<YR<1N? 6.'(-7AC4;J(Q\Z
M@TC/2!*1DJ2DEH)#2DP<QQ.?&(XK<6E+7NO2E_JA17MP\:=F(]M#XM:0,H+Q
MC'!S2%&+RJ>-B.2I>IN;H&[R1\3QI"<MN2.@]L@X/C;NJG[D22 )%<BB'/(H
M5)E<Y;82*4E9CI&<NERG1C<J4(WJDI<,75Y7UQ=/TLIUH@QL879U2E,:UI2I
MC,RQ6GD95R9/-;"DI?$D6\O*3LL!N@06+WG)ED7))AQ+,\9M<&,B$!)"0"@
MCG_,E9SER$]?^"+?N^HU/O3)UIOX B?[Q!E.^+FG.;]-)SKO0S"#Y:_^/LAQ
MI\+X)YR'/5!E$0V!;PY84.KF<Z (#.A &>C/[6;78PS:F(4<0<$%1D*#'&(H
M)DZ4"6.:0J(I.I%%6>A"%N4LAC*2D<]X$5*1]HAHQC@I2K,!C6\4Z8A/<QIH
M%UP.=%CM'#.%ATVO1&& 4!$?/ U;3W]:MC$55:E='"-&V&9&-KU$J1]6B=_>
M5!*]O81/*/Y)W0Z7.#<*2JR)(NM0>O*XLA+%QTDAY*0,N=:T2H6MC'1D736G
M.5/-)2Z8Q.M:4L6Z*%>YDWX9#*X"2\I2+L:PJJ16[QPK+=' $EJ43?-G%G#+
MR616LYQ%%05./ _0UN9GQ/Q6@B@X+F4RLYG^^?.>OG1+S?.!QSO8!,\V<;N^
M\S@ZG/&#)G#3&;!TLK-@RWGG?N!IG.$$)X "O.!Z.9&]["5PG_7<)W?K"4%4
M][-CV&V@N)#I(/.2K!*4\) F$A1"^**PA/)5!2E66%_\RG!G-KSA1T%*4AOU
MT!G+,%J!"2S$EBYIP:"%DA/=$8]Z2+'"%^Z2EZCXCX"8F\,>_J*8AKK4+[H)
M)F34R(GI)J>9Z*FI*U;Q5?<])Z" %5$U:7'  Y6H&ML1QV85Y.,(V=:U(A)3
M<D6RDANY.;+85<IXU>N4:87)O[HN,%L>I9?!G%C$AEEYKDS6\-0<6<I.ALW(
M\]TN+6F5H6J+&LS^H-$M4'A,?0)0F<5QIFO3)9UHMJ_0]$)ZN[BC3=OF:[?[
M4H_4(RUI2@_L?O1!CO[T<YQXJD"9SIWN(-9+ E*$/=6NSFX#!?A=GX/W8?J$
MT*L+VMT*(M1 Y-V0)2RA:[*3@(2B(,6*,-K"6=3"11N=!8UF.,,=YO!&SOXO
MT01,[96FU-J@5?!+W<$."$M8'C+E4D[%AJ72FWN+6$2W&-'$;A*W;=YK0R.*
MY83BO[783G%,XXH19?"ILB0F>MQJXP)UDT7Q^/C^1LI8%:X4AB\R<I@[<B(C
MSN2Y;DXN8:%DJ3R)<;UZ/Y.SRB1?FA>8UPFVRX=%+,D56RQ6^FY9DU7^L_QK
MJ9K5#*LUO?R*3L"4>=$"HWJI<$R-("#SM%KPU#VOQ2[1Y!R)%B\,V$W2I&CA
MTVB/QEOB-&CD5&G-,3#U4S#X8USOU'7,]77-!1P!M5":(%UG%W:E]EUH=W:F
MAFHQV$^FMET+(EX7E#$"2 @2HS+0U5XN0U&K(#/R)3,ODGB*1STV1$.-ET/,
MQD,]9%(#IE+;@&#!E$1,T@[@T$0T15-=HR6EYU-<4VZG%S99!":JIR9=-%0B
MMFY@5!%J.&(4X29V$V-YPQ" (V\%D1(U-E6\5R< %WQ^,E9^@E4Z$8B&HRB*
M.$A/$62.*"F3@V2:PA74QSG69XG:AW%YQ7W^J-*)'U=^7"88K>%EJ:1^J[0[
M[O=^R#(M+3=_M.09#L!FCZ4\D&$8SO-+=48;/^0SWE):'(1=JO5GS<0<KK4N
MT3&!Z5-;VL%-U(1;B=9HX&2!XZ0N&A@P!G.-(!B"R]4?PI%:H%9/)<,R9I=V
M+LAV*^A<-0B#YVB."'1:-9@Q\)B#HB8QF/"##T5V)7(*^DAX-<./.9,SU%-#
M,Z(+-?113LA# /9LRS!@*85@+)4.61A3$MEM&,8/82AA.'5%'+9%Z<9A;.AZ
M)F9&832'>O@V1N54*K8/!E$2M5=[NG=P4[43@+A'OE=\A;-O/[9CA*B3CL-P
ME:,ID]AP9_562>;^2!47%UV1?76UB5$V995$.N''.H %<EPV<NMWBL.2<JHH
MB\Q"/*TX?Z<!<S!G?Z58&);D60EQ#MX0#1]U"\7$00.H/<L$:,GE/<T1'7<Y
M@=&X'=;A@'R)C,_H3>\C35(':>OQ6N4D,,6%C?JS==O(C22(C@\"716UCI9Y
MF9C)=NEX:FHW" 55,0AE0?1X,@VU,A0%7X%W(D:8"K10>"R2>!U5D#327S\B
M><UPFT9#A=/&4IAG#MJ@A=S&>5FR-5(4AA9VAFA(;J,W>E64AEQ4 7$3G2*I
MAR &-R:98BZA5#2QG=9YDBC!-W:3;U9U57^3;X(H%(:#D\M'*) #9&C^-926
MXE95T7P-IQ7S.7'7=Q5P41:IHXG^V8E^Y7&@-'ZA*(JBN!BEF%AAAHI:^3OT
MYXJ3!8NDT:#44EAF>98VP7]5Z".W$0O@@CT/\Q_]H6F"-FC(F#[<!$[A8S[/
MZ#[LDEOG@8'^,C_S4S\=F'7YHVF<QA\+0RZ2.3(L$PH/DUJ92:0F6*1'FIEP
MMW;Y5'<'Q8.Y9C*XIE[X2%&A8$(KDD*L>7BO"4,Q%) U<D,Y=) ZQ %1&& ,
M66#59FV_^9O@ )P11@\6.459 H9VFIQDPI'HYD5DTGIPV! K:6)O&(>S!V]T
M(W"!ZITF 3AXLWN((Q3B:558E6-;Q4<\R2C^S"=(1V8Y0&D4OC2)]KDI^>D5
M29E];>$I_IF)5]9Q ?J)($<8AX%^([>@O9.*F2&67?F*EK49LN@ L51_*8=9
MRY,8?)$I,E%NH(4TO8 SQE2/^D0N(@IHQ$5TQF@OU;&BR=@NT@&8+OJBZ0$_
M\$-U-3H?!Y.CFM9,/-H_#9.D^/2#*51V9Y=:\JH][#JOSF6D](JO2BH@U-6"
M E4Q-W@Q](B"#C5J^8@B&-4*K2EL]N6E29B$.+1L_66F9XJ;#*F;M*$D+P53
M#A9ZGK<./D5N&F:&%'93.G6&8R.RSHD0& "=U F2UEEO<HA&-#M[=;.H,9D2
M'N%&+N$W=F1[-='^AV\D?(>H8T3[8\.7J9"SJ3^)%6415T59?4;)GW>AB0#*
ME.#72QX'.W]A?H+%*PH*+,O#?I9!H:JA+&B6MO&'&0[09L'Z9H5E+;#A61;6
M?T*CA!9E6L#X::M%EP4#7(@)'9!66[/E3=@J/H]&@5%7'0OH+Y,V/QZX3LFU
M/SO::0TS')+9" 3D"? :=D:JKWUF@O.*K_)*I YCNO2ZCC.HF0!K=Q%S(!&3
M,BECFBT3A*J@CRK"(@K;I1S%>#-"FR(%>0"VD%-X8%288$Z3O%L(G-SVL:%7
MLI^7LB3;G"JK4QO6IRR[ABJ)A]0YDG]:;[0'$6WD5"?A$>]6>W;S8NK^^V*[
MMQ,RR6^%PBB06GR6^BCNJ;22$Y05, %G18E*QBFCFBJE>CK^^91.B64"&CNB
M9)4E)[:J)!G&HI5LQI6F@3P5[%C#T[8RISN\DG^XJ);;,CUX.X1PB5U\RSWM
M-'2/^SVP!:[VHCZ$AAV#Z6C\$JZO!5SHI)B,>:Z5RS\-<[I+2K 5!0O:XZ/V
M>L2H>Z])^KFHU<0.PZ[J*(-PQVH19$\HXX,.Y4$E8D*XVPJRX,75@S,<I0L[
MPU^-1YO,8)MH&@TH=;PN90Y,U&#MH);#6:=9DT6B=Y'B-K+0TYPKBR8N^P\N
M>R:Q5Y)$U6[GVYT@8;ZWMY(F>2>-"B?J>Q+^\1L3+S:IY"F_R">(.;F3.8:_
M]*E6;35DTX<I49N44ZLZF5C 5\M) ?I)4^D:HUA*"7J5PL*@*)=R$6K!TG*V
MSZ+!F.5FF!7,#S#,N^0:KZ$XT-,D2#,];EE:]7A:?1:M=&FCU"JXZ+&,U^IT
MZX.M$?@N+ZI;A=D>SY'#UHR-/,RC_>$_RF2DLF8(FWL)(4 "^7K$0UJOIVND
MGC8N)@@@H]O$^QIJ-0BP"W0RL2L)!<NY6UQ"%^6/+61?]U7&OTNF.S12SC:\
MTM:0O,FFR[M$<QRG5A+25L2<(9M3>"R&**VG?UPF!R&H;9C(,NLV!0$W3]42
M#"%59)0WDBS)*D;^OI4<R9/Z1H?S>V)EM)1:%.AI?*#<OPX'E*;<%/P[JD9Y
M<:*RR@7<<9O$5Z3S<:(4&+/Z90^<E64K<Q2*MO4WB\#J9KF42XVE2J:$S&R1
M*6L21;0Q/;SXEN!2"-EUPJQU7 #C+^$ZSBL*6PQ(:#%\/C.\+C(ZHXDI'^CL
MF(_IPS_\Q-WEKISP"J=0NO6<SZAEQ*9+3T6<NO/JSZ9;VOBLNJ76NC=H( NU
M=^C%N;5;"@F"L"G"L*ZI,Z,E0SPSFT](4KYML5,X1-;68-L 80]&IW9\D<=I
M4Z9G8<Z-T@)AO2L-1D&E$!]&J-_[-B$)8MN)>WSH5-4Y;WO(G?BV$^/^BT>&
MTGM$.[]\@[3U6SCNO=3&"I].79^@*G%*1A9H47%7?=6O 5A=_;6$08J%%;80
MS#NX/&8J-RUH;;9N5AEMRTIP&[?-<ZI$P7_,O(N\6#W7@SW)Q+=_=B[+P8'4
MB,W'R(#-J*+6Q&C[<AW1.+CQ0S\>F'7T09?JO,[+1"[Z.D H* IE%P+_/+I
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M 2D5YHB:/KSTD"A]*4P200%&QL2U"QEI3:, 6SQ& B<YE6U"3%P2GF0"Q9E
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M/1+9D%;C,BRY5X<T,<3,#&676&-/1#I1_5=1YYS8\0#:I7L2Z(6Z3W0G,O'
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M=RWN:.KC4$W\@*S1%N)Q8FZ]C=8VF&;A_7IQ+_*L+7^]ZUGW8;E46RQ;'PL
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M$W))% -UW]GQSV<Q<PE-(:**O?31*0*SVGFIC&01?W@)KT_217W"9^>A#_F
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M@2(E>3U#57O3;=ZV)5DT;IVG<.A&>J W>G&72\.P/@[2/BZF4E=(+FO^]58
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M)$_3Q9IIEPVUEV)**4=MEYLG=C>\B8,EX9O^[>5>2=@T0VB0SY".*,$*!UE
M%R*HRCEXS2EK.]1H\#0+ 49$EA=M79B=VUFI&\F1TW:%.$!3H$>>9UAZDG$4
M>*(G>M(4<@.'K%>'5&&J=2.?]AEB4'5[3@6K)08XL,F3)I9&8+.KNGH701*4
M0FF4P'>@BM,I3>E5-0:)905(@:0Y]D 9#T>A_I>,?G89W==6RC1:-MI^!N):
MW0J+:+8)N$(]\)(],0I:#K*MM$5;VXJ+.;JN>,D9BVE_! B-V/=C1@HK5YF5
M^4JD27JDP]ASCUF,\EH^3,I_^"=T;15; \B75GJEB+86#:5#_$52)95UC4I.
M8)I2IWF:&J)I(UG^0-3U=S:D=B"FDVXJ:HDXH/!X;Q_V03?X=R]4;'KZ@_&%
M:SL$#82:CO/4LW^:$F#B C?UIP8)3DBXCNO5-,\@3O8CG<A5G=9)J9:JG3TP
MM1U);>!I-;C0J:TP>D A"J P=*B7)^IIJARV>G-S*!D@57VS;NNF*/395(T2
M1FV;JWSH,KDZ8H$#FV_AGV CH,.Z0<5ZH(3+. L*5@F78U0)H0YWB3Z&F$D*
MF<XDK])(HZYEF;.EKFV69IDKKL;$C)C[E9S(67&&9^KZ9MN:=,ZHBU"Z@-.Z
M?]?3KY:QKXXKNQ#G?[(KI$C*C(-9=-4JL$@7O Q;6X1&KU(W==VT$%[^(EQA
M8C!:]T/@V+'2NV#0M40P8#$LA#.?AD]LN@TZR3' %[[BVT8+A0T*Q(]_EU&)
MQX/S1;&]UJ<ZZZ<^.[_S>[W72[]%:T -*4.+QKSU(S65-F!8B'F76JE56[4\
M@,"5FGE9J[4RD6FA5YX/)AFGAR=ELQ2ERA5\4A6%TA08C,%*$49EA%VO*<)S
M*[=VXXYHV"B <[=ZB$;9U1;Z-HCC"X\LDXC*=YO'FJP'=6KX,'WI,*'YREO\
M2G%+:J%(;*'? Z/Y%[RJ=8!)+$VQNWU(EYA-*J3#&+D_9[M&6A3Z:DBO4A1>
MS,67<4C3>L1:7,9:S*1;>:_"^W//M)CMLS+^@A,2$2%2X20F6?=?CZ8,+V$B
MU%N]99<2\W1 #FDDG^9![58IP6=5'1,XC-RK?1LP=&K'Z1607K*\>QI?[\M?
M\DL_0LM#)#7*SC"18>*SAKJ<&,51(?4E%NMH4\,_+T7 6SBU/7#+N'S+4ZN=
MW]EYG#J>7>NU= )A8I,=PB$<8&$H:JL4QRP;)/RVBA+-TCS-)EQO=(N'+ZRW
MPK>W-4Q\_08DQNHX=O2(HX)!$)9CS4J)5FD98TS&2YIS^:>)U4I_!6N >>;$
M.'<]\YQGU$JM[WQ]N(N[A"G07-QC$AJM0=S.% PAE>'%A33&7MS.[HR)6JFD
M$H=SE5%;;!R ,ZK^9XHDF;QU6A+G(R?F3<$ED8W&$DVK=7X\>> H-8T:3SHQ
MM'&BOSNSIA_ACKCZO3 <;_TY(8+3R!UT0QGA>(FGOKR&A'Q:J/1+/Q9KRE!]
M4S<5@CU[D(C*@SKCF2GMQY5FA5&;G0J<R[?\ V*MP+R,M4>4)L\UTUW[J5#D
MQ9$0&\>\%!=,JA^L <)!'*!$".U&S2]#%CG-4-C@06R*PF.!MV(TD_B9S9(2
M)%8%R>&K5<8WN#%"SHCKPZI2B0L=T8\QT4IJF(?9SP)XL NHF,9(T/ZZN_Q:
MF)Y]NYTCT?-@?94QH9HS&1(MQNP<&;/;V0H-*["=VA$7F%L,HV9L?SS^%]*9
MR( >W95YUM#("S_HA3&+6C_VL\<9ZR8P_;')IA,[D2(C^#,EN+V%?8*+(H'W
MJ=C/K-/UF7>6W"46I=2&=Q*>S-1-W=U1C2)17<KX2X29G*>N3-U<?0L7:9T%
M3+5E?> 'O)U7"VV=I[5*)$_2<"2@&JJC8<QX<LQDDP%Y31PDYPC3/-Z /=XF
MZT&#7>* /<W0;)\S.9^,K8>,3!?O$XC&=WPQ(F/AD(;/EVK1QZPV@MNWK=L-
MO=M?W-K22N1D3+M&CMM #M%IU=O4=R./0=OSP-N2L="/$=%*SMF<S<Y:WJ]L
M++! 9\29L9=9?)E RHI4FH#-K9G!9X,'0;'^.@N=U6W=+)T3V2W3]JV:(IN]
MC'<DB8SB>;,H^A3->[/B>G>#.83)0EAX36.TQUF_P]5H]?,T]HW?3Z/?-$V$
M#)E1/6-UD#<F%=E<D$K@M;R=94W68WW@ELIY0^3 R!!=<2(1^%1Z4>1MM\,;
M&.XZ9?:O[]!JOJXHA<VF( $SQ,[>[0@2OV[BABVW;MN'->GB(U;#+2NXHU;M
M:5AP-1:#&516Y:!C$<3;MAW$\$"[!FWDYN[.2#[DG1W&0+[NOKWDX$[E4>XJ
ML6TREA/O/@[N#[TY$ WO[NR8PFUG;JS&\!QU#,M,9YZ <3:[6"JQ=NR;GOR9
M3+O=R9:Q4;/=Q!7^LH :>#(;W@H$,\I.S?HTWAN3PNQ],Z=049L,WV<'OU?7
M"E0=@I>.(CO!#+!P\S5OWZZP\YENU49;7^Y[(4P;"UO7,,$0M08LUC^ ZDM/
MUDM?U@O<RRX%,9W*1%:2#1,^=&'&.T_FC,=K*B0^V,-N[#E-[&8OWM>ECV5?
M]KYNL@L4[(&NPCJ-GVOWPH\<)#\IOJ&PE,W'P\I:.:>B*F8E03M6Y9U-,K,=
M#] *QA*ZV[_=[Z]2[I OVU=*&>U<[O$>Y Y7?6C5N$#\^6=%#Y0(^J$?Q ]'
M[Y9H2)0/T,$-L,!(C/1<\%&\<^KJW)\0).9K$,LKD1.)\['P^]@="P?^\_O<
MS=T:W[4V#6PWF"1F']C";KYI#_VN&>+G-26=GFM6IPJ,KISQ^[/=^-1B0NDH
M$EV^?_/A?_Q5C;T^:&N&]YEO$NIIPE(>V9V5Z@/V?_\_X /YK__[?_^W[ .
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MCHI47"@51SNFI:K5>MQ4/X6Y&A-FD+XC3G *N;L>^U@RNMFD9VS%&[?.503
MH<PF/?E)QHPUQ]$"ZV"XBE6HSH4M;624H<B(O#K9+#IK8BPO5WK:Z:F#78ZU
MI6D31,PQYXM_QOQ7,P\\BLU6]K1JWMZ7;!M-^E&SB-24)B2BV9\^%UI^6M(1
MA#!FP@("0;B]$!F'&#B,XQ[W&"=;[BQ*J#1[4.,:TV7)/UO"K?1\=A+^[H"'
M*WA0H5:[FKFO;G4!9_U=YH+WNP3,]<K<:Z(5GE"%$@*2?8W4)"?]CQY5$B*
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MMT^^I'U+B?5\8H'F&FP-)K^A1^3HL>5G2O<(2L=V.O(_2,)HOT4+M !I59=
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MTX>HB;JH1-LX3C4I4I5*T!=8]>M4[08IE!J_J!0ISQF? ,R=:=BJ5>8I?T'
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MV1DRO4>@$=ZK>=/LO)JIZ;/Y*EY4JMX)E>GNG<A!BV]9HI\VMH1/;=_\G1L
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MD):/E3":D)J4GIN=H:*CI*4P+Z@OIJNLHI.3,IZOCX^QAH8S@C,T,[W^NS3
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MJJP="S(#L81P?RJC];JNZG&<NAX0O# D=BV8 6WC.([N,9[N["[8>QWCB#W
M$CRUFIJ0G0K9H'K^D9--Y(:7A6=K& N&;)HRGY]1GT)PY>'<V@F?AA,VYD9%
M*N'<Y6 ^\46U\ \_;1$_Y6).SD?E&D.!S_E\ON*X.<81YR8?Y]1E= O43G5:
M%=(1TPL].G]^UBQ&CR2J29B4UCX6<:6T0I*^W=W]NMONT6C\+K8C+Y>EZ>FM
MWKT2/OU"$5U"%+&QPK.11\U WRDW/S+RF 3XT[,E9W7FWY2)R %N 1:@ 1^
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M<XVM,[C=S3,8^;WS'5YN?M[#D]Z3'K[>KA[^R0Y__JTC3IT_W:RS[']SPX;
M&@1KT#AH:89"A3)FR'@(,:(,&# BQI"(,2-$APPY+IQ!0X;!&08/DBQX3"#
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M&S,VAM!=;8$6&0=)=R47?6$RP'$=!=4A(;)>[95"&Q +\F4+N]9KD=< 5]@
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M^^5@1O$3>D)!B&@=<J-K+8 FVZ>+W.22B'&)Z.,8UB(9$9 ML>>)GVA>]0,
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M64:,%RY>Q)!!'GJ-&=AG-#\/O3WTY_"=DR<?8[P,&/=CP-!_'X;_^OX%*&"
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M8];"+3P'A$"X%#IY8T4( RA +DK(A$RG?51&92Y0 SA0 X8! W(G632  SP
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ML]NJJQ>[OPJ\P0N\<99%*S QQ3IWQ'N\>]B=WNF-KEPR6QL"'K *I,A=-G(
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M2-X#!PP4'#A@8(!6 0$$>!W0]:L K5O'DCU;(&T! VRQ&L *]^K;JW2O)DB
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M-.M&LF;T J^^,JZ22XP5NQ,WSTZKR>>Z?,Y)M4DEHI2G2*H"G7I&-  5*-T
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MGX!$$"C@@04&.)\1VBFA1'30*1$>$4'T@,,,+ZR@0@HIJ-"""S#(4$,..NQ
MCCD!FO.##SO<8 ,,*YQ P@=Q_=*+8QI(AH$@EEUP 08_%F+((402Z<@$F!PR
MP9),3I )(IALHLD#$CR0F2>:/>  9T@ID,HI#0PEIF:U((E!+QT(\P$(;+(9
M0@C%C&"""BN V$\TWKA8S3?6;.-GG];P&6@W?Q(*#J$WE/C7#XRNP\,..MA
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M:X!*"6"T5+&  4ZK@#])8%<::"T(5G1^Y<N(!4G#T&$U,36H,4M&#&"!#Y:
M!!J80 0**D0&H% #(_@!U "# QBH8 0@0%5B?''#4_E",9+AD4 35AD@;L4
M"?A?J]@E&M% D8FK81^Q;B*RU5 196AEGUFW2->ZVI4V-0OCS8Y3'.CHK EE
MH\X2'D38H*%Q.XCESM&^(\<B,&T]]>'C>R:;1ZM5;3[_ 636M%;(KB4H0*!-
MY-C0Z"#M,.V1@I'^Y E6JP(6N$!$.3 1$.[624_:=HX!^L$.<' #&62(>_-2
MY2X44QE##&E(C6C$("RQ.$5<8DFYA.XE=DFE442@2IFA12<R8]W0';,#Q3!&
M,TM WA*8H+SE=>8(IBF"99+ !)5\ 0QF (W:V?>^V[1![A!E*&\$JIS0>$:
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M?L\F.![F)%IR,3&!/C1604N68B:7*R4W&E-4@1/%<B6&$Q\H*QOQ*]9R%0C
M<S]!0"P89#IG0#YW%2PU/_&3%A>H,D?$@5,T  >P +1 3$ R,5O" ! @&1Q
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M_F<@+0DN*$LLLA2!28026ECAA4 '26$1AF1X](87%I*TB8.,J**))QK1HK\
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M%P-A3M%^T2A2&O9^\(<R-71P'M8R^;%#/-1#$3=Q%%=Q$#)$_S<A0V TZ$B
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M($9\N(!< Y -'#B0H",#!PX0)I2P,UV]>>W@,06KM8-IKQX^J :ANO7JU2!
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M)KR6R4S5;!>:J8$7>K?; 6RZ][WO!2>/M'G^)'"&LYRL(X0@KH0(="ZB=HX
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MVJ4R6 5#K#%#-"0SN%%XD=4HB-=JL&9[GB5JB$=9DI5S("94,*-E?58!$W!
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M-?!'LLK:KBU8%2 2QDP):=(V2# $-Y "'7 !NPT2\^E%9;8J2F$!ZBH7[%H
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MA!=.4,&!"2K88-9=6Q"A@ 5:6 &%5VO(8002J WBB$.=B.**"RP@8]TO*L#
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MK41P2Q$#YD:W!"# 19.4I(L4@#>];64#'> 1"KQQ'EX([I/?&,?M=L?^CE5
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M0 8YZ,$/?A $TX)Q/S!B/" #)^ !91,B(2=R"&(69"$6)B<!#)  +D4 ,/4
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MM(E=QJ1PE"<D9RO^B&E[#&U;5!8)MR1P+D,A 1J  C7@ \O9 W@K8@1H$C;
M B.P =3Y(7N#=WC'1P[(G?]X8>FR<@EPD) [<K-ZGNC)%^W94RD85(Z!&&R[
MN<:P#+3KN3'DK' 6948GDE?$=&7%':RK@PO#,'G5'!LJ&V[\0K8K!" 5B-
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MB>$O)-@L-V "&T !A4<!&\ "_3=B\EC1!*B%-6".&ST4"SC%#!*K7^R );T
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MD""$PP0&7+QRGU3"$JS4G,4RRM)?_I3 A+BL"PE%V$QG/L.#>04F+@RT"EG
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MT14G!!D393_-\G05MBP^EUA'8"'^\RY#40/R)"\J1T)/D4&&,2\KM00-]2O
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M4;1:K_ *J0 #1)<G)Q"\XUH1[Y815F:Z![/%X;6MS<LHY44!0P2N8:D0[]<
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M&C7@9<,--^!0( [^.>"@8((*-NA@#@1&**&$ PJ(5PT88JC77C*TD ()('"
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ML'V0\0- ,$:F56R9EQ1YI 2OY6PZD!<RH##^M)6#W6,)19-;";$T"ME;UU%
MX39<!GE)V2$2?Z<U7"-8SB-UWX,(TB21\9!I<"4P>X.1V!5:V]5*'PF2(BF2
MWS5P=16'.8@B+=";_6%*LJ4"B=$!OC(0!0&@&E!\B,(2T:1-1O)Q(!<Z/8F#
MX41.80@FK# [=));;\*42+E;2LDU2ZFD'L8F3&AS.D>5[Y1/5[I/JT F6LB5
M\&%T1J<ET? G2^=@U=9@-W9Q.98H:\B6XF,.3<)-E%*#/DH^T?0YGF,I7">"
M-%"?+^"B]-4B+05 @"F8@WF($S$K"K"H"I"8*+%W8N81Z1$2![1W%^ !_'4I
MH<B)UG*9FID^187^9WYQF4C%5#]!FJ@*58.F>9JG52FD0EX!JUNA:.XR>K"I
M,Y!6F[O(BW+ABXP%C/_AF]*2 B^0("SQ&(E! T&@ A=P NEW/#"@ S$@@B>@
M'1K "?C7H,<@ B=06#;@-GNS%WU12M"G&LZ&CA:SCNL9&JB56N-7%%<EC\N6
M0_4)>T'C'-UC;;TP?]JV;5JCE )9'F-&D)9$(D^3D".B;9N4;I^@I@]9"#C"
M#N?S$F:#H1HJ2[6Q(.$%7A8HHOZF('I5 ^C%?H*@)"OP%RRZ%WOAFWU( K-C
M0/\PD_[J7OM5#CKZ.3H)<@9V@X<P#J<3/<U E*UP.U*:<RVWE/ZH-?_^FFU.
MN6%3*85/6Y7YQ$[L-+18B(6HT)5?&AWFQ Q)UX,GQX/5A@UG^0V.L)91@H/B
M\Z99UY8^^K;]U4W,X3F?$X>#$ ,04G D\(>_(A$Q,E,!\8@"09C\TV6+F@"-
MJIB0&JDG16Z/N7<58(DH,DH_X:EV-D%TYIFAF51U%E0ZD:J@ZRVK2E6D2VBL
MZ*I=%7JB!T/"P19K09N1MHM&<"^KUZM"P#' &&W)<;(&0IE7E (A0 -"L +-
M"@0[0$\QX ,HL $FP ,G^ C5>H0?0$]-TS47=P(MT%>SM@->)"TL,#'W$&R^
M!FQ95 0TDP3&)FBFRUI887YSX6Q>]%8*HP+^AB!.-19_$\9RWQ:@6].O RE<
M* 5WRX0J2G.0!+206-NP9C@.098C/6*AJW9*#[B1&OEK^$:!&CN!<]-\? ,8
M8R<8$:PA&R)$_Z(PQ=D!.&6(,]DK2,,U+SB92K)-/#JG;5LZ"6:_A )_Z&2U
M2#JE,->4+F>$0KQA38-S'#"50RB%)(9(0@@+MG.%0#=T7-*5?&)(8!F&,6:F
M:&H-:-ACIB,E"$8.5]>SDU/&. AD;]HDA."C<WLDVA2']&L"+D W,="RTUL!
MKY(1A%JHAHBH$W&8"H"XBWIWC7@KC+M,DPH1#R !/@6#=-EF.9%1&20M>@::
MD&<MH5AG2Q6ZG"S^+JA(+JF)+NGR%5TA%J\I0Z@U+[B8J[9I6L/&BZ!!&O09
MOS1PGS&@ S70$CBP _!3 T+  A>@ FZ4$,)K A40 C<@!#!0?#A0K;L4 BVG
M'5$Y8O%!K#4 GIBQ?NF@ BT0 ]]*ONMZ6F7!>>]J0EBA,T9 %[HY ]*R#LW1
M"-V0"4$XM+L#-9HTQ-^F@@ <P/@3'B/RS^N1'@D;@%C8L Z["$_BQNT #_K1
M@/5F-]BUD1SID=KU;[2T-QN"7G!%C-1%;R+<DG#5SO#S1!A@B(]($$FC2%QC
M?&*3HSB;)()P8#ZK8+:EPRJ'I#1G<U"ZTT'LI$Y#G4\[A59Z3R168NO^M,1-
M3#S#@+52G+6MHW1ERG178B5?8V,F=X9=G"A=W UK" EM.L900E%K##KD,Z$.
MO +-P0(T<!A]6 +]4 $1 "-ZM\>&+(BWXK=<QJ@)@+@7 2-T-TG]-XF+3".2
MX\!MIBF6>V>8 D'3$GF=**J2EU09U<F4_12L2BY852Y7D2Y=T=FJ2U:QV;JS
M>59H-;NP7+LX1 1!<)[ N#?\ 6WNT+LD4 - T (:P )U@;Q#H (2X $V4 0G
M( $9$ -#8 ,?4 $M\ $MZ $I( (\-X6K, (B:%=R0QC,H8W5Q(U 8+Z[$:N=
M1T*OJD>XV'KKW,[7K9]D*V&^(*7;81#;L9#^WC9\D812DS23XX%?DQHUO;(U
M<L(E4LT-Y "Q$<MFS!+!%ZDV:Q-:&YM=' F,;P57$"Y,\H8V%Y(A(\P?D4>_
M@ .S?RFS]GP0O%"SY7"G-!C3B? ]CF)RA (*I[!R24QS1?S30+P=CA253GG$
M-9KC]J1.5=@F)%;4MU#40RL,_(0\LI G_)2U7@(? Y5T8;ETTD,]U8"F6ZQ0
MU#-CU*-0:+D(/F;&;5@?;DCB*3*'8*<B*3 #.# #+2!2(=(B$@$CC_JW?_F7
M;Y[7AXNXA!PL=4UE5;,X%$!W%< !(6C8G\A4CKV9H/IXV'*9HHH?3579D'X4
MIWB:K(HN*90N7*'^NC$$0ZFL%N+,RD?0RJ>]>KAYNPF"%_YA(&W614M"VRVP
M>T!P Z\P T;0 KV- T=@ @T@ 2U0!#  $"K@ RXP BYH LS$"R=@"S]'/ DG
MW=L2TOKQ+RA@=<1* SV0&_ 2?J2[V6RQ;&NUSH%QKS])-%:+8>[1KTJ)?]Z!
M/S,YL.)F'O:C4OW\SP>AK<D@U5PM/@I-X/(FP0\(@1PI@2#;+T*D+$>V'S5@
M7KLILBU)PC"!2R: @@WA(G$-J<L$@ L!1=;)0.C )#KK33V;XF<:E%NBWH@T
MU%3:._+TPXEDXSJ>XT(=/+A#/+P@)L)0\_Q4/'FBE4VM)T#X)<N =$'^F<68
M0 W3(SUC"G^<T E(OSI+'[96?0W>T#W?PX;BL\;;',/^93EDQQ*<1@-K7IP<
MD $NX@!F;_9^.U-S[K=FGX@+@+A[W:@4X==M5U.2.'>/V$R.3. 8%'F1)]F1
MO'B,3@\3E)F9G+F4%^F*_ZZ9K=FO*JNL":M@119E58N/QLJZZ!:F1;NDSGK,
MYJMZ15<& A.U$0\X, 2^YP) @ .N0 -&\ (3H $X@ 0F\  3X )%\ (200+9
MEP$0@ $]$ ,B4@$OX!VZ,P)4&W071YDP,40.PLZX- C=C%BYT=WAS1;IK$7K
M;#!UV1SZJ*]%G4@(H;3<EFV8%!($T7=3,US^_'??YT%N\,T++/8U7@UD6C?@
M$@D39O,?&$D@#7*!@'!S,R,#T]+"PK*BPJBRPM(",V.#@R,H6%-#0S-#& ,#
M^M)X M*Q@2&1ZO#PL)I:@8&1D1&;P>$!,D)B<M*+@I(2' R<TMMK4D*B/#(B
M(A(2 O(!(NUA[='!D<W!O<&Q >X=/DY>;GXN[LVAP;W.S?ZMGJW>3;]AVF%Z
MG\^/S?__S\,M:P.O6?OPX> UA RG27,((L2T:-2H4:PH#<3!A D->O30,23#
MAQ&AA7"&DADS925:FGCYTMBO%,!4I&"T(J?.1#PAK4!A8D6-&2U0D C!(0.%
M5@V:.FC Z@&$J1'^JCZ(P.II P8,%BCXFB#!5ZX-'%1-18%"!0L7+F"X4&&"
MA @2,'004>+$34@M7!SRVS<P8!<O6A0^9%BP"\"!$_]]C!BPD\F4*UN^C#FS
MYLV<.WN^W*3)9-&3F80V[22T:M6FERQIXCJV["5*:"])0CN);MU(>"/Y_=O(
M$2-(AALY7N2X<B-$A/S@@8-&C1LU7KRXH>.%"QQ"8IB (42'P!E&8DS04..(
MB0<37!AQ 97$<PH-,-A( D,"A!4W/& XA<)_]7"3C4#<>! ""2BL$ ,--^SP
M@Q!#".%##C.(\HL*+32( P\1%H&$$DKTAL000_3 @PTVS. 7(T"9H,S^,]7X
MDT\\&M 2BRRSZ#A+C[&T54$%%%@@I%I!6H!DDDE>P%:3;+6EXRW@Y /21,[H
M0D()O.C52$^$P?!))YNHB DA,+R02 HK!&-,+RJP((D--U@BB V9#+6))S'L
M"8,CBU3D7UH2.+ * ZNX,F2..6K0 8(C:-DF"B?\0HRDQKQ$ C/.7(301_ZT
M4X\][:2#3JGCQ+,!.^!\PRH]H+I:XS;M\+,/0+9B@VNCC7KZ$4<*,51E0QA)
M(Q%$U'P$T*C?R"JK-OX8U)!#)J$D@DI9MN123+Y0*DPC.?F9$T^((-:""B:D
M$ -11H70@5)8/=!4O%'-"\&[3&W5U5<*A#7^EE-FI3*!D6R])>1<$ES 08)<
M/G+(88L]_!=CA1VF6& 4'U:87X,-UL)G'G\,<LB=D39:9:BEEIIIJZW<!!-,
MN ;;;+C=1IN(-B=!XHC [5S<$3XO![01133W' XVT%"(#'*>R9T,*,@P! _2
MT%#>>34@@<(#%+R 1 M2R;<#! U8 $,2)30%P@Y$? #! S*DP.,+KJI#$*@>
MC(#"AC?P $011R#!W \[U%!4IKJ8H*%A,]1 B9QVRG#((B? ".,S"?$3Z@8^
MUL)CCSC^2&2001IYI))$FHYD6P//LL$'\FP$3;77QG033@Q;!V;N?BEBTZ4O
M)>,2"G#*< DF0W7^XHD,GYSYPIDY(8*1!J)'L,H#"QBZ0%9T5>"6HAEL@$L(
MNO@2Z2]Z63IY2YI"4U%'UB2K[*FL@MI-JZ>*$T_^J^+O#3ST_S\K FDC&]LH
M(.9LM:M&=81*N.+50C;"$6$)BQK1\A6-1I4J#6A0@Y[+P 8U$ Y0]0-:""G)
MM*JE$FQI:4O;FDGMO!6N1_0D$9&)G E0\ )UD: 4&K  5N(%Q+)$92I1(12^
MNN*5?2E1 0QPRE7H$C#NN:4M%)!+!"C0.KR<P!$TU-C&_*(=QBS&,9$1HV,T
MUI<QDLL%(FNC&]\X,LV@)C2C89G*7N.:E\G,-K6IF8AR1B(2_6V0Q#'^3M"4
M,S0B *$'.JB!\F20"3#AX <T4 '4=F""$=P "36P@ ;(DP((6. %1V!! R!0
M B#P0&P7>$$23K"5#N @"!)80 -.$ 07;*!M+># ?S2  1C80AONV!4XO@<^
M$)1 !2^H@0Z 0 2__:8(0=@!#5IP@A \"T$1L=8NE*&,R@$+&^2XD:)J@2//
M_0@N11*=6M02NM.A[BU/:LL%6/<Z:U#C2MGJ13&"H0*]T.08P",!M4P"C1&<
M8'ASJD29"#&#/2T/%*%P@0H6Q (54&.'TEO+H!H0@08PD0$)L&7V6''%M5C@
M+;%@%(+$1X))'2-2;4J?X39U+(/THUD [&G^_7XZM_^YRJ?_J]$ $6A4 6JC
M5@ALX*Z@]<!@!:N"T7I(ISQBU'!L\)PL_5%7T;E!^3%PJB9,B2X>A2UM&8,F
M &V$GQ0A0QKRA5R16<'DX%0X=FG@ A* 5Q#E-:]Y:84K250BOZ[7E*L S$CV
MA L%4E&7N\3T)@R#F!HO>[''3.PQ9DR,&M,H&3B*=K0@8T)F3%L9T:!&92S#
MHVST*+,^BJAF.--9(($S2)_IUI"%1"01)O0#'0Q"!LI[00RP0P,6T. '.0@&
M#I"0@T9=+907B($13"F!$@0A!V(+IA%" *\0\* 'UFM "9"@ NL]8 0_&(%2
M&@"#$%A@%J/$0/S^7E4/7"A4!3"P 80D]%LA\( H)QB!1M[7@0,_L"-'#94Y
M;^3!#JJ3GO9T9UI(-SIY*JFQ4,* !E>UJQ):9%@F1*A)*%C"V)4@!2V0 0TJ
M88E,;((3Q%4>19EGG4.H21$BX( R06 !>$I@*Q!P0%A$F@ 'D-10#'BB!(:T
M)%G<HYOC:].6T$?09#1#1C.B$>;H-]2>&HBH9"XSLY"*YEBA^7W7R,<'GKJ0
M"'9JSA*LH$[G 0X(YTA)HNOSZ=9BSQSUZ,/X&R%#$(K"E:B0A9,BQDU>N A%
MS! 2+'#!7.FJ,18 A9F%2\A>)\"*II"EB5!IA:E;,=BM+&#58!'+6$C^_<0)
M1%&*0)++!! &@BQM48:<C=C# )-9,GZ68YBN8<=(B^QD<T8TJBE9R9C-LFB_
M)F:S<0UNDG"SW8S(MCPKCK=_]K/B"&<Y0Q-"$(KFR$_$P,4P4"X/:I 3&Q3A
M!C"R 1)B<($-6)<%7]OND#<@ R2$H"D>\$$0&I ]%22A!5V!P >*  ,((( !
M)Q@""2KP@ 3$@ 3SS4 %1K ">(3#%!@,X0>@H: 5& 8&Q.V+"A34$@47!"37
M&*! :-ZI>\1#'R",\.?NV5@G+4EU@9[%/=]BS]3!98JP^!$POW>@ITXD=K(K
M 3#Z J89Y*D3-2;NNF.08[JR@$L!O84(2+#^@>U9X $,4  $2)ID!1R B6%Q
MP *23"BZ/%ET29)R!TXN.T:K=7+IPQ9*HG%G^(GPIP&<U0&)"?G(EYE^:;;5
MF]_LY35?#JI___M&JC15.X]SS-_@H*)"5R19J][6 4M+.XG481T1VAMP1L@)
M$ZW"$ZQ0)HY6DR/ %5>Y(L+2:*S8&%/ "T08!01)N0 %BBSJK4C?7UDQHJ@)
MZQ6Q\$L!B(7*620P@2 UMF!/U@""\K*7N3J,,72E6 W9G['W0P:-RJZ__5.+
M?V:C+#71;IG+8$-MU48SV.8:2K ;V!9(W)9;N^4SN/4;AI1(YO8<.; BH6 (
M+C #T:$(-O #-H#^?)LT R/@ :3T @^074*0 R'U24GP 0P  1[P T%@=P^P
M D@  W<' 2+P'G?' !\@!"[0%0G@ 3U  A<0 0M0 2_P%A[7 3(@()HC NI
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M.T97B) ($!,8GYD"(S!0)> Z* 0"%&!^I<!V>B=W"< 5!B";^V( "&")"=
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MEIIV(0T7X "JN0$5\!6GE'&R*18'4  &$!:R.7<'8*TD-7>Y>8D(H  (!U+
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M'I !9HH"S8D4)Z%-[:)  A$!U9L0%! !_Y&871$!00)WW,< U#J;!3  U9H
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M1+ "(] !(3!)&+  $W "10 ?>"H"71D6$< !JIRY"X !06 #7RF$B,H F?L
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M,2$1#=P(-Q(."]P,%17F!@,D( _GLBH3#PN_$1<-&'!+4,Z!@@(&"I@JUNT
MPV4.E37D-F!9MXD2$U[L-J!BQXX70<XK,. 7 83<4'(SP$#!+ 8-&CR8"4&"
MA DX)]B, *$GA @2*EC H(&#!Q A1BA=RG0$B1$EFHH(,36$51!8/WC0ZJ&K
MUZ]@M7X82Q9KU@]9S1XURY8LVK=CSZ(%$7>N6;=N.^C=P%=#!@P7+ C^IJ"3
MIP,' 1<H6*S U#6-'#\.$!! P(  F"M;1HG % ,&#F8"Q4D!7H4+%S"HUJ!A
M P<.';J:M2JBME,2)$KH+F'BQ D4*! )&BYHA8H4*E2P2,YB1?,5T%DTETZ]
M>HL6++!?QYY]N_?O+5QL9Y'"T8@0'#)4T"EA9L#/\!DL^!PPIGW0,6&V9+QP
MX8+Y,,D$E 2EP7-!!1100" &'8 P0F^)1'>=>."-1UUR*)Q@0@E/A4#77GYA
M8 &"A4%PCQ,HIJCBBBRVZ.*+,,8HXXPQ-M&$$S<RX003-O;8!(],!,G$$D06
M:62122RAQ!))*.&DDT@DT2022B!Q!!)89@G^)918'F%$$440(400/_3@ P\]
M\*"F#SW\$$000@A!!!%@%O'EEV#&Z0,.,[SP'730J;!""\:=\$(-.JAP @DO
M !$#"B-X8,D,'!#(@0\K3)#  I?20,)B*MB@BD,1D+#$"+\D0 $,1%3C$ 9!
M./"+ 0UH4$0U!B3   PO)/#+ 0S\@ $"W!P0@0\-L"++!SKXNE(+(8AC0#H=
M,(! -PS@()!&"93P@*\DG4#,2@JPX))&![K430(;*)"02!(UU(T OES334*0
M6721O0@A!-E()7W4+TG]BD3PP,#,VI*N,X7V ('PC+B>31+X5-,$0A&UP5&U
MV9;4>;8U-4+'4U7^Y>%=7G$%ULIXE<76RW3!?)?,-+.U%EI=?:!7!WWY%=B(
MA.G4TSWO+;80OY%]9)D 3#,- &658<:T2)UMVD!H$0QHF@6HI<9::[#M?)15
M9"N%&VZ[E> ;(B<,US9RR!T'**#2*7?A<M-9QYW>W77GW: 5CJ>"">?IG($%
M.LU$='TPS<=X3(@=AIA^\O'76#&F_/=9:#\1F.!I0-]T@08>B$"""2@DYYQV
M%CYWG&\FX#:55CRSIAH\$V1MXN1&%T/C[\ '+SR,.JY8O(HWXNBCCT$NT<02
MS3_O_)%)*FG]DD]*B64267;_))554HF$$5^*22:;::[)Y@]NRCDGG7;^DG^$
MEWB&&<2>,\ 0>*""O@"#"AF*@0YB , 1K,!1*"#!!D2 J0Q\9@,^B,$'),"
M%-C@!^Y*0 1$H(0.3 L!&"A$!VZ1  P  5? V( 0MK6I&:@ 7P=H@! ND "4
M2, 'UOH5"&Q@C5^LH .^0 @"<G !"*0D6PS02*YF$ &*%* %--0( U 01 (0
M8 ,2*,8\%/ !=Q&L(B&YUT5FI8R$I*0BRN@(TG(UDC#FZUT@(<D "/ O)6X+
M%)]QSTR",A35"&9BNNL<QE;3 ;10A6R())DB:T,;1%[E96O)V5;<0I>XS.9E
MCT0*4LBFR4UZZ).=Q,K)3J86#^RE+X Y4-#^=/> P\3G<L5XC!4)(!G,#
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M52QK$AAHQHKR 6B2TKR-/"0T-4E*$!RE974QI"?12U]0FC>4I=0+!S9@.PS
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MSG<Z-I #P"$"&\ "13"!$1 *+G #T^4 $H !.N  =_4 (. #R[8 .P "X)(
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ML> O#V #&F"2Y781N-7$(W$ -<!K!#/%7]L1)( ![R( %C #-309$NA!'\$
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MK&VM*%(!NM"18G1RBB6>[H2G6S)C4*XKAJ!@!RAC',$(1KB=$(A)#>7QH%%
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ME%R2J)R3:=H9C!70-H?+&6)VA.@$T)BR-2XYDKUCU*,*@&1 ;OF/C:B= Q"
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M&Q,ON^%(PKF<P_FH"+A#@!.<PFERR#F<R'F<QXF R_D=+L-C*1./HCJJT"D
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M8S(3J9X*'@>XKH!35)6*CI9Z@)"*J8^J8]BJ,MMJ,DB$'!-X'&]K1  P  1
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M$WS!AJ.,34+.)(::+27&O?$;X$IR6KNU,VS"(G/"X&'"DIK'+#RIYEBV*UR
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M62,-D(X"#4PTP4PT?7!D"8B8X"M/F'Q02E 86#!,! TD4 !)*@74SSCI)&/
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MACB 812X@ 8\, (3G" %*A@H08,4"4QT0 ,50%8RGB$ [YIN4L7LBIZZ]0\
M> N!'"4(4[PEOK(,X'S537%U31HO#CZ,7J(!H4IG/)J^&$-?^7@A[Q#CW&H-
MBI?I"/*AHC>9B:#F- ZSU\5^F%2+%)$N$U'Q7Z02U2I;638D\XU5KZK5E1''
M.,;18G1JMD7K>%'^.V4U*QC# X2?E2<'!MIC"U[0'@*]AT!\S;. X--&OSYH
M0AP"9&'90VA")PBQ8E,LV<J&R,8N$K(D.I&'3 0##VD(LW%[ 25?-&?.UJBS
MF@RM: \A2D0LN%>(X%4C5DVD$:@V$CP9P?PT< $*& ,?"LF*8R382]2YKD^J
M*R;L^E=<V!$WF-V$TS>:>0]M_HM1T07I/9YR#^%-=[SN,JEU 2,8JV ER$(N
M%'@5)3UL5X1AZ5,?+W0A"U^PMZ6K65/^YJF_EH18)0FXITB^58T*3F0S R:!
M(?B6MQ288 0?T("M%[ ,[XY#(;W<1K8FSN&"+-!<Y(,5B=$R)W5!A:3^%UGQ
M224P\B5[L,:E&08/5UXO$2I9(L6#5([ED<)HVO2%X 8R.6I.9+EPT&%+/C(0
M-_CD%%-7*JC*UY67GL0L8_EDK^DR<(I3Q97![#EB-K-8M3/6-)\5"6E5JP_J
M@U<XLP>-+I#!>OP*Y_? >4!M9.-?$UTB06)-0H,\K-X+^;5$*W:QCF5L(B$K
M6:Y%VK(7D@&F,:UIS6[6TY^UD0IPA"."^TW!F!_H@4=IX%$&J02T[0 &BN(
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M)4(BC'24DO:N(-+^QQ8222IR:;N[>)BD L+[?J+CMO]C<SYUG::J.ZO*#-M
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M7T]OK^_^;N  +YZ @0(""'B'T$"ZA 4,('QX\.$Z=N\H#C"00(&#9,V4/8
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M2TC"?4RX'R4@(64H$Q#+"&0@(21(03WPT,YVIK-"W&P1@GC0)79P"4=L"&A
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M5DDB&(B!;6QS3<?U>J\W#O/U&K-Q7IJ8;&J!: &$>YMH4*P$;?U3&I'^ER3
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M)E$!&5"=$A 3E2%90?$H<7AR*&<,5P<NT,-K<RF)T 26>?E[L%$ KQ%/YK
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MPQJ"**5EV9ZJLTY[J1KQ)$^"N)=IR99.NFK^ASB)L0:UQ'67&AB(34JEMH<
M"8"%L^=L^;*FH5@5Q$:8Y54O (28!TF*M3%MCBDV $,LO08E_3)N@GJHA/I
MLIBH E:+Z+:+ZP$?ZX9@]"&XPTBI*\0?*\2:K6EOXF=2G,J,1R";%B8$DPLS
MH3HT&L)2/_.;/%!Q-) #,H "*N"Y*? !(N "+Z !$6 !._8 "]  %H!'"+
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M,^9_55/+)^ !L&P"&< !*! #(9"[*@ #&_"Z)P #&##-'_ "WSJ?*- !MLL
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M2 @F)$!) 2Y$X., !KBPP#L3E##)(QYH,*4B&ER R@ .J' *)1M(H)4F!I#
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M)?QF.#3#=K9Q!@0]XI:/.^ C;\5-G>J4^]S8H0%Q8Y#(1<*;!?(&'LSE-"T
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MP@ P0*1X\0$A4,,&<#Q ; "X\!;,^D%BNE?QTJMIR*FQ*4*&%KP+%KG%^8R
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M<+6U9SHM1FS%CMP^<U<6<@M3>!=F@,IWL?="/R$P(G4G%;51UD!4!M3&CZ=
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M(8DC,J'$((04DD1#BR#2R!%%'&$$$49,\H@EEV2R29*>?,)D$$&04LHI/?A
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MK.LS_I/9O$K2FN'!QE[VZEC"C$,PW@3,)P4+3G=4PJ^!77""S$D>\VI%G:T
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MSKM_%2=4.E.B\=5AUJN] 4N@Y'8O94BP?%J@YX:6"[4;S5=@BQR71*J)5 $
MO6*7UU-O8K&^]7852 IA/PFN(NNDQ%10+,IAK5BE!Y=PLKBEYX=^'5&(],-B
M=MAB8LH6W1(_PXO^6HGQP,Y6IY]<>[:GC/V'4AC\348&K\@F&$]Y&._C&/[A
M?_KBIV;1$5)&M26RPMB815DUFXUJ1EQK".'8-168(Y(ZJ3L2-FB5A8MG=$5@
M>)RJ"? (MT8LJD@<=52'MZ=Z"_ZX"X C##(8N(L%JX9K#='0G5\LTX^[69)+
MQBEP CB]#B? TSG- E?< C@M @"*._Y@ 1P  B60 C\- X<5#%3<QRIP B9
M B$  AV@ 140 2)!&Z^6RP_EEDSZ,2\DP#9KSA"\A^/T+,J&3DN9R>OLO(28
M4S![RL!$I:ILL/[EIZ_\RL3WHC=9NP>5L Q[B;><7&,! (D]%KB"L47^.@
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ML $:@ ',%@$-D!X!QFZ9.#"XFS$"\S/E01_^VNQ^^F=DF,QL2TFO'6JT1_O
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MLQK6*K2[-XYJ5!NRGC=4U\N/-"-%I#N1Z(;^P=BT_5&0-&)3W&:YID16-A=
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M)&T^=++C&&X<X65O9P#89U!-L8K'LJ-8(17^#W4_@"E^ CNP_@- A\D6&&9
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MJ2]]G!I<NF/4R+'6"!XQ-)K/P567PGSN=@]N:HX=$0T[FS::0Z B::I X[?
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M^&P]5NU,0 LU4/-U69=L"A)-^JMG853^7JFM3<^Y3]^YO\5'F!J$<-/\X-G
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MLA&0 (XBN7G)2PX=W( *I;AUNE/8GN+<H#]Z")"^2G1_8#9+]R!M2N0N7&8
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MQ]" 2T:[&',[ZT5PSU%RN@NMN=D_[D RE34C9T>W=-N&:_FFOM=E+!-\<,A
MSW@KXJ1FR'I:C-'^+,T7B,*ZLD*%&]U+&R015(CZC(JJ(E%B?3 IDQS!B#N[
M)9#(?D#+J6!C!$/97$=[GTIW4:<HE8WR1)%R-P%J=7VF 5DW$ $4>^JRN&/E
MNMCZ9-B@@7+D31VH9LUWLB3X?&Z;5'6Y5,,A2-!K<0>Q@N!@M];H)- V#=SR
M@H;YI=WQ;[C0C8EI>.)X'F&%//O68M_*>.&ZH^L#7ZUF/@O2/>[&2D0J"44H
M (Q0KP)3Q)S+N4<,,$8<4YWKN0 04U5L1D8<  201F7D4@. Q#+5Q5QLN@E<
M&?5! &>L/%K85>2"JR.RL#Q#9Z#1#="1@1);O,;[IFYJG @$P0G$O"W^DX)R
M>ASY,,@&$7'<],&'+&;*:1K=A'QG^RQH5K+(JF 4[(<*]AN\!E2W41LDX<F?
M/!&?LHPID1PFPY)F%R6L(0'HRW+F69Z56JGAIP'OFU#PF90^]%!+QW2;QB@T
M$ .0LHHID )41 (B8+4<(1(2\"Q1A:*F$K!#R'HCDB(XU;S-.;UIZX<@%V E
MN2S;K#J!5&QVQZS%"XPSZY?6X6S:0KN/U*+540 ;]LZ&%S$BQICIL0SM5</A
MMFV1R:-D['7_ZH24NZ29N[ET9<5'3,4QA<10K-  T H'K3AHM- PU5)G!,9<
M7%^+PPC^O!F(<,8?_=$%8!\&0 #Q,TD"6;O^BV6;")D_D65K<PK(^."\_85\
M-8V'>EAWFF-'IU$</+U"Q;%")"O4&E<S'YHYT2*'2-U4'4G4>XIFS2+!ID4<
M2V6"?:@:(?<;JCRL0^6]N/')(R'*83*^IJQL-P5:+UDE+$=/C,BS18,1M9PG
M"X7+0Y1IB'(#W05U=B$I>T&U66F R RK$?!%<X; .XQZY;([*@V,%=M?9A;5
M5YW-*!MRP5J"WLQVPP;..E5\%[FF$VO.*")PM\-(5%5A2Y95B!G/W/'.V8IX
MAR>XB&.C*F;8_4R$;*2+44@PG>>D]*5&%;+16]RO#4W%;F6Z+S7&$5T9I8O<
MLT OS%T?L^#0AO#^W(0 TFC<F+A0TB2-#-F-TK4KVF0*H<N1@6Q:BV@7<<VI
MV9",K")9H<_GWK[AMLC2.9J,DO-]P>^-P1::R:ILV1ILC*$"$:DCX*;5IT*=
M9LPRO4K5H7XZ;("JS6^91][[*5[MR;^B.JYCRB9JODI%$A9@)5CR?:_<UEK2
MB8YVM YU-DR[ _N7BGI-*2>@-R*0E0?(*?F4M80##@TXVRH6:[%)IHS=Q\=7
M)!OLEI5<G9)MY"F9S<GJ+(,T)/? IM"J  CPV6&X,<\VV@2I2-Q",=A:;0?
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M)1N:&$1+IHF/929DPC*MTC)B4@[$]4SAD!'^J4A1LY)8X[!<F;<;O41%LVA
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MNTO/,DP?_59O^M9_X[M?GNNI#IX]_0K%GM+O[%0?Y#6?9Z!M]8BZII?^;>+
M%>13&+U1R:3OF?NXWWX(OGM[G+2 T, P2%@H.'C((-C J)BXZ%"(J(C8N.C(
MF*FYV>#@T,D9:MGP( K:^1GJF7J:65JJZ?# 2JH)Z\H(>_LI6VN;"^S[:GHK
M.FR*O)C,B:E9N6Q)B>DH/6IHW5A->#BJ['RXP+"@H)!0GH".?J!^T-Z.'LX
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MM0R'^=\1?J[3EX[0BQL\R>#F^"_8>W5AF9@65(+*B2K]+&@M35_4MN[@&$W
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M.HW:T%LQ)NTZP(S,Z6B6+'PR,(GCFHQ8P-6:T5RCKHDY*<F;E3I?&YHY+O)
M?<%/_AK!2^YC%UG^?(<HUDJ.S:'KZU5];<:]<J5XDC=69C@^WF',;3J^%6:<
MY%X\X]YWR4-H$."G, V8WIT0'<_1Y>2N#P9]#&7^"L?P"5YN&J41T&O4J) :
MV'ZL[;OIF4_D'\X<3"Y66^7XC=<JIL,ZZ#N<X:6M'(@.,J:C\%CI\ P?2C(Q
M'PS?Z,(K\8N>Z!!.XH?2TP&CT_71<&7XY^II80W2,F[+(9R<Q6XW:W;.ML+=
M021IDX3L3(R$@3R>H[3NP&0MUM9T[&+F;.'FH<:WD9A<;D9_HI4<7_9*WA+]
M=$Y=W$&8CUKGU@NS7S7[[5R'$/LP[N/.#[DP[F+.]6 NYK7P"NQ=&H_^7$=C
M,^\'JZ'GE<TZ>2*9(V%6K.>>S$O7NXU[MVF^*IZ9G?$:I? J].CTL2@2'Q_:
MB9T4C^%9VC$LS3&,SD*./OBCO=DR+=+7V,J)Y[6TM!RKGC2DZMU%@]L+9G(,
MEIK5WMUMJW;-3EAOJ>P0C*_"$I.H>)(C7.7#%XQP;?/_"$$?V6W$;?M_/%P^
M*L=5#M&"/<\=]+IMZY:PGZ)+99H".D53A'8+,V=;W_5PXO708?;;+QW'8 N]
M<"UFM<'I)&T@/"/)_]_%;3U6'!;ERS0B=7<'GJ0ECG$\G;6FS=D4/OD5#P@&
M!X.$A8:'@P:"!X*-A(J'BXT)B0F2!I2*F([^C(:7B8R<G9Z(HHB/GHNGAY2H
M!ZVOL:R6L0FMMJ^VM[J\E+B]P,$)"KH,M@P*Q,G)P\W#RPH+MLK$S]30"]#:
MU<P)QM[9T<S(Q\@*R SHR>GLZ P-[>;JWN?LZ^G>QO7IY_?R_ #_]>MG+V ]
M?^H*(@2XSYW#> P6I)/8;E_#@Q()+F.HL*)&=>>\Y0M9;^3'@]#DA?S&SN3
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M^;,)K:OM;O#LN(3\J940=#B]UYU.[F'3TT\0/! !40T2!9114548%%,5&N5
M51MBV&%6(&XX%ECP?!461%^199%W!ZKDXDWX'#/-C,XX QQ==N78UV!] 59+
M;7DM8LE@L!7IRBF.(;98(:9AQB0GEDE6V924?9:8DXU-N=EFE6E2FI;^ID@I
MBFF*.9:D(P4P^=AJKQV P"!O%NF78#WV\F,N=MJ%XUPX<C,C,\O$%>@UPMUT
M8Z!MT9,//?L<MU], 3WGSZ(@#<A2I %ZY])UVG5:GWX0U1?>>A&5*I9&[36W
M78#NU 2?@0(5*)ZDTOFW7TX9T3<33KD^RE,V AHJTDA$/0CA4$)-:&%245&8
MU893;=CLAR!B956)2GD53XEBE=60JMB]>"LTQ+E%HY_GZL@+GG\%IE<A/;8+
M;RVXP>L7:TB2:68IIRV6Y&F>(6:9E01O^8B77)9V69?ZAI;EPJ0!K)F2 J.R
M+[[S KF7CX89MJ,P>*H[5S/ ]5+HC-(TDW+^-C:27-S+QN"C73EL62.3=3;#
M=!&B\;!UCTBABF,6K1=QQU!:^1C]C]'\H1>T<\"N]^J R54*('WB>AK=IH].
MBG6M.T54H*CK $N0V3LED]'-\B3M#8,/1%BLW$(IE93=&2[5K(9V6^LLB%=Q
MFR)8@6_;;;CS-7<@3,H]NIRB+@,J\N2UT$E;G43"-J0D]]Z[YN>I-'EP:DMF
M6>7 "%/&,,()I[[ZEIZE#GO!!%?IKV@%JYGF 07\2PJ;<0:/B.>QR4:8;2$#
M@]OD>_Y)8P(I=Y-R<-#;0A.@PAU'KCGTQ!ACSC\SFER+)=F3-+C5Q8S2MZ>J
MJ)"KYLU7]JG\A?W^:ZDG36<3=]H=/?7ZNHK._A:E-G/D"D;CJY\!Q?&2F2BN
M;-'HFM@8J#/F\$,B<GM0@R@$MZ#X)%D?;,JR,N2WJ7BH6M6R"E72<:*NB"5%
MH_K6XF)E*,FEJQOH&ADPDK=#S+V+1T;JF& VL1=,8&PUGY =ZI9DN],]##.L
MTPSMHAA%*%+QBE*T(A2;.#'7X<X NSN3EZBDI7X] @&^.U(0];(Q=^5I<G#4
MX?-X,[+I26Y0V!N./F*F#P%.HVOC4,:J]-<H<J!C4T#C8P5;Y#.B,2X[SCD&
MUIP3O[61JE1HJU388'4K^^A,4OT(ATPDTKWW^&^!"8(D(!-X0?*)[7K^-Z$)
M+%4Y/6,X""ARDY '@5(W$]YM;U"I"@J'V15N:6LL@SM<_S0)MAKN9AV\(,>A
MX@BR7; +%WG)'"NV68EZ84QTJ[A2&0]6NC&.<715Q*(2K<@Z=JKSG?",73IG
M=[O)/#%A:E*8&3]Q1%;4BS8_LDUNX-@\YM%H>M8CF0UY@\,;Y8Q1AA1?-5;9
M2: EK7PQ8PL^P 5+:>I*18]\%4%\]A)5$3)2$^$)=,S3J:=-TI,/-)L^-+H_
M :UR?%<KZ2<;2$AG(M FE)*D+73)2Z* T&[18I8OIQ4M8F+E*F,)BPN/V:W^
MU4=Q!"*4-LSE,I/%15 #K4M CY>Q;':.-;C^@=(1(V,[TIBS2W"='3RU&$\J
MOFZN=;VB.Y7(U]KY5758:N)H5'<ETG&,$<0K'F"LF;F[W"E'/ R&-"9+O:ZN
MS([DRBQP,MHU19VE&=SSJ$\CR4>A\K$EAEP?,RL(R*OQHWL2/66KP$,JM:5J
MMJ%$D 3?Y\P)XK9G>Q0?0**6VP3M!VT\:V8 4S++6?(4F@_))5&)RJ&E4,4G
M3LTN5)/)CA0-CKM*8^EH-?O:D@TK4&*%; ]SD4V-/39CV#S3+3:AFC0^R5]T
M;9C"]&6EO>;UOUCL7>^\-&  SU.=_C58[\@()M $-I^=>-.8)&,+^\JI<NQE
MKT!_6+FPZLB.<@3^AC3ZU)N672,X6JVL'V^Z'XMZ+Z- 8]&XZ@= JGW216U9
M*2"SD1'BID>E^UM<!&6<$IOP6&S!.N!6,8I'%B]WO"1!!TW4LK9=.?=1P0KM
ML-+A$^D654/8+4JTFMJ4:@&36L4LG#&G>CC:MFIL-]5LR?STC1+G,+T:_EA@
MVELGQ6[L=TQJA1'Q95AS?NETA#7P@?E:8$TT.J\#?C08#6U@+.6NK^V<(J8W
MW=^%F1'"IZ#%887HHWA%EHW4]"J.I@?B/KU,H2C>VN-*VX_A$*>W+D;M2"BE
M/IZ,[=<SU&VMVV=2H<&OV)@497>4G65*XD23BQ3R0-Q62F)T]+G/U7'^=*!<
MPSAC^R.)3(:$DE4WI0JSS-::"C#339444@NJ\*9J^Q;"/T.U&#G9>W5!@]%A
M._6[O;-0;%F1B%@UDI/!;(4K8+\H5T5+$=*31IB ">QP>$JZXHIX=(+/N45*
MMQ5WX:R$J%6#S3U?TX>G_MC)<Y3#/94X<I&C8QZ7L]EB2))[!%R+^K:V\_-I
M;R#JR:W_U(8@"[K-I-)1]O\20MP CA(9*OT5C>N!W)@"^5:PG:"PL"&.3*[R
M@#4ENC:<:QSC&- 8U]LU,GA9;A#>K=Q)<=:T@NGN86KK*W@W'/U 6O31QEK.
M?W+U\^RB87GA14XF7T5\#S.9SD0)U!8K(\C^SRF[C;/NXA8/\.4Q'T5)%P#S
MD:;X ! V^D=S_HJF9\3I4?=6T27F]2 /79F&Q#'/E1R([N)SAN-X9Y&9MSA^
M0N^) UF,MDQTIENM67 X2[/B_[QLU1LM_H)]WDM)V][CU?H"?1U3KN.TMBCA
M,7J8PXR,6'3K7"<[*LUVOQJ&0Y;<SJTHU;[16@OPJ&]7-]RM&_<4/O59VX5W
M4R6 (])FLQ)_2^90#>4\J?9&'I-GUR0OBL<9D0 *A;4Z# ,P N-QBZ9.!3!Z
M5 2"ES>"[]1HH9=Q$5=@ G:"CD9Q*!AQ$ >#5*2"&$=/E7=PJ+$8M# )FR,;
M0I(D/ )0M]<NUI3^9WJ6  B@&\!@;;XW,@ZE8K:6637S#7K41SI79RXV43*"
M0%L%2E5C;V@!7:449+^69%"70! T=3-Q/0P  1$0%LXE?JCT$J1$#M"S*P@8
M2Q2D<^\W=CRF6<?!ACSU.*!E#1DA+6]774S1;B'R5($#.&O&72E"$918@$.#
M$'T'>%J5/7"Q;S6":CVT+A(H4!+X3<83<FYE1*^'&OP4,0[C1/'D>9\'@Q<W
MBYWG@K8(@B8X@C0X<9\7:1/W@BEH  /0.\78@L.(@L&(C#.(C+8HC)GF)'3E
M3I]6)3TX"8=A>YJS6/TFBHO%"TEXA,$0CF#E55#XB<.WA7\D([%6B(7^ DTT
M1Q+$47\^=1P2A8!MPWS/MPU]F(=C5X_=X0 /TA]^2'8;L1SZ $O[B(#/\(=6
MR(\1=&\0Z5.DI%4WHP EDI'%]%T9V5V&(XEBX33LP1Y=QQ-?P2(Z%6UK42/I
M&$<ADW*Y,58"UT\YJ @55H&4)S%-TG"MQVF:UX+/:'K-*(- "4:]2(LDJ(Q&
M.6FA)X*_&'&E=WK+6)1(&91"R8P.MW #(UB=X'A/0E\.-FJ-%1M[UF>AB(3K
MHG)-^(GH&&*WYC+Z2(B$^)#E$I<9A3UE]X_$MW, N1(WHDA\"677YH_2ERU2
M1YA;MI"$Z4PL<TA4MH9[6(^BI3Y[A(8[\2O^OA8-/ $]F(F9$<&9F*F9XU>2
MASE>F1EB+\>6ZI*:PK \\>*-,QDDPU-H!)<9&/A?EE>#[T0 +JB,*QAI(DB,
MS/B,+SB+*^AHNOB;1OF+Q[F4S*D(R9EQQSF+I1>5OOF<R\F4OKF45?F42$F4
MNAE7LR$:3)0*W#0*)H=[+^E>NA". =6 <I2:YL50,Q4,,,:.?60NQB<C,O,6
MU",L*1-<=89'6R=<79A]>(F'Z+<XBND/_1A_1#.@PC=>VC-BSD0SN34,A^EM
M]D=*Y>!WSD".;Y2$(IJ6ZB*BR9,\KEEAO;"BVGA8J3$;L.DOCK<)8Q(P%AA8
M^@1@N4EZJX=Z 4;^G-DI<<8IBZ%' ,8X>DY)B]ZII$!9I,SIB\MIG!EWC% Z
MG5'JG%0:G5(*C%6JG;\9I<])I6**G5U*I;UYE0B&16 B1N)D8<73.7-2&QOC
M&B9*EB:ZEL* +IS(@%\U(\@W*/PYETNX? GXEIBEF/:H/@T)*(#T<V[!H374
MH(^9F6)'H"GQ# ^IB1>:EY!*A81BD+!&+A8J:S7SCA@*)Z83"61"C574HQYX
ME1K7FTF)E77E>4II@F>JG&/ZE&%JBP,F@M5YI65:K+[Z><7X@<)IK,6:G<C:
MJ[R9K,>HI,68K!]HK<@JG .PK=5:K1_XK=+JK=YZK=]*C./ZB]M*G<_^NJ[I
M*JW/VJ[L:J[FRJR?AZ0$<*](^HOY2J_&*IV_*IW)^)UZQ:9>]%=A@C%M9"1H
M"5_OLGLP6:B5I:=*^*>JV0M4N"A<92/YQH3Y*9'XMEE;LVW =R@)JJ!0YA:6
MNHEKJ% 7BJA;2+(EVZEWF$=FUW6+>9#A$&Z(8H\RDJ5%.J7\BJYEZJ]!^ZOG
M&K38BJS=RJ[?VK3KRIQ+2Z[7RJWA.K7<"J[="J]42[56N[5;.[5=J[1>.[;B
M2K9>^ZY=:[9JN[9LV[9NF[99"[=7>[9QR[5SZ[;I^JX#0 ![R[=^*[9C"ZY"
M&[5YF[1/"8*(JPFZ.*5#.GK^]:-=E##81)/^-$DGB&>$;Y2YH.B  ^6)3CAX
M+'EBL-:.)3-E<P%_"<4RD#I\<Z: D_JQ&KNZ>1AX* 9S&BNH# F(Z->0*I.R
M*@M\?W<HD[69U<,3 R  W!H W(J\RJN\>(NW<GNW:MN\S[NUU#N]UNNUSCL
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M@K"+#ER#6P2+YK0YK<H:B16;@99G_S0D97EX:HD7+II>O#!H\(5X_&;!,=F
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M::9UT7R]QX2 56I1*'SL*8Z3HT[(EX7RJ8XW\IS<:4T*%S# U$.S!&MJXZ,
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MR:Y;?+?7J,WH2FIL.A>FALUQ^0!FR;;$5X5W18YN.41S6[_O,IY:.\Q@U4/
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M.X$WW==<N^-<DF!@8V)HZH).W68Y[>=MQ21_^]:(:R9O:]A#XAAX^J9><_:
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M5458'#NV>L7*HT=4#DZ5/&4*)<I2JU:N-%7^*N:H33)+T8Q)<Q I!S)OCHH
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M&RYWC^[M%B AY7,]A-Q&S J\#U1KY53A%4O^6^<2XC5XT%8@5&5XL(5XC>>
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/[^ELQH6.U_0LZ9(>"  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tm2527059d10thqreporti002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2527059d10thqreporti002.gif
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<TPNW7+.-32[!L=>RUIG476;OC&S2U5+Z0 $ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tm2527059d10thqreporti003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2527059d10thqreporti003.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M,C(R,C(R,O_  !$( 10!8@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M]2MXG_\ !?\ _95U$,,5M D$$2111J%2-%"JH'0 #H*?0!RG_"<_]2MXG_\
M!?\ _94?\)S_ -2MXG_\%_\ ]E75T4 <I_PG/_4K>)__  7_ /V5'_"<_P#4
MK>)__!?_ /95U=% '*?\)S_U*WB?_P %_P#]E1_PG/\ U*WB?_P7_P#V5=71
M0!RG_"<_]2MXG_\ !?\ _94?\)S_ -2MXG_\%_\ ]E75T4 <I_PG/_4K>)__
M  7_ /V5'_"<_P#4K>)__!?_ /95U=% '*?\)S_U*WB?_P %_P#]E1_PG/\
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M6'_;NH_]"GK/_?VS_P#C]']NZC_T*>L_]_;/_P"/T ;E%8?]NZC_ -"GK/\
MW]L__C]']NZC_P!"GK/_ ']L_P#X_0!N45A_V[J/_0IZS_W]L_\ X_1_;NH_
M]"GK/_?VS_\ C] &Y16'_;NH_P#0IZS_ -_;/_X_1_;NH_\ 0IZS_P!_;/\
M^/T ;E%8?]NZC_T*>L_]_;/_ ./T?V[J/_0IZS_W]L__ (_0!N45A_V[J/\
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M.Z(R7*'1M/*73![A3:IB9@<@OQ\QSSS6E10 R&&*V@2"")(HHU"I&BA54#H
M!T%/HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ***BN;F"SMI;FYE2&")2\DCMA54=230!+2,P12S$!0,DD\ 5
MY7!JWC>?4=<\5VBK=:-"I33]/612EU'G'F*1TP,L>Y/R]N+&D^-#\0UBLX5_
MLQ-VRYCE<;F?&2J]-WTZ^M &_=W,_BN]-A9,T>FQ',T_]_V']/SKI[.S@L+5
M+>WC"1H. /YGWI+*R@T^U2VMD"1K^9/J?>K% #51$9V554N=S$#&XX R?7@
M?A1)&DL;1R(KQN"K*PR&!Z@BJ8UK2S]J_P")C:@6C!+@F50(B>@;GBI%U.P>
MXBMTOK9II5WQQB52SKUR!G)'O0!81$BC6.-51% 5548  Z "G56GU&QMIQ!/
M>V\4Q0N(Y)55MHZG!/3@\^U1C5],80$:C:$7!Q#B=?WISCY>>>?2@"[1110
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M2S_\&X_^-5T]% ',?VOXO_Z%2S_\&X_^-4?VOXO_ .A4L_\ P;C_ .-5T]%
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M_5SVUZ@Z!\ _T_G2'5/$]SB&'28X'_BDD/R_AD_XT 73J'B,#)T&SQ_V$O\
M[77F/C_Q=<^))6\%Q0Q6TS,LMS/;W?G(% )\ML(.^T_7 ]:Z'QK%J.C>%;S6
M-3OIKN6,!8K>%3LWL< GL ">>/;TKSFQU.X>&VTGPUIL4GBW4 6U"\C0GR1N
M. "Q(0@$;B  #0!V:>);6>ULO"FG&UL%@C$8MGNN7P.A<J.3UZ<GFK&N>%5\
M7Z5;VUMI5E#<6>6@N;75<NA.,EAY?.<#KSQP13K3X(:&WA\V^HW%Q-J\C&23
M4(W((<]@IX*_7D\\CMS<^G^*/ASYPU*U?6M$==AO;5BLT*Y!YZXZ#[V1VW4
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M^?/P[_X%3_\ QNCS?'7_ #Y^'?\ P*G_ /C= '3T5S'F^.O^?/P[_P"!4_\
M\;H\WQU_SY^'?_ J?_XW0!T]%<QYOCK_ )\_#O\ X%3_ /QNCS?'7_/GX=_\
M"I__ (W0!T]%<QYOCK_GS\._^!4__P ;H\WQU_SY^'?_  *G_P#C= '3T5S'
MF^.O^?/P[_X%3_\ QNCS?'7_ #Y^'?\ P*G_ /C= '3T5S'F^.O^?/P[_P"!
M4_\ \;H\WQU_SY^'?_ J?_XW0!T]%<QYOCK_ )\_#O\ X%3_ /QNCS?'7_/G
MX=_\"I__ (W0!T]%<QYOCK_GS\._^!4__P ;KG_$'C#Q3I-U%I(7PZ=8O$/V
M6WCN)F<GL>4"CVW, <4 :OC;QY'X8N;+2[*RDU#6;XCR;6-MI"DXW$X/<$#C
ML<\"N>CT[Q5\-K?4-7?59O$6F[ YLI25E$C,,L"=V !G.,YST[CC(?%^I^#Q
M<Q:BUOJWB2:1MDK$S2V^X %%8CY1G^$9!/3CFIFN/B3'IZ7^I:-<:A8,?,V(
MQ+)_P$$GIWQ^- '=:/XD/Q*5?LKM9:>C;98G8>8S  D>_4>P[\\5W]G9P6%L
MEO;1A(U[#O[GU-?.&M^)=,\4?9?]7H6I6)/D21AHB&)YW8X'(Z\&NST_XGZ_
MIVHV&CZE96<\<RQ1Q:DTK!'RHR[L 0.>3P,>_6@#V.BN7@US5[FV6XMY?#<T
M# E9(]1=E..N"$Q6:WC:_"S.BZ/*L2[F,=Q+C''0F,#O0!W507E[:Z?;/<WD
MZ0PH,L[G %>9WGQ>MK>!RUSIT;KQM5FE;/L%'\\5P>L^+-7^)FKV7AW3,@3,
M5:5AM!7J20.B@ DGJ>GU %U[4]<^)WQ$\CP]*[6<"^7!(NY4AC(PTCG P3D_
MH!FO:/!?@C3/!>EBWM%$MW(!]HNV7#2G^B^@_F>:SO"WAG5O".D+I^FZ=HPS
M@RS-=2;Y6]6/E_IT%;?F^*?^?/1O_ J7_P"-T ;E'6L/S?%/_/GHW_@5+_\
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M4$JY4E6.XDX."3R#4,7PXLH-3AU&'6=7CNXGEDWAX3NDE8M(^#&0&;@':!P
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MMHMK!&4C9X_,N"-Q;)&<CDGJ5^E=UX<^$Y\-,);>[T:ZN@<BXO-*DD<?3_2
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M,4?V%J/_ $-FL_\ ?JS_ /C%4_ G]H_V+<?VE=O<'[2WDF6[CN9$CVK\K2(
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M8!$ZEE#'+KM8<+R #BO2JXGP?X.OO#^K2W<QLK>W: Q&VLY[B178LI#MYK$
M@*0,#^(YKMJ ,;Q7*D'A>_EDT^+4$6,$VTR%T;D<L "2!]XX!/'%>?\ A&[U
M2?7+'RI!;Z?/<R1*MA/</$PCC#L=DZ$",Y"978=QXZ9KT;Q#IMQJ^@7EA:W/
MV:>9-JR98 <@X.T@X(&#@YP:Y+PWX&U'2/$%MJ#_ -GVD46\RK:7-U(TX*L
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MT$DL3(DJ]4)! 8?3K7G6E?#O5;+5;&Z9M.@:":.22YM[J[>6158%EVO(5^8
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MG!RN#VQ]:XS6[+PIIVN,FK^(]7&IQ+%+#/(ID^R)YK,F'\HJ 6)'[S/&!Z4
M,T3XG7NK76EN;"VCM+F>VM)AN8N)94D;*]MH,8&#SSUJQXS^(=WX8U/5K.*.
MU+6]A%<6OF1.V^1I"I#%3C&T9[<]ZUK#X<:+IMW8S6TMX([,Q.L!=2DDD:NJ
M2-\N=P#MT('3CBI?$GA'1]236-0U&YNX8[JQ6"Y:)EPD4;>9N4;2<_G]* '6
MGC[1+V>^AMS<R-9Q23'9"6,B1ML8H!DG#<<@>O3FJ,7Q BO-4C6R@+V:6=W-
M.CI^]$D.SY00Q7D/[]N:J1>%O"OV%534K[[)XCA>&T0<#;+F<[<)D'C.9,X
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M^H3:/'9B![5I%LYU\N--SF5<%^, KD*N&YY. *VCXTN+CP)K^JP6Q@OM*\Z
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M2LZ.L01XER 00V?-'&..>M;]U\1(X=<O],M])N+EK0RH75P-SQQ^8PY& ,<
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M=I.-JL'VYW8('M5W2)_&3>&+\N^L'4R]F+436[J!.2?-#%QGR^FXX"@?=)H
M]9HK$\(RWDWA6P?41=B^,?\ I(NT*/YF3NX_NYSC'&,5MT %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!6L-.M-+MOLUE D$.]GV)TW,<D_B2:LT44 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
( !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>tm2527059d10thqreporti004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2527059d10thqreporti004.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
M+0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0":
M )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L \ #V /L! 0$' 0T!
M$P$9 1\!)0$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8,!BP&2 9H!H0&I
M ;$!N0'! <D!T0'9 >$!Z0'R ?H" P(, A0"'0(F B\". )! DL"5 )= F<"
M<0)Z H0"C@*8 J("K *V L$"RP+5 N "ZP+U P #"P,6 R$#+0,X T,#3P-:
M V8#<@-^ XH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C!'$$
M?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%
M!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'
M3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC[
M"1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*
M\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS #-D,\PT-
M#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/
M>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('
M$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E% 84)Q1)%&H4BQ2M%,X4
M\!42%3055A5X%9L5O17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)%ZX7TA?W
M&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;
M8QN*&[(;VAP"'"H<4AQ['*,<S!SU'1X=1QUP'9D=PQWL'A8>0!YJ'I0>OA[I
M'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B<B52*"(J\B
MW2,*(S@C9B.4(\(C\"0?)$TD?"2K)-HE"24X)6@EER7')?<F)R97)H<FMR;H
M)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I!BDX*6LIG2G0*@(J-2IH*ILJSRL"*S8K
M:2N=*]$L!2PY+&XLHBS7+0PM02UV+:LMX2X6+DPN@BZW+NXO)"]:+Y$OQR_^
M,#4P;#"D,-LQ$C%*,8(QNC'R,BHR8S*;,M0S#3-&,W\SN#/Q-"LT932>--@U
M$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.% XC#C(.04Y0CE_.;PY^3HV
M.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_
MXD C0&1 ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:
M1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+
MXDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q
M4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9
M&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV %
M8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUG
MDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>
M;WAOT7 K<(9PX'$Z<95Q\')+<J9S 7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW
M5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$
M?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B 2(
M:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI &D&Z0UI$_
MD:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:
MU9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16
MI,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVN
MH:\6KXNP +!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1
MN4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'# [,%GP>/"7\+;PUC#
MU,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZV
MSS?/N- YT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':
M=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-
MYI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_R
MC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<
M_VW____; $, " 8&!P8%" <'!PD)" H,% T,"PL,&1(3#Q0=&A\>'1H<'" D
M+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T,O_; $,!"0D)# L,& T-&#(A
M'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,O_  !$( !T D@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M^&V@MEVP0QQ+@#"*%''3I4M 'F7Q'F_X3#P!:#2XKH1W&IP0YFMWB.&.T'#
M'&YEYZ9K3A^%NFS11QZUK.N:U&A#"&]OF,61_LC'\Z[EE5QAE!&0<$=QR*6@
;"I#IEA;P1P0V5ND4:A$18@ H P **MT4 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>tm2527059d10thqreporti005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2527059d10thqreporti005.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M,C(R,C(R,O_  !$( '$ L0,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MILH_>1?\NTN/^/AAU\SC_([9H ^K:***!!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ?-/CR"+_ (3WQ 61@?/)S]E4C_CW8_>WCZ_K[5W_ ,$8
MTCM=:VJ1S;9S$$_Y9>S'US^/OQP7CI ?'VO', _?-UCMR1^X;U.?S_G7??!,
M#[/K1!0_\>OW$C7_ )9?[!/Z_P \T#/5J***!' ?&&-9/!"*REA]N@X$0D_B
MQT)'T_''>O#--AB.IZ4RHY_>Q=;1./\ 2&Q_RTX]/T]S[I\7P#X(7.SB]A^\
ML;#J>SD#_/IFO#].C U'2@TEOGS(AQ%;?\_#=]W^>G3% SZNHHHH$%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!\[?$/3K^Q\9:I=75F(K:[D=K
M>25K=1*%@.<9&3C(_,=Z/!_CF3P;%=I%I]M<_:D1R3>0Q[?+@! ^4<Y)_IUS
M7NNOZ#9>(=+FLKN./<\;I',8U9X2RE2RY'!P:\2U+X7>)HKZ:&STVYNK5#+'
M%-]N@0R+Y*HK$$9&<8Q_+J09O/\ '"X6%G&@VGWI%'_$UC_A"D=N?O=NO:GR
M_&Z>,W.-!M3Y1< ?VI'SAU4=O1C^7UKE)_ACXP>%@-%G+%I3SJ5OR&5!Z=]I
M].G;J=/3?A7KNH:Q/!JEK=6-C,\S&Y%Y#+MRRLN% SR5]OPZ$ G\9>--1\3^
M%W#Z'%;Z<EVJ_;!>PNID63&SYAC.WG]>F:X'3G!U#2R4M\^9%C][;?\ /PW;
M;_GZ8KWCQSX7FN_!R:9H&G*9!=Q3&.W>.WS@Y9R2,$]^F<_E7F5C\-O%T-]I
M\C:-.J121F0G48#@"9G_ +O. 0?\>@ /H2BBB@04444 %%%% !1110 4444
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MI UT',Y.06\G"KN^N<_49J+PM\49O"NAP:;I_A!<*H,DWFL&F?'+GY>_Z=*
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M3_\ "J]4?Q3*6NGLYC$LB8E6/RSCS#W/Z^O/3FOV>_\ D'Z]_P!=8?Y/7LY
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?.BB@1Y3X6_Y+:G_7T?Z5]*T44#84444""BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>tm2527059d10_exc1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2527059d10_exc1img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  Z +X# 2(  A$! Q$!_\0
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MIUB_VCX<_!RX8S)L:26X6:29A)O16\[:T?RAXP#^D*BORG_X*=_\%B_V/O\
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M7B;Q=XHU3SX] \'>#?#T"_;M=\2ZY-;7;6]O"L=AI^FV.I:[K.H:;HNF7U]
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MX*E/);^S;]EZ41?LT_L\8\N11\"OA#CR 5MR'\ >'EA6P)C1)(Y& 55:2/:
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M'Q9^(?Q#\3>.+Q);J>TD\1Z;J?PP\!:1K=S;,&2\;PAX6^(?B>98Y%FM[O\
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M![FWU".RCU>#7Q#$M]9>+8[U/%ECXB9_$_\ ;4^N+;7EM_$1_P $)_$NL?\
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MJ:-&='6.WFUVYDT+QJT_X*Y_&O7?^":'P8^+'A_P7\.+;_@H?\3_ -JKP?\
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M7AO]J?\ X*4?LL_M-_LE?"[]O*]_9"^+?PI_;2\;ZU\(]"\5?LW>%OB9\/\
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M9^'=,-Q?P>$O"?\ 8UW!INF_TF68"L45#&J11DQQO%]F@ED1$EM4CC<[6A:
M29V[1]H<JQ+M27KND,^QF3:UH%VL5VAIXU8+@C 9200.H.#Q5Y(HX\;(T3&_
;&Q%7'F-ODQ@#&]P'?'WF&YLGF@!]%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>tm2527059d10_exc2img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2527059d10_exc2img002.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  T +T# 2(  A$! Q$!_\0
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M&WU[!_P1R^-WQ-^.O_!>KQYXU^*WQ1\6_$+Q3<V?QYTAI]<M?#UG9Q:5X?\
M!Z:7I&G6=EH>FZ;9Z99Z9:6R+;VVG6MK%/,\U]=I/>7ES<3?WN4 ?YLVN_\
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MT3^TA/X:6SFU&U_MO5_'7Q&L?'6H:)X4L[+1_M:V&GP+J_B?4-<ETVVC\/\
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M*>EZ-<K!:^./ <_P:^*FNS>%M=1HY#<Z5)K&CZ7J+0H8R;FQ@??\I!G^,/\
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M;Q_\-]4TZPBM_"/C_6/A,-+\/6UYXU\%6L&G#^VX[/40UQ/:+%^[M !1110
M4444 %%%% !1110 4444 )GG'U_DO^-'<CV!_//^%%% $8MX!.UR(8A<O&L+
M7 C03M$K%EB:4+YC1JQ+*A8J&)( ))I)K>"X55N(8IU21)D6:-)526,YCE4.
MK!9(V^9''S(W*D'%%% $U(> 3W ./\_A110 'C\P/S./ZT#G\R/R./Z444 1
M);P1RS3QP0QS7!C-Q*D2+).8E*Q&:15#RF-3M0NS;%X7 J4]O<_T)_I110 M
M,95D5XY%5T8%'1@&5T9<,KJ<AE8,05(((."*** $ABB@C2&&..&&%5CBBB18
;XXT50%5$0*B*HX"J H'  %2444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>tm2527059d10_exc3img003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2527059d10_exc3img003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  [ ,4# 2(  A$! Q$!_\0
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MQ \ ^(FM5\7_  O^(&EVMG>:OX/\2QVDDEK.R6>H6&K:-K%FYL==T+4=/U*
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M#/C+P,M_+H^AS3VGFZA+X3\2?V$_^#FS_@M!KO@;X0?\%!KOP'^Q=^RGX?\
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MO];U*TT;1;!]1U2XMK47VL:Q?V.E:79B4W&H:E>6MC:1375Q%$_\[7PHM/\
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MQ/I7A+XU6'PXT/X7>-]!\/6EGHTEG\-_C!X8T&+1X$^)GAN2XGO-6O+WP3X
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MGPF=6LHCJ&J^'?$MOXOT;5/$-Q=ZSJ+71F%I'POC7_@CQX.7]A_]CO\ 9%^
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M_P 02NFP6NI&RTVU/B/61/ZC^P+^P[??L;:+\=/$'COXQ7WQ^^/?[4/QEO\
MXZ_'GXJMX&T'X6>'M:\87'AS0O"6F:5X+^&7AB[U'2?"'AC0?#WAVPM;>*;5
@]=US5K^74-6UG6[N6Z@M[+[_ ** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>tm2527059d10_exc4img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2527059d10_exc4img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  [ ,4# 2(  A$! Q$!_\0
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MQ \ ^(FM5\7_  O^(&EVMG>:OX/\2QVDDEK.R6>H6&K:-K%FYL==T+4=/U*
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M#/C+P,M_+H^AS3VGFZA+X3\2?V$_^#FS_@M!KO@;X0?\%!KOP'^Q=^RGX?\
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MO];U*TT;1;!]1U2XMK47VL:Q?V.E:79B4W&H:E>6MC:1375Q%$_\[7PHM/\
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MQ/I7A+XU6'PXT/X7>-]!\/6EGHTEG\-_C!X8T&+1X$^)GAN2XGO-6O+WP3X
MU*[TO6-'EN?"\*F&^O0#])**** "BBB@ HHHH **** "BBB@ KXK_:._8\A_
M:#_:+_8;_: D^(,OA.3]B[XH_$[XE0>%$\+IK:?$9_B/\(O$7PI;1I=:;Q!I
M3>%%T=-?.N+?II7B(W[6HTTV=F)OMT7VI10!\6_L=_L?0?LE:I^UEJ4/Q E\
M>']J3]K?XH?M42PR^%T\-?\ "$3?$G3/"NG-X'CD3Q!KO_"11Z,/#(F7Q&R:
M(U^;TH=#L_LX:;YO\"?\$I? N@_\$Y?C[_P3L\<?$BY\?>$_COKW[37B*Z\?
MKX,A\/:AX6U3]H+XH^,/BOH>HZ9X=_X2?6X[C5/A7XC\2Z9=:-J!UZS;5]0\
M-VFH^5HS7/V>U_6*B@#\N/@#_P $I_@A\+/^":^H_P#!-?XG:[K7QO\  WCW
MPK\0=-^-_P 2]4MG\->-/BMXY^*/B'5/%WC#XI7)?5?$]QH_C ^)M2AUG0;V
MYUGQ!<Z1=:-HCSWNIO9%YO"?#O\ P3._;RU<?#7X6?'/_@K=\6?B/^R_\+?$
M_@_7;;PIX$^"GAGX)?M&?$[2/A]J=CJ_@SP?\6?VGO!OC6;Q+J.F6MSI6EQ>
M+M;\)^&O"WB?X@PVUQ)K.J6=W?7%R?V]HH _*;]H;]C#]OKQC\8OB9X[_9K_
M ."F^L?!KX:?&+1]'TCQ+\$?BW^S/\//VBO"GPZGT[0HO#MUK7P0OM2\2> [
MGPF=6LHCJ&J^'?$MOXOT;5/$-Q=ZSJ+71F%I'POC7_@CQX.7]A_]CO\ 9%^
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M_P 02NFP6NI&RTVU/B/61/ZC^P+^P[??L;:+\=/$'COXQ7WQ^^/?[4/QEO\
MXZ_'GXJMX&T'X6>'M:\87'AS0O"6F:5X+^&7AB[U'2?"'AC0?#WAVPM;>*;5
@]=US5K^74-6UG6[N6Z@M[+[_ ** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>tm2527059d10_exc5img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2527059d10_exc5img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  [ ,4# 2(  A$! Q$!_\0
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MQ \ ^(FM5\7_  O^(&EVMG>:OX/\2QVDDEK.R6>H6&K:-K%FYL==T+4=/U*
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M#/C+P,M_+H^AS3VGFZA+X3\2?V$_^#FS_@M!KO@;X0?\%!KOP'^Q=^RGX?\
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MO];U*TT;1;!]1U2XMK47VL:Q?V.E:79B4W&H:E>6MC:1375Q%$_\[7PHM/\
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MQ/I7A+XU6'PXT/X7>-]!\/6EGHTEG\-_C!X8T&+1X$^)GAN2XGO-6O+WP3X
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MGPF=6LHCJ&J^'?$MOXOT;5/$-Q=ZSJ+71F%I'POC7_@CQX.7]A_]CO\ 9%^
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M_P 02NFP6NI&RTVU/B/61/ZC^P+^P[??L;:+\=/$'COXQ7WQ^^/?[4/QEO\
MXZ_'GXJMX&T'X6>'M:\87'AS0O"6F:5X+^&7AB[U'2?"'AC0?#WAVPM;>*;5
@]=US5K^74-6UG6[N6Z@M[+[_ ** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>tm2527059d10_exc6img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2527059d10_exc6img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  [ ,4# 2(  A$! Q$!_\0
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MQ \ ^(FM5\7_  O^(&EVMG>:OX/\2QVDDEK.R6>H6&K:-K%FYL==T+4=/U*
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M#/C+P,M_+H^AS3VGFZA+X3\2?V$_^#FS_@M!KO@;X0?\%!KOP'^Q=^RGX?\
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MO];U*TT;1;!]1U2XMK47VL:Q?V.E:79B4W&H:E>6MC:1375Q%$_\[7PHM/\
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MQ/I7A+XU6'PXT/X7>-]!\/6EGHTEG\-_C!X8T&+1X$^)GAN2XGO-6O+WP3X
MU*[TO6-'EN?"\*F&^O0#])**** "BBB@ HHHH **** "BBB@ KXK_:._8\A_
M:#_:+_8;_: D^(,OA.3]B[XH_$[XE0>%$\+IK:?$9_B/\(O$7PI;1I=:;Q!I
M3>%%T=-?.N+?II7B(W[6HTTV=F)OMT7VI10!\6_L=_L?0?LE:I^UEJ4/Q E\
M>']J3]K?XH?M42PR^%T\-?\ "$3?$G3/"NG-X'CD3Q!KO_"11Z,/#(F7Q&R:
M(U^;TH=#L_LX:;YO\"?\$I? N@_\$Y?C[_P3L\<?$BY\?>$_COKW[37B*Z\?
MKX,A\/:AX6U3]H+XH^,/BOH>HZ9X=_X2?6X[C5/A7XC\2Z9=:-J!UZS;5]0\
M-VFH^5HS7/V>U_6*B@#\N/@#_P $I_@A\+/^":^H_P#!-?XG:[K7QO\  WCW
MPK\0=-^-_P 2]4MG\->-/BMXY^*/B'5/%WC#XI7)?5?$]QH_C ^)M2AUG0;V
MYUGQ!<Z1=:-HCSWNIO9%YO"?#O\ P3._;RU<?#7X6?'/_@K=\6?B/^R_\+?$
M_@_7;;PIX$^"GAGX)?M&?$[2/A]J=CJ_@SP?\6?VGO!OC6;Q+J.F6MSI6EQ>
M+M;\)^&O"WB?X@PVUQ)K.J6=W?7%R?V]HH _*;]H;]C#]OKQC\8OB9X[_9K_
M ."F^L?!KX:?&+1]'TCQ+\$?BW^S/\//VBO"GPZGT[0HO#MUK7P0OM2\2> [
MGPF=6LHCJ&J^'?$MOXOT;5/$-Q=ZSJ+71F%I'POC7_@CQX.7]A_]CO\ 9%^
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M_P 02NFP6NI&RTVU/B/61/ZC^P+^P[??L;:+\=/$'COXQ7WQ^^/?[4/QEO\
MXZ_'GXJMX&T'X6>'M:\87'AS0O"6F:5X+^&7AB[U'2?"'AC0?#WAVPM;>*;5
@]=US5K^74-6UG6[N6Z@M[+[_ ** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image_001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.gif
M1TE&.#EA!0 ! '< ,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "'Y
=! $     +      %  $ @    /\   (#1 P% #L!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
